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CHAPTER 1 
"The eye is like a mirror, and the visible object is like the thing reflected in the mirror." -
Avicenna, early ll1h century. The quest on the theory behind vision has attracted numbers 
of prominent philosophers and scientists over centuries, from the dawn of the extra mission 
theory by Plato (428-348 BC) to Kepler's theory of retinal images and modern visual science.1 
Sight is a noble sense that allows us to perceive and experience the outside world we live 
in. The nature of seeing begins when light rays are focused by the cornea and lens onto the 
retina, and subsequently converted into neural signals that are interpreted as an image by 
the brain. The retina is a complex neural circuitry formed by intertwining networks of various 
types of neurons (Figure 1). Any structural or functional defects in this pathway may result in 
visual impairment and eventually impact a person's daily functioning and mobility. 
Inherited retinal diseases (IRDs) encompass a group of hereditary disorders, affecting 
more than 3 million people worldwide.2 Although previously deemed to be incurable, recent 
developments in the field of gene therapy provide hope for potential treatments for IRD 
patients. Nevertheless, there are two major prerequisites before such interventions can be 
implemented. First, knowledge on the molecular genetic cause of IRD is required prior to 
therapeutic intervention. Second, suitable cellular and animal models are essential to study 
the safety and efficacy of novel therapeutic intervention strategies. 
In this thesis, I describe our endeavor to discover genes responsible for IRDs in human 
and in dogs, thereby aiming to contribute towards a better understanding of the disease 
mechanisms and facilitating therapeutic development. 
1.1. The Human Retina 
1.1.1. Anatomy of the human retina 
The human sensory retina is a thin laminated network of photosensitive nerve cells that lies 
at the inner posterior surface of the eye. Retinal development takes place during the first 
month of embryogenesis when the optical vesicles pouch on either side of the embryonic 
forebrain and invaginate to form the two-walled optic cup. The inner wall of the optic cup 
gives rise to the neuroretina, while the outer wall transforms to the retinal pigmented 
epithelium (RPE).3 
The neuroretina is a transparent multilayered tissue composed of alternating neuron 
cell bodies and synapses. Based on its cellular components, the neural retina is divided into 
three nuclear layers and two neuronal synapse layers. The three nuclear layers are the outer 
nuclear layer (ONL), also known as the photoreceptor layer, the inner nuclear layer (INL), 
and the ganglion cell layer (GCL). The neurons are interconnected in the retinal circuitry via 
synapses in the inner and outer plexiform layers (IPL and OPL, respectively). Histologically, 
the retinal cytoarchitecture is arranged in the following order (Figure lA); 
The outer nuclear layer (ONL) is part of the photoreceptor cells that are the light-sensitive 
cells in the retina, with two distinct subtypes: rods and cones. Rod photoreceptors enable 
dim light vision (scotopic), whereas cone photoreceptors mediate color vision and high 
16 
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visual acuity under brighter light conditions (photopic). The human retina contains 6 million 
cones, representing -5% of all photo receptors, whilst rods outnumber cones with 120 million 
cells (-95%).5•6 The distribution of rod and cone photoreceptor cells is not uniform across the 
retina. Cones are highly concentrated in the fovea (-160,000/mm2) and decrease towards the 
peripheral region, whereas rods are absent in the fovea and rapidly increase with a maximal 
density at -20° eccentricity and subsequently decrease in density towards the periphery of 
the retina.7 
A 
Rods 
Horizontal cells 
Bipolar cells 
·Muller cells 
Amacrine cells 
Ganglion cells 
Nerve fiber layer 
B 
OS 
' 
Calyceal 
processes' 
Rod Cone 
Figure 1. Schematic representation of the retina and light-sensitive photoreceptor cells. A: The retina 
consists of different cell types, i.e. the retinal pigment epithelium (RPE), the photoreceptor cells (rods 
and cones), the interneuronal cells (bipolar, amacrine and horizontal cel ls), the ganglion cells and the 
Muller cells. B: The rod and cone photoreceptor cells consist of an outer segment (OS), inner segment 
(IS) connected via the connecting cilium (CC) . The nuclei (N) of the photoreceptor cells are situated in 
the outer nuclear layer. BB: basal body. (Figure 1 is adapted from 5/ijkerman eta/., 20154 and published 
with permission) 
Each photoreceptor is organized in four distinct compartments: the cell body, which includes 
the nucleus; the inner segment (IS); the outer segment (OS); and the synaptic terminal 
(Figure 1B). The cell body is connected to the IS and contains the nucleus.7• 8 The IS hosts 
the metabolic machinery of the cell including the mitochondria, endoplasmic reticulum, 
Golgi complex, lysosomes and ribosomes. The connecting cilium plays an important role 
in protein trafficking between the outer and inner segments.9 The OS of rods is a cylindrical 
structure comprised of about 1000 stacked discs enclosed by a plasma membrane.8 Cones 
have a similar structure, although the disks are continuous with the plasma membrane and 
are conical-shaped. Outer segments harbor proteins required for phototransduction: the 
conversion of light stimuli to electrical signals. Every night, -10% of rod OS discs are shed 
and phagocytosed by the RPE at the distal end and new discs are added at the proximal end, 
which results in the complete renewal of OS within 10-15 days.10 
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The outer plexiform layer (OPL) is a synaptic connection between photoreceptor cells and 
the interneuron cells. The OPL receives visual signals from ONL Henle's fiber layer which is 
formed by the axons of photoreceptor cells.U-13 
The inner nuclear layer (INL) is comprised of Muller, horizontal, bipolar and amacrine cell 
bodies. Muller cells are the main retinal glial cells, the processes of which span the entire 
neuroretina by forming interconnections between the retinal neurons and the blood vessels, 
vitreous body and subretinal space. Muller cells maintain the local retinal environment for an 
optimal function of the visual pathway. These cells also play a role in the recycling of cone 
photoreceptors. The bipolar, horizontal, and amacrine cells form an interneuron circuitry 
that modify and transmit electric signals from the photoreceptor cells to the GCL. 
The inner plexiform layer (IPL) is a synaptic network between bipolar cells, amacrine cells 
and the ganglion cells. 
The ganglion eel/layer (GCL) consists of around 1.2 million ganglion cells that transmit 
visual information from bipolar and amacrine cells to the brain via ganglionic axons that 
collectively form the nerve fiber layer towards the optic nerve head.14 
The retinal pigmented epithelium (RPE) is a monolayer of hexanocuboidal pigmented cells 
situated at the interface between the neural retina and the choroid. The apical membrane of 
the RPE faces the photoreceptor outer segments and the basolateral membrane faces Bruch's 
membrane, which separates the RPE from fenestrated vessels of the choroid. The RPE plays 
several key roles required to maintain structural integrity and normal function of the retina. 
First, the RPE is the principal site where all-trans-retinol is regenerated into 11-cis-retinal during 
the visual cycle. Second, the RPE melanosomes enable the absorption of excessive light that 
is not captured by photoreceptors to reduce the phototoxic effects to the retina.15 Third, it 
regulates the transepithelial transport of ions, fluid, and metabolites from the subretinal space 
to the blood and conversely, it takes up nutrients from the blood to photoreceptor cells.16 
The RPE also maintains the blood-retina barrier by forming tight junctions with endothelial 
cells, to strictly regulate the active transport of metabolites, nutrients and waste to and from 
the photoreceptor cellsY In addition, the RPE is responsible for the phagocytosis of shed 
photoreceptor outer segments to permit their renewal.18•19 
1.1.2. Physiology of the retina and associated genetic disorders 
The retina hosts several essential biochemical cascades that are required for visual processes 
and disruptions on these pathways may underlie inherited blindness. Figure 2 depicts the 
subcellular localization and potential function of proteins that have been associated with the 
phototransduction cascade, the visual cycle and ciliary transport. 
The photo transduction cascade 
Phototransduction refers to a cascade of biochemical events where photons are 
converted into electric cellular responses. The absorption of photons by the retina initiate 
photoisomerization of 11-cis-retinal to the all-trans-retinal isomer which gives rise to the 
18 
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conformational change of rhodopsin to rhodopsin R*. The photo-activated form of rhodopsin, 
R*, catalyzes guanosine diphosphate (GDP) phosphorylation to guanosine triphosphate 
(GTP) at the a-subunit of the G-protein transducin. The activated transducin elicits the 
PDE6 complex to hydrolyse cyclic guanosine monophosphate (cGMP) which is connected 
to the cyclic nucleotide gated (CNG) channels. Subsequently, the decrease of intracellular 
cGMP level leads to the closure of the CNG channels and blockage of cation influx causing 
photoreceptor hyperpolarization (-40mV>-70mV), in turn inhibiting glutamate release at the 
synapse. 
The phototransduction cascade is terminated by several mechanisms. First, activated 
rhodopsin R* is inactivated by rhodopsin kinase (GRKl) phosphorylation followed by the 
binding of arrestin to cap its residual activity. Secondly, inactivation of transducin and the 
PDE complex occurs through the hydrolysis ofGTP to GDP (Ta-GTP to Ta-GDP) by the GTPase-
activating protein (GAP) RGS9. Lastly, guanylate cyclase activating protein (GCAP) activates 
guanylate cyclase leading to the re-opening of cGMP-gated channels.20-22 
The phototransduction is regulated by a large number of proteins encoded by the 
following genes: CACNAlF, CNGAl, CNGA3, CNGBl, CNGB3, GNATl, GNAT2, GNBl, GNGTl, 
GNGT2, GRKl, GRK7, GUCAlA, GUCAlB, GUCY2D, GUCY2F, OPNlLW, OPNlMW, OPNlSW, PDE6A, 
PDE6B, PDE6C, PDE60, PDE6G, PDE6H, RCVRN, RGS16, RGS9, SAG, SLC24Al and RHO (Figure 3). 
Mutations in the majority of these genes have been associated with many different forms of 
IRDs. For instance, mutations in CNGAl, CNGBl, PDE6A, PDE6B and RHO are associated with 
RP; GUCY2D mutations with LCA and CRD; and CACNAlF mutations with CSNB. In a few of 
these genes, an association to a human disorder has never been reported, but mutations in 
animal models do lead to retinal degeneration.7• 23 
The visu(ll cycle 
The visual cycle, also known as the retinoid cycle, is a recycling process that converts all-
trans-retinal to its original11-cis-retinal state. The cycle begins with the conversion of all-
trans-retinal to all-trans-retinol, a step regulated by RDH12. The interphotoreceptor retinoid-
binding protein {IRBP) transports this compound to the RPE to be converted to its retinyl 
esters by lecithin retinol acyl transferase (LRAT). Subsequently, RPE65 isomerizes the all-
trans-retinyl ester to 11-cis-retinol, which is oxidized to 11-cis-retinal by RDHS. Thereafter, 
11-cis-retinal returns to photoreceptors by IRBP for rhodopsin renewal. 7•24 
Several genes that are known to be involved in the regulation of the visual cycle are 
ABCA4, LRAT, RBP3, RBP4, RDH5, RDH12, RLBPl and RPE65. Mutations in RPE65 and LRAT are 
responsible for LCA and early-onset RP, whileABCA4 variants are known to be associated with 
several types of IRD, ranging from Stargardt disease to arCRD and pan-retinal dystrophy.23 
Cilia assembly and intraflagellar transport 
Retinal ciliopathies were first recognized through the identification of sperm abnormalities 
in X-linked RP and Usher syndrome patients.25• 26 The similar structure of the flagellum of 
19 
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spermatozoa and the connecting cilium of photoreceptors linked these phenotypes as a 
disease spectrum named ciliopathies. Structurally, the connecting cilium bridges the outer 
and inner segments of the photoreceptors. Moreover, the p hotoreceptors sensory cilium plays 
a role in delivering cargo that is required for phototransduction. Genetic defects disrupting 
ciliary function may result in different types of IRD, both syndromic and non-syndromic forms. 
Mutations in 8851, CEP290 and USH2A are known to cause syndromic forms of ciliopathies 
that involve multiple organs, such as kidney, brain and the skeletal system. Several of these 
genes encode proteins with different functions and localisations within the connecting 
cilium. The Bardet-Biedl-associated proteins have been linked to intracellular trafficking and 
ciliary transport. Kinesin II family members regulate transport to the outer segments and 
cytoplasmic dynein 2/lb (DYNC2Hl) regulates transport from the outer segments back to 
the inner segments. Proteins encoded by CEP290, RPGR, RPGR!Pl, and RPl may play a role 
in ciliary intraflagellar transport; however the exact processes are not yet known. MAK plays 
a role in ciliogenesis and maintenance and AIPLl chaperones farnesylated proteins to their 
target locations. 
1.1.3. Inherited retinal diseases (IRDs) 
Inherited retinal diseases are genetically and clinically heterogeneous disorders. Clinically, 
IRDs can be classified based on the disease progression or the type of photoreceptor that is 
primarily involved in disease pathogenesis. For instance, according to the course of disease, 
IRDs can be classified as 'stationary' as in central stationary night blindness (CSNB) and 
achromatopsia, or as 'progressive', which include retinitis pigmentosa (RP) and cone-rod 
dystrophy (CRD). Another classification is based on whether rods or cones are predominantly 
involved, i.e. CSNB exclusively affects rod cells; cone dystrophy primarily affects cone cells; 
LCA is a generalized form of IRD that affects both cell types. Nevertheless, due to their 
overlapping features, a clear-cut distinction between different forms of IRDs is often very 
challenging (Figure 3A). 
In addition, the heterogeneous genetic architecture also attributes to the complexity 
of IRDs, as mutations in more than 250 genes have been identified, including 82 genes 
associated with RP, 23 genes with LCA and 38 genes with CD or CRDY Most of these genes 
encode proteins that are involved in three major visual pathways; the phototransduction 
cascade, the visual cycle and ciliary transport (Figure 2). Moreover, variants in one gene may 
lead to different clinical manifestations. First, variants in one gene may cause different IRD 
phenotypes. For instance, PRPH2 variants cause adRP and ad MD; A8CA4 variants underlie 
arCRD and STGDl, and RPGR variants are implicated in xlRP and xlMD (Figure 3B).2•28 Second, 
variants in several genes are known to cause IRDs both in syndromic and non-syndromic 
forms, e.g. CEP290 variants may cause Meckel-Gruber syndrome, Joubert syndrome or LCA 
and USH2A variants may cause Usher syndrome or RP. Last, several IRD-associated genes 
have been reported in more than one type of inheritance manner, for instance variants in 
20 
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Retinoid cycle RGR 
LRAT RPE65 RDHS 
~ ~. ~ 
All-tnms-REs 11-ct9-ROL 
Mg .. 
Ciliary transport , 
._._; 
Figure 2. Schematic representation of three major processes in human rod photoreceptor cells 
and the retinal pigmented epithelium. The upper panel depicts the retinoid cycle that takes place in 
the photoreceptor cells (PC) and retinal pigmented epithelium (RPE). The middle panel shows the 
phototransduction cascade in rod PCs. The lower panel represents the ciliary transport along the 
connecting cilium. More details are described in the text. (Figure 2 is adapted from den Hollanderet a/., 
201CP~ and published with permission) 
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RHO and RPl that can be inherited in an autosomal recessive or an autosomal dominant 
manner. The following sections describe the forms of IRD that are the subject of this thesis.29 
Retinitis pigmentosa 
Retinitis pigmentosa (RP) is the leading cause of hereditary retinal degeneration with a 
worldwide prevalence of 1 in 4,000 individuals. Night blindness is the most common symptom 
at the initial stage of RP, followed by gradual constriction of the peripheral visual field and 
eventually leading to total blindness at the end-stage of disease.30• 31 The classic retinal 
features of RP include intraretinal bone spicule pigment deposits, attenuation of the retinal 
arterioles and waxy-pale appearance of the optic disc. RP is clinically variable depending 
on the underlying genetic defects.31• 32 In addition, it can also be accompanied by non-
ophthalmologic features in the syndromic form, e.g. Usher syndrome (RP and neurosensory 
hearing loss) or Bardet-Biedl syndrome (RP with obesity, polydactyly, hypogonadism, renal 
failure and cognitive impairment). 
Strikingly, variants in one gene may cause both syndromic and non-syndromic forms 
of RP, displaying an exquisite genetic complexity of RP and I RD. Currently, 82 RP genes have 
been reported in non-syndromic autosomal recessive, autosomal dominant, X-linked RP, 
and a few cases with digenic or mitochondrial inheritance.34 
Leber congenital amaurosis 
Leber congenital amaurosis (LCA; OMIM 204000) is the most severe and earliest form of 
hereditary retinal degeneration, affecting around 1 in 50,000 individuals worldwide. LCA is 
clinically characterized by severe loss of central and peripheral vision in the first year of life, 
sensory nystagmus, amaurotic pupils and extinguished rod and cones signals in the ERG 
measurement. The retinal appearance of LCA patients may range from considerably normal 
with mild arteriole attenuation to severe pigment deposition as in RP. Franceschetti · s oculo 
digital sign, an eye poking, pressing, and rubbing movement in LCA children, may also 
present. The majority of the cases are inherited in an autosomal recessive manner, whilst 
a few autosomal dominant cases have also been reported.35 Currently, mutations in 21 
genes are known to give rise to LCA. These genes encode proteins with different roles in the 
retina, for instance photoreceptor morphogenesis (CRBl, CRX, GDF6), retinal differentiation 
(OTX2), phototransduction (AIPLl, GUCY20, RD3), retinoid cycle (LRAT, RDH12, RPE65), guanine 
synthesis (IMPDH1), signal transduction (CABP4, KCNJ13), outer segment phagocytosis 
(MERTK), coenzyme NAD biosynthesis (NMNATl) or intra-photoreceptor ciliary transport 
processes (CEP290, IQCBl, LCAS, RPGR/Pl, SPATA7, TULPl). 
Bietti crystalline corneo-retinal dystrophy 
Bietti crystalline cornea-retinal dystrophy (BCD) is an autosomal recessive retinal dystrophy 
characterized by chorioretinal degeneration with the presence of yellow-white intraretinal 
crystals deposits. BCD is a rare disorder affecting -100 individuals with various ethnic 
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backgrounds but the majority of the cases occur in the east-Asian population.36-38 Based on 
the frequency of first-cousin marriages in a cohort of BCD patients, Hu et al. estimated an 
allele frequency of 0.005 in the Chinese population.39 On the other hand, a more recent study 
in the Caucasian population demonstrated that BCD could be underdiagnosed in -3% of 
non-syndromic RP cases (n=l04).38•40•41 Clinical features of BCD include reduced visual acuity, 
night blindness and visual field constriction. Electroretinography showed a decrease in the 
amplitude of both scotopic and photopic response. To date, only variants in the CYP4V2 gene 
are associated with BCD. The protein encoded by this gene is homologous to other members 
of cytochrome p-450 superfamily, suggesting a role in fatty acid metabolism.42 Biochemical 
profiling of BCD patients demonstrated an abnormal metabolism of fatty acid omega 
hydroxylase. In addition, retinal sections of affected individuals showed pan-retinal atrophy, 
crystals and complex lipid inclusions in the choroidal fibroblasts, corneal keratinocytes, 
conjunctival and skin fibroblasts, and circulating lymphocytes. These findings suggest that 
BCD may result from a systemic abnormality of the lipid metabolism.43 
1.1.4. Diseo:se gene identification strategies 
The astonishing complexity of the human genome architecture has been a major challenge 
in the search of variants responsible for genetic disorders throughout the years. The 
completion of the sequence of the human genome in 2001 led to the development of many 
genomic technologies to identify the molecular genetic basis underlying inherited diseases. 
In addition, the ongoing growth of genomic variant databases that list variants identified in 
'normal' persons, i.e. 1000 genomes, HAPMAP, ESP6500 and ExAC, enable the selection of 
putative causal variants among the -40,000 sequence variants that are identified in a typical 
WES study of a single I RD case. In view of the genetic heterogeneity and recent developments 
of tailored gene-specific therapies, IRDs may pioneer the implementation of precision 
medicine. Below, I outline several genomic approaches for disease gene identification in the 
field of IRDs, including their advantages and disadvantages over other techniques. 
Genetic linkage studies using homozygosity mapping 
Homozygosity mapping is a powerful tool for disease gene discovery as it facilitated -50% of 
gene discoveries in autosomal recessive RDs. This approach utilizes genetic markers to map 
chromosomal regions associated with a disease. A microarray based technique is available to 
genotype single nucleotide polymorph isms (SNPs) across the genome. Runs of homozygosity 
are determined by the regions harboring consecutive homozygous SNPs shared by affected 
individuals using available SNP analysis tools, such as PLINK44 or Homozygosity mapper.45 
These stretches of homozygous SNPs are called identical-by-descent (IBD) regions whose 
length and position are determined by meiotic recombinations. Due to these recombinations, 
the length of a common haplotype containing a variant will decrease through generations. 
These identical haplotypes may occur in offspring as IBD or a homozygous region. In IRD 
cases in consanguineous families, the average size of homozygous regions is much larger 
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A. Clinical overlap between different form of IRDs 
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Figure 3. Clinical and genetic heterogeneity of IRDs. A: Schematic representation of phenotypic 
and genetic overlap among non-syndromic IRDs. The involvement of cone and rod photoreceptors 
and progression of diseases are shown in order to match the genetic overlap; B: Clinical and genetic 
heterogeneity of inherited retinal diseases {IRDs). Variants in several genes may lead to one form of IRD 
and variants in one gene may result in multiple IRD phenotypes. CRD/CD: cone-rod dystrophy I cone 
dystrophy; CVD: colour vision defect; ERVR/EVR: erosive and exudative vitreoretinopathy; LCA: Leber 
congenital amaurosis; MD: macular degeneration; NB: night blindness; RP: retinitis pigmentosa. (Figure 
3A is adapted from Estrada-Cuzcano eta/., 201233 and Figure 38 is derived from Berger eta/., 2011 and 
published with permission) 
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than in IRD cases in non-consanguineous families. A study by Woods et al. demonstrated that 
offspring of a first cousin union may share an average IBD region of 33Mb, and the majority 
of causal variants are located in the first or second largest region. On the other hand, non-
consanguineous families are likely to harbor relatively smaller regions of between -1 and 30 
Mb.46 Although consanguineous families or patients in isolated populations are more likely 
to benefit from the homozygosity mapping approach, this approach may also detect shared 
homozygous regions and causative mutations in non-consanguineous families.47•48 
Next generation sequencing technologies 
The breakthrough invention of DNA sequencing by Frederick Sanger in 197749 has enabled 
scientists to unravel the human genetic code. Using an enzymatic dideoxy reaction, Sanger 
sequencing provided an excellent resolution for detecting genetic variation. Nevertheless, 
this technique is relatively time-consuming and expensive, especially for genetically 
heterogeneous diseases. The introduction of next generation sequencing (NGS) technologies 
in 2005 has revolutionized our understanding on Mendelian disorders. NGS technologies 
offer a rapid, high-throughput and cost-effective genotyping analysis in comparison to 
conventional methods. This approach enables a massive parallel genotyping of the entire 
region in the human genome in a single experiment. Whole exome sequencing (WES), one 
of the most widely used NGS technologies, has resulted in a continued increase in gene 
discoveries since the first successful report by Ng et al. in 2009.50 In the field of IRDs, WES 
has contributed to the identification of more than 40 causative genes in the past 5 years. In 
comparison to the linkage method, WES also allows gene identification in sporadic cases. 
One major drawback is that this approach only covers the - 1% of the human genome that 
encodes proteins. In addition, WES is ineffective in detecting a subset of structural or complex 
rearrangements. Alternatively, whole genome sequencing (WGS) can be implemented as it 
also covers non-coding regions, allowing mutation detection in deep-intronic regions and 
regulatory elements. Moreover, recent studies showed a more even coverage distribution of 
WGS in comparison to WES.51 
1.2. Dogs as an animal model for IRD research 
The use of animals as models for human disease has been indispensable in understanding 
the genetic basis of IRDs, as well as for developing potential therapies. Numerous animal 
models have been described following spontaneous mutations or via genetic modification 
to resemble human IRDs. Nonetheless, retinal phenotypes often differ from the human 
situation due to species-specific characteristics of the retina, diverse functions of the gene 
products, or genomic differences between animal models and human (e.g. due to missing 
or duplicated genes). Thereby, several considerations in terms of genetic architecture and 
sequence homology, methods to modify genomes, anatomy of the eye, and structural details 
of the retina are essential when selecting suitable models for IRD research. The following 
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sections focus on the use of dogs as an animal model for IRDs, from the structural anatomy 
ofthe retina to its associated genetic disorders. 
1.2.1. Anatomy and physiology of the dog retina 
Anatomically, the dog's retina is comprised of highly similar cellular layers and synapses 
compared to the human retina. Unlike the human retina, the dog has an additional structure 
at the superior segment of the retina, called the tapetal zone.52 This triangular structure 
contains cells, iridocytes, which harbor crystals rich in zinc cysteins. The rod photoreceptor 
cells are predominant in the dog retina due to its ability to see well under low light intensity. 
Compared to humans, there are only two types of cones in dogs, i.e. yellow and blue.53 
The area centra/is is characterized by a small fovea-like region is enriched in cones, has a 
decreased number of rod cells and an increased thickness of the RGC layer. 52 A recent study 
identified a structure resembling a primate fovea in the area centra/is, demonstrating the dog 
as a valuable model for studying cone diseases that affect humans.55 
1.2.2. Hereditary retinal degenerations in dogs 
Similar to humans, IRDs in dogs are extensively diverse in terms of clinical features and the 
underlying genetic basis. Based on the disease onset and progression, canine IRDs can 
be categorized as developmental, stationary or progressive retinal degenerations.56 The 
developmental disorders are congenital structural abnormalities due to disruption of eye 
development during embryogenesis, e.g. retinal dysplasia or Collie eye anomaly (CEA). 
The stationary form is defined as retinal degeneration with a certain limit of progressivity. 
Achromatopsia and canine Leber congenital amaurosis, formerly known as congenital 
stationary night blindness (CSNB), are classified as stationary disorders, although it has some 
overlapping aspects with the progressive form of retinal dystrophies.57 The progressive form 
of RD is characterized by photoreceptor cell death that slowly advances to a severe visual 
impairment and may eventually lead to total blindness. Progressive retinal atrophy (PRA) 
and CRD are examples of progressive forms of canine I RD. Whilst rod cells are predominantly 
affected at the initial stage of PRA, the cones are primarily degenerated at the early stage of 
CRD.57 
PRA is the most prevalent type of IRDs in dogs, and has been described in more than 100 
different dog breeds. 56• 57 This group of diseases is very diverse based on the disease onset 
and mode of inheritance, depending on the underlying genetic causes. The ophthalmoscopic 
features include retinal vasculature attenuation, tapetal hyperreflectivity, pigment deposits 
in the RP and pale appearance of the optic disc. These features highly resemble RP in human, 
suggesting it as a valuable homologous model for studying human retinal diseases. Currently, 
18 genes are known to be associated with hereditary retinal dystrophies in dogs.58-82 
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1.2.3. Disease gene identification: strategies and challenges 
Currently, 651 traits have been reported in dogs, of which 259were passed through generations 
in a Mendelian mode of inheritance (Online Mendelian Inheritance in Animals) (http://omia. 
angis.org.au/home/, accessed July 2016). Remarkably, many of these conditions, including 
PRA, mimic the disease phenotype in humans and are caused by similar genetic defects. The 
release of the first dog genome sequence in the Boxer breed (75x) has largely contributed to 
the identification of genetic defects in manydiseases.83 The advanced genotypingtechniques 
and more complete annotation of the canine genome have facilitated the molecular 
characterization of canine RDs. Over the past few years, diverse genetic tools to study dog 
traits have dramatically evolved, ranging from a candidate gene approach, linkage analysis, 
genome wide-association analysis to the recent next generation sequencing technique. 
Earlystudiesemployingcandidate gene screening in Irish Setters with rod-cone dystrophy 
type 1 yielded PDE6B as the first gene to be mutated in PRA.69 Thisgenewas selected based on 
the biochemical and phenotypical similarities to rd mice with Pde6b mutations. Subsequent 
studies using candidate gene analysis, successfully identified causative PDE6B mutations for 
rcd1a in the Sloughi,68 PDE6A for rcd3 in the Cardigan Welsh Corgi,71 F?HO for adPRi\ in the 
Bullmastiff and English Mastiff/8 and BESTl in dogs with canine multifocal retinopathy.84 
The completion of the dog genome annotation in 2004 enabled fine mapping using SNP 
markers through the entire dog genome for linkage analysis. Currently, 11 chromosomal 
loci have been associated with canine RDs.56 Nevertheless, multigenerational pedigrees 
with reliable phenotypic data are required to perform linkage mapping. In combination 
with linkage analysis, PRCD was found to be mutated in 18 different dog breeds with PRA.57 
Thereafter, GWAS followed by positional candidate gene cloning identified a homozygous 
1-bp insertion in SLC4A3 in the CFA37 of Golden Retriever with PRA.72 This approach also 
facilitates the identification of variants in NPHP4 and ADAM9 in the standard wirehaired 
dachshund and Glan of lmaal Terrier breeds, respectively. 61• 77 
As described before, the advent of NGS technology has revolutionized genomic 
medicine, and exome sequencing has now become a routine diagnostic test in several 
western countries to identify mutations underlying genetically heterogeneous disorders in 
human. In the past few years however, WES enrichment kits for canines in combination with 
linkage data have also facilitated the discovery of genes responsible for PRA in dogs. 
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Aim of this thesis 
The main purpose of this thesis is to unravel molecular genetics defects underlying IRDs in 
humans and PRA in dogs. In humans, we employed various genotyping approaches for two 
different purposes, namely providing a molecular diagnosis for patients and discovering new 
genes mutated in I RD. In dogs, we performed WES analysis to identify genes associated with 
PRA. 
Chapter 2A provides an overview of different vertebrate animal models used to study 
IRD, and discuss the pros and cons of each animal for vision research. In Chapter 28, we 
describe WES analysis in 26 dogs from 12 different breeds. This chapter explains the set 
up, analysis, findings and challenges of performing WES in dogs. In this study, we found a 
nonsense mutation in fYSthat allows breeding of a mutant dog model, and we also identified 
PKM as a novel candidate gene for PRA and thereby perhaps also IRD in humans. 
Chapter 3A describes genetic studies for RP and LCA in a large cohort of Indonesian 
IRD patients. These data provide the first genetic repository to design a suitable diagnostic 
framework in this population. In addition, Chapter 38 outlines the identification of a 
homozygous p.(Arg338*) mutation in exon 4 of RPl in autosomal recessive RP. 
Chapter 4 describes the genetic screening for CYP4V2 in a cohort of BCD cases from 
multiple centers, and genetic screening of frequent LCA-associated variants in the Danish 
population. In Chapter 4A, we performed Sanger sequencing and copy number variant 
analysis of CYP4V2 in patients with BCD that led to the identification of the first large deletion 
of CYP4V2 in BCD patients. Chapter 48 describes a genetic screening of frequently mutated 
genes in LCA in the Danish population, which demonstrated RPE65 to be the most recurrently 
mutated LeA-associated gene in this population. 
Chapter 5 focuses on our efforts for IRD gene discovery using WES. Chapter SA explains 
the association of AGBL5 variants with autosomal recessive RP and the clinical features in 
patients with AGBL5 variants. Chapter 58 describes the identification of IDH3A as a novel 
gene associated with arRP and, in some cases, pseudo-coloboma. 
Finally, Chapter 6 provides the general discussion of this thesis. We highlight the findings 
and challenges of the implementation ofWES, both in humans and in dogs. In addition, we 
discuss the low yield of new IRD gene discoveries using WES. Finally, based on this study, we 
propose (de)glutamylation as a novel pathway that is associated with IRDs. 
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Abstract 
Over the last decade, huge progress has been made in the understanding of the molecular 
mechanisms underlying inherited retinal dystrophy (IRD), as well as in the development 
and implementation of novel therapies, especially in the field of gene therapy. The use of 
mutant animal models, either naturally occurring or generated by genetic modification, 
have contributed greatly to our knowledge on IRD. Yet, these mutant animal models do 
not always mimic the retinal phenotype that is observed in humans with mutations in the 
orthologous gene, often due to species-specific characteristics of the retina, and/or diverse 
functions of the gene products in different species. In this manuscript, we compare general 
and ocular characteristics of a series of widely used vertebrate animal models, i.e. zebrafish, 
chicken, rodents, cats, dogs, sheep, pigs and monkeys, in terms of genetic architecture and 
sequence homology, methods to modify genomes, anatomy ofthe eye, and structural details 
ofthe retina. Furthermore, we present an overview of mutant vertebrate animal models that 
have been used to study or develop treatments for the various genetic subtypes of IRD, 
and correlate the suitability of these models to the specific characteristics of each animal. 
Herewith, we provide tools that will help to select the most suitable animal model for specific 
research questions on IRDs in the future, and thereby assist in an optimal use of animals and 
resources to further increase our understanding of inherited retinal dystrophies, and develop 
novel treatments for these disorders. 
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1. Introduction 
THE PROS AND CONS OF VERTEBRATE ANIMAL MODELS FOR FUNCTI ONAL 
AND THERAPEUTIC RESEARCH ON INHERITED RETINAL DISEASES 
Inherited retinal dystrophies (IRDs) are a group of heterogeneous disorders characterized by 
a progressive toss of visual function due to degeneration of the tight-sensing photoreceptor 
celts in the retina, often resulting in complete blindness. Over the past two decades, the 
molecular and phenotypic characterization of mutant animal models resembling IRD has 
contributed greatly to our understanding of the physiological processes that regulate vision 
and of the pathophysiological mechanisms that underlie I RD. In addition, several of these 
models have shown to be instrumental for the development of novel treatments, such as 
gene augmentation therapies that are now in clinical triats. 1-'~ On many occasions however, 
animal models that carry mutations in genes underlying IRD in humans do not, or only 
partially, mimic the human phenotype. Why is that? Do the gene products have diverse 
functions in different species? Is this due to structural differences in the retinal celts of the 
various animals? In this manuscript, we witt describe the general and ocular characteristics 
of a series of vertebrate species commonty used in functional and/or therapeutic research on 
IRDs. lrr addition, we provide a comprehensive overview of currently existing IRD models, and 
assess whether they resemble the human phenotype. With this, we aim to provide insight 
in the utility of the various different animal models for IRD, and why some species may be 
particularly suited for certain types of functional or therapeutic research in the future. 
1.1. The retina 
Vision is a complex and highly regulated biological process. When light enters the eye through 
the cornea and the tens, it is refracted and focused onto the retina that tines the inner surface 
of the eye. In the retina, tight is converted into an electrical signal that is transmitted via the 
optic nerve to the visual cortex in the brain where the actual images are formed. The retina is 
a thin, multilayered and highly structured tissue composed of several different celt types that 
each play a crucial rote in the conversion and amplification of tight to electrical signals.5 The 
tight-sensing photoreceptor celts are arranged in a defined layer, that at one end contacts 
the retinal pigment epithelium (RPE) and at the other end feeds into the outer plexiform 
layer (OPL) . Here, the photoreceptor terminals form synapses with the second order neurons 
(bipolar celts, horizontal celts and amacrine celts), the nuclei of which together with the nuclei 
of the Mutter celts define the inner nuclear layer (INL). These neurons again form synapses in 
the inner plexiform layer (IPL) with the ganglion cells, whose nuclei are situated within the 
ganglion celt layer (GCL). The axons of the ganglion celts define the retinal nerve fiber layer 
(RNFL) and exit the retina through the optic nerve head (ONH) or papilla. The borders of the 
Mutter celts delineate the internal (ILM) and external limiting membrane (ELM). A cartoon 
describing the layered structure ofthe human retina is provided in Figure lA. 
When tight reaches the retina, it first passes through the ganglion and inner nuclear celt 
layer to reach the photoreceptor cells. In the photoreceptor celts, photons are captured by the 
photopigment molecules after which the phototransduction cascade is initiated, a complex 
chain of events that results in the closing of voltage-gated ion channels producing a change 
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in membrane potential. Subsequently, this electrical signal is structured and specifically 
amplified by the different cell types in the inner retina to be ultimately transported to the 
brain via the retinal ganglion cells for the generation of images. Oxygen and nutrients for 
the outer retina (i.e. the photoreceptors) are provided through diffusion from the choroidal 
vessels via the RPE. The inner retina is supplied by the retinal vasculature consisting of a 
superficial (within the RNFL) and a deep (within the INL, IPL)plexus. Therefore, the human 
retina is classified as holangiotic (different forms ofvascularised retina exist in certain animals, 
see Chapter 2). The most important features of the human retina are the macular zone and 
the foveal pit in the centre of the macula, both being specific for the primate retina, which 
contains an avascular zone around the most sensitive cones and considered to be necessary 
for high-contrast vision. The avascularity of the fovea is possible because the inner retinal 
layers have moved aside, thus forming the macular wall with a high density of ganglion cells. 
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Figure 1. Schematic representation of the retina and light-sensitive photoreceptor cells. A: The 
retina consists of different cell types. The retinal pigment epithelium is involved in the phagocytosis 
of shedded photoreceptor outer segment discs. The photoreceptor cells (rods and cones) convert 
light into an electrical signal. The interneuronal cells (bipolar, amacrine and horizontal cells) combine 
and subsequently transmit these signals to the ganglion cells. The Muller cells are radial cells that 
are present throughout the entire retina, thereby connecting all retinal cell types at adherence 
junctions. They function in photopigment recycling, maintaining retinal extracellular environment 
homeostasis, providing neurons with nutrients and removal of their waste products. B: The rod and 
cone photoreceptor cells consist of an outer segment (OS), where the primary signal transduction 
takes place, and a separated inner segment (IS) connected via the connecting cilium (CC). The calyceal 
processes are situated next to the proximal outer segment. The nuclei (N) of the photoreceptor cells 
are situated in the outer nuclear layer. The synaptic terminals, containing the ribbons, connect the 
photoreceptor cells with horizontal cells, bipolar cells and neurons. BB: basal body of the connecting 
cilium. 
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1.1.1. Photoreceptor cells 
Morphologically, photoreceptor cells can be segmented into different parts, i.e. a synaptic end 
that faces the bipolar cells, the cell body that contains the nucleus, an inner segment where 
protein synthesis occurs and a large outer segment where the actual phototransduction 
takes place (Figure lB). The inner and outer segments are linked by the connecting cilium 
(CC), a microtubule-based structure that is crucial for the transport of proteins into the 
outer segments.6 Near the connecting cilium, cellular extensions are formed, the calyceal 
processes, which can be found in other ciliated cells as well (e.g. hair cells in the inner ear). 
All the proteins needed to initiate phototransduction are present in the outer segments of 
the photoreceptor cells. When light reaches the photoreceptors, photons are captured by the 
opsin molecules, initiating a complex chain of events that includes conformational changes 
in the chromophores, activation of G-proteins and the closing of voltage-gated ion channels 
causing a hyperpolarisation of the membrane potential that ultimately results in a decreased 
neurotransmitter secretion at the synaptic terminal of the photoreceptor cells.7•8 A similarly 
complex chain of molecular events is needed to re-open the cation channels and prepare the 
photoreceptor cell for another round of phototransduction. Every night, the upper 10% of 
all outer segment discs are phagocytised by the RPE cells (see section 1.1.2.), and new discs 
evaginate from the connecting cilium region at the base of the outer segments. 
In the human eye, two types of photoreceptor cells can be distinguished, i.e. rods and 
cones, named such based on the shape of their outer segments (Figure lB). Rods are very 
sensitive to low levels of light, and are most abundant in the peripheral retina, whereas 
cone photoreceptor cells function well under bright light conditions, and are mostly present 
in the central part of the retina, i.e. the macula. Hence, cones mainly mediate our central 
vision, including color vision, and allow high visual acuity, whereas rods are responsible for 
peripheral vision and vision under dim light conditions, i.e. night vision, in addition to sensing 
contrast and motion. Besides a difference in spatial distribution, rods and cones also differ 
to some extent in their molecular content, for instance with regard to their photopigment 
molecules. In rod photoreceptor cells, rhodopsin acts as the key molecule initiating the 
phototransduction cascade, whereas in cone cells different types of photopsin molecules 
are present, depending on the cone subtype. In the human retina, three different types of 
cones can be distinguished, each sensitive to light of a different wavelength, i.e. the S-cones 
(short wavelength), M-cones (medium wavelength) and L-eones (long wavelength).9• 10 Even 
within the macula, there are local differences in the distribution of each of the different cone 
photoreceptor subtypes,11 illustrating the complexity of the human retina . The synapses 
formed between photoreceptors and the bipolar and amacrine cells within the OPL are either 
invaginating or non-invaginating, depending on the impact they play in the forwarding of the 
light-triggered signal. Invaginating synapses form specialized ribbon synapse structures, one 
per rod spherule and several per cone pedicle (Figure lB). A fully developed retina contains 
approximately 92 million rods and 4.6 million cones,n that are post-mitotic and therefore do 
not divide or regenerate following injury. 
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1.1.2. RPE cells 
The retinal pigment epithelium (RPE) consists of a monolayer of hexagonally shaped cells that 
are in direct contact with the photoreceptor outer segments (Figure lA), and has several distinct 
and important functions in the retina. As mentioned above, the RPE cells are responsible for 
the phagocytosis of the most upper part of outer segment discs that contain the highest 
concentration of toxic by-products resulting from many cycles of phototransductionP· 13 
In addition, the RPE plays an important role in the visual cycle, a molecular cascade that 
allows to replenish the photoreceptor cells with chromophore molecules following a series of 
enzymatic reactions that also partially takes place in the photoreceptor cells.14 Other functions 
of the RPE include the maintenance of the outer blood-retina barrier by the formation of tight 
junctions between adjacent RPE cells, and the active transport of metabolites, nutrients and 
waste products between the choriocapillaris and the photoreceptor cells and vice versa.15 The 
pigmented nature of the RPE is caused by melanosomes, melanin-containing organelles that 
have the ability to absorb light. As such, the RPE can absorb scattered light and thereby minimize 
phototoxic damage to the retina,16 revealing yet another important function ofthe RPE. 
1.2. Inherited retinal dystrophies 
As indicated in section 1.1., the molecular processes in the retina that initiate vision, including 
the phototransduction cascade and the visual cycle, involve hundreds of different proteins in 
any of the different retinal cells. Because many of these proteins are retina-specific, mutations in 
the encoding genes often result in dysfunction of retinal cells and concomitantly cause a retinal 
phenotype. Depending on the severity of the mutations, the cell type that is primarily affected by 
the mutation (RPE, cone and/or rod photoreceptors, or one of the other cells in the retina), and 
the function of the protein that is encoded by the corresponding gene, IRDs can be divided into 
different clinical subtypes with a varying age of onset, rate of progression and clinical hallmarks. 
The most severe subtype of IRD is Leber congenital amaurosis (LCA), with an onset of symptoms 
in the first year of life and resulting in complete blindness in childhood. Other subtypes of IRD 
include retinitis pigmentosa (RP, also known as rod-cone dystrophy), cone-rod dystrophy (CRD), 
cone dystrophy (CD), achromatopsia (ACHM) or congenital stationary night blindness (CSNB) 
that all display a large degree of clinical and genetic heterogeneity. In addition, there are some 
other subtypes of IRD that are caused by mutations in only a single gene, e.g. Stargardt disease 
(caused by mutations in ABCA4), choroideremia (caused by mutations in CHM) or Best disease 
(caused by mutations in BESTl). IRDs can be inherited in an autosomal recessive, autosomal 
dominant, or X-linked fashion, whereas mitochondrial or digenic inheritance also have been 
reported occasionally. To date, more than 200 genes are collectively known to be mutated 
in one or more of these IRD subtypes (https:/ /sph.uth.edu/retnet/). Retinal dystrophies can 
manifest either as the sole clinical symptom (non-syndromic IRD) or in conjunction with other 
abnormalities elsewhere in the human body (syndromic IRD). Examples of syndromic types of 
IRD include Bardet-Biedl syndrome (BBS), Joubert syndrome (JBTS), Usher syndrome (USH) or 
Senior-L0ken syndrome (SLS). Often, the genes mutated in these syndromes can also underlie 
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non-syndromic I RD. Although the more severe (i.e. protein-truncating) mutations might be more 
often causative for syndromic forms, establishing a clear genotype-phenotype correlation is not 
always trivial. Given this extreme genetic (and clinical) heterogeneity, establishing the correct 
molecular or clinical diagnosis can be complicated. Yet, finding the genetic cause underlying IRD 
has become increasingly important, due to several new treatment options that have reached the 
clinical trial phase over the last few years, or are currently emerging. 
1.3. Therapeutic interventions in IRD 
Formanyyears, IRDshavebeen considered incurable diseases. Yet, from a therapeutic perspective, 
the eye has several key advantages including its accessibility and its immune-privileged nature 
that is ensured by the blood-retina barrier, which would allow a robust delivery of therapeutic 
molecules that remain within the eye and thereby reducing the probability of unwanted side 
effects. In general, rRDs are progressive disorders that, following the onset of visual complaints 
in individuals with IRD, become more severe with age. In the early phases of the disease, the 
cells in the retina are not functioning well but are still structurally intact, while as the disease 
progresses, cells start to degenerate. Most of the genes in which mutations have been found to 
underlie IRD are expressed in the RPE or photoreceptor cells, inducing cell death in these cell 
types as the primary cause of the IRD- associated vision loss. Other neuronal cell types such 
as the bipolar, amacrine, horizontal and retinal ganglion cells remain intact for a longer period 
of time, or are even spared. The stage of the disease therefore has repercussions for selecting 
the most promising therapeutic approach. When the photoreceptor or RPE cells (mostly the 
primarily affected cell type in IRD) are still structurally intact, gene therapy appears to be the most 
promising therapeutic strategy, often involving a (virus-based) delivery of the wild-type eDNA of 
the gene that is mutated to the right retinal cell type via subretinal injections. This strategy has 
already revealed its promise in IRD patients with mutations in RPE6Sl·2•4•17•18 and, more recently, 
in patients with choroideremia and mutations in CHM.3 However, if the RPE or photoreceptor 
cells are fully degenerated, gene therapy can no longer be considered an option, and alternative 
strategies need to be employed such as cell replacement therapy,19•20 optogenetic therapy,21 or, 
at a very advanced stage of the disease, retinal implants.22 Ideally however, one would like to 
treat IRDs as early as possible when the majority of RPE and photoreceptor cells are still intact, 
i.e. with gene therapeutic approaches. As this requires the development of independent tailor-
made therapies for each gene, suitable cellular and animal models that mimic the molecular 
and clinical defects observed in patients are needed to assess therapeutic efficacy and safety. 
In this review, we aim to provide a comprehensive overview of the currently existing vertebrate 
animal models, their characteristics, and their suitability for functional and therapeutic research 
on IRDs. We will focus our attention on animal models carrying mutations in genes that have 
been associated with non-syndromic IRD in humans. 
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2. Vertebrate animals for IRD research 
2.1. General characteristics 
A wide variety of animal models has so far played an important role in the field of IRD, either 
for increasing our understanding of the molecular mechanisms underlying these disorders, 
or for the pre-clinical development of novel therapies. Vertebrate animals that will be subject 
to investigation are macaque, mouse, rat, dog, cat, pig, sheep, chicken and zebrafish, 
as these are the most commonly used models to study retinal function, the mechanisms 
underlying IRD, and/or in the development of novel treatments. Besides detailed genetic, 
ocular and retinal characteristics, a range of general aspects need to be considered when 
selecting the ideal animal model, including breeding time and techniques, the time needed 
to complete embryonic development and to reach fertility, and housing requirements and 
costs. As shown in Table 1, these general characteristics differ heavily between species, 
with the general observation that smaller animals are easier to maintain, have a shorter 
life cycle and generally produce a larger number of offspring. One other advantage of for 
instance zebrafish over avian and mammalian species is that offspring develops ex utero 
and therefore the development of the eye can be monitored more easily. On the other hand, 
(larger) mammalian species more closely resemble humans in terms of genetic architecture 
and sequence, or gross retinal anatomy. In the paragraphs below, we will discuss the ocular 
(section 2.2) and genomic features (section 2.3) of each of the selected animals compared to 
the human eye and genome, respectively. 
2.2. Ocular and retinal characteristics 
As discussed in section 1.1., humans possess a retina that consists of several layers of 
neurons and interneuronal connections closely connected to the RPE. Three highly specific 
mechanisms are unique or almost unique to the photoreceptor/RPE complex: the visual cycle, 
the phototransduction cascade, and the ciliary transport through the connecting cilium. As 
described in section 1.2., the majority of genes mutated in I RD encode proteins participating 
in one of these pathways. To be used in preclinical research on IRD, animal models should 
ideally display similar anatomic features and mechanisms of light transduction as humans. 
Such anatomic features include specificities at the cellular level (i.e. photoreceptor inner 
segments, outer segments, synaptic terminals and connecting cilium), as well as at the tissue 
organisation level (i.e. presence of a macula, fovea). Most currently used animal models 
for therapeutic research on IRDs lack one or more of these specific features of the human 
retina and/or have other specific features instead. These are important to consider when 
deciding on which animal model to use in future IRD research, and to include in the analysis 
of unexpected but nonetheless frequently occurring results, such as a lack of phenotype or 
difficulties in therapeutic applications. 
Below, an overview is provided of the specific ocular features of the selected animal 
models starting with the evolutionary most distantly related species (zebra fish and chicken), 
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Table 1. Summary of ocular and reproductive characteristics of the vertebrate animal models used in IRD research. 
Characteristic Zebrafish Chicken Sheep Pig Cat Dog Mouse Rat NHP Human 
Eye size ~1.21 ~12.54 265 24.85 21.95 16-225 .3.56 5.65 17.65 24.55 (visual axis,. mm) 
Lens Thickness ~0.79 3.5 1010 89 7.89 6.78 2.16 3.87 3 4 (mm) 
VA/ lens ratio 1.6 3.5 2.6 3.1 2.8 2.4-3.3 1.67 1.5 5.8 6.125 
Retina[ thickness 191±92 280 ± 10.83 261 ±2.9 239 ± 0.0058 1:245 ± 21 •13 1:198 ± 9.6b14 204 ± 5n 192 ± 712 1:270±6" 1:226.9 ± on OCT (11m) 14.3•15 
2:204 ± 11 al3 2:164 .4±6b14 2:348±5.5° 2:348.6 ± 14.9°15 
-i 
I 
3:182 ± 11"13 3:310 ± 4.5" 3:311.5 ± 16.5"15 rn 
\) 
Activity profile diurnal diurnal diurnal diurnal both (n/d) both (n/d) nocturnal nocturnal diurnal diurnal ;;u )> 0 
DominantPR rods rods rods rods rods rods rods rods rods 
z VJ 
cones 0 ~ 
Cone dominant -i o 
no no area centralis area central is area central is area centra lis no no fovea fovea I n structure rn o ;;u z 
Presence of ~ (/) 
macular pigment no no no no no no no no yes yes rn o c , 
:j < 
# of diff. opsins four five two two two two two two three three n rn ;;u Al 
rn -i 
Special cones< yes Yes no no no no yes yes no no Vl rn rn OJ 
PR structureh yes (CP, DB) yes (DB,OD) not known yes (C P) not known not known no no yes (CP) yes (CP) ~ ~ 
n rn 
Pigmented RPE inferior part yes inferior part inferior part dependsd dependsd yes yes I)> O z 
z -
Tapetum luddum no no yes no yes yes no no no no _ :;;;:: z )> 
Body weight 1-1.5 ~g 30-90 kg 65-150 kg 2-8 kg ~5-50 kg 2-8 kg ~50-120 kg I ' 0.5-0.7 g 20-50 g 200-400 g rn :;s:: ~ 0 
12-15 -i O Reprod. cycle 12-14 weeks 21-25 weeks 6-12 months 6 months 6 months 6 months 9-12 weeks 9-12 weeks 12 months rn rn months o r-;;u (/) 
Females fecund 10-14 weeks 18-22 weeks 5-12 months 4-8 months 4-12 months 7-14 months 6-8 weeks 4-6weeks 3-4 years 12-14years rn " -; 0 
- ;;u 
z , 
References used in the table: 'Collerey et al., 2014, 2Bailey et al., 2012, 3McKibbin et al., 2014, 'Monti ani-Ferreira et al., 2003, 5Howard et al., 2004, 6Puk et al., 2006, 7Bawa et al., ~ c 
2013, 8Wi lliams et al., 2004,'Gellat, 2007, 10lribarren et al., 2014, uFerguson et al., 2013, 12Lozano and Twa, 2012, 13Gekeler et al., 2007, 14Hernandez-Merino et al., 2011, 15Chopovska o z 
- n 
et al., 2011. Vl -i rn -NHP: non human primate; VA: visual axis; (n/d): nocturnal/diurnal. )> 0 
a 1: peripapillary; 2: periphery; 3: area centralis. e 1: foveal minimum; 2: superior inner macula; 3: superior outer macula. VJ Z .j:>. rn )> 
Ul b 1: superior retina; 2: inferior retina. f Data kindly provided by Dr. M.H. Greenlee, Iowa State University, US. (/) ' 
c UV cones or mixed cones. g Data kindly provided by Dr. C. Kostic, University of Lausanne, Suisse. 
d Depends on pigmentation of strain. h CP: calyceal processes; DB: double cones; OD: oil droplets. 
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and moving along the mammalian evolutionary tree to the most closely related animal 
model, the nonhuman primate. All these animals fulfil the most important request of a 
suitable model: they possess a morphologically similar retinal structure with all discernible 
retinal layers and neuronal cell types. Yet, specific and important differences exist that in 
some cases determine their suitability to be used in IRD research. A graphical overview of 
the retinal structure and species-specific features of each animal is provided in Figure 2 and 
ocular characteristics together with general reproductive peculiarities of each species are 
summarized in Table 1, based on our own investigations and data published by othersP-37 
2.2.1. Zebrafish 
Morphologically, the zebrafish retina is composed of all major cell and tissue layers that can 
be found in humans. The retina lacks a cone-rich structure and is considered holangiotic 
since one plexus of retinal vessels is present at the ILM.38 The zebrafish is diurnal and contains 
four diverse cone subtypes which by far outnumber the rod population. In addition to cones 
receptive to the three color wavelengths perceived by humans, a fourth UV-sensitive cone is 
present.39 TheM- and L-eones form double cones which consist of a principal (L-eone) and an 
accessory segment (M-cone), and the nuclei of the accessory cones form a morphologically 
distinguishable cell layer. Rods, cones and double cones possess calyceal processes 
surrounding the OS and an accessory outer segment.40• 41 Photoreceptor terminals form 
ribbon synaptic connections with bipolar and horizontal cells.41 1n contrast to mammals, the 
IS contain megamitochondria, the function of which is currently unknown.41 
Unlike any of the mammalian species mentioned below, zebrafish are well known to 
have a remarkable capability to regenerate their retina after damage.42 Damaged retinal cells 
will be replaced by newly differentiated cells originating from dedifferentiated Muller glia 
cells.42 As described in section 1.1 and Figure lA, Muller glia cells physically span all three 
different retinal cell layers (ONL, INL until GCL) with their nuclei residing in the INL, making 
them suitable for sensing and responding to retinal damage from any retinal cell.42• 43 The 
molecular mechanism underlying the activation of the regeneration process is still largely 
unknown.44 
2.2.2. Chicken 
The avian retina is highly specialized and varies among birds. Raptors, such as the common 
buzzard, possess one or several foveal structures, while other birds like chicken, do not. 
Because chicken are diurnal birds, their retina contains a relatively high number of cones 
(considered cone-dominated). The chicken retina is avascular (anangiotic) but contains a 
specific structure called pecten ocu/i.45 This structure is highly vascularised and responsible 
for oxygen and nutrient supply to the retina. Concerning the overall morphological structure 
of the retina, a wide IPL layer is observed together with a prominent INL layer, both being 
generally thicker compared to the human or mammalian.46 In contrast, the ONL is rather 
thin and contains, similar to the zebrafish retina, double cones.47 These double cones are 
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considered to be responsible for motion detection in birds. A specific feature of the avian 
photoreceptor is the oil droplet within the single and most double cones, right at the 
border between the IS and OS and spanning the entire width of the photoreceptor. These 
droplets consist of lipids in which carotenoid pigments are dissolved.48 The precise function 
of the droplets, which are coloured according to the opsin expressed within the cell, is still 
unknown, but they may serve as cut-off filters in order to optimize light input to the OS. The 
RPE possesses long, slender cytoplasmic processes filled with melanosomes that surround 
the 05.29 
The chick retina is believed not to have any retinal regeneration capacities. However, 
postnatal chicks can regenerate damaged neuronal cells via differentiation of their Muller 
glia.49•50 This capacity is lost in adulthood, although retinal progenitor cells have been found 
in the retinal peripheral edge.51•52 
2.2.3. Sheep 
Sheep belong to the order ungulata and possess a tapetum lucidum between the RPE and 
the choroid, that in contrast to carnivores, is composed of collagenous fibers. 53 This special 
layer between the RPE and choroid reflects the light in order to increase photon capture 
of the photoreceptors. The retina is holangiotic. Sheep are diurnal animals and their retina 
contains rods and two different types of cones (S and M/L cones).54 The cones are found in 
higher numbers in the visual streak and area centra/is in the dorsotemporal retina, which is 
also the region of highest ganglion cell density. 55 
2.2.4. Pigs 
Since the pig is a diurnal mammal, the porcine retina is optimized for day vision, consisting 
of a large population of cones with highest density within the area centro/is dorsal to the 
optic nerve head.56 The retina is holangiotic and pigs do not possess a tapetal structure.53 The 
cones com prise calyceal processes around the CC and OS similar to the human retina.57 The 
cone IS are usually large and can be easily identified on histological sections. Overall, due to 
the cone-rich nature ofthe retina, the presence of an area centro/is and the lack of a tapetal 
zone, the porcine retina is considered to be an ideal model for studying IRDs, especially cone-
dominated disorders. 
2.2.5. Cats & dogs 
Cats and dogs are originally nocturnal carnivores. Their retinas are holangiotic. Both species 
possess in the superior part of the retina a tapetal zone that contains cells, the iridocytes, that 
harbor crystals rich in zinc cysteins in dogs and riboflavin in cats. 53 The tapetal zone is almost 
triangular in form and the RPE adjacent to it is unpigmented. The remaining part of the 
retina is attached to a pigmented RPE and therefore, the retina can be divided into two areas, 
depending on the pigmentation of the fundus. The presence of the tapetal zone renders 
examination methods that depend on light reflectivity such as OCT more challenging. 
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Figure 2. Comparative description of ocular features in vertebrate animal models. A: Fundus image, 
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OCT scan, histological section and special features of the zebrafish retina. Special features include 
the presence of double cones (DC), calyceal processes (CP), and accessory outer segments (AOS). CP 
and AOS start at the level of the connecting cilium (CC) (TEM image adapted from Hodel et al., 2014). 
Retinal vessels located at the border of the RNFL within the OCT scan. Fundus image and OCT scan 
courtesy of Phoenix Research Labs, La Jolla, US. Histological section shows the long and pigmented 
RPE microvilli extending into the OS layer (adapted from Schonthaler et al., 2010). B: Fundus image, 
OCT scan, histological section and special features of the chicken (bird) retina. Special features include 
the presence of five different cone subtypes, double cones (DC) and oil droplets (adapted from Kram 
et al., 2010). Note the presence of the pecten oculi within the fundus image (http://people.eku.edu). 
OCT scan adapted from Moyaed et al., 2011. Histological section reveals the wide IPL and INL layer 
and the comparatively thin ONL layer (adapted from Bueno et al., 20ll).C: Fundus image, OCT scan, 
histological section and special features of the sheep retina. Special features include the presence 
of a tapetum lucidum fibrosum (cartoon modified after Ollivier et al., 2004). Fundus image adapted 
from (Galan et al., 2006). OCT scan and histological section kindly provided by Dr. M.H. Greenlee (Iowa 
State University, US). The retinal vessels are very prominent at the border of the RNFL within the OCT 
scan. D: Fundus image, OCT scan, histological section and special features of the porcine retina. Special 
features include the presence of calyceal processes (TEM image adapted from Sahly et al., 2012) and 
large cone inner segments (h istological section from Ross et al., 2012). Fundus image adapted from 
(http://www.ocularservices.com). OCT scan adapted from (Mclellan and Rassmussen, 2012). The 
retinal vessels are very prominent at the border of the RNFL within the OCT scan. E: Fundus image, OCT 
scan, histological section and special features of the dog retina. Special features include the presence 
of a tapetum lucidum cellulosum (TLC) (Cartoon modified after Ollivier et al., 2004). F: Fundus image, 
OCT scan, histologic section and specia l features of the rodent (mouse) retina. Special features include 
large outer segments and the absence of calyceal processes. Instead, a periciliary membrane complex 
(PMC) is present at the CC (TEM image adapted from Sahly et al., 2012). G: Fundus image, OCT scan, 
histological section and special features of the macaque retina . Special features include the presence 
the foveal pit, Henle fiber layer and calyceal processes (CP) (TEM image from Sahly et al., 2012). OCT 
scan kindly provided by Dr. F. Rolling (Un iversity of Nantes, Fr). H: Fundus image, OCT scan, histological 
section and special features of the human retina. Special features include the presence the foveal pit, 
Henle fiber layer and calyceal processes (CP) (TEM image from Sahly et al., 2012). Histologic section 
adapted from (http://webvision.med.utah.edu). RNFL: retinal nerve fibre layer; GCL: ganglion cell 
layer; IPL: inner plexiform layer, INL: inner nuclear layer; OPL: outer plexiform layer; ONL: outer nuclear 
layer; HFL: Henle fiber layer; ELM: external limiting membrane; IS: inner segments; ISe: inner segment 
ellipsoids; OS: outer segments; RPE: retinal pigment epithelium; Ch: choroid. 
Most partsofthedog retina are dominated by rods. Cones are not evenly distributed, but their 
retinas have a central area with a high density of cones. 58 This area centra/is can be found in 
the superior temporal retina and is defined by an increased number of ganglion cells.59 A 
recent study even described a fovea-like structure composed exclusively of cones within the 
area centra/is, albeit without a foveal pit.60 Overall, the cat retina has similar characteristics. 
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2.2.6. Rodents (mouse & rat) 
The rodent retina is optimized for activity at night (nocturnal). Like most mammals, the 
retinal vasculature is holangiotic. The retina contains highly sensitive rods with long outer 
segments loaded with many discs and cones that are not evenly dispersed throughout the 
retina but also do not form a defined cone-rich region such as the human macula. This 
characteristic has largely challenged the generation of animal models for cone disorders, as 
the phenotype may not reflect the human situation. However, in the Nrf·l- mouse, the lack of 
transcription factor neural retina leucine zipper drives the cell fate of rod photoreceptors to 
become cone-like photoreceptors.61 Moreover, rodents are dichromats, since the cones are 
either UV-sensitive or sensitive to long-wavelength light.62 L/M cones are distributed mostly 
in the superior hemisphere of the retina, while the UV cones are found mostly in the inferior 
hemisphere.63 Some cones may express both types of opsins. The CC of cones is surrounded 
by a periciliary membrane complex (PMC) instead of calyceal processes, which may hamper 
studies on IRDs related to ciliary transport.57 
2.2.7. Nonhuman primates (macaque) 
Nonhuman primates that are used in research on the treatment of IRDs belong most 
often to the species macaque and are classified, like humans, to the suborder haplorhini. 
Members of this group have evolved vision as one of their main senses and have among 
other specifications forward facing eyes positioned on the front of the skull, thus enabling 
optimized binocular (i.e. three-dimensional) vision. Like humans, macaques see with three 
different cone subtypes (trichomatic) and have a cone-only foveal pit in the centre of the 
macula. While there are no IRDs so far described in nonhuman primates, the presence of 
the specific macular structures makes this model crucial for developing treatment strategies. 
2.3. Genomic architecture and evolution of IRD genes 
In addition to anatomic and morphological features of the eye and the retina, one very 
important aspect in determining the suitability of an animal model is the genomic 
architecture and gene content of each species. As illustrated in Figure 3, between 20 and 100 
million years of evolution separate humans from most vertebrate species. The evolutionary 
distance to chicken is more than 300 million years whereas the human and zebrafish 
lineages have separated 450 million years ago.64 Hence, in terms of genetic architecture and 
sequence identity, mammalian models resemble human more closely than chicken and fish. 
The complexity of genomic evolution is further illustrated by several events that result in 
copy number differences, i.e. deletions or duplications of certain genes in the genome of 
particular species.65 One vision-related example of this is the primate-specific copy number 
polymorphism of the OPNlLW and OPNlMW gene cluster on the X-chromosome. This 
variation in copy number, combined with specific amino acid sequence changes in some of 
these copies contributes to the trichromatic nature of primate vision, and is thought to be the 
result of convergent evolution as a consequence of visual adaptation to the environment.66 
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In order to assess the degree of evolutionary conservation and copy number of genes 
associated with IRD amongst the selected species, we studied the amino acid sequence 
and orthology relationships for all genes currently listed in the RetNet database that are 
associated with any form of monogenic IRD (https://sph.uth.edu/retnet/). The percentages 
of identity at the amino acid or nucleotide level were based on those levels as recorded 
in Ensembl.67 To obtain an average across various proteins, their levels of identity were 
weighted by their sequence length. In case multiple orthologous proteins were present in 
one species (i.e. deriving from duplicated genes), the one with the highest level of identity to 
the human protein was used to calculate the average. The orthology relationships are based 
on the annotation in the ENSEMBL database.68 For all genes that were absent or predicted to 
be duplicated in any given species, we manually checked whether this was indeed consistent 
with other data sources of orthology. Specifically, for genes predicted to be duplicated, we 
examined Treefam69 for orthology relationships, including examining the existence of RNA 
transcripts for inferred species-specific duplications. For species not present in Treefam, 
Blast analysis was performed to find homologues that were used to create Neighbor Joining 
phylogenies after which we inferred orthology relationships from those. For genes that 
appeared to be missing in the genomes from certain species, we examined the nucleotide 
collection for those species at the NCB I database using tBlastn,70 in order to detect genes that 
may have gone unnoticed in the DNA or that have only been sequenced as cDNAs. 
When comparing the sequence identity of the selected 215 genes at the amino acid level, 
zebrafish proteins show an overall identity of 54% to their human counterparts, a number 
that increases up to 92% for the macaque (Figure 3). In terms of absent and duplicated genes, 
it immediately becomes apparent that zebrafish shows a high number of duplicated genes 
(Figure 3; Supplementary Table 1). This is due to the ancient genome duplication event in 
the teleost fish that gave rise to many genes with two copies in the present day zebrafish 
genome.71 In contrast, only two genes appear to be deleted in zebrafish, among which the 
transcription factor Crxthat plays a crucial role in photoreceptor development in mammals. 
A relatively large number of genes appear absent in the genomes of chicken and pig (Figure 
3), although we cannot rule out that these are not actually lost but rather the result of the 
incompleteness of these genomes. Intriguingly, EYS, one of the most frequently mutated 
arRP genes in humans72• 73 has no orthologues in the rodent genomes, i.e. in mouse and rat. 
Interesting duplications are those of T/MMBA in three species (sheep, mouse and rat) and 
RPGR, in which mutations are a recurrent cause ofX-linked RP, in pig. Whether these deletions 
and duplications have any functional relevance or selective advantage in the corresponding 
species needs to be established, but most certainly they are important when one considers 
generating a mutant animal model for a particular gene or genetic defect. 
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identity IRO proteins gcn~s IRO genes 
Homo sapiens (Human) 
Macaca mu/ata (M2caque) 92 
Mus musculus (Mouse) 79 
Rattus norvegicus (Rat) 79 
Canis fami/iaris(Dog) 84 
Felis cattus (Cat) 82 
Sus scrofa (Pig) 77 
Ovis aril!s(Soleep) 81 
Gallus gallus (Chicken) 65 
Danio rerio (Zebrafish) 54 
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Figure 3. Comparative genomics and evolutionary distance genes involved in IRD. Phylogeny 
and divergence time of the selected animals. The numbers on branches indicate the evolutionary 
divergence time in million years. The average percentage of amino acid (a.a.) sequence identity of 
proteins encoded by IRD genes was calculated, and ranges from 92% in macaque to 54% in zebrafish. 
Genes that are predicted to be deleted or duplicated in the genome of certain species are indicated. 
*Due to the poor quality annotation oft he chicken and porcine genome, some genes that are predicted 
to be deleted may in fact be missed in our analysis. **Given the high number of duplicated genes in the 
zebrafish genome (n = 67), these genes are listed separately in Supplementary table 1. 
3. Genetic modification and naturally occurring 
mutant animal models 
In studies on IRD, many different animal models have been used. Some animals have 
developed IRD as the result of a naturally occurring mutation, whereas in others, specific 
mutations have been introduced in their genomes, via different ways, i.e. either non-targeted 
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or targeted. Attempts have been undertaken to systematically create mutant animals 
independent of the genomic sequence by using mutagenic chemicals such as N-Ethyi-N-
nitrosourea (ENU) or by disrupting genes with a viral DNA insertion ortransposons. Employing 
such forward genetic screens can be advantageous for mutating lots of different loci at the 
same time, in order to obtain as many different mutant animals as possible. Because of the 
high number of animals to be screened, such screens are only cost- and labor-effective for 
small animals with a large offspring and short regeneration times. In contrast, reverse genetic 
screens can be used to specifically modify a genomic region of interest in a cost-effective way 
for nearly all animals, because of its targeted approach. The characteristics of the different 
approaches to modify a genome (non-targeted vs. targeted) that are described in this chapter 
are listed in Table 2. A summary of the use of these methods per species is provided in Table 
3. 
3.1. Naturally occurring models 
Like in humans, naturally occurring mutations can result in the disruption of gene function 
and a concomitant phenotype. Especially in mice, many naturally occurring models have 
been identified and used for research over the last three decades.74 A prerequisite for 
employing these animals however is the identification of the causative genetic defect, which 
in the past was often done by linkage analysis combined with Sangersequencingofcandidate 
genes. In some species, this has been very challenging, due to the relative lack of knowledge 
on polymorphic regions (e.g. SNPs and CA-repeats) within their genome, and/or little 
knowledge on the exact genomic sequence. Nowadays, the method of exome sequencing, 
when possible in combination with linkage analysis, is generally applied to identify naturally 
occurring variants, also in pigs and dogs.75• 76 The poor annotation of the genome of some 
species however still complicates manners, as for instance exome sequencing data cannot be 
robustly analyzed. Once the causative mutation has been identified, these animals are ideal 
for experimental research since no genetic modification and, as a result of that, potential 
off-target effects are involved. Exome sequencing data derived from blind pet canines are 
nowadays employed in order to find suitable large animal models for gene characterization 
and gene therapy trials.75 Visually impaired chickens suffering from naturally occurring 
founder mutations have been identified and are currently used for research purposes.77 
Furthermore, retinal degenerative disorders have been observed occasionally in cats and 
sheep. 
3.2. Forward genetic approaches I phenotype-based screens 
3.2.1. ENU mutagenesis 
ENU is an efficient mutagenic agent used in the premeiotic male germ line, where it is 
estimated to induce one sequence change per 100 kb on average.78 However, only ten percent 
of these mutations are thought to have functional consequences, i.e. the induced point 
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Non-targeted (forward genetics) 
Viral inserted Transposon ENU mutagenesis 
mutagenesis mediated 
mutagenesis 
High throughput 
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Efficiency in genome 
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Sequence specificity 
Identification specific 
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mutational events 
Genotoxicity + + + 
Off-target effects + + + 
Homologous 
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Targeted (reverse genetics) 
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Cas9 
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Characteristics of different genome modifying methods. Each method has been described in the text and is classified into non-targeted, used in forward genetic screens, or 
targeted, used in reverse genetic studies. Practical characteristics mentioned which are used to choose a method of choice are compared by giving them an artificial score 
from++ to--.++ very well applicable;+ well applicable;± moderately applicable; -less applicable; -- hardly/not applicable. 
a Large linkage studies and sequence efforts are needed to identify causative mutations. 
b Improvements have been made, resulting in minimal off-target effects (Fu et al., 2014). 
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Each genome modifying method has been described in the text and is classified into non-targeted, used in forward genetic screens, or targeted, used in reverse genetic 
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mutations lead to a nonsense, missense or splice site mutation resulting in a phenotype.78-80 
A subsequent assessment of visual function in these mutant animals can reveal many 
new suitable model systems for retinal degeneration, e.g. in zebrafish and mice.81-83 An 
unavoidable coincidence of using such mutagenic agents however, is the chance of having 
multiple induced mutations per genome, potentially leading to a combined phenotype or 
the involvement of different genes contributing to one phenotype in some cases. A large ENU-
screen on the zebrafish genome covered over 38% of the protein-coding genes and revealed 
10,043 genes to be mutated.79 The identification of affected genes and corresponding 
mutations as such remains challenging in using ENU-treated mutant animals. 
3.2.2. Viral and transposon-based insertions 
Insertional mutagenesis is another approach for large mutagenic screens. By using viral 
DNA, capable of randomly integrating into a host genome, some genes will be targeted by 
chance and thereby deregulated. Nowadays the mostly used viral vectors are pseudotyped 
retroviruses, which are able to introduce their eDNA into a host genome. For example, 
zebrafish embryos infected with a pseudotyped murine leukemia (MLV)-based virus at the 
1,000 to 2,000 cell stage, gave rise to an average of 63 integrations per cell.84 The mosaic 
male parent animals are then outcrossed with wildtype females to generate heterozygote 
F1 fish with on average 10.4 ± 5.0 proviral insertions per genome.84 In this zebrafish study, 
approximately 20% ofthe viral integrations led to more than 70% reduction in mRNA levels, 
originating from viral integrations into exons, introns or sites close to annotated genes.84 
Intriguingly, from all insertions into introns, by far (59%) the most hits were in the first intron 
of the corresponding gene.84 Offspring animals are phenotyped to identify specific functional 
and/or morphogenetic defects, such as defects in optokinetic responses.85 For mutants with 
the desired phenotype, the identification of disrupted genes can easily be done using the 
inserted DNA sequence as a molecular tag, which is a huge advantage over other mutagenic 
screening methods. Such forward genetic-driven research has yielded animal models for 
studying several retinal defects.85 ln a similar way, also transposon elements can be used to 
integrate foreign DNA into a genome for genome-modifying purposes.86 However, the reason 
why transposon-based methods are not often used is the lack of active transposon elements 
for the vertebrate genome. One exception is the tol2 element derived from the medaka fish, 
which is found to be naturally and autonomously active in all tested vertebrate genomes.87 
The Tol2 system can be modified to incorporate a sequence of interest very efficiently into 
the genome of at least zebrafish, frog or mouse.8a-9o In addition, researchers have activated 
another transposon element from teleost fish, named Sleeping Beauty (SB), to randomly 
integrate into the human genome, which therefore can be used for insertional mutagenesis 
as well as for gene delivery by pronuclear injections in at least zebrafish, mouse and rats.91-93 
Transposon elements, such as the Tol2 system, SB and also the PiggyBac system, are now 
used in preclinical studies as an alternative for viral gene therapy delivery.94 
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3.3. Reverse genetic approaches 
3.3.1. Homologous recombination 
Homologous recombination is naturally used by cells to repair DNA double-stranded breaks 
and interstrand crosslinks, but can also be used to introduce foreign DNA into the genome 
of a host cell, e.g. embryonic stem cells, by using two flanking homologous arms allowing 
a targeted way of integration. Once the DNA sequence of the gene of interest is known, 
homologous recombination can exchange or introduce DNA up to several kilobases of 
DNA. With the same mechanism, also knock-out or knock-in animals can be generated. For 
screening purposes of the growing stem cell colonies, mostly a selection gene (e.g. neomycin) 
is co-incorporated within the homologous flanking arms. The surviving cells can be injected 
into a fertilized blastocyst and implanted in a pseudo-pregnant female animal to generate 
chimeric offspring.95 Because the homology arms are sequence-specific, the major limitation 
of homologous recombination is the low ability (<1 %) oftargeting some loci.96 Nevertheless, 
the European Conditional Mouse Mutagenesis (EUCOMM) and the National Institutes of 
Health Knockout Mouse (KOMP) consortia are using homologous recombination in a high-
throughput and systematic manner to generate knock-out mice.97 In addition, gene trap 
methods have been using homologous recombination to insert DNA cassettes into genes of 
interest.96 
3.3.2. Sequence-specific endonucleases: zinc-finger nucleases and TALENs 
Large mutagenesis screens are all based on the introduction of random mutations and 
are phenotype-driven. Since more detailed genetic information becomes apparent from 
patients, also the need for generating models with specific mutations arises with it. One of 
the first approaches of targeted gene modification made use of one class of specific DNA 
binding proteins, zinc fingers, which are peptides that can recognize and bind 3-bp DNA 
motifs. These peptides are usually clustered into three to six DNA binding domains capable 
of recognizing around 9 to 18 bps. The fusion of zinc-fingers with the endonuclease enzyme 
Fokl into a zinc finger nuclease (ZFN) complex led to the possibility of targeted DNA cleavage. 
Cellular non-homologous end-joining (NHEJ) repair processes will join the DNA ends, 
sometimes introducing mutations such as insertions and/or deletions at this position.98 The 
nucleotide specificity remains critical, since off-target effects can result in false phenotypes. 
The targeting options using Fokl, however, were limited to its DNA restriction motifs. In order 
to increase DNA restriction possibilities, a more flexible form of DNA cleavage was used. By 
fusing a transcription activator-like (TAL) effector DNA-binding domain to a general DNA 
cleavage domain, a wide range of possible restriction motifs is estimated to be present 
once in every 35 bp of DNA.98 The encoded amino acids of the DNA binding domain of these 
artificial endonucleases are easier to design than previously used ZFNs and are, together 
with an endonuclease domain, referred to as transcription activator-like effector nucleases 
(TALENs). TALENs have been shown to be suitable for gene-specific mutagenesis in zebrafish,99 
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rat,100• 101 mouse102 or human derived embryonic stem cells and induced pluripotent cells.103 
Attempts to make a less genotoxic TALEN-mediated endonuclease system recently yielded 
a re-engineered very specific endonuclease (1-Scel) without efficiency loss compared to 
traditional TALENs.104 Following induction of DSBs by either ZFNs or TALENs, repair can also 
be directed towards homologous recombination by the addition of donor template DNAs 
(section 3.3.1.). 
3.3.3. Crispr/Cas9 
Over the last two years, a new tool has become available to efficiently modify a genome. 
Although the principle has not changed, clustered regulatory interspaced short palindromic 
repeat (CRISPR)/Cas9-based RNA-guided DNA endonucleases are very easy in both design 
and use, and have increased efficiencies compared to previously used methods like ZFNs 
or TALENs. 105 CRISPR arrays were first discovered in the Escherichia coli genome106 and were 
found to play a role in the adaptive immune system by protecting bacteria from invading 
viruses when combined with Cas9 genes.107 The transition of this system from a biological 
phenomenon to a genome engineering tool was the result of combining targeted specificity 
(crRNA) with the structural Cas9-binding properties of the tracrRNA in a chimeric single 
guide RNA (gRNA).108 The Crispr/Cas9 system has been adapted for efficient use in a wide 
variety of organisms, including zebrafish, mouse, rat, human, pig and sheep.109-112 Two recent 
studies however, show major off-target binding of catalytically active Cas9 endonuclease, 
leading to possible genotoxicity.112•113 Although only a few off-target mutations were found in 
one of these two studies, the other shows higher off-target mutagenesis efficiency in some 
cases, even when Cas9 was targeted to positions with up to five nucleotide mismatches 
compared to the -20-nucleotide guide RNA sequence.113 A method which can improve the 
target specificity of active endonucleases to the genome is needed for future use. Shortening 
guide RNAs to less than twenty nucleotides can reduce off-target binding up to 5,000 fold 
or more, without reducing any on-target functionality_114 Another improvement, which can 
be combined with truncated guide RNAs, was made when researchers introduced the use 
of a Cas9 endonuclease mutant able to induce only a single strand break called nickase.115 
Targeting two nickases to the same genomic position is thus required for a double strand 
break, via which the specificity can be increased by 50- to 1,500-fold, as two different guide 
RNAs can be used.115 Since the genome-directed Cas9 nickases are catalytically active, they 
will still induce single-strand breaks, contributing to genotoxicity and potential mutations. 
To circumvent these limitations, a Fokl endonuclease can be fused to a catalytically dead 
Cas9 protein used by guide RNAs to target the desired genomic location.116 The advantage 
of using Fokl over previous versions of the Crispr/cas9 system is that Fokl endonucleases 
are only catalytically active after dimerization, overcoming therefore all earlier mentioned 
genotoxicity. Following the induction of the double strand break by the cas9 endonuclease 
activity, the break can be repaired by either nonhomologous endjoining (NHEJ) or homology-
directed repair. NHEJ will induce insertions and/or deletions since no template is present, 
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while homology directed repair can use any template to repair the breaks (see section 3.3.1.) . 
Thus, by providingCrisprjcas9treated genomeswith an organism-foreign DNAdonorfragment 
containing DNA of interest, the possibilities for genome editing are enormous. Indeed, this is 
an established technique and larger DNA templates have been successfully incorporated in 
genomes of zebrafish117 or mouse.U8 With higher specificities, it now becomes possible to not 
only mutate a gene, but also to repair a mutated allele back to the wild-type sequence. First 
tests in a mouse model for cataracts showed successful repair of the mutated Crygc gene 
by using its healthy counterpart as a template, which led to fertile wildtype mice.112 Along 
the same line, researchers have been able to repair mutations in human derived induced 
pluripotent stem cells.105 
4. Mutant vertebrate animal models used in IRD research 
4.1. Historical overview on the use of mutant IRD animal models 
For centuries, sdentists have attempted to better understand human physiology and 
pathology by employing animals in research. Already in the first half of the 201h century, the 
first studies on retinal degeneration in animals were published,119• 120 and soon after that, 
the first animal models displaying retinal degeneration segregating in a Mendelian fashion 
were identified, i.e. the rd (retinal degeneration) mice, and the rds (retinal degeneration slow) 
mice.121• 122 Although the genomic regions harbouring the causative genetic defects were 
mapped, it took until the late eighties before the actua I genes carrying these mutations were 
identified, i.e. Prph2 in the rds mice123· 124 and Pde6b in the rd mice.125 From that point on, 
the genetic defect underlying retinal degeneration in many mouse models was elucidated, 
and mutations in the human orthologous genes were identified at a very rapid pace. At 
the same time, positional cloning combined with sequencing analysis in humans revealed 
other genes to be mutated in IRDs,U6•127 genes that automatically served as good candidates 
to be mutated in animal models with naturally occurring types of IRD, not only in mice 
but for instance also in dogs128 and, somewhat later, in rats.129 Ever since, many different 
animal models carrying spontaneous mutations in genes associated with IRD have been 
identified, and studied in great detail to increase our understanding on retinal function 
and dysfunction. The discovery of homologous recombination in mouse embryonic stem 
cells upon transfection of exogenous DNN30 and possibilities to use this technology for the 
generation of genetically modified mice131 1ed to novel opportunities to study the function of 
proteins encoded by the various genes that are mutated in IRDs. Targeted disruption (knock-
out) or targeted insertion of specific pieces of endogenous or exogenous DNA (knock-in) via 
homologous recombination in mouse ES cells, has resulted in the generation of many animal 
models with genetic defects in genes underlying IRD in humans. The development of other 
novel technologies to modify genomes (see Chapter3) has even further expanded the number 
of animal models for IRD, and to date, more than 250 different animal models have been 
described (Supplementary Table 2). Yet, in several animal models, the phenotype does not 
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(exactly) resemble the phenotype that one would expect based on the clinical characteristics 
of human IRD patients with mutations in the corresponding gene. Below, we discuss these 
discrepancies, and aim to find correlations between the disparity of the phenotype and the 
molecular, anatomical or retinal characteristics of the particular animals. 
4.2. Mutant IRD models that do not mimic the human phenotype 
Comparing the clinical characteristics of a mutant animal model with those of IRD patients 
with mutations in the orthologous gene is complicated due to intrinsic differences in retinal 
development and structure, as well as by the different procedures that are applied to 
describe this phenotype. Hence, establishing whether a mutant animal model exactly mimics 
the human phenotype is not always straightforward. In several cases however, a detailed 
molecular or phenotypical analysis ofthe mutant animal models clearly shows the absence 
or presence of unexpectedly mild, retinal abnormalities (Supplementary Table 2). In the 
following paragraphs, we cluster these discrepancies into groups, describe several examples, 
and hypothesize on the molecular or retinal structure-related reasons for the differences in 
phenotypic outcome. 
4.2.1. Gene- or mutation-related discrepancies 
As described in section 2.3, the genomic architecture of the selected species can differ 
significantly, resulting in the absence of certain genes in some species, or the presence of 
multiple copies of one gene in a given genome (Figure 3; Supplementary Table l).ln addition, 
supported by alternative splicing, the same or slightly different protein products derived from 
the same gene can have diverse functions, in different organisms, within the same organism, 
and even within the same cell. It is therefore not surprising that different mutations can result 
in various molecular defects, either because the mutation affects only a single isoform of the 
gene, or because the type of mutation results in complete loss-of-function, partial loss-of-
function, a gain-of-function, or has a dominant-negative effect on the wild-type allele in case 
of heterozygous mutations. In several cases, a discordance between a mutant animal model 
and the clinical phenotype in humans can be explained by such gene- or mutation specific 
reasons, as illustrated below. 
4.2.1.1. Embryonic lethality 
In case a particular mutation, or compound heterozygous mutations, in humans result 
in only a partial loss-of-function, this may affect the function of only one or a few specific 
organs or tissues, resulting in for instance I RD. If the corresponding genes are ubiquitously 
or broadly expressed in the human body, a complete loss-of-function of these genes could 
result in a much more severe phenotype, or even be incompatible with life. Similarly, a 
targeted disruption of the orthologous mouse genes can result in embryonic lethality, as 
has been shown for Chm, E/ov/4, Prpf3 and Prpf8 (Supplementary Table 2). In some cases, 
this embryonic lethality is unexpected, for instance in Chm, since the mutations that cause 
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choroideremia in humans are also true loss-of-function mutations. Further studies revealed 
that this observation is most likely explained by preferential inactivation of the paternal 
X-chromosome in murine extraembryonic membranes, together with a crucial function for 
the Rep-1 protein (encoded by Chm) during early embryonic development.132 
4.2.1.2. Differences in mutational mechanisms 
One other explanation for discrepancies in the phenotypic outcome between humans 
and animals are differences in the mutational mechanisms, which is particularly true for 
disorders that are inherited in an autosomal dominant matter. When causative heterozygous 
missense mutations are identified, the pathophysiological mechanisms underlying IRD in 
those cases could be haploinsufficiency in case of loss-of-function mutations, the mutation 
could act in a dominant-negative way, or the mutation can cause a gain-of-function. Without 
a clear understanding on these exact mechanisms, correlating the phenotype observed in 
mutant animal models with different mutations in the same gene to the human situation is 
challenging. 
Mutations in the cone-rod homeobox-containing (CRX) gene, encoding a transcription 
factor essential for the development of photoreceptor cells, in humans are associated with 
different subtypes of IRD, depending on the type and zygosity of the mutations, i.e. Leber 
congenital amaurosis, cone-rod dystrophy or RP.133-137 The majority of these mutations are 
thought to act in a dominant-negative manner, i.e. the mutant CRX protein impairs the 
transcriptional activity ofthe wild-type copy. 
Homozygous Crx-t- mice clearly demonstrate a functional impairment of photoreceptor 
cells, resulting in a progressive photoreceptor degeneration (Furukawa et al., 1999). This 
knock-out mouse however fails to model the dominant inheritance of CRX-associated 
IRD in humans, as heterozygous mice display only a mild phenotype and normal retinal 
morphology.U8 Thereafter, the generation of mouse models carrying mechanistically distinct 
mutations has further revealed the complexity of studying CRX-associated phenotypes. 
CrxR90w knock-in mice, carrying the exact missense mutation associated with autosomal 
recessive LCA in humans,137 appear healthy in heterozygous state, whereas the phenotype 
in homozygous mutant mice closely resembles that of the Crxl- mice. In contrast, studies 
in Cr.x€168d2 mice carrying a frame-shift mutation, have revealed that a truncation in the CRX 
trans-activation domain preserves DNA-binding activity and disrupts the trans-activation 
activity of the wild type protein_139 As a result, both Cr.x€168d2'+ and Cr.x€168d2/ El68d2 mice show clear 
signs of retinal degeneration, although more severe in the homozygous mutant mice. The 
characterization of a spontaneous heterozygous frameshift mutation in the Crxfl.iP mice with 
congenital blindness,140 and a naturally occurring cat model Crxfl.d:t with a frameshift mutation 
more closely resembling the human CRX-associated phenotype141 has further revealed the 
complexity of modeling phenotypes caused by mutations in the same gene that display 
different mutational mechanisms.Another example is the diversity of mutations in RHO that 
encodes rhodopsin. IRD-associated mutations in RHO can be subdivided into two classes_ 
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Some mutations, clustering in the first transmembrane domain or near the carboxy-terminal 
end oft he protein, like the Q334* mutation tend to aggregate at the plasmamembrane of the 
photoreceptor cell body, as was shown in a mutant mouse model with this mutation,142 as 
well as in transgenic zebrafish carrying the exact same mutation.143 Likewise, knock-in mice 
expressing rhodopsin with a *349Q mutation demonstrate a severe and early-onset retinal 
degeneration with mislocalization and improper disc formation.144 
The majority of RHO mutations however, including the most recurrent mutation P23H, are 
predicted to undergo protein misfolding, thereby accumulating in the endoplasmic reticulum 
and inducing apoptotic cell death. Studies in transgenic mice, rats, dogs and, more recently, 
pigs with this mutation indeed supported this pathophysiological mechanism,145-148 again 
illustrating that different mutations in the same gene can exert different pathophysiological 
mechanisms, in humans as well as in different animal models. 
4.2.1.3. lsoform-specific expression and differential pre-mRNA splicing 
As described in section 4.2.1, the majority of protein-coding genes encode several protein 
isoforms that are the result of alternative splicing, a process that determines the inclusion 
or exclusion of specific exons in the mature transcript. For several genes that are associated 
with IRD, retina-specific isoforms have been described that often contain exons exclusively 
present in these isoforms, e.g. CERKL, RPGR, and 8853.149-151 The use of alternative promoters 
driving the expression of one or more of these isoforms complicates matters even further. For 
genes with such a complex transcriptional profile, generating a mutant animal model that 
mimics the human phenotype can be a challenging task. For instance, attempts to knock-out 
Cerkl in mice revealed only very mild phenotypic abnormalities, and further studies revealed 
the use of several promoters driving the expression of a multitude of Cerk/ transcripts, in mice 
as well as in humans.149• 152 
Besides naturally occurring alternative splicing, many mutations have been described 
that somehow affect the recognition of splice sites by the spliceosome, and thereby alter 
the composition ofthe transcript and final protein product. One example of such a mutation 
is a recurrent change in CEP290, a deep-intronic mutation c.2991+ 1655A>G that activates a 
cryptic splice donor site in intron 26, and results in the inclusion of a pseudo-exon to -50% 
of all CEP290 transcripts in LCA patients.153 Attempts to mimic this recurrent mutation and 
the associated phenotype in a humanized knock-in mouse model failed, apparently because 
the mouse splicing machinery did not effectively recognize the pseudo-exon present in LCA 
patients with this mutation.154 Further studies recently showed that the recognition of such 
cryptic splice sites can vary heavily in different species (Garanto et al., 2015). 
Another intriguing relationship between splicing and IRD exists through the PRPF-
associated retinal dystrophies. Proteins encoded by PRPF genes are an essential component 
of the spliceosome in all cells of the human body, yet mutations in several of these genes 
cause a phenotype that appears to be restricted to the retina.155-159 Hypotheses to explain 
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this phenomenon include dual, retina-specific functions for these proteins, a higher demand 
of splicing in retinal cells, or specific mis-splicing of some key components within the 
retina. Many studies involving animal models have attempted to uncover the molecular 
mechanisms involved in the retinal-restricted phenotype caused by mutations in these PRPF 
genes,l55•157• 16a-162 yet these studies were severely hampered by either early lethality or severe 
phenotypes not restricted to the eye. A more recent study demonstrated the RPE to be the 
primary retinal cell type affected by these mutations, thereby revealing new insights into the 
pathophysiology of splice factor-associated IRD.163 
4.2.1.4. Genetic redundancy 
Genetic redundancy is occurring when the protein products of two different genes have an 
identical or at least overlapping function in the same biological process. In such cases, defects 
in one of the two genes could have a less detrimental effect on the phenotypic outcome of 
the organism than what could expected based on the physiological function of the encoded 
proteins. Redundant genes are found in almost all signaling, developmental, or metabolic 
contexts. The fact that these genes are believed to originate from a single ancestral gene, 
explains why there might be overlapping functions remaining.164 
Due to an ancient genome duplication event, the zebrafish genome is largely duplicated, 
giving rise to many genes with two copies.71 Some of these duplicated genes have acquired 
split functions. One example is protocadherin-15 (PCDH15}, a gene that in zebrafish has two 
orthologues (pcdhlSa and pcdhlSb) . Zebrafish lacking PcdhlSa (orbiter) reveal no defects in 
optokinetic responses, whereas the absence of PcdhlSb results in reduced optokinetic and 
ERG responses.165 It might therefore be expected that genes for which one of the copies has 
been lost following the genome duplication, or duplicated genes with a clear split function, 
are less tolerant to mutations and would therefore be overrepresented in the non-targeted 
screens that most of the mutant zebrafish models originate from (Supplementary Table 2). 
Yet, only four out of the seven zebrafish IRD models carry mutations in genes that are not 
duplicated wh-en compared to the human genome. However, as exemplified above, some of 
the genes that are assigned as being duplicated indeed might actually have acquired a split 
function or are at least not be fully redundant in the zebrafish retina anymore. 
One example of two functionally redundant genes in humans that have arisen after a 
gene duplication event in humans are GUCAlA (expression in cones and only weakly in rods) 
and GUCAlB (expression in both rods and cones) .166168 These two genes, that share more 
than 90% sequence similarity, are sequentially located tail-to-tail at human chromosome 
6 and encode the calcium-sensing part of guanylate cyclase enzyme (GC) that is involved 
in the recovery phase of the phototransduction cascade. 168• 169 Mouse models with a 
disruption in only one of the two Guca genes do not show any abnormal histological retinas 
(Supplementary Table 2: Gucolatm1111 and GucolbtmlAmd), although single Guca knock-out 
rods became more sensitive to flashes and to steps of illumination as a result of reduced 
calcium sensitivityY0•171 However, the combined loss of both genes does result in a clear and 
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severe photoreceptor degeneration 171 which is indicative for Gcapl and Gcap2 (encoded by 
Gucala and -lb, respectively) being functionally redundant. This was further strengthened 
by the complete rescue of the Gucala/Gucalb double knockout phenotype with a healthy 
copy of only the Gucala gene.172• 173 Intriguingly however, expression of only Gucalb was 
not enough to completely restore the phenotype.171 In humans, GUCAlA mutations result 
in cone-dystrophy, with GUCAlB apparently not being fully redundant in these cones.174 
Mutations in GUCAlB in contrast have been reported to lead to autosomal dominant retinitis 
pigmentosa,175 although the exact involvement of these mutations in retinal disease remains 
controversialY6 One other difference between mice and human cone photoreceptor cells 
that could influence the phenotypic outcome, is the presence of a third calcium sensing 
domain (GCAP3) in human, but not in mouse, cone photoreceptors.166 A similar mechanism 
for reduced guanylate cyclase activity is also seen in the rd chickens that carry a spontaneous 
mutation in the GCl gene.177 Mechanistically, this phenotype can be explained by the same 
mechanism as seen with mutations in GUCAlA. Already before any pathological disruption 
can be observed, the retinal cGMP levels are below normal.177 Altogether, these data suggest 
that there is some redundancy between GCAPl and GCAP2 (and perhaps also GCAP3 in 
humans), but GCAPl seems to be the main actor which cannot be fully replaced by GCAP2 
(orGCAP3). 
Following rhodopsin activation and the conformational change of 11-cis-retinal to all-
trans-retinal, this all-trans-retinal can be re-converted into 11-cis-retinol via the visual cycle. 
The rate-limiting step in this cycle is the enzymatic conversion of all-trans-retinal into all-
trans-retinol. This process is performed by retinal dehydrogenases: RDH8, RDH12 and retSDRl 
(retinal short-chain dehydrogenase reductase 1) in photoreceptor outer segments, and 
RDHlO in the RPEY8 Oxidation of 11-cis-retinol in the RPE is catalyzed by 11-cis-RDHs (RDHS 
and RDH11) to yield 11-cis-retinal. Since the two enzymes RDH8 + RDH12 and RDHS + RDH11 
in fact catalyze the same reaction, one might expect that a functional loss in one of these 
enzymes due to mutations can be compensated for by the other unaffected gene. Indeed, 
knocking out either Rdh979• 180 or Rdh11,181 and Rdh8 or Rdhl2178 in mice for example only 
results in a delayed dark adaptation after high bleaching levels. In contrast, the double (Rdh5 
& Rdh11 or Rdh8 & Rdhl2) or triple (Rdh5, Rdh8 & Rdhl2) knock-out mice do indeed suffer 
from rod-cone dystrophy, indicating that the different RDHs are functionally redundant in the 
mouse retina.178• 181 ln humans however, mutations in either RDHS (fundus albipunctatus),182 
RDHll (Retinal dystrophy, juvenile cataracts and short stature syndrome (RDJCSS), or RDH12 
(LCA) do already result in apparent phenotypes.182·185 
4.2.2. Retinal function- & structure-related discrepancies 
As described in chapter 2.2, differences in retinal architecture and the presence or absence of 
anatomical structures in retinal cells are apparent in the selected species. It is therefore not 
surprising that animal models with a differential distribution of rod vs. cone cells, mainly due 
to a difference in nocturnal versus diurnal activity, as well as models for IRDs in which the 
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human pathology resides in anatomical structures that are underdeveloped or even absent, 
will not entirely mimic the human clinical phenotype. In the next paragraphs, some examples 
will be outlined in which a different clinical outcome in mutant animal models as compared 
to the human situation can be explained by retinal structure-related differences. 
4.2.2.1. Calyceal processes in rodent Usher models 
Calyceal processes are axially oriented microvillus-like structures that emerge from the inner 
segment and form a collar around the base of both rod and cone outer segments. Scanning 
electron-microscopy analyses revealed that these F-actin-rich structures are conserved in 
at least NHP, pigs and zebrafish,186• 187 but absent in mice and rats. Recently all five known 
proteins involved in Usher syndrome type 1 (myosin7a, harmonin (=Ush1c), cadherin-23 
(=Cdh23), protocadherin-15 (=Pcdh15) and Sans (=Ush1g) were shown to co-localize to the 
junction between the inner and outer segment of retinal photoreceptors in human and 
macaque but not in mouse. Closer examination by electron microscopy revealed that these 
proteins localize to the photoreceptor calyceal processes.57 The differential distribution in 
photoreceptors of humans and rodents strongly supports evidence that the difference in 
phenotypic outcome of mutations in these genes is explained by the presence/absence 
of these calyceal processes. Although their exact function remains elusive, they have been 
proposed to serve a structural role by providing the outer segment strength and rigidity.57 
Another attractive hypothesis, that was raised based on the presence of the fastest known 
neuronal Ca2+ pump (PMCA2), is that the calyceal processes might be mechanosensitive, 
similar to the inner ear hair cells and therefore fulfill a role in signaling.188 
The membrane of the periciliary region, a collar-like extension of the apical inner segment 
that surrounds the connecting cilium, is also thought to function in the organization of the 
transport of post-Golgi-derived vesicles which are indicated to dock at the membrane of the 
periciliary membrane.189 All known Usher syndrome type 1 and type 2 proteins are located 
in this (peri)ciliary region,57• 189-191 which is also underdeveloped in rodents as compared to 
humans.192 Fibrous links connect the membrane of the periciliary region to the membrane 
ofthe connecting cilium. Gpr98 (Ush2c) was found to be essential for the formation of these 
links because they were absent in Gpr98-deficient (Vlgr1/del7TM) mice.189 Since also usherin 
(Ush2a) and whirlin (Ush2d) are present in this peri ciliary region, the fibrous links are thought 
to be the analogs of the ankle links in the hair bundle of cochlear hair cells. The fibrous 
links may be formed by homo- and/or heteromeric binding of the extracellular domains 
of Ush2a and Gpr98 which are intracellularly tethered by whirlin. SANS and whirlin directly 
interact and SANS thereby may provide the molecular link to the microtubule transport 
machinery.189•193 The fibrous links may function as structural support of the periciliary region 
and the connecting cilium189 and analogous to the function of the links in the hair bundle, 
they could play a role in development of this region of the photoreceptor. However there 
are no, or in case of Ush2a·l· and whir/in+ mouse mutants only mild,194• 195 retinal aberrations 
due to ablation ofthe Usher genes. In addition to their structural role, it was postulated that 
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these proteins play a role in defining the membranous regions and thereby contribute to 
the control of vesicle docking and cargo transfer from the inner segment transport system 
to that of the cilium 189 or play a role in outer segment disk formation and renewal.57 Since 
whirlin associates with the calcium channel subunit Cavl.3 it is likely to have a role either 
in the transport to or the organization of the voltage-gated calcium channels at the plasma 
membrane and thus contributes to the control of vesicle docking and/orfusion via regulation 
of local Ca2+ concentrations.196 
4.2.2.2. Differential distribution of cone and rod photoreceptor cells 
Cones and rods serve different functions in the retina and are differentially distributed 
amongst species. As described in this review, the human retina contains a cone-rich area 
(fovea centra lis) whereas in zebrafish the retina is built up almost exclusively by cones that 
are distributed throughout their entire retina. Moreover, in zebrafish, rod development 
is not matured until 20 days post fertilization (dpf) which therefore gives rise to a retina 
overrepresented by cones at 5 dpf when functional measurements in forward genetic 
screens are often conducted.197 However, the overall anatomy of the retina is similar in both 
species. This would make rod-specific degeneration less pronounced in the zebrafish retina 
as compared to other species such as humans. A cone and rod difference is for example seen 
in the zebrafish cacnalfa mutant. In both humans and mice, the CACNAlF gene is expressed 
in both rods and cones, whereas zebrafish contains two cacnalf orthologues that are 
differentially expressed: cacnalfa (cone-specific) and cacnalfb (rod-specific). This is most 
probably also the reason that, in contrast to the cacnalfa zebrafish mutant, Cocnolfknock-
out mice mimic the human ERG measurements and congenital stationary night blindness.198• 
199 On the other hand, when comparing animal models for genes specifically expressed in 
cones (PDE6C or GNAT2), a similar phenotype is observed in case of any mutation. In humans, 
dogs, mice and zebrafish, a cone-specific degeneration is observed related to achromatopsia 
(Supplementary Table 2). 
A more subtle difference between cone and rod photoreceptor cells amongst species is 
observed with mutations in the PDE6 complex. In the rod photoreceptor cells, PDE6 forms 
a heterotetrameric complex of PDE6a, PDE6~ and two PDE6y subunits to make an active 
cGMP phosphodiesterase capable of cGMP hydrolysis. Both mice and dogs have a relatively 
rod dominated retina, which is the result of their high nocturnal activity as compared to 
the more cone-rich human retina. As a result, one could expect that rod-specific null alleles 
have a great impact on vision in mice and dogs as compared to humans. Indeed, it can be 
observed that mutations in the mouse and dog Pde6b gene lead to rapid rod photoreceptor 
degeneration and eventually to complete retinal degeneration and loss of visual function.200• 
201 Also, in humans with PDE6B mutations, the initial symptoms include night blindness 
as a result of rod-specific dysfunction and eventually they show a more advanced retinal 
degradation, probably induced by the proposed bystander effect,2°2 but with a progression 
rate that is significantly slower than in mice and dogs.200 However, phenotypic variability in 
66 
THE PROS AND CONS OF VERTEBRATE ANIMAL MODELS FOR FUNCTIONAL 
AND THERAPEUTIC RESEARCH ON INHERITED RETINAL DISEASES 
terms of disease progression often occurs even within the same species. For instance, the rdl 
mouse that carries nonsense mutation in Pde6b displays a rapid photoreceptor degeneration 
starting at postnatal day 8, and absence of nearly all rods by week 3.203 In comparison, rdlO 
mice with a Pde6b missense mutation (p.R560C) show a relatively slower disease progression, 
starting at postnatal day 16 and complete absence of photoreceptor cells within 2 months.204 
A PDE68 nonsense mutation in rcdl Irish setter dogs leads to a rapid disease progression, 
which starts one month after birth and continues until3 months.205 1n contrast, crdl American 
Staffordshire terrier dogs carrying an in-frame deletion have a milder phenotype and later 
onset compared to rcdl dogs. Histological examination ofthe retina at 11 weeks shows that 
photoreceptors and the ONL in homozygous crdl dogs are more preserved compared to 
those in crdl/rcdl or rcdljrcdl dogs.206 Similar results were seen in Pde6a mutant mouse 
and dog models, encoding the other PDE6 rod-specific subunit.207•208 These studies highlight 
the importance okonsidering genetic background, and the type of mutation when selecting 
suitable animal models to mimic the human phenotype. 
5. Mutant animal mode!s for therapeutic studies on IRD 
As outlined above and shown in Supplementary Table 2, the vast majority of vertebrate 
animal models for IRD research at least to a significant part mimics the phenotype present 
in humans. Most models can be found in the mouse, since this species has several practical 
advances in terms of generating, maintaining and analysing the underlying pathologic 
mechanisms. Consequently, over the last years a growing number of pharmacologic and 
gene therapeutic studies have been performed in these mouse models, demonstrating the 
conceptual possibility to treat the mimicked human retinal disorders.209•210 Most often, viral 
vectors were employed as vehicles for the transfer of genes, with AAV- and lentivirus-based 
vectors being the most regularly used ones.211 Zebrafish models have also been used to study 
pharmacologicalinterventions, such as translational read-through approaches, but have so 
far not been used for gene therapeutic applications.212 Gene therapeutic approaches were 
described in one chicken model carrying mutations in GUCY20.213 
However, when translating these results to humans, several key features cannot be 
sufficiently modelled in small animal models and, therefore, large animal models become 
more and more important.214-216 Successful proof-of-principle therapeutic studies have been 
published in several canine models of IRD.214• 217-222 But even in large animal models, certain 
features cannot be comprehensively analysed due to interspecies-related differences. These 
features include the limited similarity of the retinal anatomy among the different species and 
humans (primates), as well as major differences concerning efficacy and cellular tropism 
of viral vectors between species. The published use of animal models for different types of 
experimental therapeutic approaches is summarized in Table 4. In the following paragraphs, 
the different vertebrate animal models will be discussed with regard to the current hot topics 
in retinal gene therapy research, i.e. viral vector tropism and gene transfer approaches with 
regard to the varying retinal anatomy. 
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Table 4. Overview on therapeutic and vector-related studies on IRD in the various animals. 
Model 
Treatment approach/vectorology 
Pharmacologic• Optokinetics Cell therapy Gene therapyb Vectorology< 
Zebrafish X 
Chicken 
Sheep 
Pig 
Cat 
Dog X 
Rat X 
Mouse X X X 
NHP 
a Includes translational read through drugs, retinoids, neuroprotection. 
b Includes gene addition, gene silencing, gene editing. 
X 
X 
X 
X X 
X X 
X X 
X 
c Includes studies on cellular tropism, vector distribution, and host immune responses to AAV-, lentivirus-, 
adenovirus- and nanoparticle-mediated gene transfer. 
5.1. Vector tropism in different species 
For specific as well as non-specific gene therapeutic approaches, subretinal viral vector-
mediated gene transfer is still considered to be the most efficient way to enable transgene 
expression in retinal cells. While AAV-based vectors are considered the gold standard due 
to their varying cellular tropism depending on the serotype, its limited packaging capacity 
represents a major roadblock for the development of therapeutic strategies for IRDs in 
which the disease-causing mutations are often located in genes that have open reading 
frames larger than 4kb. For those genes, lentivirus-based vectors have been generated and 
successfully tested in mouse models for several IRDs, such as Usher syndrome type 18 or 
Stargardt disease.223• 224 In order to evaluate safety aspects, the authors also included data 
on non-human primates (NHP) in these papers. Since an efficient uptake of most vectors is 
dependent on receptor-mediated endocytosis, the tropism of a vector is usually defined by 
the presence or absence of certain cell surface receptors. For AAV, a large number of different 
receptors have been defined that interact with various serotypes.225-229 Knowledge about these 
capsid-surface interactions led to the development of tyrosine-mutated capsid variants with 
better transduction efficiencies.230 Nonetheless, the efficacy of serotypes to transduce a given 
cell type varies among species, which makes it crucial to test all serotypes in the species 
in which a treatment strategy is to be explored. For example, the expression profiles of the 
serotypes currently considered to be most efficient for photoreceptors in mice, AAV2/5, 2/8, 
and 2/9 (either tyrosine-mutated or not), differ among several large animal model species 
such as cat, dog and pig.231-234 
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Thanks to the experiences gained with different viral vectors in the aforementioned 
species, a set of MV vector tools is now present for targeting photoreceptor cells and RPE, and 
researchers are able to choose among more than a dozen different serotypes and isolates. 
With the increasing focus of translating preclinical proof-of-concept studies to the clinic, it 
becomes more and more an issue to identify the most optimal MV serotype for expression of 
transgenes in primate photoreceptors. Following several studies with sometimes contradictory 
results, it seems that MV serotype 9 may be the most efficient vector to target photo receptors 
(both rods and cones) and RPE cells following subretinal injection.235 Targeting exclusively 
RPE cells was shown to be possible using MV serotype 4 in all species tested so far.236 There 
is at present no vector known to exclusively target photoreceptor cells following subretinal 
injection. 
Lentivirus-based vectors are usually pseudotyped with the vesicular stomatitis virus 
glycoprotein {VSVG), which has been shown to target predominantly RPE cells, but also allows 
photoreceptor tra.nsduction in mice and rats.237• 238 Other pseudotyping approaches, such as 
hemagglutinin (HA) or venezuelean equine encephalitis virus (VEEG), did so far not show an 
advantage, regardless of the species tested.238•239 
Since subretinal injections only allow the targeting of a locally defined area of the retinal 
surface, the treatment of the entire retina by this transfer approach is not possible. A second 
way of introducing vectors to the retina represents the intravitreal approach, through which at 
least theoretically the entire retina can be brought into contact with the vector. Unfortunately, 
none of the standard MV serotypes or lentivirus-based vectors is capable of transducing 
a significant number of photoreceptor or RPE cells via this approach. The MV serotype 2 
showed significant transduction of retinal ganglion cells, which does not help for specific gene 
therapy of photoreceptor or RPE cells.240 The reason is seen in the ILM barrier, which hampers 
an efficient invasion of the retina by most MV serotypes.241 Recently however, in vivo directed 
evolution of MV capsids allowed the generation of MV vectors with the capacity to target 
most retinal cell types panretinally in mice and at certain spots in NHP following intravitreal 
injection.242 At least in mice, transgene expression in photoreceptor cells was sufficiently 
high to change the phenotype of severaliRD models (rslh+ and rdl2). However, since there 
is no IRD model in NHP, it is unknown how the efficacy of intravitreal injection concerning 
photoreceptor transduction would be in degenerated retina of humans. A different approach, 
again using capsid-modified variants where tyrosine or phenylalanine residues were mutated, 
likewise yielded MV capsid mutants able to transduce photoreceptors following intravitreal 
injection in mice.243 
Although a panretinal transduction of retinal cells is likely only possible following 
intravitreal injection, this transfer approach may be blocked by the immune system, which 
is more effective in responding to foreign proteins in the vitreous compared to the subretinal 
space. Especially in NHPs, where the immune system is similar to the human one, immune 
reactions against capsid proteins following intravitreal injection were recently observed.244 
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5.2. The impact of anatomical differences on gene transfer 
As discussed in Chapters 1 and 2, primates possess a foveal depression that exclusively 
contains cones with long dendrites (Henle fibers) and the inner retinal layers, they also have 
a comparably large eye and a small lens, which results in a high axial length ratio between 
eye globe and lens (Table 1). These anatomical differences between primates and other 
vertebrates hinder the advancement of preclinical studies and are currently at the height of 
translational research. 
Since there is no foveal depression in any of the animal models for IRD, the subretinal 
injection cannot be studied preclinically in diseased retina and therefore always poses an 
unknown risk factor. While foveal subretinal injections in healthy primates do not result in 
significant destruction, the data from clinical trials on RPE65 gene augmentation therapy 
indicate that a foveal treatment may not be beneficial.245 In contrast, another study related 
to treatment of patients with choroideremia observed no unwanted side effects in treated 
patients.3 
While a panretinal transduction is possible in mice following intravitreal injection of 
MV serotype 2 or the newly generated capsids, the situation in NHP is more complex. Here, 
a relatively strong transduction of the macular ring of ganglion cells surrounding the fovea 
can be observed, which may be due to a different molecular composition of the ILM in this 
zone compared to more peripheral parts of the retina.246 Alternatively, the tyrosine-mutated 
MV serotype 9 vector was shown to transduce the central nervous system following systemic 
administration in mice, and combined with a rhodopsin promoter, transgene expression was 
limited to retinal photoreceptor cells.247 It remains to be seen, whether this observation is 
similar in large animal models. 
6. Concluding remarks 
In this review, we have attempted to provide a comprehensive overview on the use of animal 
models in functional and therapeutic research on IRD, and discuss the lessons learned so 
far by comparing the genetic architecture, and the gross and fine structural and functional 
characteristics of the retina in different species. Obviously, the human retina has clear 
anatomical differences with most animal models considered so far. However, the anatomy is 
notthe only majorfeature important for deciding which model species would be the ideal one 
for a given question. The possibilities to generate transgenic or genetically modified animals 
may sometimes outweigh the differences in ocular and retinal anatomy. Or, the absence of 
a phenotype in a certain species may prevent this model from being used for therapeutic 
research. While the pros and cons of each animal model are summarized in Figure 4, this 
chapter attempts to address a number of questions that need to be answered when deciding 
for the optimal model species for a given research question. 
When studying the phenotype of IRDs, the eye size or the ratio between lens and visual axis 
may not impact the outcome as much as it would be the case when studying therapeutic 
approaches. However, since most animal models for IRDs will be used at some point for 
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therapeutic applications, this question needs to be answered in the beginning. Generally, 
from the mouse onwards, techniques have been developed to reliably perform gene transfer 
to retinal cells. This may not be the case for the zebrafish, and was only once performed in 
chicken. 
Apart from their different gross anatomy ofthe eye, zebrafish and chicken possess a higher 
number of cone photoreceptors, and have double cones and oil droplets (chicken) which 
may interfere with the interpretation of data in cone-related disorders. On the other hand, all 
mammalian models except NHP only have two cone types and thus less than humans, which 
again may complicate analysis of cone-related disorders. In addition, only the large animal 
models cat, dog, sheep, and pig possess an area centra/is corresponding at least in part to the 
cone-only foveal region in humans. Studying cone-rod or pure cone dystrophies will always be 
biased in the remaining model species, since a cone-enriched region does not exist and the 
interaction between rods and cones may complicate analysis of data. 
Several animal models possess a tapetal structure behind the retina that increases photon 
capture by the photoreceptors through the reflection of light. This may increase photopic 
stress to the diseased retina and results in localized differences of neuronal cell death among 
the different photoreceptor cell types, which was at least suggested by a recent study in a dog 
model of RP£65 insufficiency.248 In addition, the presence of this reflecting structure renders 
OCT imaging, which is more and more accepted as a tool for in vivo thickness measurements, 
problematic.249 
A major drawback for IRD research in large animal models is the slow reproduction 
rate and the high costs of housing these animals. While it takes only few weeks to generate 
hundreds of zebrafish or chicken, and few months to have double-digit numbers of mice and 
rats, it takes between 6 months and a year to generate a small number of offspring in cats, 
dogs, sheep or pigs. Hence, research on the phenotype of IRDs, let alone therapeutic research 
in these large animal species is cost-intensive and requires a significant time investment. 
However, the human size of their eye, the similarity of their immune system to the human one, 
and the possibility to work with vector titers close to what will be injected in human patients 
warrants the use of large animals for therapeutic research. 
Special features related to the photoreceptor structure such as calyceal processes can 
be found in species that are considered to be closely related to humans (pig) but also in 
evolutionary distant species like zebrafish. Since this structure has recently gained attention 
in the scientific community due to the localization of certain Usher syndrome proteins, it 
became clear that when working on these disorders, choosing the right models species is 
crucial. Mice do not possess such calyceal processes and a lack of phenotype development in 
mouse models of the disease became understandable. 
As discussed in section 2.3, and shown in Figure 3, certain genes are either duplicated 
or not present at all in the genome of some species, and therefore cannot be studied in 
these species. For instance, EYS, one of the most frequently mutated genes in patients with 
autosomal recessive72• 73 is not present in the rodent genome, which has prevented a better 
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understanding on the mechanisms underlying fYS-associated I RD. A detai led knowledge on 
the absent and duplicated genes in the selected vertebrate species as provided here (Figure 
3, Supplementary Table 1) may potentially avoid the generation of animal models without a 
phenotype, and instead guide scientists to using alternative model species. 
Becausevertebrateanimal models all have limitations in their use to study IRDs, the search 
for alternatives to model ocular disorders is a very active one. The development of a technique 
to induce pluripotency in somatic cells (i.e. to generate induced pluripotent stem cells (iPSCs) 
from adult somatic cells) and differentiate these into any given cell type, and thus to have the 
principal capacity to generate photoreceptor or RPE cells from patients suffering from IRDs 
has gained much attention in recent years.20 These cells contain the exact same mutation 
present in the human patients and therefore, the specific consequences can be studied in the 
affected cell type. Furthermore, gene editing technology allows to correct the mutation and to 
observe the consequences this treatment has on the intracellular pathways. Overall, the use of 
iPSCs to study pathomechanisms of IRD represents an important alternative to in vivo animal 
studies, but limitations are also eminent. While the advantage of this technique is obvious, the 
organ-specific influences and the interaction with other cells, the consequences of altered cell 
function on the surrounding cells and the immune system cannot be extensively studied using 
this approach, and it will therefore not be able to fully replace animal experimentation. 
With the increasing knowledge about the genetic causes of retinal blinding disorders 
in men, the use of vertebrate animal models becomes more and more important, not only 
for studying the pathophysiological mechanisms but also to develop therapeutic strategies. 
While a number of different species have been used for modeling IRDs, it became clear 
that not every species can be used for a given genetic defect. The present review aimed at 
generating a comprehensive overview on the currently used animal models and to identify 
pros and cons for each species. Only when the ideal animal model system for a given question 
is chosen, optimal output can be generated from in vivo experiments, which will serve both 
human health and will prevent unnecessary research on animals, an ethically important goal 
to achieve. 
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Supplementary Table 1. Duplicated IRD-associated genes in the zebrafish genome 
Human gene Zebrafish genes 
ABCA4 abca4a and abca4b 
ACBDS acbdSa and acbdSb 
C12orf65 si:ch211-275j6.5 
CA4 ca4a and ca4b 
CACNAlF cacnalfa and cacnalfb 
CACNA204 cocna2d4a and cacna2d4b 
CAPNS copnSa and capnSb 
CDHRl cdhrla and cdhrlb 
CNGAl cngal 
CNGA3 cnga3a and cnga3b 
CNGBl cngbla and cngblb 
CNGB3 cngb3 
CNNM4 cnnm4a and cnnm4b 
COLllAl colllala and colllalb 
COL2Al col2ala and co/2alb 
COL9Al co/9ala and co/9alb 
CSPPl csppla and cspplb 
CYP4V2 cyp4v8 
DFNB31 dfnb31a and dfnb31b 
EFEMPl efempl 
ELOVL4 elov/4a and e/ov/4b 
FSCN2 fscn2a and fscn2b 
GDF6 gdf6a and gdf6b 
GPR179 gpr179 
GPR98 gpr98 
GRKl grkla and grklb 
GRM6 grm6a and grm6b 
GUCAlA gucala and gucale 
GUCY2D gc3 and gucy2f 
IMPDHl impdhla and impdhlb 
IMPGl impgla and impglb 
ITM28 itm2ba and itm2bb 
JAGl jagla andjaglb 
KCNV2 kcnv2a and kcnv2b 
KIM1549 kiao1549/a and kiool549/b 
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LRIT3 lrit3a and lrit3b 
MY07A myo7aa and myo7ab 
NR2Fl nr2fla and nr2flb 
OPAl opal 
OPNlLW opnllwl and opnllw2 
OPNlMW opnlmwl, opnl mw2, opnlmw3 and opnlmw4 
PAX2 pax2a and pax2b 
PCDH15 pcdhl5a and pcdhlSb 
PCYTlA pcytlaa and pcytlab 
PDZD7 pdzd7a and pdzd7b 
PROMl promla and promlb 
PRPH2 prph2a and prph2b 
RGR rgra and rgrb 
RGS9 rgs9a and rgs9b 
RIMSl rimsla and rimslb 
RLBPl rlbpla and rlbplb 
ROMl romla and romlb 
RPE65 rpe65a and rpe65b 
RPGR rpgra and rpgrb 
RSl rsla and rslb 
SAG saga and sagb 
SEMA4A sema4aa and sema4ab 
SLC7Al4 slc7a14a and slc7a14b 
TEADl teadla and teadlb 
TMEM237 tmem237a and tmem237b 
TOPORS toporsa and toporsb 
TRPMl trpmla and trpmlb 
TULPl tulpla and tulplb 
UNC119 unc119a and unc119b 
USHlG ushlga and ushlgb 
VCAN vcana and vcanb 
WFSl wfsla and wfslb 
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Supplementary Table 2. Overview of vertebrate mutant animal models used in IRD research 
Species Mutated 
gene 
Zebrafish cacnalfa 
(CACNAlf) 
pde6c 
ushl c 
gnat2 
gc3 
(GUCY2D) 
gucy2f 
(GUCY2D) 
myola 
crb2a 
(CRB2) 
Genetic defect Name of the model Origin of Ace ot which first obnormalitiet Cell type Specific characterlstks Humon IRD 
the model I symptoms were noticed primarily associated 
c.626T>A, p.l209' Wait until Dark (WUD) ENU 
c.3403C>T, p.Q113S' 
c.1468-2A>G pde6c·"' ENU 
c.48ST>A, p.L162' ush1""" ENU 
c.154C>T, p.Q52' no optokinetic response ENU 
f(nof) 
zatolchi ENU 
(zat11:5 and zat~76) 
inserted human GCJ, mutation p.E837, RETGC-1 E837D RS:?ES Targeted 
p.R838S mutation 
c.l597A>T, p.K533' Mariner (rnyo7aaty220d ENU 
allele) 
c.l478G>A, p.W493' Orne (aka meduzy m98 ENU 
allele) 
c.2290A>T, p.R764' Ome(oko meduzy m289 ENU 
allele) 
Histological Phenotypical affected 
72 hpf <7dpf 
<7dpf 
<4dpf <S dpf 
<4dpf <S dpf 
<S dpf 
< 6 dpf 
<Sdpf 
6-Sdpf <5 dpf 
<72 hpf <36 hpf 
photoreceptors Lacking synaptic ribbons CSNB, CRD, CD 
photoreceptors 
cones photoreceptor 
degeneration via necrosis 
photoreceptors t.IOlterglial cells in 
and MUller cells supporting harmonin-
mediated ribbon synapse 
stability and function 
cones normal retinal 
photo receptors 
morphology, but 
severely affected 
Phototransduction 
photoreceptors No OKR deficits at s dpf 
photoreceptors Mild photoreceptor 
degeneration 
nearly all retinal loss of apico-basal 
celts polarity in the 
nearly all retinal 
celts 
neuroepithelial 
primordium and later 
severe disorganization of 
neuronal architecture in 
the differentiated eye 
CSNB, CRD, CD 
arCD,ACHM 
arRP, USH1c 
ACHM 
LCA, CRD 
ROD/CRD 
USHlb 
RP, LCA 
RP, LCA 
Model mlmics 
human 
phenotype 
partly 
yes 
Reference 
(Jia, Mute et al. 
2014) 
(Jia, Mute eta\. 
2014) 
(Stearns, 
Evangelista 
et at. 2007; 
Viringipurampeer, 
Shan etal. 2014) 
yes (Phill ips, Blanco-
Sanchez et al. 2011) 
yes (Brockerhoff, Rieke 
et al. 2003) 
not described (Muto, Orger et al. 
2005) 
yes (Callery, Cederlund 
et al. 2013) 
yes (Ernest, Rauch eta I. 
2000; Wasf.j, Matsui 
etal. 2014) 
no (Malicki and Driever 
1999; Omori and 
Malicki 2006) 
not described (Malicki and Driever 
1999; Omori and 
Malicki 2006) 
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rn )> (/) r-
lD 
rho insertion human RHO with p.Q344• Targeted Sdpf rods increased apoptosis of n N RP yes (Nakao, Tsujikawa I 
mutation mutation rod photoreceptors et al. 2012) )> 
-o 
Chicken GCl null allele rd chicken Naturally embryonic day 18 at hatch photoreceptors loss of outer segments LCA, CRD yes (Semple-Rowland, --i m 
(GIJY20) occurring Lee eta I. 1998; ;;o 
N 
Williams, Coleman )> 
eta I. 2006) 
GNB3 c.459_ 461del, p.D153del retinopathy globe Naturally 1 day post hatch 3-Bwk photoreceptors ACHM, LCA, AM D no (Tum mala, Ali et 
enlarged (rge) occurring al. 2006) 
MPDZ c.1372C> T, p.R45s• retinal dysplasia and Naturally embryonic day 18 <10wk RPE (and the The earliest pathologic RP, LCA yes (Beattie, Finnegan 
degeneration (rdd) occurring outer nuclear, signs are holes in eta I. 2012) 
outer plexiform, the retinal pigment 
and inner nuclear epithelial (RPE) layer and 
layers) undulations in the outer 
nuclear, outer plexiform, 
and inner nuclear layers 
in prehatched embryos. 
TYR c.727_732del, p.PV243-244del Albino chick Naturally < 4-5 days post < 13-15 days RPE photophobia DCA yes (Rymer, Choh et al. 
occurring hatch post hatch 2007) 
Sheep Cnga3 c. 706C> T, p. R236• Avo~assi Naturally none 4mo photo receptors diminished function of ACHM yes (Reicher et al. 
occurring cones but not of rods 2010; Shamir et al. 
2010; Ezra-Elia et 
al. 2014) 
Pig Elov/4 Sbp del overexpression domestic pig Targeted 14.5mo 26mo photo receptors photoreceptor loss and STGD3 partly (Sommer et al., 
mutation disorganised inner and 2011) 
outer segment 
Elov/4 Y270terEYFP overexpression domestic pig Targeted 12mo 12 mo photoreceptors photoreceptor loss and STGD3 partly (Sommeretal., 
mutation disorganised inner and 2011) 
outer segment 
Rho p.P23H NIH mini-pig Targeted 18mo 3mo photoreceptors abnormal scotopic RP yes (Ross et al. 2012) 
mutation and photopicfull-field 
electoretinography after 
3 months 
Gucy2d p.E837D/p.R838S overexpression domestic pig Targeted 4.5mo 3mo photoreceptors early functional loss with cone dystrophy partly (Kostic et al. 2013) 
mutation only mild morphological 
alterations 
Rho p.P347L domestic pig Targeted 2wk 4wk photo receptors early and severe rod loss, RP yes (Pettors et al. 1997; 
mutation slower cone degeneration Li et al., 1998) 
1.0 
w 
C.t 
Dog 
Cep290 
Crx 
Rpe65 
Adam9 
Ccdc6 
cngb3 
Cngb3 
Cngbl 
Pde6b 
Pde6b 
Pde6a 
Rd3 
(Clorf36) 
C2orf71 
Stk38lj 
Ndr2 
11.1SS0+9T>G (intron 50) 
c.546del 
c.486_ 489del 
g.del_ex15_16' 
c.521_522insA, p.A174' 
c.784G>A, p.D262N 
Vlhole gene deletion 
c.2387delA;2389_2390insAGCTAC 
c.2420G>A. p.W807' 
c.2449_2456insTGMGTCC, p.K817' 
c.1939delA. p.N616T 
c.418ins22nt 
c.3149_3150insC, p.C1051' 
c.233ins233nt 
Abyssinian and other Naturally 
breeds 
Abyssinian 
occurring 
Naturally 
occurring 
1.5-2 yr 
1wk 
Briard Naturally periphery: 4 mo; 
occurring area centralis:2yr 
Glen of lmaal Terrier Naturally 
occurring 
Shapendoe Naturally 
occurri ng 
German Short-haired Naturally 
Pointer occurring 
Alaskan Malamute, Naturally 
Miniatur Australian occurring 
Shepherd 
Papillons and Phallmes Naturally 
occurring 
Irish Setter Natura lly 
occurring 
Sloughi Naturally 
occurring 
Cardigan Welsh Corgi Naturally 
occurring 
Collie Naturally 
occurring 
Gordon Setter Naturally 
occurring 
Norwegian Elkhound Natura lly 
occurring 
5-1Bwk 
Gyr 
6mo 
6mo 
5 mo 
1mo 
early 
very early 
very early 
late 
ea rly 
8 mo 
7wk 
1mo 
15 mo 
unknown 
8-10wk 
8-lOwk 
10 wk 
3mo 
early 
very early 
6wk 
late 
earl~' 
photoreceptors Gradual progressive 
photoreceptor 
degeneration 
photoreceptors Severe earty-onset retinal 
degeneration 
RPE Early loss of function, late 
morphological alterations 
in superior part 
photo receptors cone rod dystrophy type 3 
photoreceptors 
photoreceptors progressive and specific 
degeneration of cone 
photo receptors 
photoreceptors progressive and specific 
degeneration of cone 
photoreceptors 
photoreceptors 
photoreceptors Very ea rly PR loss with 
rapid rod and cone 
degeneration 
progressive retinal 
degeneration 
Very early PR loss 
with rapid rod cone 
degeneration 
photoreceptors rapid rod degeneration 
photoreceptors 
photoreceptors 
photoreceptors 
and slow cone 
degeneration 
progressive retinal 
degeneration 
photoreceptors early retinal degeneration 
LCA partly 
LCA yes 
LCA partly 
CRD partly 
RP partly 
ACHM yes 
ACHM yes 
RP yes 
RP partly 
RP partly 
RP partly 
RP partly 
RP partly 
RP partly 
(Menotti-Raymond 
eta I. 2007, Hyman 
et al2005) 
(Menotti-Raymond 
et al. 2010, Curtis 
1987, Leon 91) 
(Aguirre et al. 1998; 
Veske et al. 1999) 
(Goldstein et al. 
2010; Kropatsch et 
al. 2010) 
(Dekomlen et al. 
2010) 
(Aguirre et al., 1974 
and 1975; Sldjanin 
et al. 2002) 
(Aguirre etal.,1974 
and 1975; Sidjanin 
et al. 2002; Yeh et 
al. 2013) 
(Winkler eta I. 2013; 
Ahonen et al. 2013) 
(Suberetal.1993; 
Aguirre and Lubin 
1975) 
(Dekomien et al. 
2000) 
(Petersen-Jones et 
al. 1999 and 02, OS) 
(Kukekova et al. 
2009, Santos-
Anderson 1980) 
(Downs et al. 2013) 
(Goldstein et al. 
2010, Acland 1987) 
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l.O Rpgripl g.8228_8229 insA29GGMGCMCAGGATG Miniature Longhaired Naturally within 1yr 2mo photoreceptors early loss of cone function LCA partly (Mellersh et al., n ..j>. :r: 
Dachshund occurring 2006; Turney et al., )> 
2007, Lh eriteau 09) ::!:1 m 
Nphp4 c.480_526+133del, p.K1ss· Standard Wire-haired Naturally 12mo Swk photoreceptors early-onset and CRD partly (Wiik et al. 2008, :;o 
Dachshund occurring progressive cone-rod Ropstad 07) );: 
dystrophy 
Rpgr c. 1028_1032del Siberian Husky and Naturally 1yr 1yr photoreceptors fast retinal degeneration RP partly (Zhang et al. 2002) 
Samoyed (XLPRAl) occurring 
Rpgr c. l084_1085del Mongrel-<lerived Naturally 1mo 2mo photoreceptors early-onset with abnomal RP partly (Zhang et al. 2002; 
(XLPRA2) occurring photoreceptor maturation Beltran et al., 2006) 
followed by progressive 
rod-cone degeneration 
and early inner retina 
remodeling 
Rho c.llC>G, p.T4R English Mastiff Naturally 6-12 mo 1yr photoreceptors progressive adRP partly (Kijas et al., 2002) 
occurring photoreceptors loss 
Prcd c.SG>A, p.C2Y more than 18 breeds Naturally late late photoreceptors Progressive loss of RP yes (Zanger! et al. 2006) 
occurring photoreceptors fol lowing 
maturation 
Slc4a3 c.2601_2602insC, p.E868Rfs•1o4 Golden Retriever Naturally late late photoreceptors progressive retinal RP partly (Downs et al. 2011) 
occurring degeneration 
Slc45o2 4081 bp del causing loss of exon 7 White Doberman Naturally unknown unknown RPE photophobia, OCA partly (Winkler et al. 2014) 
Pinscher occurring hypopigmented adnexal 
structures, blue iridis and 
hypopigmented RPE 
Vmd2 c.73C>T, p.R2s• Great Pyrenees Naturally llwk 7wk RPE multifocal serous retinal BMD partly I Grahn and Cullen 
occurring and retinal pigment 2001, Guziewicz 07) 
epithelial detachments 
Mouse Abca4 del prom+ex1 Abcr-/-; Abca4tm1Ght Targeted 16-20wk 20-52wk RP E Lipofuscin accumulation arSTGD, arCD, yes (Weng et al., 1999) 
(ABCR) deletion arCRD, arRP 
del ex1 Abca4tm1Kpal Targeted RP E arSTGD, arCD, not described (Golczak et al) 
deletion arCRD, arRP 
Abhdl2 del exB-10 Abdh12-/- Targeted PHARC syndrome, no PHARC syndrome; no (Biankman eta I., 
deletion ocular abnormalities arRP 2013) 
Adam9 del aa32-66 Mcd9-/- Targeted 12mo 12mo photoreceptors abnormal gap between arCRD yes (Weskamp et al., 
deletion OS and RPE 2002; Parry et al., 
2009) 
<.0 (Jl 
Aipll 
Ari6/Bbs3 
Bbsl 
Bbs2 
Bestl 
Ciqtnf5 
Ca4 
Cabp4 
Cacnalf 
del ex2-5 
neo insertion in intron 2 
del ex1+2 
del ex6+ 7 
c.ll69T>G, p.M390R 
del exS-14 
p.W39C 
del prom+ex1 
c.489C>G, p.S163R 
c.489C>G, p.S163R 
c.399-16_544+13del 
del ex1+2 
c.913G>T, p.G305' 
c.l39insETn 
c.(86l+?)ins70bp 
c.2234T>C, p.l745T del ex14-17 
Aipl1-/-
Aipll·/-
Aipll-/ -
Bbs3-/-; Arl6tm2Vcs 
Targeted 
deletion 
Targeted 
deletion 
Targeted 
deletion 
Targeted 
deletion 
Bbs1M390R; Bbsltm1Vcs Targeted 
Bbs2-/-; Bbs2tm1Vcs 
BestW93C/W93C 
Vmd2-/-
C1qtnf5Serl63Arg 
CtrpS+/-
mutation 
Targeted 
deletion 
Targeted 
mutation 
Targeted 
deletion 
Targeted 
mutation 
Targeted 
mutation 
Ca4-/- Targeted 
Cabp4-/-
CacnalfG305'/G305' 
nob2 (nob-wave 2) 
Cacnalf-/-
Cacnalft.ex14-17 
deletion 
Targeted 
deletion 
Naturally 
occurring 
Naturally 
occurring 
Targeted 
mutation 
Targeted 
mutation 
lldy 
3mo 
12dy 
2-S.Smo 
6mo 
6-Bwk 
6mo 
normal 
normal 
Smo 
2mo 
6wk 
since birth 
5-6wk 
11 wk 
10wk 
normal, LP 
alteration 
normal 
normal 
12mo 
6wk 
2-3mo 
photoreceptors enhances POE stability adCRD, arlCA 
rods less PDE in rods adCRD, arLCA 
photoreceptors rapid degeneration, adCRD, arlCA 
massive Muller cell gliosis 
photoreceptors infertility, increased body 
mass 
BBS 
rods 
photoreceptors 
RPE 
cones 
rods 
photoreceptors 
rods 
photo receptors 
photoreceptors 
normal axoneme, affect 
ciliary assembly and 
function 
arRP, BBS 
infertility, renal cyst, BBS 
olfaction defect 
Lipofuscin accumulation RP, Best 
retinopathy, BVMD 
RP, Best 
retinopathy, BVMD 
l-ORMD, ad MD 
slow rod-b \'lave recovery, L-OR MD, ad MD 
hyperautofluorescence 
spots 
accumulation,Drusen 
modulate Cav 1.4 
adRP 
LCA, CSNB 
XL-CSNB, AlED-like 
disease, XL-CRD 
CSNB,Retinopathy, 
CD/CRD 
CSNB,Retinopathy, 
CD/CRD 
CSNB,Retinopathy, 
CD/CRD 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
no 
no 
yes 
no 
yes 
yes 
partly 
partly 
yes 
(Ramamurthy et 
al., 2004; Llu et al., 
2004; Makino et al., 
2006) 
(Liu et al., 2004) 
(Dyer et al., 2004\ 
(Zhang et al., 2011) 
(Davis et al., 2007) 
(Nishimura et al., 
2004). 
(Zhang eta I., 2010) 
(Marmorsteln et al., 
2006) 
(Shu et al., 2011) 
(Chavall et al., 
2011) 
(Shah et al., 2005); 
(Ogilvie et al., 2007) 
(Haeseleer et al., 
2004) 
(Lodha et al., 2010) 
(Changetal., 
2006b) 
(Mansergh et al., 
2005) 
(Specht et al., 2009; 
Michalakls et al., 
2014) 
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(/) ,---
<.0 Cacna2d4 c.2367insC, p.A790Rfs'39 C57BL/10 Naturally 6wk 6wk rods early rod degeneration arCRD (Wycisk et al., 2006) n 0'> yes I 
occurring )> 
Cdhrl del exl0-17 prCAD-/-; Cdhrltm!Nat Targeted 1 mo 8-9wk photoreceptors arCRD yes (Rattner et al., ~ m 
deletion 2001) :;J;J 
N 
Cep290 del ex35-39 rd16 Naturally 14dy 18 dy cones JBTS, BBS, MKS, yes (Chang et al., )> 
occurring LCA 2006c) 
del ex36+37 Cep29otml.1Jgg Targeted JBTS, BBS, MKS, yes (Lancasteret al., 
deletion LCA 2011) 
c.2991 + 1655A>G Cep290lca/lca Targeted JBTS, BBS, MKS, no (Garanto et al., 
mutation LCA 2013b) 
Cerkl del exS C-CERKLtm1NPA Targeted normal normal normal arRP, arCRD no (Graf et al., 2008) 
deletion 
del prom, exl+part ofintron 1 Cerkltml.lGeno Targeted ganglion ce ll arRP, arCRD no (Garanto et al., 
deletion 2013a) 
Cfh del400 bp, including ex3 Cfh-/- Targeted 2yr 2yr AMD partly (Pickering et al., 
deletion 2002; Coffey et al., 
2007) 
Chm neor insertion at c.l172 Chm-/- Targeted photoreceptors causing embryonic Choroideremia partly (van den Hurk et 
deletion lethality al., 1997) 
del ex4leads to frameshift mutation Chm3lox Targeted RPE Choroideremia yes (Tolmachova et al., 
deletion 2006) 
Cln3 del ex7,8+ surrounding non-coding DNA Cln36ex7/8 Targeted cones Batten disease yes (Cotman et al., 
(lkb) deletion 2002) 
Clml del UTR, ex!+ 269 bp of intronl Clm1-/- Targeted Mullerglia arRP, ar Usher no (Geller et al., 2009) 
deletion syndrome type 3 
Cnga3 c.492A>G, p.Al64T cpflS Naturally 3wk cones CRD yes (Hawes et al., 2006; 
occurring Pang et al., 2010) 
del ex5-7 Cng3-/- Targeted normal 2mo cones CRD yes (Biel et al., 1999) 
deletion 
Cngbl del prom, ex1+2 Cngb1-X1 Targeted 20 dy rods arRP yes (Z hang et al., 2009) 
deletion 
del ex26 Cngbl-/- Targeted 4mo 17 dy rods arRP yes (Huttl et al. , 2005) 
deletion 
Cngb3 c. 733 _7 49del Cngb3-/- Targeted 30 dy 30dy cones reduces CNGA3 arCHM, arCRD, yes (Ding et al., 2009) 
mutation biosynthesis, CNG arCD 
channel impairment 
Cnnm4 del ex1+2 Cnnm4-/- Targeted normal normal hypomagnesemia arCRD no (Yamazaki et al., 
deletion 2013) 
Crbl c.348ldel, p.Rl161Gfs'48 Crblrd8 Naturally 2wk 3wk Mullerglia retinal spotting in inferior arRP, LCA, PPCRA no (Mehalow et al., 
occurring nasal quadrant 2003; Aleman et al., 
2011) 
c.747T>G, p.C249W CrblC249W Targeted l8mo 18mo Mullerglia late photoreceptor arRP, LCA, PPCRA no (van de Pavert et 
mutation degeneration al., 2007) 
del prom+exl Crb1-/- Targeted 3mo Mullerglia AJs maintenance during arRP, LCA, PPCRA no (van de Pavert et 
deletion light exposure al., 2004) 
Cr" del ex3+4 Crxtm!Clc Targeted 14dy lmo photoreceptors adCRD, RP, LCA yes (Furukawa et al., 
deletion 1999) 
c.830T>A, p. L277' Crxtvrm65 ENU 14dy photoreceptors adCRD, RP, LCA yes (Won etal.,2011) 
Cyp4v3 del exl-exl! Cyp4v3 -/- Targeted 12 rna 6mo RPE crystalline deposits in BCD yes (Lockhart et al., 
--1 
(CYP4V2) deletion corneoretinallayer 2014) I m 
Efempl p.R345W EfemplR34SW Targeted normal 2mo RPE AMD, Doyne yes (Fu et al., 2007) -o 
:::0 
mutation honeycomb retinal )>0 
dystrophy/Malattia zV> 
Leventinese 0~ 
--10 p.R34SW Efemplki Targeted 4mo normal RPE AMD, Doyne yes (Marmorstein et al., In 
mutation honeycomb retinal 2007) mo :::oz 
dystrophy/Malattia ~(/) 
Leventlnese mo c., 
deletion of ex4+5 Efempl-/- Targeted normal normal AMD, Doyne no (Mclaughlin et al., ::::!< n m 
deletion honeycomb retinal 2007) ;:o :::O 
m --1 
dystrophy/Malattla V> m 
mCJJ 
Leventlnese 55~ E/ov/4 near insertion in exon 2 Elovl4-/- Targeted normal 9mo photoreceptors homozygous: STGD, adMD no (Li et al., 20071 nm 
deletion perinatal lethal, I)> Oz heterozygous: enhanced z-
_:;;: 
scotopic+photopic, z)> 
normal structure I ' m :;::: 
c.797 _80ldelAACTT, p.l266Qfs'99 Stgd3-/- Targeted 17-19 rna 7-10mo RPE Lipofuscin accumulation STGD,adMD no (McMahon et al., 22 0 
--1 0 
mutation 2007a; McMahon et m m 
o r 
al., 2007b) :::0(/l 
STGD,adMD (Vasireddy, 2007) m -n c. 797 _801delAACTT, p.L266Qfs'99 E_mut+/- Targeted 2mo RPE no __, o 
- :::0 
mutation z -n 
del ex2 Elovl4+/- Targeted 17-19mo normal RPE homozygous: lethal STGD, ad~ID no (Raz-Prag et al., ~ c 
o Z deletion 2006) - n Vl --1 m -)>0 
V> Z 
<D m)> 
-..J Vl r 
<.D floxed, upstream ex2 and downstream ex3 Elovl4flox/flox Targeted normal STGD, adMD (Barabas et al., n co no :::c 
deletion 2013; Ca meron et )> 
al., 2007) ~ 
m 
Faml6la p.L362' Fam161aGT/GT Targeted 1 mo 1mo rods shortened connecting arRP yes (Karlstetteret al., :::0 
r-0 deletion cillium 2014) )> 
Fscn2 del ex1 Fscn2g/g Targeted 4wk 24wk photoreceptors resemble human RP adRP, adMD yes (Yokokura eta!., 
deletion not MD 2005) 
c.208deiG Fscn2p/ p Targeted 4wk 24wk photoreceptors resemble human RP adRP,adMD yes (Yokokura et al., 
mutation not MD 2005) 
c326G>A; p.R109H Fscn2ahl8 Naturally adRP, adMD not described (Johnson et al., 
occurring 2008) 
Fzd4 gene del, exc 70 bp C terminus of coding Fzd4tm1Nat Targeted progressive cerebellar, FEVR not described (Wang et al., 2001) 
region deletion auditory, esophageal 
dysfunction 
del ex2 Fzd4 20 dy retinal required for retinal FEVR yes (Paes KT, et al, 
vasculature angiogenesis and blood 2011) 
retinal barrier 
Tra{GNATl} c.189_62ldel, p.? Tra-/- Targeted 13wk 8-lOwk rods adCCRD yes (Calvert et al., 2000) 
deletion 
Gnat2 c. 598G>A, p.D200N cpfl3 Naturally 27wk 9mo cones adMD,adRP yes (Chang et al., 
occurring 2006a) 
Gnm6 c619T>C, p.S207P nob3 Naturally normal until at since birth rods lack of scotopic and CSNB!B yes (Dryja et al., 2005; 
occurring least 12 mo photopic b-waves Maddox etal.,2008) 
c.493T>C, p.Sl65P nob4 Naturally rods lack of scotopic and CSNBlB no (Dryja et al., 2005; 
occurring photopic b-waves Pinto et al., 2007) 
GucalA del ex2-4 Gca p-/- Targeted cones ad CD, adCRD yes (Pennesi eta I., 
deletion 2003) 
del ex2-4 ofGucala and ex3-4 of Guca1b Guca1a/Guca1btm1Jnc Targeted rods adCD, adCRD yes Mendez et al., 2001) 
deletion 
del exl Guca1atmllt l Targeted normal up to rods ad CD, adCRD yes (Makino eta!., 
deletion 6mo 2012) 
c.464A>G, p.ElSSG Guca1atm1.1Hunt Targeted Smo 3 mo cones ad CD, adCRD yes (Buch et al., 2011) 
deletion 
GucalB del ex2-4 of Guca1a and ex3-4 of Guca1b Guca1a/Guca1btm1Jnc Targeted rods adCD,adCRD yes Mendez et al., 2001) 
deletion 
del exl Guca1btm1Amd Targeted normal rods ad CD, adCRD no (Makino et al., 
deletion 2008) 
Gucy2E 
(GUCY2D) 
lmpdhl 
ltm2b 
Kia1549 
LeaS 
Lrat 
Lrp5 
Mak 
Mertk 
Mfrp 
Nr2e3 
Nrl 
Nyx 
del exS 
del ex3-13 
del after codon 243 
insertion oftransgene in intronl 
gene trap insertion in intron 3 
del ex1 
del ex1 
lacZ gene insertion to express 
~-galactosidase 
c.4846insC, p.P1573Pfs' 
del exS-8 
c.2237G>A, p.H716R 
del ex18 
c.l74de!G, p.? results in skippingex4 
c.568+2insAAGT 
del ex4-5 
del ex2-3 
c.795_880del 
Gc1-KO 
lmpdh1-/ -
ADanPP7 
f-BRAF 
LcaSgt/gt 
Lrat-/-
Lrp5uex1 
Lrp5tm1Dgen/ 
LrpStmlDgen 
r18 
Mak-KO 
Mertknmf12 
Mertktm1Grl 
rd6 
rd6 
rd7 
Nrl-/ -
nob1 
Targeted 
deletion 
Targeted 
deletion 
Targeted 
deletion 
Targeted 
mutation 
Gene trap 
Targeted 
deletion 
Targeted 
deletion 
Targeted 
deletion 
ENU 
Targeted 
deletion 
ENU 
Targeted 
deletion 
Naturally 
occurri ng 
Naturally 
occurring 
Naturally 
occurring 
Targeted 
deletion 
Naturally 
occurring 
5wk 
12 dy 
6-Swk 
2wk 
14dy 
30 dy 
10dy 
4.5mo 
12.5 dy 
normal 
Swk 
25 dy 
2.5mo 
3mo 
normal 
10 wk 
1 me 
16.5 dy 
5wk 
4-Swk 
cones 
photoreceptors slowly progressive in 
contrast to human 
photoreceptors 
photoreceptors 
arLCA, adCRD 
LCA 
adRD 
arRP 
LCA 
LCA 
yes (Boye et a!., 2010) 
no (Aherne et al., 2004) 
not described (Coomaraswamy et 
al.,2010) 
not described (Kaul eta!., 2013) 
yes (Boldt et al., 2011) 
yes (Batten eta!., 2004) 
retinal vasculature FEVR not described (Holmen et a!., 
2004) 
photoreceptors persistence of hyaloid FEVR yes (Blake JAetal., 
2014) 
retinal vasculature FEVR yes (Xi a eta!., 2008) 
photoreceptors regulate ciliary length arRP yes (Omori et al. , 2010) 
and subcompartmen-
talization 
RPE slow progression arRP no (Maddoxet al., 
201lj 
arRP not described (Lu et al., 1999) 
rods, cones, RPE atrophy of RPE atlater arRP no (Fogerty and 
stage Besharse, 2011) 
photoreceptors arRP no (Kameya eta!., 
2002) 
cones outer nuclear layer waves, arRP, adRP, yes (Akhmedov et al., 
whorls, and rosettes enhanced S-cone 2000), (Halder et 
syndrome a!., 2001) 
rods loss, whorl and rosette adRP ~es (Mears eta!., 2001) 
enhanced S-cones formation 
rods cone ERG XLCSNB1A yes (Gregg eta!., 2003) 
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f-' Ofdl del ex4-5 Ofd1ilexon4-5 Targeted Jobert syndrome, XLRP not described (Zullo et al., 2010) n C) I C) 
mutation Orofaciodigital syndrome, )> 
Simpson-Golabi-Behmel ~ 
m 
syndrome ;:o 
Opnlmw del ex2-5 Opn1mwtm1(0PN1LI") Targeted cones XLCD yes (Smallwood et al., N )> 
Nat mutation 2003) 
Otx2 del transcriptional start sites Otx2tm10Asim/ Targeted pituitary dysfunction adLCA not described Acampora D, et 
Otx2tm10Asim deletion al., 2009 
Pde6a c.2159G>A, p.V685M Pde6anmf282/nmf282 ENU 12 dy photoreceptors Dark-rearing of in arRP yes (Sakamoto et al., 
mutants able to slow 2009) 
the photoreceptor 
degeneration 
c.2115A>G, p.D670G Pde6anmf363/nmf363 ENU 14dy photoreceptors rapid complete arRP yes (Sakamoto et al., 
photoreceptor loss 2009) 
Pde6b Xmv-28 virus ins intronl,c.l041C>A, p.347* rd1 Naturally 15 dy rods arRP, adCSNB yes (Bowes et al, 1993) 
occurring 
c.2335+ 1G>A rd1-1H ENU 15 dy rods arRP, adCSNB yes (Hart et al., 2005) 
c.2395C>T, p.R799' rd1-2H ENU 15 dy rods arRP, adCSNB yes (Hart et al., 2005) 
c.1133G>A, p.W378' rd1-3H ENU 15 dy rods arRP, adCSNB yes (Hart et al., 2005) 
c. 2067T>A, p.Y689' rd1-4H ENU 15 dy rods arRP, adCSNB yes (Hart et al., 2005) 
c.1860T>A, p.H620Q atrd1 ENU 3.5wk >6wk rods atrd 1 has milder arRP, adCSNB yes (Hart et al., 2005) 
phenotype than atrd 2 
c.1534+5G>A, p.? atrd2 ENU 3.5wk 6wk rods arRP, adCSNB yes (Hart et al., 2005) 
c.1817A>G, p.N606S atrd3 ENU 3.5wk 3.5wk rods has a very mild arRP, adCSNB no (Hart et al., 2005) 
phenotype 
c.1976T>C, p.L659P Pde6bnmfl37 ENU 16dy 24dy rods arRP, adCSNB yes (Chang et al., 2007) 
c.1678C> T, p.R560C rd10 Naturally 16dy 18 dy rods arRP, adCSNB yes (Chang et al., 2007) 
occurring 
Pde6c c.864_865insll6, p.E289fs'297 I c.1042deiT, cpfll Naturally 3wk 3wk cones arCRD, arACHM yes (Chang et al., 2009) 
p.L348fs'362 occurring 
Pde6g p.W70A PDE6GW70A/W70A Targeted rods arRP yes (Sal chow et al., 
mutation 1999) 
del ex7 Pdegtml Targeted 10 dy 8wk rods arRP yes (Tsang et al., 1996) 
deletion 
Proml del ex2 Prom-/- Targeted 15 dy 30 dy photo receptors arRP, adSTGD, partly (Dellett et al., 2014) 
deletion ad MD, adCRD 
c.1117C>T, p.R373C PromR373C/R373C Targeted 16 dy 3mo cones arRP, adSTGD, no (Yang et al., 2008) 
mutation ad MD, 3dCRD 
del start codon Prom1tm1(cre/ERT2)Gilb Targeted arRP, adSTGD, not described (Zhu et al., 2009) 
deletion adMD,adCRD 
c.A>T p.K269• rd19 Naturally 3wk 1mo cones arRP, adSTGD, yes (Blake et al., 2014) 
occurring adMD, adCRD 
del ex3-8 Promltm1Rafi, Targeted arRP, adSTGD, not described (Shmelkov et al., 
CD1331acZ, Prom11acZ deletion ad MD, adCRD 2008) 
Prpl3 p.P494M Prpf3P494M Targeted 2yr 2yr rods lethal? adRP no (Grnziotto et al., 
mutation 2011) --j I 
c.(?_-l)_(•l_?)del Prpf3·/ · Targeted normal normal adRP no (Grnziotto et al., m 
deletion 2008) "U ;;o 
Prpl31 del ex7 Prpf31 -/· Targeted normal normal adRP no (Bujakowska et al., )>0 
zUl 
deletion 2009) 0~ 
c.646G>C, p.A216P Prpf31A216P Targeted normal normal adRP no (Buja kowska eta!., --Jo 
In 
mutation 2009) mo 
Prpl8 c.689A>C, p.H2309P Pnpf8H2309P/ H2309P Targeted embryonic lethal adRP not described (Farkas et al., 2014) ;;oz ;;(/) 
mutation m o c, 
Prph2 10kb ins after codon899 Prph2Rd2/Prph2Rd2 Naturally lldy 4mo rods adRP,adMD, yes (Hilgers et al, 1979) ='< 
occurring adCRD, ad central nm ;;oAJ 
areolar choroidal m--1 Ulm 
dystrophy miJJ )>AJ 
c.307del Prph2tm1Nmc/ Targeted Swk 1mo rods adRP,adMD, yes (McNally et al., ;;o~ 
n m Prph2tm1Nmc mutation adCRD, ad centrnl 2002) I)> 
areolar choroidal O z 
z-
dystrophy :s:: 
z )> 
c.554T>C, p.Ll85P L185P rds-/- Targeted 9mo 9mo photoreceptors very mild phenotype adRP,adMD, yes (Kedzierski et al., I 
' m :s:: 
mutation adCRD, ad central 2001) ::<::10 
areolar choroidal --10 m m 
dystrophy o r-;;o (/) 
ins 9.2kb in ex2 rds/ rd2 Naturally adRP, ad MD, no (Ma eta!., 1995) mm 
--JO 
occurring adCRD, ad central - ;;o 
zm 
areolar choroidal f":c 
dystrophy oz 
-n Ul --j 
m-)>0 
I-' (/) z 
C) m)> 
I-' (/) ' 
,_. 
c.514C> T, p.R172W Rl72W-/- Targeted 1mo 1mo photo receptors adRP, ad MD, (Ding et al., 2004) n 0 yes I N 
mutation adCRD, ad central )> 
-u 
areolar choroidal -l 
m 
dystrophy :::0 
Pxmp3 del exS Pex2-/- Targeted normal normal arCCRD, arCSNB no (Faust and Hatten, N )> 
(PEX2) deletion 1997) 
Rbp3 del prom-ex1 lrbp-/- Targeted 11 dy 1mo photoreceptor, arRP yes (Liou et al., 1998) 
deletion RPE 
Rd3 c.319C>T, p.R107' rd3 Naturally 27 dy 24dy photo receptors severity depends on arLCA yes (Chang eta I., 1993; 
occurring the mouse strains: Friedman et al., 
4Bnr>30Rk/J>RBF/DnJ 2006) 
Rdhl2 del ex1-3 Rdh12-/- Targeted 10 mo Bmo photo receptors very mild phenotype arLCA, adRP no (Kurth et al., 2007) 
deletion 
Rdh5 del ex1-3 11-cis-RoDH-/- Targeted normal normal no fundus albipunctatus arFundus no (Driessen et al., 
deletion Albipunctatus, 2000) 
arCRD 
del ex2-3 cRDH-/- Targeted rods mild impaired dark arFundus yes (Shang et al., 2002) 
deletion adaptation Albipunctatus, 
arCRD 
Rgr del ex2 Rgr-/- Targeted normal normal arRP, adChoroidal no (Chen et al., 2000) 
deletion sclerosis 
Rho c.68C>A, p.P23H RhoP23H Targeted 20 dy 11 dy rods arRP, adRP, yes (Olsson et al., 1992) 
mutation adCSNB 
c.59T>G, p.V20G/ c.68C>A, p.P23Ht Rho-/- Targeted 20 dy 30 dy photoreceptors arRP, adRP, yes (Naash et al., 1993) 
c.BOC>T, p.P27L mutation adCSNB 
del ex2 Rho-/- Targeted 24dy 13wk photoreceptors arRP, adRP, yes (Humphries et al., 
deletion adCSNB 1997) 
c.1_333del Rho-/- Targeted 15 dy photoreceptors arRP, adRP, yes (Lem eta I., 1999) 
deletion adCSNB 
p.C322T and p.C323S Palm-/- Targeted 12 mo photoreceptors arRP, adRP, (Wang et al., 2005) 
mutation adCSNB 
c.364G>C, p.E122Q Rho-/- Targeted photoreceptors arRP, adRP, yes (Chisaka and 
mutation adCSNB Capecchi, 1991; 
lmai et al., 2007; 
Onishi et al., 2005) 
c.1039C>T, p.P347S Rho-/- Targeted 4mo 30 dy photo receptors arRP, adRP, yes (Li et al., 1996) 
mutation adCSNB 
Rimsl c.l23IT>G, p.S413A Rimsltm2Sud Targeted adCRD not described (Kaeser et al., 2008) 
mutation 
del exl Rimsltm1Sud Targeted adCRD not described (Schoch et al., 
deletion 2002) 
Rlbpl near insertion in intronl4 Rlbp-/- Targeted normal not mentioned retina of Rlbp1 +/+ arRP, arBothnia no (Saari eta!., 2001) 
deletion had fewer nuclei than dystrophy; ar 
Rlbp1-/- retinitis punctata 
albescens; ar 
Newfoundland CRD 
Roml del exl-2 Rom1tm1Mci Targeted 2mo 9mo rods adRP yes iClarke et al., 2000) 
deletion 
Rpl del e;Q-3 Rpl-/- Targeted 3 mo 2mo photo receptors adRP,arRP yes (Gao et al., 2002) -1 
deletion I rn 
c.1984C>T, p.Q662' Rp1myc Targeted 30dy 4-5wk photoreceptors adRP,arRP yes (Liu et al., 2003) IJ ;;o 
deletion )>0 
Rplll del ex2-4 Rplll-/- Targeted 12mo 6mo rods ~dOMD (Yamashita et al., zUl yes 0~ deletion 2009) 
-Jo 
Rp2 del ex2 Rp2null Targeted 5 mo 1mo rods xlRP yes (Li et al., 2013). In rno 
deletion ~z 
c.130C>T, p.R44' rd12 Targeted 6 wk(jaxlab) 3wk rods (Pangetal., 2005) IJ{f) Rpe65 arLCA, arRP yes rno 
mutation c., 
:::!< 
c.229T>C, p.F77S Rpe65tvrm148/ Targeted lmo 1mo rods arLCA, arRP yes (Won et al, 2011) nrn AJ~ Rpe65tvrm 148 mutation rnrn 
del ex1-3 Rpe65tm1Tmr/ Targeted 28dy rods arLCA, arRP (Fan et al., 2005) (/)OJ yes );;;o 
Rpe65tm1Tmr mutation AJ~ 
del ex4-6 Rpgr-KO Targeted 6.5mo XLRP, arRP, adRP, (Hong eta!., 2000) nrn Rpgr 2mo cones yes :r:)> 
deletion XLCRD,XLMD O z z -
del prom-ex1 Rpgr-/- Targeted 11-13wk ll-13wk photoreceptors XLRP, arRP, adRP, yes (Huang et al., 2012) :;;;:: z )> 
deletion XLCRD,XLMD :r: ,--
m :;;;:: 
32bp dup in ORF15, unidentified pas rd9 Naturally 2mo 6wk photo receptors XLRP, arRP, adRP, yes (Thompson et al., ~0 
occurring XLCRD, XLMD 2012) -10 mm 
del ex4 Rpgrtm1Wbrg/ Targeted 6mo 3mo rods strain B6.129P2 XLRP, arRP, adRP, partly (Brunner eta!., ou; 
AJ , Rpgrtm1Wbrg deletion XLCRD,XLMD 2010) ~ 0 
del ex4 Rpgrtm1Wbrg/ Targeted 9mo 1mo cones strain C.129P2 XLRP, arRP, adRP, partly (Brunner eta!., z:;;o )> Tl 
Rpgrtm1Wbrg deletion XLCRD,XLMD 2010) ,--c 
Rpgripl del ex7 Rpgrip1nmf247 Naturally 7 dy 21dy photoreceptors arLCA, arCRD (Won etal.,2009) oz yes v;C1 
occurring rn -)> 0 
,_. Ul Z 
C) rn)> 
w {f) ,--
I-' ins neo in intronl4 RpgripltmlTili/ Targeted 21 dy 20-30 dy photoreceptors arLCA, arCRD (Zhao et al., 2003) n C) yes I 
-1>- RpgripltmlTili deletion )> 
--u 
Sag p.L374A, p.V375A, p.F376A Sagtm1Jnc Targeted 4wk rods arRP, ar Oguchi yes (Nair KS et al., 2005) -i m 
deletion disease AI 
N 
Sema4a c.1049T>G, p.F350C Sema4aF350C/F350C Targeted 2wk 2wk RPE adRP, adCRD yes (Nojima et al., 2013) )> 
mutation 
Spata7 del ex1-10 Spata7-/- Targeted 15 dy 60 dy rods arRP, arLCA yes (Eblimit eta I., 2014) 
deletion 
Tub c.1605+1G>T rd5 Naturally 21 dy 4mo photoreceptors obesity recessive retinal yes (Change\ al., 2002; 
occurring dystrophy and Coleman and 
obesity (RDOB) Eicher, 1990) 
Tulpl del exB-9 Tulp1-/- Targeted 3wk 4wk photoreceptors arRP, arLCA yes (Hagstrom eta I., 
deletion 1999) 
del exB-9 Tulp1-/- Targeted 2wk 19 dy photoreceptors arRP, arLCA yes (Ikeda et al., 2000) 
deletion 
Uncll9 termination codon ins at codon57 Mrg4/Hrg4-/- Targeted 6mo 14mo photoreceptors adCRD yes (lshiba et al., 2007; 
deletion Kobayashi et al., 
2000) 
Ush2a del ex5 Ush2a-/- Targeted >1 yr 70 dy cones very mild retinal USH, arRP no (Liu et al., 20071 
deletion phenotype with a very 
late age of onset 
Wdrl9 c.2249T>C, p.L750P lft144\\'1 ENU Jeune, yes (Ashe et al., 2012; 
Sensenbrenner, Blewitt et al., 2005) 
NPHP, arRP 
c.1836+2T>C, p.Q592' lft144dmhd ENU Jeune, yes (Liem et al., 2012) 
Sensenbrenner, 
NPHP, arRP 
Rat Mertk A deletion leading to exclusion of exon2, Royal College of Surgeon series of 20 days after photoreceptors phagocytosis defects RP yes (Sidman etal.1965; 
leading to a frameshift rat inbreds birth D'Cruz et al. 2000) 
and albino 
outcross 
Rho Inserted mutant (p.P23H) mouse p.P23H Targeted 15 days old photoreceptors progressive ONL thinning RP yes (Mach ida eta I. 
rhodopsin gene mutation and ROSshortening 2000) 
Rho p.S334' Targeted 8 days old photoreceptors degeneration via RP yes (Liu et al. 1999) 
mutation apoptosis (caspase-3 
activation) 
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Abstract 
Purpose: Dogs segregating progressive retinal atrophy (PRA) are attractive animal models 
to better understand the mechanisms underlying inherited retinal diseases (IRD) in humans. 
In this study, we aim to identify the molecular genetic defects underlying PRA using whole 
exome sequencing (WES). 
Methods: Twenty-six dogs from twelve different breeds were employed in this study. For 
each breed, DNA from at least one dog affected with PRA, together with additional affected 
or unaffected dogs from the same breed were analyzed via exome sequencing analysis. A 
bioinformatics pipeline was built to annotate and interpret genomic variation in canines. 
Identified variants were filtered based on (1) recurrence in WES data from unaffected dogs 
of the same breed, SNP databases and WES data of 250 unrelated dogs; (2) presence in 
the coding region or splice sites of genes; and (3) pathogenicity prediction using in silica 
programs. In addition, we paid particular attention to genes that are known to be mutated in 
humans with I RD. All remaining variants in these IRD genes and protein-truncating or splice 
site variants in other genes were considered candidate variants. Sanger sequencing was 
performed to confirm selected variants and for segregation purposes. 
Results: In the Finnish Lapphund dog, a homozygous missense variant was detected in 
AGBLS (c.2606G>A:p.(Arg869Gln)) that on one hand affects a highly conserved amino acid 
residue and was absent in all other dog breeds, but however was also not present in a 
related affected Finnish Lapphund. The causality of this variant to underlie PRA in this breed 
therefore remains uncertain. In addition, monoallelic protein-truncating variants in EYS 
(c.1566C> T:p.(Arg556*)) and in CNGB3 (c.2106_2017del:p.(Ser706*)) were found in the PRA-
affected Chihuahua and Husky, respectively. Sanger sequencing ofthe entire protein-coding 
region and copy-number variant analysis did not yield a second variant in these dogs. Finally, 
in the PRA-affected Old German shepherd, we identified a homozygous 15-bp deletion in 
PKM that disrupts the splice site of an alternatively spliced exon of this gene. PKM encodes 
different isoforms of pyruvate kinase, an enzyme that is expressed in many tissues including 
retina. 
Conclusions: Here, we describe the discoveries but also the challenges that are associated 
with exome sequencing in dogs. The identification of heterozygous protein-truncating 
variants in EYS and CNGB3 opens avenues to generate homozygous mutant models for 
these genes via selective breeding. In addition, our study revealsAGBL5 as a weak, and PKM 
as a strong candidate gene to underlie PRA in the Finnish Lapphund and the Old German 
Shepherd, respectively. 
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EXOME SEQUENCING IN TWELVE DOG BREEDS SEGREGATING 
PROGRESSIVE RETINAL ATROPHY: DISCOVERIES AND CHALLENGES 
Inherited retinal diseases (IRDs) constitute a group of highly heterogeneous disorders that 
together affect approximately one in 2,000 human individuals worldwide.1 Clinically, different 
subclassesofiRD have been defined based on the ageofonset(varyingfrom congenital to adult), 
the primary involvement of rod or cone photoreceptor cells, the rate of progression and/or some 
specific characteristic features that can be determined based on detailed ocular examinations.2 
Genetically, mutations in over 200 different genes have been associated to IRD, both in non-
syndromic or syndromic forms of IRD.l The implementation of next-generation sequencing 
technologies over the last few years, has significantly contributed to an improvement of the 
molecular diagnostics of IRDs in humans, allowing mutation detection in 65% of all cases.3-8 
For a long time, IRDs have been considered incurable diseases. Over the last decade 
however, enormous progress has been made in this field, for instance with the development 
of gene therapy. Pioneer successes include the treatment of patients with mutations in RPE65, 
via a subretinal injection of a recombinant adena-associated virus (AAV) carrying wild-type 
RPE65 cDNA.'>-11 A similar approach has recently been used in patients with choroideremia12 or in 
patients with retinitis pigmentosa (RP) due to mutations in MERTKPin addition, for several other 
genes, preclin ical studies in mutant animal models are ongoing.2•14•15 For many genes however, 
the development of a treatment is severely hampered by the fact that no suitable mutant animal 
model is available. One attractive animal model is the dog, since the retina of dogs resembles 
that of humans with respect to size, immune privilege and gross anatomy, allowing similar 
surgical approaches to be implemented.15 In addition, many dog strains suffer from inherited 
form of retinal dystrophy called progressive retinal atrophy (PRA) which highly resembles retinitis 
pigmentosa (RP) in humans. This is corroborated by the use of the PRA-affected Swedish Briard 
dog as an excellent model for the development of RPE65 gene replacement therapy in humans.16 
Despite the enormous diagnostic value of whole exome sequencing (WES) in humans, this 
method has not been broadly applied in other species, although the combination of WES and 
linkage analysis in several prior studies has successfully shown its robustness for gene discoveries 
in PRA-affected dogs.17-19 In this study, we performed exome sequencing in PRA-affected dogs 
from twelve different breeds, and describe the construction of an automated pipeline to map 
sequence reads, annotate and interpret genomic variation in dogs. 
Materials and Methods 
Canine sample collection 
Twenty-six PRA-affected or healthy dogs from twelve different breeds (Airedale Terrier, 
Pyrenean Shepherd, Saarloos Wolfhond, Chihuahua, Lowchen, Old German Shepherd, Coton 
de Tulea r, Husky, Rauhaar Teckel, Boxer, Miniature Schnautzer and Finnish Lapphund) were 
included in this study (Supplemental Table 1). Permission to use the DNA for conducting our 
studies was obtained from each of the dog owners and, in addition, for the Finnish samples, 
by the animal ethics committee of County Administrative Board of Southern Finland 
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(ESAVI/6054/04.10.03/2012). Genomic DNA was isolated from peripheral blood cells, either 
by standard salting out procedures and ethanol precipitation as described elsewhere20, or by 
a semi-automated Chemagen extraction robot (PerkinEimer Chemagen Technologie GmbH, 
Baeswieler, Germany) according to the manufacturer's instructions. Ten micrograms of genomic 
DNA were purified using a QiaAmp DNA mini purification kit (Qiagen) according to manufacturer's 
instructions. DNA concentration and quality were assessed with the Qubit® 2.0 fluorometer (Life 
Technologies, Foster City, CA, USA). Thirty nanograms of purified genomic DNA was used for the 
enrichment of exonic sequences and subsequent exome sequencing analysis. 
Clinical characterization ofPRA-affected dogs 
All animals included in this study have been examined by board-certified veterinary 
ophthalmologists. Standard ophthalmological examination of the dogs for the diagnosis of PRA 
included slit-lamp biomicroscopy, indirect ophthalmoscopy and tonometry. For some animals, 
additional studies such as electroretinography (Pyrenean shepherd) or optical coherence 
tomography (Miniature Schnautzer) were performed.lnclusion criterion for all cases was bilateral 
progressive retinal atrophy. A short clinical description of each PRA-affected dog is provided in 
Supplemental Table 2. 
Exome sequencing analysis 
Canine exome sequencing was performed following protocols adapted from human exome 
sequencing.21 In the Airedale Terrier, Pyrenean Shepherd, Saarloos Wolfhond, Lowchen, Boxer, 
Old German Shepherd and Husky, whole exome sequencing (WES) was performed in one affected 
and one unaffected dog from each breed (Supplemental Table 1). In the Rauhaar Teckel, Coton 
de Tulear, Miniature Schnautzer and Finnish Lapphund, WES was performed in two affected dogs 
from each breed. In the Chihuahua, WES was performed in three affected and one unaffected dog. 
In brief, enrichment of exonic sequences was achieved by using the SureSelectxr Canine All Exon 
Kit (Agilent, Santa Clara, CA, USA), that targets 18,857 canine genes. Massive parallel sequencing 
of genomic DNA from each of the 26 canine exome libraries was performed using the SOLiD 
5500xl platform (Life Technologies, Foster City, CA, USA). Color space reads were mapped to the 
canFam3.1 canine reference genome with SOLiD LifeScope software version 2.1, which uses an 
iterative mapping approach. Single-nucleotide variants were subsequently called by the DiBayes 
algorithm using high-stringency calling settings, and small insertions and deletions were detected 
using the SOLiD Smalllndel Tool. 
Annotation and filtering of variants 
To annotate all sequence variants and predict their effect at the DNA, RNA and protein level, an 
automated pipeline was built based on the existing pipeline for the annotation of human exome 
sequencing projects.22•23 Four different gene prediction programs, i.e. Gnomon, N-scan, Ensembl 
and the mapping of human genes to the canine genome, were used to define canine genes and 
transcripts. To prioritize potentially pathogenic variants that could underlie PRA in the various 
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affected dog models, variants were filtered in a systematic way as follows: i) removal of variants 
homozygously (>80%) present in the unaffected samples of the same breed; ii) removal of canine 
SN Ps; iii) removal of variants that are present in more than 1% of our exome cohort; iv) removal 
of variants located outside genes; v) removal of variants located outside exons or splice sites; 
vi) removal of synonymous changes, vii) selection of homozygous or compound heterozygous 
variants assuming an autosomal recessive mode of inheritance, viii) selection of all remaining 
variants residing in genes that are known to be associated with IRD in humans, or homozygous 
protein-truncating variants in other genes. The IRD gene list includes 256 genes which have been 
described to have associations with any fonms of retinal degenerations in human (https:/ /sph.uth. 
edu/retnet/). 
Validation of variants by Sanger sequencing 
To assess the reliability of the exome data, 160 variants resulting from the exome sequencing 
analysis of the first ten samples we analyzed were randomly selected, i.e. 16 variants per sample. 
These variants wer.e grouped based on the number of reads (four groups: 2-4 reads, 5-9 reads, 10-19 
reads and >20 reads), predicted zygosity (heterozygous or homozygous) and the type of mutation 
(insertion/deletion or single nucleotide substitution). Primers flanking the selected targets were 
designed using the online tool Primer3Plus.24 PCR products were purified using modified Exo-
SAP method25 with lOU of Exonuclease I and 0.5 U FastAP thermo sensitive alkaline phosphatase 
(Fermentas) and sequenced in either sense or antisense direction with a dye termination chemistry 
on a 3730 DNA analyzer (Applied Biosystems). Variants that were considered potentially pathogenic 
following variant filtering were validated as described above, and, if appropriate, analyzed in DNA 
samples from additional dogs of the same breed. Primer sequences and PCR conditions are 
available upon request. 
CNV analysis 
The bedtools coverage tools were used to compute coverage depth and calculate mean coverage 
for each target by using bam. file and target-bed. file as input. Thereafter, CNVs were calculated 
based on the combination of ratio scores and z-scores of sample of interest in comparison to the 
control samples that were analyzed using the same platform and exome enrichment kit. 
Prediction of pathogenicity missense variants 
To assess the potential pathogenicity of missense variants, PhyloP and Grantham scores 
were assessed, which reflect the evolutionary conservation of the mutated nucleotide, and 
the physicochemical properties difference of the wild-type and mutant amino acid residue, 
respectively. In addition, bioinformatic software programs SIFT26 and PolyPhen-227 were used to 
predict the pathogenic effect of the amino acid substitutions. 
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Results 
Variant annotation 
In this study, we analyzed DNA of PRA-affected dogs from 12 different breeds, and unaffected 
samples from the same breed using exome sequencing analysis (Supplemental Table 1). All 
affected animals suffered from generalized PRA with classical signs of retinal degeneration 
in form of hyperreflective retina and attenuated vessels. A large localized chorioretinal 
dystrophy was observed in the Saarloos Wolfhond. Some animals also had a secondary 
cataract (Supplemental Table 2). Age at first clinical diagnosis ranged from 2 to 10 years. WES 
analysis of 26 canine samples on average yielded almost 114 million sequence reads per 
sample. Of these, more than 86% could be mapped in or near regions that were targeted by 
the Canine All Exon kit (data not shown). Reads that did not map to the target regions almost 
exclusively represented regions that were not unique in the canine genome. After mapping 
the sequence reads to the canFam3.1 reference genome28, single-nucleotide variants and 
small insertions and deletions were called by the DiBayes algorithm and the SOLiD Small 
lndel Tool, respectively. In each canine sample, approximately 61,000 variants were detected, 
the majority of which were single nucleotide substitutions (Supplemental Table 3). More than 
43,000 of the called variants resided in genes that were present in the gene prediction pipeline. 
Of further interest is the high amount of variants that were predicted to be homozygous, i.e. 
41.8% of all variants, demonstrating the high degree of inbreeding in these dogs. 
To determine the reliability of the produced sequence reads, and the subsequent 
mapping and variant calling, 160 variants present in the first ten samples that were analyzed 
were randomly selected to be validated with Sanger sequencing analysis. For each sample, 
16 variants were chosen, equally divided in groups with respect to predicted zygosity 
(>80% variant reads were considered homozygous, between 20 and 80% of variant reads 
heterozygous), read number and type of mutation (nucleotide substitutions or indels). Upon 
Sanger sequencing analysis, 92.5% (148/160) of all variants were confirmed (Supplemental 
Table 4). There appeared to be no significant correlation between the variants that were not 
confirmed, and the type of mutation, the numberofreadsorthe predicted zygosity. For several 
variants, the predicted zygosity did not match the observed zygosity, i.e. variants that based 
on the exome sequencing analysis were thought to be homozygously present appeared to be 
heterozygous upon Sanger sequencing analysis, or vice versa (Supplemental Table 4). Taken 
together, although the mapping of especially indels requires further improvement, the overall 
high percentage of variants that were confirmed with Sanger sequencing demonstrates a 
high quality of our exome sequencing and variant calling pipeline. 
A systematic filtering analysis was implemented to prioritize candidate variants that 
could underlie PRA in each of the affected dogs. First, variants were filtered based on their 
occurrence in other dogs, and included i) the removal of variants that were homozygously 
present in unaffected dogs from the same breed when available, ii) removal of known SNPs, 
and iii) removal of variants with an allele frequencyof>1% in a large cohort of dogs without 
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any ophthalmological problems. With this, the number of variants greatly reduced to an 
average of 1966 variants in each dog (Figure 1, Table 1). Subsequent filtering included the 
selection of variants located within exons or canonical splice site sequences of (predicted) 
genes, and excluding synonymous changes, further reducing the number of candidate 
variants drastically. 
All genes 
62127 
49748 
37294 
1966 
1418 
385 
227 
29 
Total variants 
Remove homozygous variants 
of non affected same breed 
Remove SNPs 
RD genes 
·.·.· 1317 
1114 
746 
39 
39 
9 
5 
0 ·2 
Figure 1. Average number of variants in all genes and in IRD-associated genes in each filtering step. 
This scheme depicts the variant prioritization strategies with the corresponding number of variants that 
on average were remaining after each step of filtering. WES identified approximately 62,127 variants in 
each dog sample, of which -1,317 variants occur in the IRD-associated genes. Initial filtering based on 
the occurrence of variants in other dogs was performed by exclusion of 1) variants that homozygously 
occur in unaffected dogs from the same breed, when available, 2) known SNPs, and 3) the inclusion of 
rare variants, which is defined as variant with an allele frequency of> 1% in a large cohort of unrelated 
dogs without any ophthalmological problems. This step greatly reduced the number of variants to an 
average of 1,966 variants. Thereafter, only non-synonymous changes located within exons or canonical 
splice site of genes were included. Eventually, assuming an autosomal recessive inheritance, we 
selected biallelic variants (either homozygous or compound heterozygous variants) for further analysis. 
This filtering strategy led to an average of29 biallelicvariants in all genes, of which only a few dogs carry 
biallelic variants in the human IRD-associated genes. 
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f-' Table 1. Exome sequencing variant statistics and filtering steps n f-' I 
-!>- )> 
Canl (Airedale Can3 CanS Can7 CanS Canll Can13 Can17 ~ {Pyrenean (Saarloos {Old German CanlS {Husky) (Rauhaar m Terrier) (Chihuahua) (Lowchen) (Boxer) ;:o Shepherd) Wolfhond) Shepherd) Teckel) N OJ 
All IRD All IRD All IRD All IRD All IRD All IRD All IRD All IRD All IRD 
Total# variants 554 76 1230 59449 1237 61681 1258 59745 1189 57974 1117 65897 1306 45513 1126 68368 1480 62667 1370 
Variants not 
homozygous in 34974 733 38626 754 34237 669 45605 918 37642 680 49600 963 35900 867 48821 1025 62667 1370 unaffected dog 
of same breed 
Variants after 
removal of 26334 547 29066 532 27365 495 34288 637 28309 466 36747 660 24749 607 37989 782 43098 862 
SNPs 
Rare variants* 1850 41 1912 42 4271 102 2777 39 1894 28 1506 34 956 19 3157 61 1609 36 
Variants in 1338 41 1459 genes 42 2957 102 2026 39 1403 28 1103 34 688 19 2357 61 1159 36 
Variants in 
exonsand 374 11 412 10 929 16 619 12 438 16 308 5 178 4 707 9 322 7 canonical 
splice sites 
Non-
synonymous 243 8 249 10 412 3 342 10 266 6 176 5 115 2 360 5 172 4 
variants 
Genes with 
homozygous 20 2 10 48 2 33(0) 0 11 1 10 0 3 0 42 0 14(0) 0 
variants 
Genes with 
compound 9 0 8 0 37 0 9(0) 0 7 0 10 0 3 0 26 0 8(0) 0 heterozygous 
variants 
*Variants that occur in less than or equal to 1% of samples, both in the Finnish dog cohort and the cohort of dogs in this study. IRD: inherited retinal disease genes. In case 
two affected dogs from the same breed were analyzed, the number of shared variants is indicated in between parentheses in the two lower rows. 
Can18 Can19 Can20 Can21 Can22 Can23 Can24 Can25 Can26 (Rauhaar (Coton de (Coton de (Chihuahua) (Chihuahua) (Miniature (Miniature (Finnish (Finnish Teckel) Tulear) Tulear) Schnautzer) Schnautzer) lapphund) lapphund) 
All IRD All IRD All IRD All IRD All IRD All IRD All IRD All IRD All IRD 
Total# 62758 1338 68725 1446 64196 1401 65691 1483 65434 1431 62300 1309 61886 1276 63218 1332 67308 1384 
variants 
Variants not 
homozygous on 62758 1338 68725 1446 64196 1401 51524 1483 51074 1104 62300 1309 61886 1276 63218 1332 67308 1384 
unaffected dog 
of same breed 
Variants after 
removal of 43327 846 47562 946 43781 895 37284 993 37064 748 42265 822 41936 816 43556 878 46569 898 
SNPs 
-o 
Rare variants* 1691 35 1932 17 1692 30 1826 37 2025 41 1368 22 1354 23 1602 56 1968 35 :::0 0 
Variants in G'lm 1245 35 1384 17 1238 30 1301 37 1449 41 921 22 933 23 1146 56 1416 35 :::Ox mo genes ~:;;:: 
Variants in <:m 
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canonical mD ~c 
splice sites - m Z z 
Non- f!::n 
synonymous 194 4 225 2 222 6 211 3 222 4 151 3 136 2 183 11 214 4 ~z :::0~ 
variants o z 
Genes with -o~ ~~ 
homozygous 9(0) 0 16(0) 0 14(0) 0 26(0) 0 18(0) 0 19(4) 0 21(4) 0 8(0) 1 15(0) 0 . . m S2< variants Vl m 
Genes with 8o 
<0 
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Finally, biallelic variants (either homozygous or compound heterozygous variants) were 
selected, since an autosomal recessive mode of inheritance was assumed in all dogs. 
Together, this filtering led to an average of 29 biallelic variants in all genes, whereas if we 
would only focus on genes that are known to be mutated in IRD in humans, only in a few 
canine samples such bi-allelic variants were observed. 
Variants in genes associated with IRD in humans 
For further analysis, we initially focused our attention on those genes that are associated 
with IRD in humans, as these are obviously good candidates. In six different breeds, rare 
homozygous and/or compound heterozygous missense variants in these genes were 
identified (Supplemental Table 5), variants that were all confirmed by Sanger sequencing, 
although a presumed homozygous ALMSl variant in the Pyrenean shepherd turned out to 
be heterozygous upon Sanger validation. When access to larger cohorts of affected and 
unaffected samples from these breeds was available, the occurrence of the corresponding 
variants was assessed in these samples. This led to the exclusion of PANK2 andABCA4variants 
in theSaarloosWolfhond, and of a VCANvariantin the Lowchento underlie PRAin these breeds 
(Supplemental Table 5). A homozygous CERKL variant in the Airedale Terrier was excluded 
since the mutant serine residue appears to be the wild-type amino acid at the orthologous 
position in the human CERKL protein, and in addition, prediction programs deemed the 
amino acid change benign. Also, this variant occurred heterozygously in four other dogs that 
were analyzed with exome sequencing, suggesting a polymorphic nature of this change. In 
the same dog, a homozygous change in CRBl was detected (c.4198A>G), predicted to lead to 
a substitution of a threonine residue for an alanine residue (p.(Alal400Thr)). This variant was 
absent in the large exome cohort of other dogs, but also in an additional affected Airedale 
terrier. In addition, both SIFT and PolyPhen-2 predicted this alteration to be benign. Finally, at 
the orthologous position in the squirrel and hedgehog CRBl protein, also a threonine residue 
is present. Taken together, this CRBl variant is therefore also considered benign. In the Coton 
de Tulear (canl9), we identified compound heterozygous variants in CRBl, but both changes 
had a low PhyloP and Grantham score, and were deemed benign by SIFT and PolyPhen-2. In 
addition, both variants were absent in the other affected Coton de Tulear (can20) that was 
analyzed with exome sequencing, and thus also deemed benign. With that, only one variant 
was remaining as a candidate, namely a homozygous AGBLS change (c.2606G>A) in the 
affected Finnish Lapphund (can25) that is predicted to lead to a substitution of a glutamine 
residue for an arginine residue. Although this variant was not detected in the second Finnish 
Lapphund (can26) that was analyzed, the high degree of conservation, the pathogenicity 
predictions, and the fact that the variant was absent in all other dogs except heterozygously 
in two other unaffected Finnish Lapphunds still render this change an interesting candidate 
variant to underlie PRA in this breed. 
Besides looking at homozygous and compound heterozygous variants in the genes 
associated with IRD in humans, we also scrutinized our data for clear-cut heterozygous 
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protein-truncating mutations that, in conjunction with an unidentified second allele (e.g. 
copy number variants, or variants in regions not covered in the exome sequencing analysis) 
could explain PRA in the corresponding breeds. This analysis led to the discovery of two 
mutations, in the affected Chihuahua (can7) and the affected Husky (canlS), respectively. In 
the Chihuahua, a heterozygous c.l666C> T:p.(Arg556*) nonsense mutation was identified in 
fYSthat at the protein level is predicted to result in premature termination causing the loss of 
several important functional domains of EYS (Figure 2A). To assess the possibility of a missed 
second allele, we performed copy number analysis by comparing the read counts of the PRA-
affected Chihuahua to the other dogs from our exome data analysis. However, no differences 
that would point towards a heterozygous deletion or duplication were detected. Similarly, 
Sanger sequencing of all coding exons and exon-intron boundaries of the canine EYS gene 
did not reveal any additional variants. In the affected Husky, a heterozygous frameshift 
mutation in CNGB3 was detected (c.2106_2107del:p.(Ser706*)) that is also predicted to result 
in premature termination of the protein, although without the loss of important functional 
domains (Figure 2B). No second CNGB3 allele was detected upon copy number variant 
analysis and Sanger sequencing analysis of all coding exons and intron-exon boundaries. 
Although these results do not support a causal relationship between these variants and PRA 
in the affected dogs that were tested, they still could prove very valuable as it allows selective 
breeding to generate homozygous mutant models. The latter would be of particular interest 
for EYS, since despite its discovery to be one of the most frequently mutated autosomal 
recessive RP genes almost a decade ago29• 30, no mammalian animal model with EYS 
mutations exists. 
Variants in genes not associated with IRD in humans 
Next, we assessed whether genes that were previously not associated with IRD could 
underlie PRA in any ofthe dog breeds studied . As shown in Figure 1 and Table 1, on average 
29 bi-allelic variants that survived the initial filtering criteria were remaining in each breed. 
Given the difficulties to prove causality for missense variants, we only focused on those 
variants that are predicted to result in premature termination of the encoded proteins or 
would disrupt the splice acceptor or donor sites. This led to the selection of 32 variants, 
evenly distributed amongst all affected dogs that were analyzed. The majority of variants 
(31 out of 32) could be excluded because they were either homozygously present in 
unaffected dogs from the same or other breeds, did not map to true genes, or were found 
to be heterozygous instead of homozygous upon manual inspection of the BAM-file and/or 
Sanger sequencing validation. The only candidate variant remaining was a homozygous 15-
bp deletion in PKM (c.34_34+ 14del) that was detected in the affected Old German Shepherd 
(canl2). This deletion affects the last nucleotide of exon 2 and the first 14 nucleotides of 
intron 2, and is predicted to either result in a frameshift (p.(Giy12Thrfs*22)) or to disrupt PKM 
pre-mRNA splicing (Figure 3) . PKM encodes the metabolic enzyme pyruvate kinase that is 
involved in the glycolytic pathway, by mediating the transfer of a phosphoryl group from 
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A. EYS variant in the affected Chihuahua 
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Figure 2. Heterozygous truncating variants in the known IRD-associated genes. Monoallelic protein-
truncating variants in EYS (c.1566C>T:p.(Arg556*)) and CNGB3 (c.2106_2017del:p.(Ser706*)) were 
identified in the affected Chihuahua and Husky dogs, respectively. A: The heterozygousfYS c.1666C>T:p. 
(Arg556*) variant is predicted to either result in premature termination codon of which abolishes the 
majority of functional domains of Eys (14 EGF, 7 EGF-like, 5 LamininG and 1 cbEGF domains) or may be 
subjected to nonsense-mediated decay. B: The CNGB3 c.2106_2107del:p(Ser706*) variant likely results 
in premature termination, yielding a protein that is 76 amino acids protein shorter compared to the 
wild type protein. However, important functional domains are predicted to be retained. 
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Figure 3. Homozygous frameshift PKM variant in the affected Old German Shepherd . A: Pedigree of 
the Old German Shepherd dogs. Squares represent male and circles represent female dogs. Filled 
and crossed out symbols indicate affected and deceased dogs, respectively. This pedigree suggests 
an autosomal recessive mode of inheritance. B: The upper panel displays the homozygous 15 bp 
deletion that spans the last nucleotide of exon 2 and the downstream 14 nucleotides of intron 2 of 
PKM. Th is change is predicted to result in a frameshift (p.(Glyl2Thrfs*22)) or disrupt ion of pre-mRNA 
splicing. The lower panel depicts different PKM isoforms in dog and human: 1) The first two bars are 
predicted PKMtranscripts in canine; 2) The third bar is derived from the spliced expressed-sequence tag 
(EST) subtracted from dog retinal tissue; 3) ln grey are all six protein-coding PKM transcripts in human, 
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which can be divided into two main isoforms, Ml which contains exon lOa and lacks exon lOb, and 
vice versa for isoform M2; 4) The two lower bars represent domains that are encoded by isoform Ml 
and M2. C: Fundus picture of the PRA-affected Old German Shepherd dog (canll) displaying retinal 
degeneration with tapetal hyperreflectivity and generalized vascular attenuation. The non-tapetal 
fundus is discolored and hyperpigmented with striae and patches. Large choroidal vessels are visible 
in the non-tapetal fundus. 
phosphoenolpyruvate to ADP, yielding ATP and pyruvate.31 In humans, PKM is alternatively 
spliced, giving rise to two major isoforms, Ml and M2, that slightly differ in the composition 
of their kinase domain, depending on the inclusion of either exon lOa or lOb (Figure 38). 
At the 5'-end of the gene, PKM also undergoes alternative splicing, giving rise to a total of 
seven different isoforms that differ in transcriptional and translational start sites, and thus 
in composition of the final protein product (Figure 38). The exon that is affected by the 15-
bp deletion in the canine PKM gene corresponds to an exon that is present in only two of 
the seven PKM isoforms in humans. Given the ubiquitous expression of PKM and the fact 
the Old German Shepherd did not display any extra-ocular abnormalities, we hypothesized 
that the isoform containing exon 2 is predominantly or exclusively expressed in the retina. 
This hypothesis was supported by the identification of a canine EST (DT538122) that was 
isolated from canine retinal tissue. Recently, Casson et al. demonstrated that in particular 
PKM isoform M2 is abundantly expressed in the rodent retina, providing additional evidence 
for an important function of this molecule within the retina.32 Taken together, we therefore 
propose PKM as an excellent candidate to underlie PRA in the Old German Shepherd. 
Discussion 
In dogs, more than 450 genetic disorders have been identified, the majority of which are 
counterparts for human diseases.36 For several of these diseases, the respective dog models 
have shown to be very valuable for disease modelling and/or to develop new treatments, 
including narcolepsy37• 38 and Duchenne muscular dystrophy.39 For inherited retinal 
dystrophies in particular, dogs are a widely used model, for two important reasons. First 
of all, the anatomy of the dog's eye is comparable to that of humans and also the onset 
of progression of PRA highly resembles human RP. Second, RP and allied inherited retinal 
dystrophies in humans display a tremendous amount of genetic heterogeneity. A similar 
degree of genetic heterogeneity is expected in dogs, since mutations in 22 different genes 
are known to date to underlie PRA in over 52 different breeds.15•40' 44 The vast majority of these 
genes is also mutated in humans with retinal dystrophy, demonstrating the genetic overlap 
between human RP and canine PRA. Following the identification ofthe causative mutation 
in canine models of PRA, these animals have shown to be instrumental for the pre-clinical 
development of new therapies. For seven different genes (BESTl, CNGB3, PDE6A, PDE6B, 
RPE65, RPGR and RPGR!Pl), AAV-mediated delivery of wild-type eDNA of the corresponding 
genes to either photoreceptor or retinal pigment epithelium cells has shown a phenotypic 
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rescue in the respective dog models4s-50, and most likely will serve as the basis for initiating 
clinical trials. Moreover, currently ongoing clinical trials assessing gene augmentation therapy 
in LCA/juvenile RP patients with mutations in RPE65 most likely would not have reached the 
clinic so fast without the rescue of retinal degeneration in the Swedish Briard dog model with 
a mutation in RPE65. 16 Together, these examples illustrate the enormous value of mutant dog 
models for therapeutic studies, and the importance of identifying genetic defects as such. 
In the current study, exome sequencing in dogs followed by an automatic annotation 
of variants yielded a total number of sequence variants that was comparable to that found 
in human exome sequencing studies, with a reasonable coverage of all target regions, albeit 
somewhat lower than that detected in human studies. An extensive quality assessment of 
exome data in a set of 160 randomly selected variants has also proven the accuracy and 
high reliability of this method, since the vast majority of variants (>91%) was confirmed using 
Sanger sequencing, including those with a low number of sequence reads (2-4 reads). Despite 
its tremendous potential, there are two main challenges hampering a rapid identification of 
the underlying genetic defects. First, the poor annotation of the canine genome is still one of 
the main hurdles in the mapping of identified genetic variants. By utilizing several available 
gene prediction software tools, we have been able to increase the number of mapped genes 
to more than 19,000 canine genes. Nevertheless, the imperfect annotation of the canine 
genome most likely results in a lack of information on some of the identified variants, plus 
the fact that not all exons of all genes are represented in the enrichment kit and therefore 
not sequenced at all. Both these items contribute to the fact that some genetic variation that 
could underlie PRA in any of these models is not detected by our current approach. 
A second major hurdle is the lack of large-scale publically available data on natural 
genetic variation in dogs. Whereas the human and canine genome display a high degree of 
similarity in terms of architecture and sequence identity 28•51.52, the number of reported single 
nucleotide polymorph isms in dogs represents only a small fraction (4.9%) of those reported 
in humans. A typical exome sequencing experiment in humans yields a comparable number 
of variants compared to those reported here. Nevertheless, variant filtering in humans is 
eased by the availability of publically available datasets such as the ExomeVariantServer 
(http://evs.gs.washington.edu/EVS/), the 1000 Genomes Project (http:/ /www.1000genomes. 
org/) or dbSNP, and easily narrows down the number of potentially pathogenic variants 
underlying recessively inherited monogenic disorders to a handful of candidates. Therefore, 
in addition to the sequencing data of the 26 canine samples described here, we incorporated 
allele frequency data of 250 unrelated dogs without any ophthalmological conditions from 
either WES or WGS data. 
In this study, we performed a stringent filtering assuming that the same variant would 
not underlie PRA in multiple breeds. Whereas most dog breeds studied here are genetically 
not closely related, there have been reports on a single mutation being causative in different 
breeds. The most common example is a mutation in Prcd (p.(Cys2Tyr)) that causes PRA in no 
less than 22 different dog breeds. 53-57 Other examples include a C2orf71 mutation in the Irish 
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and Gordon Setter breeds58, or a recently identified mutation in FAM161A in Tibetan Spaniels 
and Terriers44, although in these particular cases, the two breeds are closely related and 
share a common ancestor. In contrast, mutations in different genes could also each account 
for a proportion of PRA cases in the same breed, as exemplified by mutations in PDE6B 
and C2orf71 that are each found to segregate in a subset of Irish Setter dogs. 58· 59 Ideally, 
one would like to combine exome sequencing with positional cloning information from a 
well-characterized pedigree in order to increase the chances of genetic homogeneity within 
the study, and to narrow down the genomic region to be scrutinized for causative variants. 
Despite all the challenges in mapping and variant annotation, this study has demonstrated 
its potential for identifying genetic variation in dogs that could potentially underlie PRA, both 
in IRD-associated genes and novel candidate genes. 
In one of the PRA-affected Finnish Lapphund dogs, we identified a homozygous 
c.2606G>A:p.(Arg869Gln) variant in theAGBLS gene. This variant occurs in a highly conserved 
nucleotide with a PhyloP score of 2.835 and is predicted to be deleterious by both SIFT 
and PolyPhen-2. Several recent studies have established the association of AGBLS, a gene 
encoding a-tubulin deglutamylase, with autosomal recessive RP.6().63 Together with TTLL564, 
this gene regulates the strict balance between poly- and de-glutamylation to maintain 
retinal homeostasis. Likewise, the glutamylation process can be a crucial pathway in the 
dog retina and any imbalance may lead to PRA. However, since this variant was absent in a 
second affected Finnish Lapphund that was also analyzed in our exome sequencing study 
and is related to the dog with the AGBLS mutations, it is not yet possible to draw any firm 
conclusions about the causality of this variant in this dog breed. 
Another intriguing finding of our study is the identification of heterozygous protein-
truncating variants, affecting EYS in the PRA-affected Chihuahua and CNGB3 in the Husky. 
Both variants were unique in our cohort, and were only detected in the corresponding 
affected dog. In the Chihuahua, the EYS c.1666C> T:p.(Arg556*) variant is predicted to lead 
to the absence of 2,587 amino acids that comprise all five LamininG domains and fourteen 
EGF, seven EGF-like and one calcium-binding EGF domains. As the result of the absence of 
these important domains, the truncated protein will most likely have no residual function. 
Alternatively, the mutant EYS mRNA may be degraded by nonsense mediated decay. The 
c.2106_2107del :p.(Ser706*) variant in the Husky occurs in the last exon of CNGB3 and thus 
may escape NMD. The resulting truncated protein would lack the 103 most (-terminal amino 
acids of the CNGB3 protein. Both in the Chihuahua and the Husky, Sanger sequencing of the 
entire coding region and CNV analysis of EYS and CNGB3, respectively, did not reveal any 
additional variants in the second allele. The possible explanations forth is are that the second 
variant is located in the non-coding region, or is constituted of a complex rearrangement that 
could not be detected by WES.In these cases, whole genome sequencing (WGS) or targeted-
intronic sequencing of these genes followed by RNA analysis may enable the identification 
of variant in the 2nd allele. Alternatively however, the identification of the protein-truncating 
variants are just coincidental findings. Yet, the identification of such heterozygous null alleles 
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as discovered in this study does point to an unexpected advantage of analyzing any dog 
using exome sequencing, as it offers the possibility to perform selective breeding to generate 
homozygous mutant animal models. For CNGB3, three mutant animal models have already 
been described, i.e. the CngbJ-1· mice,65 the German short-haired pointer dogs that carry 
a missense mutation c.784G>A:p(Asp262Asn), and the Alaskan malamute and Miniature 
Australian Shepherd that carry a deletion encompassing all exons of CNGB3. 66 On the other 
hand, the generation of a mammalian model with mutations in EYS has not yet succeeded, 
although recently, a mutant zebrafish model has been described.67 The absence of an Eys 
orthologue in the rodent genomes has been the major drawback of developing a vertebrate 
mutant animal model for this gene.15 Therefore, the incidental finding of the heterozygous 
p.(Arg556*) variant in the Chihuahua dog will enable selective breeding to generate a large 
vertebrate animal model to study fYS-associated IRD.68-7° Consequently, this model could 
contribute to thedevelopmentoftherapyfor mutations in a gene that is associated with 5-16% 
of all autosomal recessive cases in Europe, and the most prevalent form of IRD in Japan.71•72 
In humans, it is estimated that one in five 'healthy' individuals carries a heterozygous IRD-
associated variant.73 Assuming a similar mutational load in dogs, exome sequencing may 
reveal heterozygous loss-of-function variants that in homozygous state could lead to PRA in 
a significant percentage of dogs. 
The most exciting discovery of this study was the identification of a homozygous 15-
bp deletion (c.34_34+ 14del) in PKM in the affected Old German Shepherd. This deletion 
removes the last nucleotide of exon 2 and the first 14 nucleotides of intron 2, and affects 
some but not all PKM isoforms. As demonstrated in Figure 3, in humans, there are at least 
seven isoforms described that have different N-terminal parts, and differ in the content of 
their kinase domain. lsoforms in which exon lOa is present are generally coined Ml isoforms 
whereas those that harbour exon lOb are called M2. Pyruvate kinase Ml isoforms are 
predominantly expressed in the muscle and brain tissues, whereas M2 isoforms are mainly 
found in proliferative cells, including the retina.74• 75 A recent study detected pyruvate kinase 
M2 in the rod and cone photoreceptors and revealed higher expression in the rodent retina 
in comparison to brain tissue. It is hypothesized that dimeric and/or tetrameric PKM2 in the 
mammalian photo receptors may play a crucial role in the high energy production needed for 
opsin synthesis.32 The homozygous deletion that was identified in the Old German Shepherd 
most likely affects only a subset of PKM isoforms, as the exon that harbors the mutation, at 
least in human orthologues, is alternatively spliced. A more detailed analysis of PKM isoform 
distribution in different canine tissues including retina, as well as testing more PRA-affected 
Old German Shepherds for the PKM deletion, are needed to shed further light on a potentially 
causal relationship between PKMvariants and PRA. 
In conclusion, we have here shown the potential of exome sequencing in dogs to identify 
pathogenic mutations underlying monogenic disease, without the availability of positional 
information. Based on our current data, we propose AGBL5 as a weak, and PKM as a strong 
candidateto underlie PRAin the Finnish Lapphund andtheOld German Shepherd, respectively, 
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the latter automatically being a good candidate to be causative for IRD in humans. The 
search for additional causative mutations remains a challenging task, since in the majority 
of breeds tested, no strong candidate genes were identified. A further improvement of the 
mapping and annotation pipelines, together with an increased availability of datasets on 
normal genetic variation in dogs will only ease these types of studies in the near future, and 
allow us to identify naturally occurring canine models for various types of inherited diseases. 
Such models likely will turn out to be instrumental towards our understanding of disease 
mechanisms as well as for developing therapeutic interventions, in particular for inherited 
retinal dystrophies but potentially also for other diseases. 
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Supplemental Table 1. Dog breeds analysed with exome sequencing 
DogiD Breed Affected/ non affected 
Canl Airedale Terrier Affected 
Can2 Airedale Terrier Unaffected 
Can3 Pyrenean Shepherd Affected 
Can4 Pyrenean Shepherd Unaffected 
CanS Saarloos Wolfhond Affected 
Can6 Saarloos Wolfhond Unaffected 
Can7 Chihuahua Affected 
Can8 Lbwchen Affected 
Can9 Chihuahua Unaffected 
CanlO Lbwchen Unaffected 
Canll Old German Shepherd Affected 
Canl2 Old German Shepherd Unaffected 
Canl3 Boxer Affected 
Canl4 Boxer Unaffected 
CanlS Husky Affected 
Canl6 Husky Unaffected 
Canl7 RauhaarTeckel Affected 
Canl8 RauhaarTeckel Affected 
Canl9 Coton de Tulear Affected 
Can20 Coton de Tulear Affected 
Can21 Chihuahua Affected 
Can22 Chihuahua Affected 
Can23 Miniature Schnautzer Affected 
Can24 Miniature Schnautzer Affected 
Can25 Finnish Lapphund Affected 
Can26 Finnish Lapphund Affected 
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Supplemental Table 2. Clinical characteristics of PRA-affected dogs 
Gender Age at Clinical observation PRCD RPGR 
diagnosis status status 
(yrs) 
Airedale Terrier M 7 Advanced retinal atrophy, neg 
(canl) secondary cataract 
Pyrenean Shepherd F 4 Advanced retinal atrophy, neg 
(can3) pale disc, thin vessels, 
peripheral depigmentation, 
flat ERG recordings 
Saarloos Wolfhond M 2 Large, localized chorioretinal neg 
(canS) dystrophy in temporal 
tapetal zone 
Chihuahua (can7) F 8 OD: advanced retinal neg 
atrophy, secondary 
immature cataract, IOL 17 
mmHg; OS: advanced retinal 
atrophy, secondary mature 
cataract, posterior luxation 
of the lens, IOL 11 mmHg 
Lowchen (can9) F 4 Advanced retinal atrophy neg 
Old German M 3 Advanced retinal atrophy neg 
Shepherd (canll) 
Boxer (can13) M 3 Advanced retinal atrophy neg 
Husky (can15) M 6 Progressive retinal atrophy neg neg 
Rauhaar Teckel F ? Progressive retinal atrophy neg 
(can17) 
Rauhaar Teckel F 
(canlS) 
? Progressive retinal atrophy neg 
Coton de Tulear M 
(can19) 
5 Progressive retinal atrophy n.a. 
Coton de Tulear M 
(can20) 
3 Progressive retinal atrophy n.a. 
Chihuahua (can21) M 10 Progressive retinal atrophy, n.a. 
cortical and posterior polar 
cataract 
Chihuahua (can22) F 10 Progressive retinal atrophy n.a. 
Miniature Schnautzer M 
(can23) 
4 Progressive retinal atrophy n.a. 
Miniature Schnautzer M 
(can24) 
4 Progressive retinal atrophy n.a. 
Finnish Lapphund F 
(can25) 
4 Progressive retinal atrophy neg 
Finnish Lapphund M 
(can26) 
7 Progressive retinal atrophy neg 
neg: negative; n.a.: not analyzed 
131 
CHAPTER2B 
Supplemental Table 3. Exome sequencing variant statistics 
Average 26 canine Average 144 human 
exomes exomes* 
Total# variants 61,214 42,178 
Single nucleotide substitutions 55,991 39,706 
Insertions I deletions 5,223 2,472 
Variants in genes 43,677 39,640 
Variants in exons 15,315 16,873 
Variants in splice sites 3,461 3,024 
Variants in canonical splice sites 48 55 
Variants overlapping with SN Ps 21,782 39,224 (dbSNP 135) 
Nonsense variants 170 81 
Missense variants 4,922 8,117 
Synonymous variants 10,435 8,526 
Homozygous variants 25,586 13,799 (#variant with reads >80%} 
%of homozygous variants 41.7 32.7 
*Exome sequencing variant statistics for all 26 individual samples, and a comparison to the average variant 
statistics of 144 human exome sequencing projects using Agilent SureSelect v4. 
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Gene Chr. Startpos. Endpos. Abbe ration Reference allele Variant #reads #variant %variation Predicted Observed Confirmed 
allele reads zygosity zygosity 
ARHGEF2 chr7 44819057 44819057 in del AA 11 3 27.27 heterozygous heterozygous yes 
C3 chr20 56516120 56516120 substitution T A 13 5 38.46 heterozygous heterozygous yes 
CELF2 chr2 27858838 27858838 in del G 7 7 100.00 homozygous homozygous yes 
CLPTMlL chr34 14280532 14280532 substitution T c 9 9 100.00 homozygous homozygous yes 
CUL4B chrX 95575319 95575319 indel A 91 54 59.34 heterozygous homozygous yes 
EIF2C2 chrl3 38243005 38243005 substitution T c 5 3 60.00 heterozygous heterozygous yes 
EIF253 chrX 19627695 19627695 substitution A G 56 12 21.43 heterozygous wild type no u ;;o 
... EPRS chr38 17801797 17801797 substitution c G 88 87 98.86 homozygous homozygous yes 0 
1: Clm 
.. ;;ox 
u GOLGAS chrB 4881812 4881812 substitution c T 10 10 100.00 homozygous homozygous yes mo ~ ~ 
HMMR chr4 50969742 50969742 in del A 99 88 88.89 homozygous homozygous yes :;::m mU> 
;;om 
KTNl chr8 34427703 34427706 in del AGTI 2 2 100.00 homozygous homozygous yes mO 
--1C 
-m 
NTANl chr6 31494521 31494521 indel CA 4 3 75.00 heterozygous heterozygous yes Zz f!::n 
OGFOD2 chr26 6528975 6528975 substitution G c 4 4 100.00 homozygous homozygous yes ~z ;;o~ 
chrS in del A 11 11 100.00 homozygous homozygous Oz PPP2R18 24342909 24342909 yes u__, 
heterozygous heterozygous ~~ TIEl chr15 19852853 19852853 in del G 9 5 55.56 yes .. m S2'< 
chr5 substitution G A 4 3 75.00 heterozygous heterozygous Ulm USP28 22480984 22480984 yes So 
<0 
mCl 
2:2 0J 
m;;o Ul m )>m 
zO 
0(/) 
n~ 
:CG) )>;;o 
'm 
r:;:;Cl z~ 
...... 
G)-
w rnZ 
w (/)Cl 
I-' () 
w ATHLl chr18 28437341 28437341 substitution G A 4 3 75.00 heterozygous heterozygous yes I 
-I'- )> 
chr5 in del 
-o 
DCPS 11212098 11212098 c 4 3 75.00 heterozygous heterozygous yes __, 
m 
:::0 
0/CSl chr4 10729540 10729540 in del T 90 26 28.89 heterozygous homozygous yes N 
OJ 
DNMlL chr27 19172736 19172736 in del CT 13 13 100.00 homozygous homozygous yes 
DNMlL chr27 19192413 19192413 substitution G T 4 4 100.00 homozygous homozygous yes 
FANCL chr10 61692315 61692315 indel CG A 9 5 55.56 heterozygous homozygous yes 
HECTD2 chr28 9047624 9047624 substitution A c 34 34 100.00 homozygous homozygous yes 
N NOLl chr35 16072742 16072742 substitution G A 11 8 72.73 heterozygous heterozygous yes 
" .. v NSMCEl chr6 19362592 19362592 substitution G A 8 4 50.00 heterozygous heterozygous yes 
POLG2 chr9 15419743 15419743 in del A 16 5 31.25 heterozygous heterozygous yes 
PTPN13 chr32 13285972 13285972 substitution T c 70 40 57.14 heterozygous heterozygous yes 
RALGAPAl chr8 17380127 17380127 in del A 8 8 100.00 homozygous homozygous yes 
SMAD9 chr25 6800442 6800442 substitution c A 9 9 100.00 homozygous homozygous yes 
TMPRSS15 chr31 17655768 17655768 indel TA 4 4 100.00 homozygous homozygous yes 
TOMl chr10 31865423 31865423 indel AA GCT 36 36 100.00 homozygous homozygous yes 
WFDCl chr5 71064422 71064422 substitution T c 13 12 92.31 homozygous homozygous yes 
ABCC2 chr28 15733839 15733839 in del GGGA 2 2 100.00 homozygous homozygous yes 
C6Hlorfl73 chrti 71788471 71788471 substitution c T 44 11 25.00 heterozygous heterozygous yes 
CBLB chr33 14334220 14334220 substitution c G 12 3 25.00 heterozygous heterozygous yes 
CEACAM28 chr1 114705949 114705949 substitution T c 3 2 66.67 heterozygous wild type no 
CLSTN3 chr27 40929180 40929180 substitution A G 17 17 100.00 homozygous homozygous yes 
DNER chr25 41887490 41887490 substitution c T 3 3 100.00 homozygous homozygous yes 
FLNC chr14 10754381 10754381 indel AG 7 3 42.86 heterozygous heterozygous yes 
... GPR107 chr9 57088266 57088266 in del 
c 
G 1!> 6 40.00 heterozygous heterozygous yes 
.. 
u HSP9081 chr15 42464714 42464715 indel TC 11 11 100.00 homozygous homozygous yes 
u 
IT GAll chr30 35358178 35358178 substitution c T 7 4 57.14 heterozygous heterozygous yes ;;o 0 
Glm 
MYCBP2 chr22 33706810 33706810 substitution T c 69 69 100.00 homozygous homozygous yes ::>ox 
mo 
MYOlH chr26 20695149 20695161 in del AGGCTGTGAAAAC 4 2 50.00 heterozygous heterozygous yes ~s <:m 
m(f) 
PKDlLl chr16 3166941 3166941 indel CTT 93 82 88.17 homozygous homozygous yes ;;om mD 
-1C 
SKAl chr7 83613495 83613497 indel GGG 28 11 39.29 heterozygous heterozygous yes zm )>Z 
,--() 
TOPl chr24 32136855 32136855 substitution c G 8 8 100.00 homozygous homozygous yes )>Z 
--1 G'l 
homozygous homozygous 
;;o_ 
ZNF148 chr33 31274634 31274634 in del A 6 6 100.00 yes Oz 
-o_, 
~::2: 
.. m S2< (f)m 
no ~0 
mGl 
2'=20J 
m ;;o (f) m )>m 
z O 
0(/) 
()~ 
IGl )>;;o 
'm ~Gl 
z2:j 
..... IGl-w mZ 
U'1 c.nGl 
,_. () 
w ADAMTS20 chr27 10557350 10557350 in del TGTC 10 10 100.00 homozygous homozygous yes I 0) )> 
chr32 in del heterozygous 
-u 
AGXT2Ll 29075152 29075152 CA 7 2 28.57 homozygous yes ---i 
m 
;;o 
ANXA2 chr30 25178178 25178178 substitution G A 3 3 100.00 homozygous heterozygous yes N 
(JJ 
CCDC129 chr14 44145840 44145840 substitution T A 57.14 heterozygous heterozygous yes 
COL14Al chr13 19108399 19108399 substitution A G 186 97 52.15 heterozygous heterozygous yes 
EFTUD2 chr9 18603277 18603277 indel A 5 5 100.00 homozygous homozygous yes 
GNMT chr12 11502058 11502058 indel T 2 2 100.00 homozygous wildtype no 
... HOMERl chr3 27523266 27523266 in del 
c 
A 15 9 60.00 heterozygous heterozygous yes 
.. 
u HSPA4 chr11 21330806 21330806 in del T 35 9 25.71 heterozygous heterozygous yes 
KHK chr17 21090110 21090110 in del c 22 20 90.91 homozygous homozygous yes 
MLXIP chr26 7195274 7195274 indel c 4 2 50.00 heterozygous homozygous yes 
PHACTRl chr35 12405631 12405631 substitution c T 27 27 100.00 homozygous homozygous yes 
RARRESl chr23 52018987 52018987 substitution T c 4 3 75.00 heterozygous heterozygous yes 
TRANKl chr23 6764541 6764541 substitution G A 17 7 41.18 heterozygous wild type no 
TXNDC15 chr11 22956058 22956058 substitution T c 5 5 100.00 homozygous homozygous yes 
ZPBP2 chr9 22609341 22609341 substitution c T 10 9 90.00 homozygous homozygous yes 
BLOCl$2 chr28 16039597 16039597 substitution c T 44 18 40.91 heterozygous heterozygous yes 
CAMKK2 chr26 10903577 10903577 substitution A G 10 10 100.00 homozygous homozygous yes 
CDC27 chr9 12392818 12392818 indel ACAA 7 3 42.86 heterozygous homozygous yes 
CERKL chr36 27790924 27790924 indel T 6 6 100.00 homozygous heterozygous yes 
CTRBl chrS 78519173 78519173 substitution G A 3 2 66.67 heterozygous heterozygous yes 
DNAH2 chrS 35658594 35658594 in del G 2 2 100.00 homozygous heterozygous yes 
DRGl chr26 27370951 27370951 substitution A G { 7 100.00 homozygous homozygous yes 
"' 
GPR107 chr9 57096980 57096980 in del G 65 14 21.54 heterozygous heterozygous yes 
c 
.. 
v HLA-DOB chrl2 5381729 5381729 indel AAGT 18 16 88.89 homozygous homozygous yes 
-o 
KCNC4 chr6 44813238 44813238 substitution c G 8 4 50.00 heterozygous wild type no ;;o 0 
Gl m 
NLRP2 chr1 105709343 105709343 indel A 4 3 75.00 heterozygous heterozygous yes ;;ox mo 
OROBGOB chr18 38042037 38042037 substitution T c 3 3 100.00 homozygous homozygous yes ~:;;:: <: m 
m Vl 
RABGEFl chr6 4149628 4149628 indel T 12 3 25.00 heterozygous heterozygous yes ;;om m.O 
--! c 
SUSDl chrll 69610185 69610185 substitution G T 82 82 100.00 homozygous homozygous yes =; m ~ z ~n 
TRO\IE2 chr38 5989467 5989469 indel TAT 20 18 90.00 homozygous wildtype no ~z 
41.67 heterozygous heterozygous 
;;o ::: 
XAFl chr5 30636140 30636140 substitution G A 12 5 yes o z 
-o --1 ~~ 
.. m Q< Vl m 
n o 
o o ~Gl 
;;<::lQJ 
m ::u Vl m )> m 
zO 
0(/' 
n ~ 
I Gl )> ;;o 
'm F;;Gl 
z ~ 
...... IGl :z w Gi Gl 
--..J 
f-' () 
w TARBPl chr4 8439591 8439591 in del A 3 3 100.00 homozygous homozygous yes :r: (X) )> 
ANOl chr18 51155524 51155524 in del G 165 97 58.79 heterozygous homozygous yes ~ 
m 
;;o 
DNAHl chr20 40428102 40428102 substitution A G 9 5 55.56 heterozygous heterozygous yes N 
OJ 
EPB41 chr2 74379919 74379919 in del G 84 71 84.52 homozygous homozygous yes 
EPHAS chrl3 59033740 59033740 indel G 5 5 100.00 homozygous homozygous yes 
IRS4 chrX 85358978 85358978 substitution G c 116 58 50.00 heterozygous heterozygous yes 
KCNQ2 chr24 47066763 47066763 substitution A G 4 4 100.00 homozygous homozygous yes 
<D KIF2A chr2 51564176 51564176 substitution T c 10 9 90.00 homozygous wildtype no 
" .. u MT/F3 chr25 15154507 15154509 in del AAG 3 2 66.67 heterozygous heterozygous yes 
PIK3C28 chr38 4011009 4011009 in del c 8 6 75.00 heterozygous homozygous yes 
RBBPS chr38 4633922 4633922 indel ACA 12 10 83.33 homozygous homozygous yes 
RHBOL3 chr9 43977579 43977579 substitution A c 4 3 75.00 heterozygous heterozygous yes 
SOAT2 chr27 5059299 5059299 substitution T c 17 9 52.94 heterozygous heterozygous yes 
SRPR chr5 11250477 11250480 in del AGCT 14 9 64.29 heterozygous homozygous yes 
SYT9 chr21 34257008 34257008 substitution G T 8 8 100.00 homozygous homozygous yes 
TLR4 chr11 74394631 74394631 substitution A T 327 326 99.69 homozygous homozygous yes 
ACSBG2 chr20 56902711 56902711 substitution G A 14 9 64.29 heterozygous heterozygous yes 
AN03 chr21 50582296 50582296 indel A 16 10 62.50 heterozygous homozygous yes 
AN06 chr27 8919223 8919223 substitution A T 4 3 75.00 heterozygous homozygous yes 
ARAP2 chr3 78481536 78481536 substitution G A 99 97 97.98 homozygous homozygous yes 
CEP192 chr7 81585353 81585353 in del T 13 13 100.00 homozygous homozygous yes 
CHLl chr20 19820218 19820218 substitution c G 320 155 48.44 heterozygous heterozygous yes 
EIF3A chr28 32306935 32306935 indel c 35 35 100.00 homozygous homozygous yes 
.. GALNTlO chr4 58570007 58570007 substitution T c 6 6 100.00 homozygous homozygous yes 
c 
.. 
u GSK3A chr1 115023195 115023195 substitution G c 8 4 50.00 heterozygous heterozygous yes 
-u 
LCP2 chr4 44855360 44855360 indel n 6 6 100.00 homozygous homozygous yes ;:o 0 
Cl rn 
M/CALLl chr10 29799859 29799859 in del G 3 2 66.67 heterozygous homozygous yes ;:o x Cio 
NEDDl chr15 39597509 39597517 indel GCCAGTTTT 2 2 100.00 homozygous heterozygous yes (/) _;;::: <: m 
rn l/l 
NLRCS chr2 62191400 62191400 substitution c T 4 4 100.00 homozygous homozygous yes ;:om rnD 
-I C 
RP527L chr30 30748835 30748836 indel AT 26 15 57.69 heterozygous heterozygous yes zm )>Z 
,-n 
TBCK chr32 29933060 29933060 in del AACA 8 6 75.00 heterozygous homozygous yes ~ z 
homozygous homozygous ;:o ~ UMODLl chr31 38810001 38810001 substitution T c 14 14 100.00 yes O z 
-u -1 3i ::2: 
.. m 
'02 < l/l rn 
n o 
S2 o 
rnCl 
2;1QJ 
rn ;:o l/l m )>m 
zO 
ol/l 
n~ 
ICl )>;;o 
'm 
F;;Cl z~ 
,__. ICl-w mZ 
<.0 l/'JCl 
f-' n 
-!'- AGER chrl2 4578129 4578129 in del c 12 11 91.67 homozygous homozygous yes :r: 0 )> 
ANKRD13A chr26 20163709 20163709 substitution c T 156 156 100.00 homozygous homozygous yes ~ 
m 
;;o 
ARF/Pl chriS 53723055 53723055 substitution A G 294 82 27.89 heterozygous wildtype no N 
OJ 
ATP6V1El chr27 48260025 48260025 in del A 113 39 34.51 heterozygous heterozygous yes 
Cl1H9orf5 chrll 67261918 67261918 in del A 4 100.00 homozygous homozygous yes 
DLGS chr4 30995012 30995012 substitution G c 4 4 100.00 homozygous homozygous yes 
EGF chr32 33036273 33036273 in del c 7 2 28.57 heterozygous heterozygous yes 
.. G2E3 chr8 12956917 12956918 indel 
c 
TA 5 5 100.00 homozygous homozygous yes 
.. 
u GGA3 chr9 8240912 8240912 indel c 3 2 66.67 heterozygous wildtype no 
ITCH chr24 26590145 26590148 indel TGTT 16 4 25.00 heterozygous heterozygous yes 
NOTCH4 chrl2 4606488 4606488 substitution T c 9 6 66.67 heterozygous heterozygous yes 
NPCl chr7 67833803 67833803 in del TGTG 47 43 91.49 homozygous homozygous yes 
OLFM4 chr22 13020215 13020215 substitution T c 4 3 75.00 heterozygous heterozygous yes 
POU2F3 chrS 16693861 16693861 substitution T c 15 15 100.00 homozygous homozygous yes 
SMTN chr26 27130746 27130746 substitution G A 8 8 100.00 homozygous heterozygous yes 
TMEM146 chr20 57235260 57235260 substitution c T 13 8 61.54 heterozygous heterozygous yes 
ACTA2 chr26 41771799 41771799 substitution G A 18 9 50.00 heterozygous heterozygous yes 
BCLllA chr10 63745575 63745575 indel A 44 44 100.00 homozygous homozygous yes 
C7 chr4 71696932 71696934 indel CTC 81 27 33.33 heterozygous heterozygous yes 
CDYL2 chrS 74094876 74094876 indel A 14 14 100.00 homozygous homozygous yes 
CEBPE chrB 6426949 6426949 substitution G A 59 59 100.00 homozygous homozygous yes 
MUC16 chr20 54868391 54868391 substitution c T 1 33 54.10 heterozygous heterozygous yes 
MYBPC3 chr18 45316305 45316305 substitution G A 4 3 75.00 heterozygous heterozygous yes 
... OCLN chr2 57413837 57413846 in del 
" 
ATGATIAAAC 7 7 100.00 homozygous homozygous yes 
.. 
u OR9G4 chr18 42305675 42305693 in del AGAAAAAATCACAAAATGA 4 3 75.00 heterozygous wild type no 
-o 
PCDH15 chr26 34042467 34042467 substitution G A 15 15 100.00 homozygous homozygous yes :::0 0 
chr38 indel c homozygous homozygous 
G\ m 
PLEKHA6 3819108 3819108 3 3 100.00 yes ::o x 
m o 
RC3Hl chr7 28271768 28271768 in del GGA 18 5 27.78 heterozygous heterozygous yes 
(;l :;;:: 
<: m 
mV> 
RCNl chr18 35373780 35373780 substitution c T 9 9 100.00 homozygous homozygous yes :;o m m.O 
--iC 
SLC6A5 chr21 45805974 45805974 in del c 7 3 42.86 heterozygous homozygous yes :z m )> Z 
chr1 substitution 
,n 
TAGAP 48392246 48392246 G A 8 3 37.50 heterozygous heterozygous yes ~z 
UBASH3A chr31 36748592 36748592 substitution A G 3 homozygous homozygous :::0~ 3 100.00 yes O z 
-o --i ~ ~ 
.. m 
S2'< V> m 
n o O o 
;$iGl 
:=:2 0J 
m ;;o 
V> m )> m 
zO 
0(/) 
nV> I m )> C) 
, :::o 
, m 
mGl z ~ 
,__. C) -
.1>- m Z 
,__. V>Gl 
I-' n ~ CEP250 chr24 24438154 24438154 substitution G A 4 4 100.00 homozygous homozygous yes :r: N )> 
-u 
cOR51R2 chr21 29803491 29803491 substitution c A 18 18 100.00 homozygous homozygous yes --i 
m 
AJ 
DUSP15 chr24 24301077 24301077 substitution G A 5 5 100.00 homozygous homozygous yes N 
OJ 
EMLS chr8 63002447 63002447 in del T 3 3 100.00 homozygous homozygous yes 
ENPP3 chr12 3127492 3127494 indel TTG 40 39 97.50 homozygous homozygous yes 
FUBP3 chr9 56666246 56666246 substitution c T 9 77.78 heterozygous heterozygous yes 
GYG2 chrX 1462358 1462358 substitution G A 15 7 46.67 heterozygous heterozygous yes 
0 KIF3A chrll 23999169 23999169 indel GAG 7 3 42.86 heterozygous homozygous yes .. 
1: 
.. LCAT chr5 84564642 84564642 indel G 4 2 50.00 heterozygous wildtype no v 
MY016 chr22 60604420 60604420 substitution A T 229 77 33.62 heterozygous heterozygous yes 
OBSCN chr14 3612696 3612696 in del G 11 3 27.27 heterozygous heterozygous yes 
RBM27 chr2 43523097 43523097 in del TCTC 134 81 60.45 heterozygous homozygous yes 
RSADl chr9 29740134 29740134 in del c 6 6 100.00 homozygous homozygous yes 
STXBPSL chr33 27413552 27413552 in del A 15 12 80.00 homozygous wildtype no 
TEK chrll 48397826 48397826 substitution G A 30 30 100.00 homozygous homozygous yes 
TPCN2 chr18 51994515 51994515 substitution c T 4 3 75.00 heterozygous heterozygous yes 
Supplemental Table 5. Rare homozygous and compound heterozygous variants in IRD-01ssociated genes 
eDNA Protein 
Start End # Amino acid Canine breed Chromosome tReads Variant % eDNA Gene position position variation change change 
reads Reference Variant Reference Variant Human 
allele allele amlnoacid amino reference 
acid amino acid 
Can 1 (Airedale CERKL chr36 24737532 24737532 53 53 100 c.l342G>A p.Gly448Ser c Gly Ser Ser Terrier) 
Can 1 (l.lredale CRBl chr7 5277967 5277967 22 22 100 c.4198G>A p.Ala1400Thr c T Ala Thr Pro Terrier) 
Can3 (Pyrenean 
ALMSl chr17 49513485 49513487 100 c.141GAC> p.Gln47del CTG Gin Glu Shepherd) 
"0 
CanS (Saarloos :;v PANK2 ch r24 17476447 17476447 63 63 100 c.385A>G p.Lys129Glu c Lys Glu Lys 0 Wolfhond) Gl m 
:;ox 
Cans (Saarloos ABCA4 chr6 55161895 p.Gly1744Ala c Gly Ala Phe mo Wolfhond) 55161895 28 28 100 c.5231G>C G ~ s: 
<:rn 
CanS VCAN chr3 24191702 24191702 102 100 c.2320G>C p.Glu774Gln c G Glu Gin mVl (Lowchen) 102 Met :;om m.O 
Can19 (Caton -1C CRBl chr7 5313116 5313116 39 13 33.33 c.3751A>G p.Thr1251Ala c Thr Ala Gin -rn deTulur) Zz ~n 
Can19 (Coton CRBl chr7 5316820 5316820 45 20 44.44 c.2871A>T p.Gln957His T A Gin His Gin ~z deTuloar) ;:o~ 
Can25 (Finnish O z AGBLS chr17 21063407 21063407 24 22 91.67 c.2606G>A p.Arg869Gin G A Arg Gin Arg -o_, Lapphund) ~~ 
.. m Q< (/) rn 
n o S2o 
mGl 
~OJ 
m ;:o Vl rn )> rn 
zo 
0(/) 
n~ 
IGl )> ;:o 
'rn 
r:;:;Gl z~ 
>-' Gl-
.)>. mZ 
w (J)Gl 
.__. Supplemental Table 5. Rare homozygous and compound heterozygous variants in IRD-associated genes (continued) (") .,. :r: .,. )> 
-u 
Occurence in canine exome --j m 
seq. cohort ;u 
N 
Canine breed Observed zygosity Grantham PhyloP SIFT PPH-2 Additional remarks Conclusion OJ 
Total number (homozygous I 
heterozygous) 
Can 1 (Airedale Terrier) ~-1(M 56 2 486 4(0/4) likely benign 
Can 1 (Airedale Terrier) MIM 58 5.927 likely benign 
Can3 (Pyrenean 
Shepherd) M(+ n.a 0.42 n.a. n.a. likely benign 
occurs homozygously in 2 affected 
CanS (Saarloos M(M 56 4.622 D B and 4 unaffected, and heterozygously likely benign Wolfhond) in 3 unaffected Saarloos Wolfhond 
dogs 
occurs homozygously in 2 affected 
CanS (Saarloos 
MIM 60 4.925 tolerated B 4 (0/4) and! unaffected, and heterozygously likely benign Wolfhond) in 1 unaffected Saarloos Wolfhond 
dogs 
occurs homozygously in 1 unaffected, 
CanS (Lowchen) MIM 29 -0.201 D p 1 (0/1) and heterozygously in 2 unaffected likely benign 
Lowchen dogs 
Can19 (Coton de Tulear) M(+ 58 0.564 T 1 (0/1) 
likely benign 
Can19 (Coton de Tulear) M(+ 24 0.783 
Can25 (Finnish M(M 43 2.835 D 2 (0/2)' candidate gene Lapphund) 
n.a.: not analyzed 
*These two dogs were also Finnish Lapphunds 
B:benign; P: possibly damaging; T: tolerated 
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CHAPTER3A 
Abstract 
Purpose: The field of inherited retinal diseases (IRDs) has made great progress in the past 
two decades with the identification of mutations in more than 250 genes. As the fourth 
most populated nation in the world, it is estimated that -85,000 individuals suffer from IRD 
in Indonesia. Nevertheless, little is known regarding the genetic basis of IRD in Indonesia 
and other South East Asian countries. The present study aimed to provide an overview of 
genetic causes underlying retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) 
in Indonesia. 
Methods: DNA samples were obtained from affected and non-affected individuals from 
46 families with RP and four families with LCA. Homozygosity mapping was previously 
performed in 28 families using single nucleotide polymorphism (SNP) microarrays followed 
by sequencing of known genes residing in the homozygous regions. In addition, we performed 
targeted sequencing of 108 genes associated with non-syndromic IRD using molecular 
inversion probes (MIPs) in 33 genetically unexplained cases. 
Results: Putative causal variants were found in four cases using homozygosity mapping 
prior to MIPs analysis. In addition, screening of previously reported variants resulted in the 
identification of causal variants in another two cases. Targeted sequencing of 108 genes 
using MIPs identified biallelic variants in 21 cases. Altogether, this study detected potential 
causative variants in 27/50 cases (54%) in 181RD-associated genes. CRB1 was found to be the 
most frequently mutated gene, with the p.(Pro1305Leu) as the most prevalent variant (3/30) 
in this cohort. 39/44 (88%) of the variants were novel. 
Conclusions: The identification of a high proportion of novel variants demonstrates the 
unique genetic architecture of IRD in the Indonesian population. Moreover, we revealed CRB1 
as the most frequently mutated IRD gene, with p.(Pro1305Leu) as a founder mutation in the 
Indonesian population. 
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Introduction 
Inherited retinal diseases (IRDs) encompass a wide spectrum of hereditary retinal 
degenerations with clinical, genetic and allelic heterogeneity.l-3 Clinically, IRDs can be 
classified based on whether rod or cone photoreceptors are primarily involved. Based on 
the course of diseases, they can be subdivided into stationary disorders, such as congenital 
stationary night blindness (CSNB), and progressive degenerations, such as retinitis 
pigmentosa (RP) and cone-rod dystrophy (CRD).3 However, the distinction between disease 
phenotypes is often challenging as the clinical features may overlap between different types 
ofiRD. 
In the last two decades, advances in genotyping technologies, ranging from positional 
cloning to next generation sequencing (NGS), have resulted in the identification of more than 
250 genes associated with IRDs (https:jjsph.uth.edu/retnet/).4 These genes are involved in 
the major processes of the retina, for instance retinal development, the phototransduction 
cascade, the retinoid cycle and intra photoreceptor ci liary transport processes.5• 6 IRDs are 
genetically diverse, as mutations in different genes may lead to the same IRD subtype. In 
addition, different variants in the same gene may result in distinct phenotypes. For example, 
ABCA4 variants may cause a spectrum of phenotypes, ranging from Stargardt disease to 
panretinal diseases depending on the combinations of different types of variants.7• 8 These 
genetic complexities pose major challenges in establishing a molecular diagnosis and 
providing a proper genetic counseling. Prior knowledge on the population-specific genetic 
data underlying IRDs may assist the development of a systematic genotyping approach 
in a time- and cost-effective manner. For instance, most of achromatopsia cases can be 
explained by variants in either CNGB3 (50-87%) or CNGA3 (5-20%).9• 10 The same holds true 
for variants in RHO and RPGR ORF15 that account for approximately 30% of adRP11 and 70% 
ofXLRP cases,1H4 respectively. In terms of population-specific genetic defects, an example is 
the identification of RPE65 as the most prevalent causal gene in LCA patients from the Danish 
and Indian populations.15· 16 
Indonesia is one of the most populated nations worldwide with an exquisite genetic 
mixture between Asian ancestry, Melanesian, Polynesian and ultimately Austronesian.n One 
can assume that the genetic architecture underlying IRDs may differ in comparison to what 
has been previously described for other ethnicities. Yet to date, little is known about this 
group of disorders that is estimated to affect more than 85,000 individuals in lndonesia.1a-20 
In this study, we aim to elucidate the molecular genetic causes of 50 IRD families of the 
Indonesian population and to give an overview of the genetic architecture of IRDs in the 
Indonesian population. 
Material and methods 
Subjects 
A total of73 affected individuals from 50 families were ascertained in this study. Seven of these 
families were previously described, but not genetically solvedY The cl inical phenotypes in 
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these families are isolated RP (iRP) (n=34), autosomal recessive RP (arRP) (n=8), autosomal 
dominant RP (adRP) (n=3), X-I inked RP (XLRP) (n=1), and Leber congenital amaurosis (LCA) 
(n=4). The study protocol adhered to the tenets of the Declaration of Helsinki and received 
approval from the respective local ethics committees. Written informed consent was obtained 
from all participants or parents of children prior to their inclusion in this study. 
Clinical examination 
Clinical assessment was performed in the Dr. Kariadi Hospital, William Booth Hospital or Panti 
Wilasa Hospital in Semarang, Central Java, Indonesia. Medical histories were obtained with 
focus on the onset of disease, initial symptoms and overall disease course. Best-corrected 
visual acuity (BCVA) was measured using Snellen chart, followed by visual field analysis, and 
slit lamp ophthalmoscopy. Humphrey visual field analysis (HVFA), fundus photography and 
optical coherence tomography were performed when feasible. 
Genetic analysis 
DNA isolation 
Peripheral blood samples of probands and their family members were obtained in EDTA 
(ethylenediaminetetraacetic acid) tubes. DNA was isolated from peripheral blood leukocytes 
using a standard salting out procedure.22 
Homozygosity mopping 
Genome wide single nucleotide polymorphism (SNP) microarray analysis was performed for 
probands of 28 families. Genotyping of eight probands was performed using the Affymetrix 
SOOk array (Affymetrix, Santa Clara, CA) and 20 probands using the lllumina 700k Omni 
express array (lllumina, San Diego, CA). Runs of homozygosity were analysed using PLINK 
software,23 with a cut-off of 4Mb and allowing two heterozygous SNP calls per window of 50 
SNP markers. Genes known to be associated with IRD flanking the homozygous regions were 
selected as candidate genes associated with the disease. 
Candidate variant screening 
Screening of variants identified from a previous study,23 i.e. ABCA4: c.302+4A>C:p.(?); CRBl: 
c.3914C> T:p.(Pro1305Leu); EYS: c.9082G> T:p. (Asp3028Tyr); MERTK: c.2487-2A>G:p. (?); NR2E3: 
c.l025T>G:p.(Vai342Giy); PDE6A: c.l675C>A:p.(Tyr558*) and RHO: c.403C> T:p.(Argl35Trp) was 
performed using restriction fragment length polymorphism (RFLP) analysis or amplification-
refractory mutation system (ARMS) PCR. Primers and PCR conditions are available upon request. 
Molecular Inversion Probe analysis 
A total of -6,200 molecular inversion probes (MIPs) were designed to capture - 1,600 protein-
coding exons and flanking intronic sequences of 108 IRD-associated genes (obtained from 
RetNet, accessed October 2013) using a previously described method .24The size of the 
targeting arms was 20 bp on each side and the gap-fill length was set to 112 bp. The captured 
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targets were sequenced on a NextSeq500 instrument (lllumina, San Diego, CA) according to 
the manufacturer's protocol (300 cycles High Output sequencing kit, v2) and subsequently 
analyzed using the Seq Next module of JSI SeqPilotrM (version 4.2.0 build 503). This study is 
part of a large collaborative project in identifying genetic causes of -4,000 probands with 
non-syndromic IRDs ascertained in the European Retinal Disease Consortium (ERDC). 
Songer validation 
Validation of candidate variants identified by MIPs was performed using the Big Dye 
Terminator Cycle sequencing kit v3.1 on a 3130 automated sequencer (Applied Biosystems, 
Foster City, CA). Primers flanking coding regions and exon-intron boundaries were designed 
with Primer3 plus (http://www.bioinformatics.nl/cgi-bin/primer3plus/ primer3plus.cgi). 
Primer sequences and PCR conditions are available upon request. 
Pathogenicity assessment 
To evaluate the pathogenicity of identified variants, we assessed minor allele frequencies 
(MAF) in the population databases and pathogenicity prediction from computational 
(in silico) programs. MAF were obtained from the Exome Aggregation Consortium (ExAC) 
database (http://exac.broadinstitute.org/) containing variant frequencies in 60,706 
unrelated individuals. For missense variants, Polymorphism Phenotyping v2 (PolyPhen-2) 
(http://genetics.bwh.harvard.edu/pph2/); Sorting Intolerant From Tolerant (SIFT) (http:/ I 
sift.jcvi.org/) and Combined Annotation Dependent Depletion (CADD) score (http://cadd. 
gs.washington.edu/) were used. Splice variants were evaluated using Alamut version 2.7.1 
which combines five splice prediction tools, i.e. SpliceSiteFinder-like/5 MaxEntScan,26 
NNSPLICE,2' GeneSplicer28 and Human Splicing Finder.29 
The aforementioned ExAC database and in silico predictions were used to assess 
missense variants, according to the American College of Medical Genetics and Genomics 
(ACMG) guidelines.30 
Results 
Overview of the molecular genetic basis of IRDs in the Indonesian population 
Homozygosity mapping analysis identified CRBl c.3914C>T:p.(Prol305Leu), CNGAl 
c.1270C> T:p.(Arg424 *), RPl c.1012C> T:p.(Arg338*) and RPE65 c.730C> T:p.(Giy244Ser) variants 
in four RP families (Table 1). In addition, screening of previously reported variants yielded the 
homozygous CRBl c.3914C> T:p.(Prol305Leu) variant in two iRP cases and the heterozygous 
RHO c.403C> T:p.(Argl35Trp) variant in one adRP case. Subsequently, targeted sequencing 
of 1081RD-associated genes using the MIPs approach yielded potentially causative variants 
in 21/33 cases, of which 12 were isolated RP cases (Figure1). Altogether, this study detected 
potential causative variants in 27/50 cases (54%) in 18 different IRD-associated genes (Table 
1 and Figure 2) . 
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Figure 1. Schematic workflow of genotyping Indonesian persons with I RD. Fifty IRD probands were 
included in this study. Screening of previously described IRD-associated variants in the Indonesian 
population were performed in 22 probands, while 28 other probands were analysed using homozygosity 
mapping of genome wide SNP array data. Thereafter, the remaining 33 unsolved cases were included 
in the MIPs study. Using these combined approaches, biallelic variants were identified in 27 pro bands 
{54%). 
We revealed CRBl as the most frequently mutated gene (17%), followed by CEP290 
(10%). Mutations in the remaining genes were identified in one or two IRD cases (Table 
1). Interestingly, the majority of these variants (39/44, 88%) have never been described in 
other populations, underscoring the notion that the genetic architecture of the Indonesian 
population is very different from the Caucasian population that thus far have been studied 
extensively. These variants consist of 21 missense variants, 16 protein-truncating variants 
and 7 splice site variants. 
The CRBl c.3914C> T:p.(Prol305Leu) and the RHO c.403C> T:p.(Argl35Trp) were detected 
in more than one IRD case in this population and were absent in the ExAC database, 
indicating a more abundant occurrence of these variants in the Indonesian population. 
Another interesting finding in this study is the identification of compound heterozygous 
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Table 1. IRD-associated variants identified in this study 
Allelel Allele2 Segregation FamllylD Gene Phenotype 
DNA change Amino acid change DNA change Amino acid change analysis 
F1 RHO c.403C>T p.(Argl 35Trp) + adRP no 
F2 CNGBl c.263ST>G p.(Met873Leu) c. l 997G>A p.(Aia660Val) arRP yes 
Cl 
F3 KIM1549 c.2419T>A p.(Thr807Ser) c.l304G>A p.(Thr435Met) iRP yes m z 
F4 PROM I c.ll96G>A p.(Arg399His) c.785-18C> T p.(?) iRP m no -1 
FS C2orfll c.l695_1696insA p.(Giu566Argfs'l4} c.l02G>A p.(=} iRP n yes )> 
:::0 
F6 CRBl c.3914C>T p.(Prol305Leu) c.3914C>T p.(Prol305Leu) iRP yes n 
I 
F7 CNGBl c.3516G>C p.(Ginll72His) c.2747G>A p.(Arg910His) iRP no =i 
m 
FB BBSl c.670G>A p.(Giu224Lys) c.670G>A p.(Giu224Lys) iRP yes n 
-1 
F9 CRBl c.2783G>A p.(Cys816Tyr) p.(Cys816Tyr) c c.2783G>A iRP yes :::0 
m 
FlO ABCA4 c.2396C>T p.(Pro 799Leu) c.3523-3C> T p.(?) iRP yes 0 
"T1 
Fll CNGAl c.l477G>A p.(Arg424'} c.1477G>A p.(Arg424'} iRP no z 
Fl2 EYS c.9082G>T p.(Asp3028Tyr) c.3890del p.(Thrl297Lysfs'l7} iRP I yes m 
:::0 
F13 RPl 836C>T p.(Ser279Phe) 836C>T p.(Ser279Phe) IRP yes =i 
m 
Fl4 PDE6A c.2372A>C p.(Phe791Cys) c.l66linsG p.(Arg554Profs' 47} arRP yes 0 
:::0 
FlS CHM c.l564_1565insTAGA p.(Ser522Leufs'l3) y y CHM/arRP yes m 
-1 
Fl6 CRBl c.3914C>T p.(Prol30Sleu) c.3914C>T p.(Prol305Leu) iRP no z )> 
r 
Fl7 RHO c.403C>T p.(Argl35Trp) + + adRP no 0 
Fl8 CEP290 c.3252_3253insCT p.(Thrl085Leufs' 4} c.3252_3253insCT p.(ThrlOBSLeufs' 4} iRP Vi no ~ 
Fl9 PDE6A c.858+1G>A p.(?) c.858+1G>A p.(?) iRP yes (./1 m 
(./1 
F20 RPl c.l012C>T p.(Arg338*) c.l012C>T p.(Arg338'} arRP yes z 
F21 RP£65 c.730C>T p.(Giy244Ser) c.730C>T p.(Giy244Ser) arRP yes -1 I 
F22 CNGAl c.l477G>A p.(Arg424') c. l477G>A p.(Arg424*} iRP no m 
z 
F23 CEP290 c.5602G>A p.(Aspl868Asn) c.5602G>A p.(Aspl868Asn) arRP yes 0 0 
F24 FAM161A c.943T>A p.(Lys315*} c.943T>A p.(Lys315') arRP yes z m 
F25 CEP290 c.3255T>G p.(=} c.325ST>G p.(=} iRP (./1 no 5> 
F26 RP£65 c. l 07 114del p.(Leu36Hisfs'13) c .. l07 _114del p.(Leu36Hisfs*l3} arRP z yes 
"'0 
F27 USH2A c.7379G>A p.(Arg2460His) c.441T>A p.(=) LCA yes 0 "'0 
c 
F28 AIPLl c.970C>A p.(=} c.33G>C p.(=} LCA yes r 
F29 CRBl c.l084C>T p.(Gin250'} c.4168C>T p.(Argl278') LCA ~ ,__. yes 6 U1 
U1 F30 CRBl c.3914C>T p.(Pro1305Leu) c.3914C>T p.(Prol305Leu) iRP yes z 
adRP: autosomal dominant ret in it is pigmentosa; arRP: autosomal recessive retinitis pigmentosa; CHM: choroiderem ia; iRD: isolated retinitis pigmentosa;LCA: Lebercongenital 
amaurosis; Y: Y chromosome 
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Figure2. Family pedigrees and segregation analysisofpotentiallycausativevariants. Squares represent males and circles represent females. Filled and crossed 
out symbols indicate affected and deceased persons, respectively. All variants segregated as expected for causal variants in the families. #These variants are 
likely benign. There is no proof of pathogenicity for the AIPLl c.970C>A:p.(=), C20RF71 c. l02C> T:p.(=), CEP290 c.3255T>G:p.(=), PROMl c.785-18C> T:p.(?) and 
USH2A c.441A>T:p.(=) variants. 
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,_. Table 2. In silica analyses of novel missense variants identified in this study n Ul :r: co )> 
Grantham ~ MAF ExAC SIFT PolyPhen2 CADD PhyloP* Evidence for ACMG ACMG 
Gene DNA change Amino acid change score m {%) (0·1) (0·1) {1-99) (·14.1-6.4) classification30 classification30 ;;o (0-215) w )> 
A8CA4 c.2396C>T p.(Pro799Leu) 0.0041 0(0.01) 8(0.0017) 15.59 2.55 98 PS3, PM1, PP3 vus 
AIPLl c.40A>G p.(Lys14Glu) 0(0) 0(1) 15.82 2.05 56 PS3, PM2, PP3 vus 
8851 c.670G>A p.(Glu224Lys) 0.0008255 0(0.02) 0(1) 34 2.65 56 PS3, PP3 vus 
CEP290 c.S602G>A p.(Asp1868Asn) T(0.36) P(0.897) 6.29 2.59 23 PS3, PM2, PP1 vus 
CNG81 c.3516G>C p.(Gln1172His) T(0.19) 8(0.380) 10.88 0.29 24 PS3, PM2, 8P4 vus 
CNG81 c.2747G>A p.(Arg910His) 0.056 0(0) 0(1) 32 5.53 29 PS3, PP3 vus 
CNG81 c.2635T>G p.(Met873Leu) T(0.03) P(0.598) 13.8 4.56 15 PS3, PP1 vus 
CNG81 c.1997G>A p.(Ala660Val) 0.00083 0(0.03) 0(1) 16.2 5.86 64 PS3, PP1, PP3 likely pathogenic 
CR81 c.3914C>T p.(Prol305Leu) 0(0.03) 0(1) 22.7 4.32 98 PS3, PS4, PM1, PM2, PP3 pathogenic 
CR81 c.2783G>A p.(Cys816Tyr) 0(0) 0(0.999) 14.6 1.33 194 PS3, PM1, PM2, PP3, likely pathogenic 
EYS c.9082G>T p.(Asp3028Tyr) T(O.l5) 0(0.976) 19.38 0.95 160 PS3, PM2, PM3, PP3 likely pathogenic 
KIM1549 c.2419T>A p.(Thr807Ser) 0.005809 T(O.l7) P(0.869) 13.55 -0.05 58 8P4 vus 
KIM1549 c.l304G>A p.(Thr435Met) 0.007457 T(0.07) 0(0.998) 15.5 1.19 81 PP3 vus 
NR2E3 c.1025T>G p.(Val342Gly) 0.00094 0(1) 0(1) 22.3 7.76 109 PS3, PM1, PP3 vus 
PDE64 c.2372A>C p.(Phe791Cys) 0(0.03) 0(1) 16.91 1.79 205 PS3, PM2, PM3, PP1, PP3 pathogenic 
PROMl c.ll96G>A p.(Arg399His) 0.034 T(0.27) P(O.S23) 9.579 -0.14 29 8P4 vus 
RHO 403C>T p.(Argl35Trp) 0(0) 0(1) 19.55 0.57 101 PS3, PS4, PM1, PM2, PP3 pathogenic 
RPl 836C>T p.(Ser279Phe) 0.001652 0(0.02) 0(0.995) 14.5 1.09 155 PS3, PP3 vus 
RPE65 c.730C>T p.(Gly244Ser) T(0.44) 0(1) 32 2.79 56 PS3, PM2, PP3 vus 
RPE65 c.95G>T p.(Gly32Val) 0(0) 0(1) 27.2 2.79 159 PVS1, PS3, PM2, PP3, PVS1 pathogenic 
RPE65 c.l304A>G p.(Tyr435Cys) 0(0) 0(1) 16.14 1.95 194 PS3, PM1, PM2, PP3 likely pathogenic 
B: Benign; D: Probably damaging; P: Possibly damaging; T: Tolerated 
*PhyloP: evolutionary conservation score at the nucleotide level based on a 44-vertebrate species alignment 
SIFT (http://sift.jcvi.org/); Polymorphism Phenotyping v2 (PolyPhen-2, http://genetics.bwh.harvard.edu/pph2/); CADD (cadd.gs.washington.edu/) 
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variants (i.e. c.2419T>A:p.(Thr807Ser) and c.l304G>A:p.(Thr435Met)) in the KIAA1549 gene, 
which has previously been described as a candidate gene for non-syndromic RP by Abu-
Safieh et al.32 However, these variants have allele frequencies of 0.006% and 0.007% in 
the ExAC database, which is relatively high for variants implicated in a rare disease like RP. 
Moreover, SIFT predicted both variants to be benign and the p.(Thr807Ser) variant has a 
CADD score lower than 15 suggesting that this variant is likely benign. 
In silico analyses of missense and non-canonical splice site variants 
Using the ACMG classification,30 four variants were classified as pathogenic, four variants as 
likely pathogenic and 13 as variants with unknown significance (Table 2). Based on the fact 
that the CNGBl p.(Gin1172His) and p.(Met873Leu) segregated, we cannot exclude them to be 
pathogenic. Still, in silico programs predicted these variants to be benign. The homozygous 
PROMl p.(Arg399His) variant in F4 occurs in a low conserved region and is deemed to be 
benign by SIFT and CADD. The relatively high minor allele frequency (39/116,386 = 0.034%) 
also suggests that this variant is not causative. 
In this study, we identified four synonymous variants (AIPLl c.970C>A:p.(=); C2orf71 
c.102C> T:p.(=); CEP290 c.3255T>G:p.(=} and USH2A c.441A> T:p.(=).); one intronic variant 
(PROMl c.785-18C>T:p.(?)) and one novel non-canonical splice site variant (ABCA4 c.3523-
3C> T:p.(?)). All variants were absent in the ExAC database, except the c.102G>A:p.(=) variant in 
C2orf71 which occurs in 84 of 120,398 alleles (0.070%}. Beside the ABCA4 variant c.3523-3C> T, 
which weakens the corresponding splice acceptor site by all in silico prediction programs, 
the other variants were not predicted to have a strong effect on splicing nor is there any proof 
that they are causative (Supplemental Table 1). 
The CRBl p. (Prol305Leu) variant is a potential founder mutation for RP in the 
Indonesian population 
In this study, we found the CRBl c.3914C> T:p.(Pro1305Leu) variant in 3/50 (6%) of IRD 
probands, and it thereby is the most frequent mutation. This substitution was not detected 
in 149 ethnically matched control individuals. This variant has never been reported in IRD 
studies employing individuals from other ethnicities and is absent in the ExAC database. 
The variant affects a highly conserved nucleotide with a PhyloP score of 4.32, and all in 
silica programs (PolyPhen-2, SIFT, Mutation Taster and CADD) predicted this variant to be 
damaging. The variant results in the change of proline to leucine which resides in one of the 
EGF-Iike calcium-binding domains of CRBl . 
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RP1(2; 5%) 
p.(Pro1305Leu) 
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"v. p.(Arg135Trp) 
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Figure 3. Frequencies of variants in IRD-associated genes identified in this study and previous 
studies. 20• 21• 31 In combination with previously reported variants in the Indonesian population, CRBl is 
the most frequently mutated gene (14%), followed by RHO (10%), RPE65 (10%), CEP290 (7%) and PDE6A 
(7%). Variants in the remaining genes were identified in one or two IRD cases. The CRBl c.3914C>T: p. 
(Prol305Leu) variant was found to be the most frequent variant, i.e. in four cases (10%), followed by the 
RHO variant c.403C> T:p.(Argl35Trp) (5%) and c.482G>A:p.(Trp161*) (5%) in RHO. 
Discussion 
In this study, we performed the most comprehensive genetic study ever reported for 
Indonesian IRD patients. Using a combination of homozygosity mapping, candidate gene 
screening and a MIPs approach, we identified variants in 27/50 (54%) IRD probands. The 
MIPs technology revealed the highest number of causal variants. Although previous studies 
in the Indonesian IRD cohort demonstrated the effectiveness of homozygosity mapping to 
detect genetic variants, the structure of the Indonesian population is relatively complex. 
Certain rural regions or tribes may consist of consanguineous families, or parents that share 
a common ancestor, while in the urban areas, consanguinity probably is lower. 
Remarkably, in this study we identified the CRBl p.(Prol305Leu) variant in three 
IRD cases. In a previous study by Siemiatkowska et al}3 this variant was already found in 
one proband. Haplotype comparison of the CRBl chromosomal region of three affected 
individuals showed a shared homozygous region of700 kb (rsll802085 to rsll35810), which 
suggests that this variant is a founder mutation. This variant is predicted to affect the protein 
structure by several prediction programs. The amino acid proline is also known as a helix-
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breaker, due to its role in disrupting the regularity of the a helical secondary structure. The 
alteration to leucine may significantly change the protein structure. 
Another interesting finding in this study is the identification of the compound 
heterozygous variants c.2419T>A:p.(Thr807Ser) and c.l304G>A:p.(Thr435Met) in KIM1549. 
Abu-Safieh et al.32 identified a homozygous KIM1549 c.2399_2400insAA:p.(Glu801Metfs*9) 
variant in an autosomal recessive family from Saudi Arabia and proposed this gene as a novel 
candidate gene for arRP. Moreover, the reduction of KIM1549 in the mouse retina results in 
photoreceptor degeneration.33 Nevertheless, both variants occur in the ExAC database with 
a relatively high frequency. In addition, the occurrence of these variants in a low conserved 
region and their prediction to be benign by SIFT weaken the possibility for these variants to 
be causative in this proband. Nevertheless, functional studies are required to fully analyze 
the effect of these variants on the protein product. 
In a previous study by Siemiatkowska et al.,21 seven out of 14 Indonesian families with 
IRD were genetically solved. Previous studies by Sitorus et al.31 and Kartasasmita et al.20 
identified possible causative variants in 3/21 and 2/38 families, respectively. Together with 
results from this study (Supplemental Table 1), CRBl is the most frequently mutated gene 
{14%), followed by RHO (10%), RPE65 (10%), CEP290 (7%) and PDE6A (7%). The remaining 
genes were mutated in one or two IRD cases (Figure 3).23•30•34 Among all the identified variants, 
the CRBl p.(Prol305Leu), RHO p.(Argl35Trp) and RHO p.(Trp161*) were reported in two or 
more unrelated RP cases, suggesting the recurrence of these variants in the Indonesian 
population. A genotype-phenotype database may contribute to our understanding on IRD, 
and open the possibility to find novel associations. 
The genetically unexplained IRD cases are candidates for whole exome sequencing 
analysis, which may enable the identification of noveliRD-associated genes. 
In conclusion, we identified the underlying variants in a significant proportion of 
Indonesian IRD cases by combining different approaches. The MIPs approach represents the 
most cost-effective method to identify IRD-associated defects. Patients with clear-cut causal 
variants thereby may become eligible for gene augmentation therapies that are currently 
being developed. 
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m Supplemental Table 1. Non-canonical splice-site and synonymous variants identified in this study and their predicted effects :r: _j:>. )> 
in silico prediction using SSF, 25 
-u 
-j 
MAFExAC PhyloP Evidence for ACMG ACMG m 
Gene DNA change Amino acid change MaxEnt,26 NNSPLICE,27 classification30 classification30 
:;o 
{%) score GeneSplice~8 and HSF29 w )> 
ABCA4 c.3523-3C> T p.(?) 0 -1.33 72.3% (HSF) PM2 vus 
AIPLl c.970C>A p.(=) 0 -0.2 PM2, BP4, BP7 likely benign 
AIPLl c.33G>C p.(=) -1.09 PM2, BP4, BP7 likely benign 
C2orf11 c.102G>A p.(=) 0.070 -0.44 PM2, BP4, BP7 likely benign 
CEP290 c.3255T>G p.(=) 0 -0.04 PM2, BP4, BP7 likely benign 
USH2A c.441T>A p.(=) 0 -1.65 PM2, BP4, BP7 likely benign 
MAF, minor allele frequency; SSF, SpliceSiteFinder-like; HSF, Human Splice Finder; BP, benign supporting; PM, pathogenic moderate 
Supplemental Table 2. Previously published IRD-associated variants from the Indonesian population 
Allelel Allele 2 
Gene 
DNA change Amino acid change DNA change Amino acid change 
MERTK complex rearrangement p.(Gly654Alafs'41) complex rearrangement p.(Gly654Alafs' 41) 
NR2E3 c.l025T>G p.(Val342Gly) c.l025T>G p.(Val342Gly) 
ABCA4 c.302+4A>C p.(?) c.302+4A>C p.(?) 
MERTK c.2487-2A>G p.(?) c.2487-2A>G p.(?) 
EYS c.9082G>T p.(Asp3028Tyr) c.9082G>T p.(Asp3028Tyr) 
PDE6A c.l675C>A p.(Tyr558") c.l675C>A p.(Tyr558*) 
CRBl c.3914C>T p.(Prol305Leu) c.3914C>T p.(Prol305Leu) 
AIPLl c.40A>G p.(Lysl4Glu) c.40A>G p.(Lysl4Glu) 
RHO c.482G>A p.(Trpl61') c.482G>A p.(Trpl61*) 
RHO c.482G>A p.(Trpl61*) c.482G>A p.(Trpl61*) 
RPE65 c.l06 114del p.(Leu36 Leu38del) c.l06 114del p.(Leu36 Leu38del) 
RPE65 c.95G>T p.(Gly32Val) c.l304A>G p.(Tyr435Cys) 
N.A.: not available 
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CHAPTER3B 
Abstract 
Purpose: The purpose of this study was to identify the underlying molecular genetic defect 
in an Indonesian family with three affected individuals who had received a diagnosis of 
retinitis pigmentosa (RP) . 
Methods: Clinical evaluation of the family members included measuring visual acuity and 
fundoscopy, and assessing visual field and color vision. Genomic DNA of the three affected 
individuals was analyzed with lllumina 700k single nucleotide polymorphism (SNP) arrays, 
and homozygous regions were identified using PLINK software. Mutation analysis was 
performed with sequence analysis of the retinitis pigmentosa 1 (RPl) gene that resided in 
one of the homozygous regions. The frequency of the identified mutation in the Indonesian 
population was determined with Taql restriction fragment length polymorphism analysis. 
Results: A novel homozygous nonsense mutation in exon 4 of the RPl gene, c.l012C> T:p. 
(Arg338*), was identified in the proband and her two affected sisters. Unaffected family 
members either carried two wild-type alleles or were heterozygous carriers of the mutation. 
The mutation was not present in 1841ndonesian control samples. 
Conclusions: Most ofthe previously reported RPl mutations are inherited in an autosomal 
dominant mode, and appear to cluster in exon 4. Here, we identified a novel homozygous 
p.(Arg338*) mutation in exon 4 of RPl, and speculate on the mutational mechanisms of 
different RPl mutations underlying dominant and recessive RP. 
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IDENTIFICATION OF A NOVEL NONSENSE MUTATION IN RPl THAT CAUSES 
AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA IN AN INDONESIAN FAMILY 
Retinitis pigmentosa (RP, OMIM 268000) represents a clinically heterogeneous group of 
progressive inherited retinal disorders that primarily affect rod photoreceptor cells, followed 
by secondary cone photoreceptor cell degeneration.1-3 RP is the most frequent cause of 
inherited blindness, affecting approximately 1 in 3,500 to 1 in 5,000 people worldwide. This 
disease is initially characterized by night blindness followed by visual field constriction that 
can ultimately lead to legal blindness at a later stage.4 
In addition to the clinical diversity of RP, the disease is genetically heterogeneous. RP 
can be inherited in an autosomal dominant (adRP, 30% to 40%), autosomal recessive (arRP, 
50% to 60%, with sporadic cases accounting for about 45% of all RP)4, or X-linked (xiRP, 5% 
to 20%)1.4, and rarely in a digenic mannerY At present, of 55 genes known to be mutated in 
individuals with RP, most display allelic heterogeneity, and some have been implicated in 
both dominant and recessive modes of inheritance e.g., bestrophin 1 (BESTl), neural retina 
leucine zipper (NRL) , nuclear receptor subfamily 2, group E, member 3 (NR2E3), rhodopsin 
(RHO), retinitis pigmentosa 1 (RPl), and retinal pigment epithelium-specific protein 65 kDa 
(RPE65); RetNet-Retinallnformation Network; provided in the public domain by the University 
ofTexas Houston Health Science Center, Houston, TX). 
Mutations in the retinitis pigmentosa 1 gene (RPl, OMIM 603937) are thought to account 
for approximately 5.5% of adRP cases and only 1% of arRP cases, depending on the type 
and the position of the mutations.6 To date, more than 50 disease-causing mutations in the 
RPl gene have been identified. They are predominantly frameshift or nonsense mutations in 
individuals with dominant RP, clustered in a region spanning codons 500-1053 in exon 4.6-24 
Only a few cases of recessive RPl mutations in exon 4 have been reported,6.2°·2s-29 the majority 
of which is located very close to the 3' end of exon 4. Here, we report an early truncating 
mutation in the 5' part of exon 4 (c.1012C> T:p.(Arg338*)), which we found was homozygously 
present in an Indonesian family segregating arRP. A heterozygous carrier of this nonsense 
mutation did not display any clinical abnormalities characteristic of RP. Therefore, our 
findings suggest that this particular null allele of RPl causes recessive rather than dominant 
RP. 
Methods 
Subjects 
An Indonesian family of Javanese origin with three affected individuals and two available 
unaffected relatives was included in this study (Figure 1). Affected family members were 
diagnosed by an ophthalmologist at the Dr. Kariadi Hospital in Semarang, Central Java, 
Indonesia. This study was approved by the ethical review boards of the centers involved. 
Informed consent adhering to the tenets of the Declaration of Helsinki was obtained from all 
participating affected individuals and unaffected family members. In addition, 184 ethnically 
matched and unrelated control individuals took part in this study. 
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Clinical characterization 
The three affected individuals (11:4, 11:6, and 11 :7) and two unaffected relatives (1:1 and 11:2) 
underwent a detailed ophthalmologic examination that included evaluation of visual acuity 
measurement, fundoscopy, and fundus photography after pupillary dilation. Color vision 
was tested using Ishihara plates. The size and extent of the visual field defects were assessed 
with a Humphrey Visual Field Analyzer (Carl Zeiss Meditec, Dublin, CA). Fundus photographs 
were taken using a Visucam Pro NM (Carl Zeiss Meditec). 
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Figure 1. Pedigree structure and mutation analysis of the Indonesian arRP family. A: In the family 
pedigree, affected individuals are indicated with filled symbols whereas unaffected relatives are 
indicated with open symbols. Genotypes are indicated below the pedigree symbols. M represents 
the c.l012C>T:p.(Arg338*) substitution, and+ represents the wild-type allele. B: Shown are sequence 
chromatograms of RPl corresponding to the three affected individuals (11:4, 11 :6, 11 :7), the proband's 
father 1:1), and one unaffected sibling (11:2). The substituted nucleotides are indicated with arrows. 
Homozygosity mapping 
EDTA blood samples were obtained from all participants. Total genomic DNA was extracted 
from peripheral leukocytes using a standard salting out procedure.30 DNA aliquots of each 
individual were stored at -20 oc. Affected individuals were genotyped on lnfinium Human 
OmniExpress 700 K arrays (lltumina, San Diego, CA) containing approximately 700,000 single 
nucleotide polymorphisms (SNPs). Array experiments were performed according to the 
protocol provided by the manufacturer. Homozygous regions were determined using PLINK 
software,31 with parameters manually set at a cut-off of 1Mb, and allowing two heterozygous 
SNPs and ten missing SNPs per window of 50 SNPs. 
Homozygous regions were ranked based on the size of the regions. The SNP positions 
were derived from the UCSC Human Genome Browser build NCBI36/hg18, March 2006. 
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Primers for RPl were designed using Primer3 software32 and are listed in Table 1. All coding 
exons and exon-intron boundaries ofthe RPl gene (NM_006269) were amplified with touch-
down polymerase chain reaction (PCR) from 50 ng of genomic DNA. PCR reactions were 
performed in a volume of 25 !Jl containing 50 ng genomic DNA, 0.2 1-JM of each primer, 2 mM 
MgCl2, 1 mM deoxyribonucleotide triphosphates, PCR buffer provided by the manufacturer, 
and 0.5 U Taq polymerase (cat. no. 18,038-042; Invitrogen, Breda, The Netherlands). 
PCR products were purified on NucleoSpin Plasmid QuickPure columns (Macherey-Nagel 
GmbH & Co, Duren, Germany) and analyzed either in the sense or antisense direction using 
dye termination chemistry (BigDye Terminator Cycle Sequencing Kit version 3.1; on a 3130 
DNA automated sequencer; Applied Biosystems, Foster City, CA). Segregation analysis of the 
RPl mutation identified in the family was performed with sequence analysis. The frequency 
of this mutation in 184 unrelated and unaffected ethnically matched Indonesian controls 
was assessed by digesting PCR products with Taql (New England Biolabs, Ipswich, MA), the 
recognition site of which is abolished by the alteration in RPl. 
Table 1. Primer sequences for the amplification of the RPl gene 
Primer Sequence (5'-3') Product size (base pairs) 
RPl exonl F CCATGTATTCGCTATGGTGC 
421 
RPl exon1 R TGTCCAGGTCTACAGGCTGC 
RPl exon2 F GGCAGGCACAGCATCAC 
434 
RPl exon2 R CACCATTCATATCCCACACG 
RPl exon3 F TTCAAGCCTAGGAGGTTGTTG 
357 
RPl exon3 R ATTGAAGCATGGATTTTGCC 
RPl exon4_1 F GATATTTCTAACTTCTCTGCCTTCC 
595 
RPl exon4_1 R CCCTGGATGATATCTGTGTCC 
RPl exon4_2 F ATCAAGAGGGCAGTTTGGC 592 
RPl exon4_2 R TTGAAGTTCTTGATACCAGTTTTG 
RPl exon4_3 F TCACATAATAATGGTTTGCCATC 
599 
RPl exon4_3 R TTTCTATGGAAATTCTTGGAAATC 
RPl exon4_ 4 F TCCCCTTAAAGGAGGGATAC 
580 
RPl exon4_ 4 R AATTGAATGATGAGCAATAGCC 
RPl exon4_5 F GAATGGCAAAGAAGAGTTTAGTTTC 
739 
RPl exon4_5 R ACTGAAGCTTGCAATTGGTG 
RPl exon4_6 F GCTTATTTGGTTCCCCTGC 
678 
RPl exon4_6 R AGAGCAACCTCCATCCAAAG 
RPl exon4_7 F ACTTGAAAGCTGCTGTTGCC 659 
RPl exon4_7 R GCTTAAATTACTGACATTTTGATGTG 
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RPl exon4_8 F CAATGTCTGCAATACCATTGAC 
658 
RPl exon4_8 R TCCTTCATTGGTCTCCTTTTC 
RPl exon4_9 F TTAATCCAAGAAGAGGTAGAGGC 
616 
RPl exon4_9 R CCTGGAATTCCTGCAACATAG 
RPl exon4_10 F TGGAATTTCAGTGTTCCAGG 
592 
RPl exon4_10 R TGATGACTACCCTTCTCCTCTG 
RPl exon4_11 F CATGGTAGTGACTCAGAACCTTTTC 
590 
RPl exon4_11 R CCTTCTTCCTCTAACCCCAAG 
RPl exon4_12 F GATAATGCCATTGGTGATATATTTG 
600 
RPl exon4_12 R CGTATTCGTCACATGTGCTTC 
Results and Discussion 
All three affected individuals (11 :4, 11:6, and 11 :7) presented with night blindness that started at 
an early age. They displayed gradual constriction of their visual field and low visual acuity. 
Fundus examination revealed typical RP including the bone spicule-like pigment deposits 
in the mid-peripheral retina and narrowing of the retin al vessels (Figure 2). The unaffected 
sibling (11 :2) did not experience night blindness or any other symptoms of RP. Apart from 
slightly decreased visual acuity, which is probably age-related, the proband's father (1:1) did 
not display any ophtha lmological symptoms either. The clinical data for all participating 
individuals are summarized in Table 2. 
Table 2. Clinical characteristics of participating family members 
Patient Current age Gender Age of onset Visual acuity Fundus 
ID (y) (y) appearance 
OD OS 
11:4 37 F 8 LP+ LP+ AA, BS, POD 
11:6 29 F 9 1/300 1/300 AA, BS, POD 
11:7 27 F 11 1/300 2/60 AA, BS 
1:1 64 M NA 20/40 20/25 Normal 
11:2 42 M NA 20/15 20/20 Normal 
Genome-wide SNP array analysis revealed four homozygous regions larger than 1 Mb that 
were shared among the three affected sib lings (Table 3). Whereas no obvious candidate 
genes resided in the three largest homozygous regions, the fourth largest homozygous region 
(1.3Mb, on chromosome 8q12.1) encompassed RPl. 
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Figure 2. Fundus photographs of affected individuals. Fundus photographs of the right eye from 
affected individual11:4. A: affected individualll:6 B: affected individual11:7 C: and the unaffected father 
1:1 D: who carries the mutation heterozygously. The ages at the time of investigation of individuals 11:4, 
11:6, and 11:7 were 36, 28, and 26, respectively. Fundus examination of the affected individuals revealed 
typical features of retinitis pigmentosa, bone spicule-like pigmentations were found in the mid 
periphery of retina {indicated with arrows), and retinal vessels were attenuated (arrowheads). 
Table 3. Overview of homozygous regions shared between the three affected individuals 
Start End Known 
Chr position position (hg Flanking Flanking Size Rank arRP gene Mutation Mutation 
(hg18) 18) SNPl SNP2 (Mb) in the (DNA) (protein) 
region 
16 77.098.649 80.083.138 rs8056971 rs12445748 3 
8 50.357.738 52.191.973 rsl7664823 rs10090890 2 2 
16 65.737.699 67.289.958 rs11643507 rs1886699 1.5 3 
8 55.432.038 56.765.392 rs7827900 rs7011147 1.3 4 RPl c.1012C>T pArg338' 
Sequence analysis of RP 1 revealed a novel homozygous substitution (c.l012C> T) in the 
proximal portion of exon 4, replacing an arginine residue at position 338 with a stop codon 
(p.Arg338*). Sequence chromatograms and segregation analysis of the RP 1 mutation are 
shown in Figure 1. This nonsense alteration was not present in the unaffected sibling, and 
was identified heterozygously in the unaffected father, who did not show any symptoms 
of RP. To rule out the possibility t hat the second allele (inherited from the mother) harbors 
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a deletion of RP 1 responsible for the loss of heterozygosity, we employed copy number 
analysis of our genome-wide SNP data and did not find any abnormalities in this genomic 
region. The mutation was not detected in 184 ethnically matched and unrelated Indonesian 
control subjects. 
The RP 1 gene consists of four exons and gives rise to a transcript of approximately 7.1 
kb encoding a protein of 2,156 amino acids. The RP1 protein is localized in the region of 
the connecting cilium and axoneme of photoreceptor sensory cilia.7 RP1 is a photoreceptor-
specific microtubule-associated protein that regulates the length and stability of the 
photoreceptor axoneme mediated by the two putative doublecortin domains at the 
N-terminus of RP1.33 The doublecortin domain is essential for the correct localization and 
proper stacking of outer segment discs.34' 36 Moreover, a region of the RP1 protein between 
codons 486 and 635 bears some homology to the Drosophila melanogaster bifocal protein 
that is required for normal photoreceptor morphogenesis in the fruit fly.7 
The many mutations in exon 4 of RP1, which cause autosomal dominant RP, all tend 
to cluster in a "hot spot" region between amino acid residues 500 and 1053 (Figure 3).&-24 
Since these mutations are expected to be insensitive to nonsense-mediated decay due to 
the absence of a downstream intron, they result in the production of truncated proteins.33 
Previously, mutant RP1 mRNA was found to be present in a human lymphoblast cell line 
carrying the p.(Arg677*) variant, providing evidence that this mRNA indeed escapes the 
nonsense-mediated mRNA decay process. The resulting truncated proteins lack important 
functional domains, but are still able to interact with wild-type RP1 and/or microtubule-
associated proteins.35 This hypothesis is supported by a previous study, which showed that 
in Rp1-myc mice that expressed only the 661 N-terminal amino acids of RP 1, truncated 
proteins are produced and localize correctly to the axonemes of photoreceptor cells.36 Due 
to the retained ability to interact with microtubule-associated proteins and/or wild-type RP1, 
these mutated proteins are thought to abolish the function of the normal RP1 molecules in a 
dominant-negative fashion . 
For RP 1 mutations that cause recessive RP, the story is more complex. These mutations 
can be clustered in four different groups (Figure 3). First, protein-truncating mutations that 
reside in exon 2 or exon 3 are expected to undergo nonsense-mediated decay, and therefore 
can be considered true loss-of-function alleles.26•28•29 The second group consists of missense 
mutations that appear not to cluster.25•28 These changes cause autosomal recessive RP 
because the produced proteins retain residual function and therefore are not pathogenic when 
present in the heterozygous state. The third group includes protein-truncating mutations 
near the 3' end of the gene.6•20•26.27 Most likely, the resulting proteins display only a minor loss 
of their (-terminal portion, preserving the majority of functional domains, and have residual 
activity. Therefore, these variants are also pathogenic only when present homozygously. 
Finally, the most interesting group of mutations encompasses the few nonsense changes 
located in the proximal part of exon 4,2°·26 and includes the mutation identified in this study. 
Since the mRNAs deriving from these alleles are expected to escape nonsense-mediated 
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• DCX domains • BIF domain 
Figure 3. RPl gene and identified mutations. Schematic representation of the location of mutations 
in the RPl gene. Below are mutations responsible for dominant retinitis pigmentosa (adRP) whereas 
mutations above the gene cause autosomal recessive RP (arRP). The mutation identified in this study is 
indicated with a black rectangle. The portion ofthe gene that encodes the doublecortin (DCX) domains 
(amino acids 36-118 and 154-233) is indicated with green, and the Drosophila melanogaster bifocal 
(BIF) domain (amino acids 486-635) is depicted in red. Missense changes, for which the pathogenicity 
is uncertain, are not included in this scheme. Four groups of arRP-causing mutations are marked with 
numbers. GR.l=protein-truncating mutations that reside in exon 2 or exon 3 (nonsense-mediated 
mRNA decay); GR.2=missense mutations; GR.3=protein-truncating mutations near the 3' end of the 
gene, preserving residual activity; GR.4=truncating mutations located in the proximal part of exon 4. 
mRNA decay, truncated RPl proteins are likely to be produced. However, unlike the adRP-
causing proteins, the truncated RPl proteins apparently lack some domains that are crucial 
for the interactions with wild-type RPl or microtubule-associated proteins, and therefore no 
dominant-negative effect emerges. This is supported by the absence of clinical symptoms in 
the father, who carried the p.(Arg338*) mutation heterozygously. 
Taken together, the results of our study indicate that early protein-truncating 
mutations in RPl, including p. (Arg338*), cause autosomal recessive RP, supporting the 
idea that haploinsufficiency is probably not causative for autosomal dominant RP. A better 
understanding of the pathophysiology of RP 1 mutations may ultimately lead to an improved 
prognosis, and provide new tools for therapeutic interventions. 
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Abstract 
Bietti's crystalline dystrophy (BCD) is a rare, autosomal recessive retinal degenerative disease 
associated with mutations in CYP4V2. In this study, we describe the genetic and clinical 
findings in 19 unrelated BCD patients recruited from five international retinal dystrophy 
clinics. Patients underwent ophthalmic examinations and were screened for CYP4V2 
mutations by Sanger sequencing and quantitative polymerase chain reaction (qPCR) copy 
number variation screening. Eight CYP4V2 mutations were found in 10/19 patients, including 
three patients in whom only monoallelic mutations were detected. Four novel mutations 
were identified, i.e. c.604G>A:p.(Giu202Lys), c.242C>G:p.(Thr81Arg), c.604+4A>G:p.(?), and 
c.1249dup:p.(Thr417Asnfs*2). In addition, we identified a heterozygous paternally inherited 
genomic deletion of at least 3.8 Mb, encompassing the complete CYP4V2 gene and several 
other genes, which is novel. Clinically, patients demonstrated phenotypic variability, 
predominantly showing choroidal sclerosis, attenuated vessels, and crystalline deposits 
of varying degrees of severity. To our knowledge, our study reports the first heterozygous 
CYP4V2 deletion and hence a novel mutational mechanism underlying BCD. Our results 
emphasize the importance of copy number screening in BCD. Finally, the identification of 
CYP4V2-negative patients with indistinguishable phenotypes from CYP4V2-positive patients 
might suggest the presence of mutations outside the coding regions of CYP4V2, or locus 
heterogeneity, which is unreported so far. 
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NOVEL INSIGHTS INTO THE MOLECULAR PATHOGENESIS OF 
CYP4V2-ASSOCIATED BIETII'S RETINAL DYSTROPHY 
Bietti crystalline dystrophy (BCD) {OMIM 210370) is a rare retinal degenerative disease that 
is inherited in an autosomal recessive pattern.1 First described in three patients by the 
Italian ophthalmologist Bietti (1937) in Rome, BCD is defined and characterized by glistening 
crystalline deposits in the fundus associated with atrophy of the retinal pigment epithelium 
(RPE) and choroidal sclerosis.2• 3 Crystal deposits at the corneal limbus have also been 
documented.2 Clinically, patients affected with BCD present between the second and fourth 
decade of life with impaired vision, nyctalopia, and paracentral scotomas. Vision loss and 
concentric visual field constriction continue progressively, often resulting in severe visual 
impairment by the fifth or sixth decade.1.4 
BCD has been reported to be more prevalent in Asian populations, although patients 
of European, Middle Eastern, African, and North and South American origin have also been 
documented.1•5 Moreover, it has been estimated that up to 3% of patients initially diagnosed 
with nonsyndromic retinitis pigmentosa can be accounted for by BCD.6 BCD is known to be 
caused by mutations in the CYP4V2 gene, localized on chromosome 4q35.1 Currently, up to 
57 mutations in CYP4 V2 have been associated with BCD; the majority are missense/nonsense 
mutations, as well as several small insertions, deletions, and splicing mutations.1•4• 7"21 CYP4 V2 
encodes a member of the cytochrome P450 superfamily, characterized as a fatty acid oxidase 
involved in lipid metabolismY Surprisingly, evidence of altered lipid metabolism has also 
been demonstrated in fibroblasts and lymphocytes of patients with BCD, in which synthesis 
of n-3 polyunsaturated fatty acids was decreased.23 Crystalline deposits have also been 
reported in these cells.24 Furthermore, patients with BCD have been shown to have abnormal 
serum fatty acid profiles, with increased stearic acid and reduced oleic acid concentrations.25 
These findings suggest that BCD represents a systemic condition that is not limited to the 
eye. However, it is still unclear whether these systemic abnormalities are actually disease-
causing or whether they are subclinical.1 It has been hypothesized that the retinal crystals 
represent lipids or fatty acids.25 Finally, the phenotypic spectrum of CYP4V2 mutations has 
been expanded to autosomal recessive retinitis pigmentosa (arRP), without intraretinal 
crystals being observed in affected patients.6 
In this study, we present novel genetic and clinical findings in a large international cohort 
of 19 probands from unrelated families with apparent Bietti crystalline retinal dystrophy. 
Material and methods 
Subject enrolment and clinical evaluation 
Nineteen patients were recruited from and evaluated at the McGill Ocular Genetics 
Laboratory and Clinic at the McGill University Health Centre, in Montreal Canada; the Centre 
for Ophthalmology at the University ofTubingen, in Germany; the Ophthalmic Genetics Clinic 
at the Ghent University Hospital, in Belgium; the Rare Retinal Disease Centre (Siegburg Eye 
Center), Germany; and INSERM in Montpellier, France. Informed consent was obtained and 
research protocols adhered to the tenets of the Declaration of Helsinki. Institutional Review 
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Board (IRB)/Ethics Committee approval was obtained. Patients had histories and pedigree 
analysis taken, and underwent ophthalmic examination including visual acuity (VA) testing, 
Goldmann visual field testing, refraction, slit lamp examination, dilated fundus examination, 
fundus photography, fundus autofluorescence (FAF), optical coherence tomography (OCT), 
and full-field flash electroretinography (ERG), recorded in accordance with the guidelines of 
the International Society for Clinical Electrophysiology of Vision (Marmor et al. 2009). One 
patient did not have Goldmann visual field testing nor OCT testing. In addition, fluorescein 
angiography was also performed in two patients. Phlebotomy in ethylenediaminetetraacetic 
acid tubes was performed to collect venous blood for genetic studies. 
Mutation analysis 
Homozygosity mapping (only performed in Lebanese family A) 
Genomic DNA was isolated from lymphocytes by standard salting out procedures.26 DNA 
samples of all four affected individuals from family A were genotyped on the GeneChip 
Genome-Wide Human SNP Array 5.0 that contains 500,000 polymorphic SNPs in addition to 
420,000 non polymorphic probes for the detection of germ line copy number variations (CNVs) 
(Affymetrix, Santa Clara, CA). Array experiments were performed according to protocols 
provided by the manufacturer. The 5.0 array data were genotyped using Affymetrix Genotype 
Console (version 2.1), subsequently regions of homozygosity were identified using Partek 
Genomics Solution (version 6.1), as described previously.27 Regions containing more than 
250 consecutive homozygous SNPs were considered as homozygous regions, on average 
corresponding to a genomic size of 1Mb or more. 
Sanger sequencing of CYP4V2 
All exons and intron-exon boundaries of CYP4V2 (N M_207352) were amplified under 
standard polymerase chain reaction (PCR) conditions using primers listed in Table Sl. PCR 
products were purified on Nucleospin Plasmid Quick Pure columns (Machery Nagel, Duren, 
Germany) and sequenced in sense and antisense directions with dye termination chemistry 
on a 3730 or 2100 DNA analyzer (Applied Biosystems, Carlsbad, CA). 
Bioinformatic analysis and evolutionary comparison for missense mutations 
For each of the missense changes identified in this study, the potential pathogenicity was 
assessed using online prediction software tools SIFT (Sorting Intolerant from Tolerant) and 
PolyPhen.28 Grantham and PhyloPscoreswerealsodetermined.ln addition, the ExomeVariant 
Server database was checked for the presence and minor allele frequencies of these novel 
mutations. Four computational programs, SpliceSite finder-like, MaxEntScan,29 NNSPLICE,30 
and Human Splicing Finder31 were employed to predict the effect on the canonical acceptor 
and donor splice sites. 
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CNV screening using qPCR and SNP chip arrays 
CNVscreeningon genomic DNA was performed in the families with onlyoneCYP4V2 mutation 
(probands F, I, and J), using 13 quantitative PCR (qPCR) assays, covering the 11 exons of 
CYP4V2 and two reference genes (ZNFBO and GPR15) on the LightCycler 480 (Roche, Basel, 
Switzerland). Four controls were included in each experiment. Conditions and primers can 
be found in Table 52. Data analysis was performed using qBasePius (Biogazelle, Zwijnaarde, 
Belgium). 
Genome-wide SNP chip analysis was performed using the HumanCytoSNP-12 BeadChip 
platform (lllumina, San Diego, CA) (proband F) in order to delineate the deletion. 
Results 
Patient demographics and genotyping 
In a consanguineous Lebanese family that was initially diagnosed with atypical RP (Figure 
1A), genome-wide SNP array analysis was combined with homozygosity mapping to identify 
genomic regions that could potentially harbor the causative genetic defect. In total, only 
two homozygous regions were identified that were identical between the four affected 
siblings, one of which harbored the CYP4V2 gene, located on chromosome 4. Sequence 
analysis revealed a homozygous missense mutation in CYP4V2, c.332T>C:p. (lle111 Thr) 
that completely segregated in the family (Figure1A). Most notably, the proband presented 
with severe choroidal sclerosis but no crystals were found on fundus examination. Upon 
further family examination, an affected younger sibling, however, was noted to have diffuse 
crystalline deposits in the fundus. 
Subsequently, 18 additional patients were ascertained that were diagnosed with retinal 
dystrophy and presented or had presented with crystalline deposits. Sequence analysis of all 
exons and intron-exon boundaries of CYP4V2 in this cohort revealed nine more patients with 
CYP4V2 mutations, four carrying apparent homozygous mutations, three with compound 
heterozygous mutations, and two individuals with only one heterozygous intragenic variant 
(Figure 1). All these patients were of Caucasian origin. 
Patients with CYP4V2 mutations included seven females and three males, with ages 
rangingbetween33 and 77years.lnitially,eightdifferent mutations in CYP4V2were identified, 
including four previously documented and four novel mutations. The novel mutations were 
two missense, one splice site and one frameshift mutation; namely c.604G>A:p.(Giu202Lys), 
c.242C>G:p.(Thr81Arg), c.604+4A>G:p.(?), and c.1249dup:p.(Thr417Asnfs*2) (Table1) . 
The novel missense mutations were not observed in the comprehensive Exome Variant 
Server database, while the already published variants p.(Arg400Cys) and p.(Arg465Giy) have 
been identified with low minor allele frequencies of 0.0154and 0.0077, respectively. The most 
prevalent mutations identified in our cohort were the c.ll98C> T:p.(Arg400Cys), c.332T>C:p. 
(lle111 Thr), and c.802-8_810delinsGC:p.(?) mutations, each accounting for 3 of the 18 mutant 
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Family A FamilyB 
"* .. m cs. MIM MIM Ml+ Ml+ MIM Ml+ MIM 
M: c.332T>C:p.(llel11Thr) M: c.604G>A:p.(Giu202Lys) 
FamllyC FamilyD Family E Familyf 
T T ¥ T .....  
MIM MliM2 MliM2 MIM 
M: c.604+4A>G:p.(?) Ml: c.802--8_810delinsGC:p.(?) Ml: c.242C>G:p.(Thr81Arg) M: c.1249dup:p.(Thr417Asnts•) 
M2: c.l198C>T:p.(Arg400Cys) M2: c.1198C>T:p.(Arg400Cys) 
FamllyG FamlfyH Family I FamilyJ 
T T T T 
MliM2 MIM Mi+ Ml+ 
Ml: c.802-8_810delinsGC; p.(?) M: c.l393A>G:p.(Arg465Giy) M: c.332T>C:p.(llell1Thr) M: c.802-8_810delinsGC:p.(?) 
M2: c.l198C>T:p.(Arg400Cys) 
Figure 1. Pedigrees of 10 families with Bietti crystalline dystropy carrying mutations in CYP4V2. Affected 
individuals are indicated with filled symbols, whereas unaffected relatives are indicated by open 
symbols. The pro bands are indicated with an arrow and slashed symbols indicate deceased. Mutated 
alleles are indicated with M symbols and wild-type allele with plus symbols. 
alleles identified in the probands. We found the p.(Arg400Cys) mutation in three patients, the 
p.llelll Thr in two patients, and the c.802-8_810delinsGC:p.(?) change in three patients. 
To evaluate the pathogenicity of the novel mutations, in silico analysis using a variety of 
prediction programs was performed. The two novel missense mutations, p.(Thr81Arg) 
and p.(Giu202Lys), affect amino acid residues that are highly conserved among vertebrate 
species. Both substitutions have a high Grantham score (Table2). Moreover, the p.(Giu202Lys) 
mutation, is predicted to be pathogenic by the two in silica programs SIFT and PolyPhen 
(Table2) . 
The p.(Thr417Asnfs*2) frameshift mutation is presumed to create a premature stop 
codon one amino acid residue downstream, and in addition might be targeted for nonsense-
mediated decay (NMD). In silico prediction of the c.604+4A>G splice site mutation showed a 
decrease in the strength of the splice donor site due to the alteration (i.e., 12% decrease in 
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Table 1. Identified CYP4V2 mutations in this study 
Proband Type Allele 1 Allele 2 
A Homozygous c.332T>C p.(llelllThr) c.332T>C p.(llelllTh r) 
B Homozygous c.604G>A p.(Giu202Lys) c.604G>A p.(Giu202Lys) 
c Homozygous c.604+4A>G Splicing c.604+4A>G Splicing 
D Compound c.802- Splicing c.1198C>T p. (Arg400Cys) heterozygous 8 810delinsGC 
E Compound c.242C>G p.(Thr81Arg) c.1198C>T p.(Arg400Cys) heterozygous 
F Compound c.l249dup p.(Thr417 Asnfs*2) Genomic Genomic heterozygous deletion deletion 
G Compound c.802- Splicing c.1198C>T p. (Arg400Cys) heterozygous 8 810delinsGC 
H Homozygous c.l393A>G p.(Arg465Giy) c.l393A>G p.(Arg465Giy) 
Heterozygous c.332T>C p.(llelllThr) No second allele found 
J Heterozygous c.802- splicing No second allele found 8 810delinsGC 
SpliceSite finder-like, 52% in MaxEntScan, 89.5% in NNSPLICE, and 9% decrease in Human 
Splicing Finder [HSF]), suggesting that this mutation might alter CYP4V2 splicing. 
Upon assessing the segregation of mutations in available family members, an 
inconsistency was noted for proband F, who carried an apparent homozygous mutation 
c.1249dup:p.(Thr417Asnfs*2). The mutation was found to segregate in the patient's mother 
however not in her father, while paternity was confirmed. Subsequently, genomic qPCR 
analysis revealed a heterozygous deletion encompassing all exons of CYP4V2, in both 
proband F and her father (Figure 2A). 
To further delineate the breakpoints and determine the extent of this new deletion, SNP-
chip analysis was performed. The deletion size was demonstrated to vary between 3.8 and 
4.1 Mb, spanning the entire CYP4V2 gene and several other genes, including two OMIM genes 
(KLKBl and Fll) (Figure 28). No CYP4V2 deletions were detected in the two other probands 
who carried a single heterozygous allele (data not shown). 
Patient phenotypes 
The clinical data for all10 patients that carried one or two CYP4V2 alleles are described in 
Table3. Disease onset in these patients ranged from 18 to 57 years of age, with duration of 
illness ranging from 8 to 33 years. Visual acuities (VA) varied extensively and ranged from 
20/20 to light perception (LP), with large discrepancies in VA between both eyes occasionally 
noted. With the exception of three patients with no refractive error, all subjects were myopic 
with astigmatism with refraction ranging from -0.50 to -6.00 dioptres. Goldmann visual 
fields also revealed a wide spectrum of severity, ranging from relatively normal to severe 
constriction (5-10° remaining). Central, paracentral, and ring scotomas were also noted. 
Crystalline deposits were noted in the corneal limbus ofthree patients. 
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In proband D, crystalline deposits were seen on the lens as well as the limbus (Figure 3). 
Posterior subcapsular cataracts (PSCC) and cortical opacities were noted in several patients. 
Table 2. Pathogenicity predictions for missense and splice site mutations based on in silica 
analyses 
Mutation 
consequence 
p.(Thr81Arg) 
p.(llelllThr) 
p. (Giu202Lys) 
p.(Arg400Cys) 
p.(Arg465Giy) 
eDNA 
c.604+4A>G 
PhyloP 
2.55 
4.56 
5.61 
4.48 
1.25 
Amino 
acid 
p.(?) 
Amino acid change predictions 
Grantham 
score 
71 
89 
56 
180 
125 
Mutation 
consequence 
Altered splicing 
SIFT 
Tolerated 
Deleterious 
Deleterious 
Deleterious 
Deleterious 
PolyPhen 
Benign 
Probably 
damaging 
Probably 
damaging 
Probably 
damaging 
Probably 
damaging 
Splicing predictions 
SSF MaxEnt NNSPLICE 
(0-100) (0-12) (0-1) 
84.07 Q 8.95 Q 0.98 Q 0 
73.99 4.29 
(-12.0%) (-52.1%) (-100%) 
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List of missense and splice site mutations identified in this study and predictions of their consequences with the 
use of in silico program (SIFT and PolyP hen). Splicing prediction shows the percent decrease in comparison to 
the original splice donor site scores. In addition, HSF predicted a novel splice donor site in position c.604+4. SIFT, 
sorting intolerant from tolerant; MAF, minor allele frequency; HSF, Human Splicing Finder; SSF, Splice Sequence 
Finder; NNSPLICE, Splice Site Prediction by Neural Network. 
'Heterozygous alleles of total number of chromosomes. 
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Figure 2. Detection and delineation of a CYP4V2 deletion in proband F using qPCR and SNP-chip 
analysis. C (control), P (patient), WT (wild type). A: I and II: qPCR on proband F revealed a copy number 
of one for allll assays of CYP4V2, corresponding with a heterozygous total gene deletion. The same was 
found for the other deleted genes; KLKBl and Fll. Ill : Demonstration of paternal origin of the delet ion. 
B: 1: SNP-chip analysis demonstrates deletion with size -4 Mb, spanning the entire CYP4V2 gene and 
several other genes, two of which are OMIM genes (KLKBland Fll) 
Figure 3. Crystall ine deposits seen on the lens (i) and corneal limbus (ii) of 54-year-old proband D with 
compound heterozygous mutations in CYP4V2 c.802-8_810delinsGC:p.(?) and p.(Arg400Cys). 
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The predominant findings on fundus examination were extensive choroidal sclerosis, 
crystalline intraretinal deposits, attenuated vessels, and intraretinal spicular pigmentation 
in varying degrees of severity (Figure 4). Macular atrophy was often seen. Of note is proband 
A, whose fundus examination revealed choroidal sclerosis and peripheral pigmentation 
but no crystal deposits. On OCT, however, crystal deposits were observed in the subretinal 
space (Figure 4A and SA). Proband J was similarly reported to have a "choroideremia-like" 
fundus appearance, with deposits seen in the subretinallayer on OCT. Proband G was also 
noted to have an unusual fundus appearance, consisting of large discoid patches of atrophy 
separated by ridges of relatively intact tissue, along with the presence of choroidal sclerosis 
and crystalline deposits (Figure 4G). 
On OCT, two types of crystals were visualized in patients- tiny intra- and inner retinal 
crystals and larger, encapsulated subretinal crystals. All nine patients who had OCT were 
noted to have fine inner retinal crystals; five among these patients also showed larger 
subretinal crystals (Figure SA, B, D, and E, no image available for proband J). Foveal thinning 
and remodeling of retinal architecture were other pertinent findings. In addition, cystoid 
macular edema (CME) was documented in two patients. ERG was abnormal in all patients 
who underwent testing, ranging from non recordable to subnormal photoreceptor function. 
Disease progression was noted in most patients for whom previous clinical data were 
available, with declining VA and visual fields. Progression of disease in the fundus of proband 
F over 18 years was documented photographically (Figure 4F) and shows the development 
of the choroidal sclerosis and the clinical disappearance of the retinal crystals. The clinical 
presentation of patients without identified CYP4V2 mutations was indistinguishable from 
that of the CYP4 V2-positive patients. The phenotypes of five of the CYP4 V2-negative patients 
are shown in Figures Sl and S2. These patients demonstrated the same severe changes that 
were present in the patients with CYP4V2 mutations, including choroidal show and sclerosis, 
the diffuse nature of disease, bone spicules, and macular involvement with or without 
crystalline deposits. OCT images similarly reveal the fine inner retinal crystals as well as the 
larger sometimes encapsulated subretinal crystals. 
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Figure 4. Fundus photographs. Proband A: 57-year-old patient with homozygous mutations in 
CYP4V2 p.(llelllThr). Fundus photograph shows choroidal sclerosis and peripheral pigmentation. No 
crystal deposits are seen in this patient's fundus. Proband B: 67-year-old patient with homozygous 
mutations in CYP4V2 p.(Giu202Lys). Fundus photograph shows severe choroidal sclerosis involving 
the entire macula and fovea, narrowing of the retinal vasculature, with relatively normal optic nerve 
appearance. Several crystalline deposits can be seen in the macula. Proband C: 47-year-old patient with 
homozygous mutation in CYP4V2 c.604+4A>G:p.(?). Severe choroidal sclerosis and crystalline deposits 
in macula. Proband D: 54-year-old patient with compound heterozygous mutations in CYP4V2 c.802-
8_810delinsGC:p.(?), p.(Arg400Cys). Severe choroidal sclerosis and area of visible sclera. Few crystalline 
deposits seen in midperiphery. Proband E: A 41-year-old patient with compound heterozygous 
mutations in CYP4V2 p.(Thr81Arg), p.(Arg400Cys). Mild choroidal sclerosis, crystalline deposits, and 
pigment clump. Some maculopathy is seen. Retinal vasculature remains relatively normal. Proband 
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F: 49-year-old patient with homozygous mutations in CYP4V2 p.(Thr417Asnfs*2). Fundus photographs 
show progression of disease in left eye (left to right). Of note is the progressive choroidal sclerosis, 
vascular attenuation and decreasing presence of crystalline deposits over time. Photos taken at ages 
31, 38, and 49, respectively. Proband G: 77-year-old patient with compound heterozygous mutation 
in CYP4V2 c.802-8_810delinsGC; p.(?}, p.(Arg400Cys). Unusual fundus appearance (left) showing large, 
similarly-sized discoid patches of atrophy separated by small ridges of intact tissue with presence of 
crystals and choroidal sclerosis. Optic disk and retinal vasculature appear relatively normal. Fundus 
autofluorescence (middle) confirms areas of atrophy with patches of decreased autofluorescence 
surrounded by walls of lipofuscin metabolism. Proband H: 38-year-old patient with homozygous 
mutations in CYP4V2 p.(Arg465Giy). Choroidal sclerosis with diffuse crystalline deposits and pigment 
clumps in midperiphery. Proband 1: 33-year-old patient with one heterozygous mutation in CYP4V2 
p.(lle111 Thr). Fundus photograph reveals nondescript retina with few crystalline deposits. 
51 
Figure 5. Optical coherence tomography images. Proband A: 57-year-old patient with homozygous 
mutations in CYP4V2 p.(llelllThr). Optical coherence tomography shows severe foveal thinning and 
cystoid macular edema. Of note are two types of crystal that can be seen; tiny intraretinal crystals and 
large encapsulated subretinal crystals (red arrows). Proband B: 67-year-old patient with homozygous 
mutations in CYP4V2 p.(Giu202Lys). Shown are remarkable thinning of the fovea and remodeling of 
retina, as well as presence of both intra retinal and subretinal crystals. Proband C: 47-year-old patient 
with homozygous mutation in CYP4V2 c.604+4A>G:p.(?}. Remodeling of retina with almost complete 
loss of architecture is seen, as well as tiny intraretinal crystals. Proband D: 54-year-old patient with 
compound heterozygous mutations in CYP4V2 c.802-8_810delinsGC:p.(7), p.(Arg400Cys). Optical 
coherencetomographyshowssevere foveal thinning, remodelingofthe retina, a swell as both intraretinal 
crystals and larger subretinal crystals. Proband E: A 41-year-old patient with compound heterozygous 
mutations in CYP4V2 p.(Thr81Arg), p.(Arg400Cys). Presence of both intra retinal and subretinal crystals. 
Photoreceptors in fovea remain intact. Proband F: 49-year-old patient with homozygous mutations in 
CYP4V2 p.(Thr417Asnfs*2) . Optical coherence tomography shows fine intraretinal crystals. Proband 
1: 33-year-old patient with one heterozygous mutation in CYP4V2 p.(llelllThr). Optical coherence 
tomography reveals presence of intra retinal crystals. 
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Table 3. Clinical features of 10 BCD patients 
Visual acuity Visual field 
Age at Initial Initial 
Family ID Ase Gender Visual Visual 
onset vlsuol visual Refraction Refraction (OSl' .-. - Initial visual Initial vlsuol Visual field 
acuity acuity 
Acuity Acuity (OD) fleld(OD) field(OS) (OD) Visual field (OS) 
(OD) (OS) (OD) (OS) 
A MOGL3254 57 30 M N/A N/A 20/100 20/50 
-o.so 70' (V4e) 65' 
Plano+ !.SOx 180' N/A N/A 70' 014e) 65' (1114e) 
+2,QQ X 18Q' (1114e) 
70"with 
pericentral 
70' 1·1ith patchy 
MOGL3138 67 45 M N/A N/A 20/150 12/400 -J.SQ +1 X 180' -1.50+1x 180' N/A N/A defect 0l4e), defects (V4e), 5' with 
peripheral peripheral island 
island (14e) (14e) 
20/100 20/200 
-4.75 
Concentric narrowing;to sn with target 
residual islands peripheral (targetV4e), 
c 13573-BD 47 30 (age (age 30-Jan LP -5.0 - 1.5 X 9Q' 1114e, peripheral residual slim islands z 
38) 38) -1.75 X 95' central island <3' 0 (age38) 
< m 
- 1.75 r 
D 3338-BD 54 24 N/A N/A HM HM -Q. 75 -1.0 X 66' N/A N/A Residual is lando peripheral (targetV4e) nz - 0.5 X 76' 
Normal outer boundari es with 1114e, 
~~ 
..,_G) 
3549-BD 20/20 20/20 20/20 20/20 
-1.25 
N/A N/A decreased sensitivity and 'patchy" iS ~ 41 20 -1.0-0.75x77' 
-0.5 X 105' ' Vl defects with l4e and 13e targets ) > -VlZ 
Mild concentric Vl-1 
Nonmal peripheral oo 
Normal constriction, Q _, limits, pericentral 
peripheral limits, central 
Mild concentric ~I 
sensitivity loss constriction, central mm pericentral scotoma 0~ 
Plano Plano 
(12 not seen), (V4), residual scotoma with small OJO IW'I 49 31 20/40 20/40 HM 20/400 sensitivity loss 
central relative preserved patch -r (12 not seen), temporal mm 
scotoma (13 and nasal to blind spot -1n 
enlarged blind crescent (1114), ::::lc 
14), en larged blind (V4) -, 
spot 12 and 13 not Vl)> 
spot ;;o ;;o 
seen ~j;l 
20/50 20/200 
+1.0 Z -1 )> I G 1090&-BD 77 57 (age (age 20/100 20/400 10 N/A N/A N/A N/A 
'0 
75) 75) -2.0 X 110' OG) 
-<m 
Vlz 
-1m 
;;oVl 
o -
I-' -uVl 
<.D IO 
U1 -< "T1 
f-' n 
lO Mild concentric I Ol )> 
constriction, Considerable -o 
---1 
enlarged concentric m ;:o 
blind spot (V4) constriction, :t considerable enlarged blind spot 
H RCD 38 30 20/30 20/25 20/40 20/30 Plano Plano N/A N/A 
sensitivity (V4) considerable 
loss, doughnut sensitivity loss, 
shared doughnut shaped 
annular annular scotoma 
scotoma (14), (14), 12 and 13 not 
12 and 13 not seen 
seen 
20/25 20/40 
-3.25 Concentric narrowing to 40° with target Concentric narrowing to 10°, no 
11431-USHll 33 21 (age (age 20/40 20/50 -4.0-1.5xl74o 
-us x r 1114e (age 22) peripheral islands (target 1114e) 
22) 22) 
Constriction 
Concentric 
of peripheral 
reduction, ring 
visual field, 
scotoma and 
6284-BD 51 18 M 20/20 20/20 20/40 20/40 Plano Plano 
residual central 
ring scotoma, N/A N/A 
visual field island 
finally residual 
of central so 
central island of 
central 5o 
Symptoms Morphology 
Family Color vision 
t/.yctalopia Photophobia Co mea Lens Macula Peripheral Retinl 
defect 
A N 
'" 
Clear Early cortical changes OS Relative foveal sparing 
Areas of RPE atrophy and choroidal sclerosis, normal 
vessel caliber, peripheral bony spicules 
B N Clear PSCC Macular involvement 
Crystals in periphery and posterior pole, choroidal 
sclerosis, tigroid 
c y N Clear Cortical Opacities Atrophic 
Optic disks vital, narrow vessels, generalized RPE atrophy, 
crystalline deposits 
D N N 
Limbus: crystalline 
Crystalline deposits, PSCC 
Huge macular hole with neurosensoric Optic disks vital, na rrow vessels, generalized RPE atrophy, 
deposits detachment on OD, macula atrophic OS crystalline deposits 
Optic disks vital, peripapillary atrophy, vessels moderately 
N Clear Clear None commented attenuated, posterior pole Y!ith patchy RPE-atrophy and z 
crystalline deposits, some pigment clumps ~ 
m 
,-
Patchy outer retinal and choriocapillaris atrophy with fine nZ 
-.:: !£> 
Y (severe R/G; Very small Extreme outer retinal and choriocapillaris white retinal crystals mostly in mid periphery, spicular )2 Cl y N Mild lenticular sclerosis Inner retinal pigment migration with some larger pigment ;s ~ 
severe B/Y) peripheral crystals atrophy, small white inner retinal crystals patches, small scalloped patches of preserved retina in ' Vl )> _ 
periphery VlZ Vl--; 
o o 
0--; 
G Y(mild) N/A Clear Pseudophakic Severe atrophy, crystals and yellow white Pigmentary changes ~I flecks mm o s: 
m O 
Patchy outer retinal and choriocapillaris atrophy with fine - ,-
Y (medium R/G Patchy outer retinal and choriocapillaris mm 
white retinal crystals mostly in midperiphery, spicular =j n 
H N defect; severe Clear Clear atrophy with fine white inner retinal _ c inner retinal pigment migration, with some larger pigment - ,-
B/Y) crystals Vl )> patches Al;;o 
~ j;l 
Cortical opacities Macular edema and inferior gliosis 
Optic disks vital, narrow vessels, RPE atrophy, crystalli ne z :....; 
Clear deposits )>I 
' 0 
O Cl 
Initially clear, finally Crystalline deposits, progressive atrophy during follow up, 
u;m 
Diffuse crystalline deposits and reduced --; Z y y Crystalline deposits primarily subcapsular post 
reflexes finally choroideremia-llke fundus 
;;om 
o !£1 cataract 
-u Vl ,_. 
1.0 I O 
--..J -<m 
f-' n 
lO Family Electrophysiology OCT/FAF Other ocular Other systemic :r: 00 )> 
-u 
FAF: Patchy hypofluorescence OCT: intra retinal and subretinal -l 
A Cone: 25% residual function, rod: 20% residual function N/A N/A m 
crystals and edema ;;o ~ )> 
Cone: SuV out of 120uV b wave, Rod: 12uV out of 220uV 
Foveal thinning, remodeling, intraretinal and subretinal crystals N/A N/A bwave 
c Non recordable Retinal atrophy, crystalline deposits N/A N/A 
D Non recordable 
OD: huge macular hole and neurosensoric detachment OS: 
retinal atrophy, crystalline deposits N/A 
Depression, elevated blood pressure, elevated 
cholesterol levels 
Ganzfeld: scotopic and photopic responses on the lower 
normal limits, somewhat delayed IT; mfERG: central Retinal atrophy, crystalline deposits, central retina (fovea) with Patient notes central vision defects and 
N/A 
responses with almost normal amplitudes and IT, in almost intact photoreceptors difficultyreading 
outer rings IT delayed, amplitude subnormal 
Outer retinal atrophy with fine retinal crystals at all levels, 
ERG: absent rod-specific and cone-specific responses crystals most visible on infrared and redfree reflectance N/A N/A 
imaging, blue light fundus autofluorescence virtually absent 
Full-field ERG: Dark adapted ERG 55% of normal, light 
G ad apted 45% of normal, flicker40% of normal; mfERG: OCT not available, FAF multiple patchy areas of intensity loss N/A N/A 
severe central amplitude reduction 
Outer retinal atrophy with fine retinal crystals at all levels, 
ERG: absent rod-specific responses; residual cone- crystals most visible on infrared and redfree reflectance 
H 
specific responses 
imaging, blue light fundus autofluorescence shows N/A N/A 
hypofluorescent scalloped patches surrounded by thin 
interconnecting bridges of norma- and hyperautofluorescence 
Ganzfeld ERG extinguished, mfERG central emaining 
Cystoid macular edema, crystalline deposits N/A 
Hearing problems, thalassemia minor, chronic 
responses nephropathy 
Initially negative scotopic ERG. Finally nondetectable. 
Deposits in deep retinal layer, obscured in fluorescein 
N/A N/A 
angiography 
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We identified eight different CYP4V2 mutations in 10/19 patients in our cohort of crystalline 
retinal dystrophies, clinically diagnosed as Bietti crystalline dystrophy. We identified four 
novel mutations and one genomic rearrangement (deletion). This is the first large deletion 
reported for BCD. Eight patients were found to have two mutations in CYP4V2, while in two 
patients only one mutation was detected, despite extensive analysis of the coding region 
using Sanger sequencing and CNV analysis. Until now, 57 mutations in CYP4V2 have been 
associated with BCD. These include 43 missense/nonsense mutations, eight splicing 
mutations, four small deletions, one small insertion, and one small indel.l· 4• 7"21 To our 
knowledge, we are the first to identify a deletion including CYP4V2 and several other genes 
in a patient with BCD, expanding the molecular pathogenesis of BCD. Interestingly, previous 
studies have reported five patients in which only single heterozygous mutations were found 
in CYP4V2, possibly implicating CYP4V2 CNVs as found in proband F.1• 2•8•10 
The pathogenic role of CNVs and the importance of their detection has been previously 
described in recessive retinal dystrophies such as retinitis pigmentosa, Leber congenital 
amaurosis (LCA), and cone dystrophy with supernormal rod response (CDSRR).32•33 Ultimately, 
the detection of such CNVs clarifies diagnosis, and may influence genetic counseling. Our 
results demonstrate that CNV is a mutational mechanism that can lead to BCD as well, and 
that screening for such variations may be necessary to avoid diagnostic uncertainties. 
The deletion in proband F also covers two genes KLKBl and Fll, both of which are 
involved in the contact activated coagulation pathway. KLKBl encodes plasma prekallikrein 
- also known as Fletcher factor- a glycoprotein in the kallikrein-kininogen-kinin system 
(KKS) which participates in coagulation, fibrinolysis, and inflammation. Plasma prekallikrein 
is converted to the serine protease plasma kallikrein by factor Xlla through cleavage of 
an internal Arg-Ile bond.34 Kallikrein then cleaves both low- and high-molecular-weight 
kininogens to release bradykinin and lys-bradykinin, mediating the effects of the KKS. 35 
Recessively inherited mutations in KLKBl are known to cause plasma prekallikrein deficiency, 
resulting in a prolonged activated partial thromboplastin time (aPTT) without increased 
bleeding tendency in affected patients.36 Heterozygous patients have been reported to have 
decreased prekallikrein activity but normal aPTT values.37 
Factor XI is a homodimericglycoprotein thatcirculatesin plasma as a noncovalentcomplex 
with high-molecular-weight kininogen.38 Factor XI is activated by factor XII, a-thrombin, and 
factor XI (autoactivation); it participates in contact activated coagulation by catalyzing the 
conversion of factor IX to factor IXa and thereby sustaining thrombin generation.38• 39 Factor 
XI deficiency (sometimes referred to as "hemophiliaC") is a rare mild-to-moderate bleeding 
disorder associated with mutations in Fll . Both autosomal recessive and dominant modes 
of inheritance have been described, the latter possibly being secondary to dominant-
negative mutations resulting in mutant proteins forming nonsecretable heterodimers with 
wild-type subunits.40 Moreover, earlier studies demonstrated considerable variability in 
rates of bleeding in heterozygotes, with some studies even noting no distinction between 
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homozygotes and heterozygotes.41•42 Upon revisiting proband F's medical records, we found 
no history of coagulopathy. 
In addition to the two patients in whom only single mutations were detected, we failed to 
identify any CYP4V2 mutations in nine other patients. The rate of CYP4V2 mutation detection 
demonstrated in our study was relatively low, especially when compared to a previous study 
byXiao et al.,14 in which CYP4V2 mutations were found in >95% of BCD patient families. 14 Our 
results suggest that CYP4V2 mutations in our patients may reside in genomic locations that 
were not studied in our gene sequencing protocol, that is, in promoter, untranslated region, 
or deep intronic regions. Alternatively our data suggests locus heterogeneity and a second 
Bietti's gene. We were able to re-examine five CYP4V2-negative crystalline retinal dystrophy 
patients and found that their phenotypes (Figs. Sl, 52) are indistinguishable from our BCD 
patients. 
In accordance with previous studies, we found considerable phenotypic variability in 
our cohort, with no obvious correlation of severity or features with patient demographics. 
Although disease progression was noted in most patients (for whom historical clinical 
data were available), length of progression was not clearly associated with a more severe 
phenotype. Previously, it has been postulated that environmental factors affecting lipid 
metabolism (e.g., diet) may also contribute to the spectrum of disease.2• 23 Significant clinical 
variabilitywas also noted forpatientssharingcommon genotypes, and even within one family. 
However, it can be observed that in general within our cohort, those with genotypes resulting 
in splicing defects or nonsense mutations (i.e., c.802-8_810delinsGC:p.(?), c.604+4A>G:p.(?), 
and c.l249dup:p.(Thr417Asnfs*2)) demonstrated greater clinical severity. Notably, proband 
F with the genomic deletion was documented to have one of the most clinically severe 
phenotypes in our cohort. It is possible that the heterozygous CYP4V2 deletion contributes 
to her advanced disease state, however this remains unclear as the patient was also found to 
have a severe frameshift mutation. 
Furthermore, proband E, with a mild phenotype despite 21 years of disease, was found 
to have compound heterozygous mutations, with one allele c.242C>G:p.(Thr81Arg) predicted 
to be comparatively benign (Table 2). 
It should be noted, however, that these correlations between mutation and disease 
severity have not been consistently shown in previous studies; for instance, although Lai 
et ai.U and Halford et al.20 document a similar pattern, Rossi et al.2 note that this correlation 
was not present in their patients. As well, two patients (one with mutation c.l526C> T:(p. 
Pro509Leu) and the other c.l393A>G:p.(Arg465Giy)) in whom only single mutations were 
identified in previous studies failed to show the same severity of disease as seen in proband 
F.2•10 The clinical features of the three other heterozygous patients in the literature were not 
described.1•8 
In our patients, we documented four locations and typesofthecrystals: small, widespread 
inner retinal crystals; large, encapsulated subretinal crystals; corneal limbus crystals; and 
lenticular crystals. The presence of encapsulated subretinal crystals (in addition to inner 
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retinal crystals) on OCT has previously been reported.43 lnitially described by Zweifel et al.44 in 
a series of patients with various retinal disorders, these structures were termed "outer retinal 
tubulation." However, a more recent study with BCD patients found that the hyperrefractive 
structures identified were in fact spherical.45 
It is of note that proband D with compound heterozygous mutations c.802-
8_810delinsGC:p.(?) and c.ll98C> T:p.(Arg400Cys) was found to have crystalline deposits 
on the lens, which is atypical for BCD. Two separate reports of lenticular crystals have been 
documented previously, with both patients described carrying the c.802-8_810delinsGC 
mutation as well, though in a homozygous state.15•46 
The phenotype of BCD is progressive and severe. In the later stages, as retinal crystals 
become increasingly difficult to detect on clinical examination and disappear with disease 
progression, the phenotype can overlap with choroidal sclerosis and some phases of 
choroideremia:for instance, as reported in the late-stage fundus appearance of probands A 
and J.6• 14• 47 lt is therefore likely that when patients are seen in the later stages of disease, a 
diagnosis of a nonspecific retinal dystrophy or atypical retinitis pigmentosa may be made. 
However, in both these patients we documented that OCT reveals nevertheless the presence 
of retinal crystals. Our results therefore indicate that OCT plays an essential role in the 
diagnosis and differentiation of BCD from other retinal pathology presenting primarily with 
choroidal sclerosis. 
In conclusion, we identified four novel CYP4V2 mutations in 10/19 BCD patients as well as 
the first genomic rearrangement (large deletion) implicating CYP4V2. Our results emphasize 
the importance of CNV screening in BCD. Although the phenotype of the patient with the 
CYP4V2 deletion was severe, no clear genotype-phenotype correlation could be established. 
It would be interesting to note what patterns emerge in future when more patients with large 
deletions as such are reported. Finally, the nine patients in whom no CYP4V2 mutations were 
found suggest that CYP4V2 mutations may reside in genomic locations that were not covered 
by our protocol. Alternatively, locus heterogeneity might underlie BCD:further investigations 
will follow to explore these possibilities. 
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Supplemental Table 1. CYP4V2 primers 
Ex on Primer forward (5'-3') Primer reverse (5'-3') Product size (bp) 
1 GAAACGTCGTTCCGGGG TGACAGGCTCCTCTCTCCTG 482 
2 GAGAAAACAAACCTTTGTCCAATAC AGGACACGTTATATTGATTCTGG 273 
3 GGAGAAAATAAATGTTGTGAATGC TTCTTGAAATAACAAGTTGCACG 278 
4 TGCTTTAATCGTTTTGGATGTTAC GTGTGATTTCCTGTTTGGGC 345 
5 CGCTGCAAAATAAACACGAG GATACAACGCAGAAATTGTTAGC 224 
6 GACAATCATCGTCATTCCCAC TGCACTTAATACCACCAAACTG 336 
7 TCACAAGAGCCTATGTTGTCG AAGAAGTTGAGCTGGTACTTAATCAG 506 
8 TCACTCCTAATCATCGCAGC GCCTTCCTGCTCATTACACTG 256 
9-10 ATGCCTTGATCCACCTGTTC CACTGTGAGAAACCCACCATC 559 
11 TCTTGTTTCTCACATTTGGGG TTAGGTCTAGGGGATTCAAGC 348 
Supplemental Table 2. qPCR Conditions and primer sequences 
Primers Forward Reverse 
CYP4V2_CNV_1 CGCCAGTCTGGTCCTGAG TGATCGGAGGGTGGGAAC 
CYP4V2_CNV_2 TGCTCTCTACCTGGCTTCCT TTCTGGGGAAAAACATCAAA 
CYP4V2_CNV _3 TGTATGTCTCTAAAGTATGTTTTTCTCTTC GACAGCTTTACAAAGGTACACTGG 
CYP4V2_CNV_ 4 GCTCCAGGAGAAAGATGTTA ATCTAAGGCACAAAGAGTGAT 
CYP4V2_CNV_5 GTCTGCCGCTGCAAAATAA TTTACCTATAAACTGCACGGACA 
CYP4V2_CNV_6 GAGTGAGATGATATTTCGAAGAATAAAG ACATAAGGTACCAGAGATCAAG 
CYP4V2_CNV_7 AGTCCAAACAGAAGCATGTGA AAGGCCCTGCGTTTATTTTT 
CYP4V2_CNV_8 TATTGTTTTCTGCATTTGTAGGG GGGTTAGAACCCAACAGGTATAA 
CYP4V2_CNV_9 CCCACTGCTCTTTCAGGTC TCCAGATACCGAAGTTTCTTCA 
CYP4V2_CNV _10 AGGAGTTCCAGCCTGAGC CATCAAGTGGGCCTGAAAG 
CYP4V2_CNV _11 TGGTCTAGAAGGACAGTTGA AGATCAGTGGGATCAAGGAA 
Protocol SsoAdvanced (for gDNA) 
Enzyme activation 98·c-->2min 
Am plification 98·c-->5sec 40x 60°C-->30sec 
MixqPCR 1 reaction 
2x mastermix Bio-Rad 2,5 ~I 
Forward primer (5 ~M) 0,25 ~I 
Reverse primer (5 ~ M) 0,25 ~I 
DNA template (10 ng/~1) 
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Supplemental Figure 1. Shown are fundus photographs ofCYP4V2 negative Bietti crystalline dystrophy 
patients. As in those with identified CYP4V2 mutations, predominant findings include choroidal sclerosis 
with or without visible crystalline deposits, pigment deposition, and vascular attenuation. 
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Supplemental Figure 2. OCT images ofCYP4V2 negative patients, with presence of small hyperreflective 
intraretinal crystals and larger subretinal crystals (red arrows) 
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Abstract 
Leber congenital amaurosis (LCA) represents the most severe form of inherited retinal 
dystrophies with an early onset during the first year of life. Currently, 21 genes are known to 
be associated with LCA and recurrent mutations have been observed in AIPLl, CEP290, CRBl 
and GUCY2D. In addition, sequence analysis of LRAT and RPE65 may be important in view of 
treatments that are emerging for patients carrying variants in these genes. Screening of the 
aforementioned variants and genes was performed in 64 Danish LCA probands. Upon the 
identification of heterozygous variants, Sanger sequencing was performed of the relevant 
genes to identifythesecond allele. In combination with prior arrayed primer extension analysis 
this led to the identification of two variants in 42 of 86 cases (49%). Remarkably, biallelic RPE65 
variants were identified in 16% of the cases, and one novel variant, p.(AspllOGiy), was found 
in seven RPE65 alleles. We also collected all previously published RPE65 variants, identified in 
914 alleles of 539 patients with LCA or early-onset retinitis pigmentosa, and deposited them 
in the RPE65 Leiden Open Variation Database (LOVD). In silico pathogenicity assessment of 
the missense and non-canonical splice site variants, as well as an analysis oftheir frequency 
in -60,000 control persons, rendered 864 of the alleles to affect function or probably affect 
function. This comprehensive database can now be used to select patients eligible for gene 
augmention or retinoid supplementation therapies. 
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COMPREHENSIVE GENOTYPING REVEALS RPE65 AS THE MOST FREQUENTLY 
MUTATED GENE IN LEBER CONGENITAL AMAUROSIS IN DENMARK 
Leber congenital amaurosis (LCA; OMIM 204000) is a group of rare inherited retinal 
dystrophies that affects -1:50,000 individuals worldwideY LCA is characterized by a severe 
visual impairment in the first year of life, sensory nystagmus, amaurotic pupils and markedly 
diminished or extinguished rod and cone electroretinograms (ERG).3•4 LCA is predominantly 
inherited in an autosomal recessive manner, although autosomal dominant inheritance 
has also been reported a few times.4 To date, mutations in 21 genes underlie at least 70% 
of LCA cases.5·6 These genes encode proteins that exert their functions in diverse processes 
and pathways in the retina, such as photoreceptor morphogenesis (CRBl, CRX, GDF6), retinal 
differentiation (OTX2), phototransduction (A!PLl, GUCY20, R03), retinoid cycle (LRAT, ROH12, 
RP£65), guanine synthesis (!MPDHl), signal transduction (CABP4, KCNJ13), outer segment 
phagocytosis (MERTK), coenzyme NAD biosynthesis (NMNATl) or intra-photoreceptor ciliary 
transport processes (CEP290, !QCBl, LCAS, RPGR!Pl, SPATA7, TULP1) .4•6 Mutations in many of 
these genes can also give rise to early-onset retinal dystrophies. 
The RP£65 and CHM gene augmentation trials in patients with LCN-9 and choroideremia,10 
respectively, have been milestones in the retinal therapeutics field. An oral retinoid-based 
treatment was also reported to be beneficial for persons with RP£65 or LRAT mutations.U 
Preclinical gene augmentation studies in animal models due to mutations in several other 
genes have also demonstrated safety and efficacyY However, the identification of molecular 
genetic causes is a prerequisite to assess the patients' eligibility in receiving suitable 
treatments. Various techniques, including classical genetic linkage analysis, identity-by-
descent (IBD) mapping, Sanger sequencing of candidate genes or next-generation sequencing 
have been used for gene discovery and diagnostic methods in LCA. Previous studies in LCA 
revealed the intronic CEP290 variant c.2991 + 1655A>G as the most frequent in the Caucasian 
population, explaining - 12% of cases in Caucasian populations originating from the North-
West of Europe_l3-15 ln add ition, the AIPLl variant p.(Trp278*) in exon 6, a conspicuous cluster 
of CRBl variants in exons 7 and 9, and the GUCY20 exon 12 variant p.(Arg768Trp), together 
may explain - 14% of the cases.16.l7 Therefore, pre-screening of these 5 exons potentially 
identifies 28% of the mutations, serving as a cost- and time-effective genotyping procedure 
for LCA. Finally, screening of RP£65 and LRATshould uncover the cause of disease in 7% and 
1% of LCA cases, respectively. The identification of persons with mutations in these genes is 
very relevant in view of the above-mentioned treatment options. 
By using a combination of different genotyping techniques, we identified the underlying 
mutations in approximately half of the Danish LCA probands, and most significantly found 
RP£65 variants to be the most prevalent causes of LCA and early-onset RP. In addition, we 
collected all published RP£65 variants and completed the RP£65 Leiden Open Variation 
Database. These results are essential for genetic counseling and for the selection of persons 
that are eligible for therapeutic interventions. 
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Materials and methods 
Subjects and Clinical Evaluation 
A total of 86 unrelated Danish families comprising of 80 isolated and 6 multiplex families 
diagnosed with LCA were ascertained in this study. The diagnosis of LCA was based on 
clinical history, a full eye exam including slit lamp and retinal examination, full field-
electroretinography (ffERG), visual acuity, refraction, visual field, and optical coherence 
tomography (OCT) in some cases. The diagnostic criteria were based on a congenital or 
early infantile onset of a generalized retinal dystrophy with substantially reduced cone and 
rod ffERG responses. Many patients showed nystagmus and/or hypermetropia, but these 
clinical signs were not compulsory for the diagnosis.18•19 ln this study, we consider LCA and 
early onset retinitis pigmentosa as a continuum of phenotypes, since they are clinically 
and genetically overlapping and the true age at disease onset can be difficult to establish. 
Research procedures were in accordance with institutional guidelines and adhered to the 
tenets of the Declaration of Helsinki. An ethics committee approval was obtained and all 
samples were acquired after written informed consent was obtained from the patient or in 
the case of children, their legal guardians. 
Genetic analysis 
Genomic DNA of participating individuals was isolated from peripheral leukocytes using a 
standard salting out procedure.20 Acandidate gene approach and an arrayed primer-extension 
(APEX) analysis were performed in several probands prior to recurrent mutation screening. 
Complete genotyping methods for the affected individuals are listed in Supplementary Table 
Sl. 
Sanger sequencing in selected LeA-associated genes 
Sangersequencing based on a candidate gene approach was performed in the LCA-associated 
genesAIPLl, CRB1, CRX, GUCY20, LRAT, RDH12, RPE65, RPGRIP1, and TULP1, by a commercial 
supplier (Seq lab, Gottingen) using the BigDye® Terminatorv3.1 Cycle Sequencing Kit (Applied 
Biosystems™) on a ABI3730XL plattform (Applied Biosystems™). 
SSCP and APEX analysis 
Single strand conformation polymorphism (SSCP) analysis was applied to 52 index patients 
as described previously21 followed by subsequent Sanger sequencing of exons with aberrant 
bands i nAIPLl , CEP290, CRX, CRB1 , GUCY20, LRAT, RDH 12, RPE65, RPGRIP, and TULP 1. Thereafter, 
APEX LCA microarray analysis, versions 2007- 2012 (Asper Ophthalmics, Tartu, Estonia) was 
performed in the 15 remaining unsolved cases.22 This microarray-based genotyping method 
allowed the simultaneous analysis of previously identified disease-associated sequence 
variants in the LCA-associated genes AIPLl, CEP290, CRB1, CRX, GUCY20, JQCB1, LCAS, LRAT, 
MERTK, RDH12, RD3, RPE65, RPGRJP1, SPATA7, and TULP1. The methods employed in this 
analysis have been described elsewhere (www.asperbio.com; Asper Biotech, Ltd.).23 
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LCA recurrent mutation screening 
The screening was performed in cases carrying one or no variant identified using Sanger 
sequencing of selected LCA-associated genes or APEX analysis, and 19 additional cases 
that had not been previously analysed. Recurrent mutation screening was performed in 13 
amplicons of four LCA-associated genes. The CEP290 c.2991 + 1655A>G variant was assessed 
by utilizing the amplification-refractory mutation system (ARMS) as described by Den 
Hollander et al. 2006.U In addition, AIPLl exon 6, GUCY2D exon 12 and CRBl exons 7 and 9 
were amplified and sequenced by the Sanger method. Primers were designed using Primer3 
software and are listed in Supplementary Table 52. Purified PCR products were analyzed 
in either sense or antisense direction using dye termination chemistry (BigDye Terminator, 
version 1.1, on a 3730 DNA analyzer; Applied Biosystems, Inc., Foster City, CA). All identified 
sequence variants were validated with independent PCR reactions. 
Sequence analysis of RPE65 and LRAT 
All coding exons and flanking intronic sequences of RPE65 and LRAT were amplified by 
PCR, purified and analyzed using Sanger sequencing as described above. PCR primers and 
conditions are available upon request. 
Ethnically-matched control frequencies 
The allele frequency of each identified variant in the Danish population was assessed using 
whole-exome data of 2,000 ethnically-matched individuals from the Danish exome study.24 
Pathogenicity interpretation of sequence variants 
To determine the pathogenicity of missense variants, we used the following in silica 
prediction methods: Sorting Tolerant from Intolerant (SI FT),25 Polymorphism Phenotyping v2 
(PolyPhen-2)26 and PhyloP,27 the latter of which assesses the evolutionary conservation at 
the nucleotide level. We also assessed the allele frequency data of identified variants derived 
from an available 'control' exome dataset provided by NHLBI Exome Variant Server (EVS)28 
and the Danish exome study.24 For the RPE65 variants deposited in the RPE65 LOVD, we also 
assessed their prevalence using the Exome Aggregate Consortium (ExAC) database.29 Four 
computational prediction programs, SpliceSite finder-like,30 MaxEntScan,31 NNSPLICE,32 Gene 
Splicer33 and Human Splicing Finder34 were used to determine the pathogenic effect of non-
canonical splice variants. 
Sequence variants nomenclature 
All identified variants are described as recommended by the Human Genome Variation 
Society (HGVS) nomenclature guidelines, considering nucleotide + 1 as the A of start codon 
(ATG).35 When the nucleotide position is indicated, the GenBank eDNA reference sequences 
were used as follows: AIPLl (NG_008474.1); CEP290 (NG_008417.1); CRBl ( NG_008483.1); 
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GUCY2D ( NG_009092.1); LRAT ( NG_009110.1); RDH12 ( NG_008321.1); RPE65 ( NG_008472.1); 
RPGR/Pl (NG_008933.1); and TULPl (NG_009077.1) .36 
RPE65 Leiden Open source Variation Database variant depositions 
RPE65 variants were collected from all articles published until 2014 (Supplementary Tables 
S5 - S7). To assess the pathogenicity of missense variants, we combined three prediction 
programs, i.e. PhyloP, SIFT, PolyPhen-2, as well as the allele count in the ExAC database that 
contains exome data of -60,000 persons29• A PhyloP score of :::2.5 was employed as one of the 
criteria to consider a variant to be potentially disease causative. Subsequently, we classified 
missense variants as "probably no functional effect", "variants of unknown significance" or 
"affects function". They were considered to have "probably no functional effect" when none 
of the prediction programs described the variant as damaging and/or if the ExAC allele count 
was higher than or equal to 18. The latter cut-off number was chosen as the three most 
frequent pathologic RPE65 variants, p.(Arg91 Trp), p.(Tyr368His), and c.ll +5G>A, representing 
11.6%, 8.0% and 7.2% of the published 864 autosomal recessive RPE65 function-affecting 
variants, respectively, are found in 10, 8 and 11 alleles in the ExAC database. Statistical 
analysis of the most frequent RPE65 variant c.ll +5G>A, with a total allele count of 120,956 in 
the ExAC database, results in a 95% confidence interval between 0.3x10·4 - 1.4x104 . From this 
we can infer that any variant with an allele frequency higher than 1.4x104 can be considered 
to be benign with 95% certainty. Assuming the maximum number of alleles present in the 
ExAC database (122,972 alleles), benign variants are expected to be present higher than or 
equal to 18 alleles. The pathogenicity of a variant was considered as "variants of unknown 
significance" if one of three prediction programs described the variant as damaging and the 
allele count in ExAC was less than 18. Finally, a variant was considered to "affect function" 
when at least two prediction programs described the variant as damaging and the ExAC 
allele count was less than 18. 
Results 
Molecular genetic analysis 
Genotyping analysis before recurrent mutation screening 
For diagnostic pu rposes, genotyping analysis using Sanger sequencing of selected LeA-
associated genes and/or APEX analyses were performed in 27 and 40 LCA cases, respectively 
(Figure 1). Using the selected Sanger sequencing approach, two function-affecting variants 
were identified in eight cases and one variant in three cases. In addition, APEX analysis 
detected two variants in 14 cases and one variant in three cases. Subsequently, forty-one 
cases without any identified variants were included in our recurrent mutation screening. 
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Figure 1. Genotyping workflow in this study. Eighty-six individuals with LCA were included in th is 
study. Twenty-seven cases were sequenced for variants in several LCA-associated genes, 40 cases were 
analyzed using APEX analysis and 19 cases had not been analyzed. Thereafter, 60 patients carrying no 
variants and four patients with one variant were included in the screening of common LCA mutations 
in AIPLl exon 6, CEP290 c.2991 +1655A>G variant, CRBl exons 7 and 9, GUCY2D exon 12, and all coding 
exons of RP£65 and LRAT. Together with the previous genotyping analysis, this screening yielded one 
variant in seven cases and two variants in 41 cases. 
LCA recurrent mutation screening and second allele sequencing 
Sixty-four persons carrying no or one variant were included in the screening for the presence 
of frequent recurring LCA mutations. Two function-affecting variants were identified in 11 
cases and 15 carried only one variant Additional Sanger sequencing to find a 2nd allele 
identified additional variants in nine of the latter individuals. Taken together, the LCA 
recurrent mutation screening followed by a search for a 2nd allele by Sanger sequencing 
identified two variants in 20 cases (23%) and one variant in 6 cases (7%), as shown in Figure 1. 
Interestingly, based on the number of cases with two causal variants, this study revealed the 
RPE65 gene as the most frequently mutated gene in this Danish LCA cohort (16%). Seventeen 
out of 45 identified variants are novel variants (Table 1, Supplementary Table S3) with the 
three most frequent alleles being c.2991 + 1655A>G in CEP290 (8 alleles), p.(Trp278*) in AIPLl 
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N Table 1. Overview of function-affecting variants identified in Danish LCA patients n f-' I co )> 
-u 
Allele 1 Allele2 Allele3 ---i 
Fam. Segregation m Gene Gene ;;o ID Nucleotide Amino acid change Nucleotide Amino acid change Nucleotide Amino acid analysis -"'" 
change change change change OJ 
GUCY2D c.2513G>C p.(Arg838Pro) + + NA 
2 CRBl c.2549G>T p.(Giy850Val) c.4006G>A p.( Val13401le) ND 
4 CEP290 c.2991 + 1655A>G p.(Cys998*)/p.=# c.2991 + 1655A>G p.(Cys998*)/p.=# ND 
5 CEP290 c.2991 + 1655A>G p.(Cys998*)/p.=# + + NA 
14 RP£65 c.329A>G p.(AspllOGiy) + + GUCY2D c.l093C>T p.(Arg365Trp) NA 
17 CEP290 c.2991+1655A>G p.(Cys998*)/p.=# c.5364+2T>G p.(?) ND 
20 CRBl c.2290C> T p.(Arg764Cys) c.2843G>A p.(Cys948Tyr) ND 
21 RP£65 c.495+1dup p.(?) c.130C>T p.(Arg44*) Yes 
23 CEP290 c.299l + 1655A>G p.(Cys998*)/p.=# c.2119_2123dupCAGCT p.(Gin709Serfs*ll) ND 
26 GUCY2D c.2302C>T p.(Arg768Trp) c.1877T>C p.(Ser626Phe) ND 
27 CEP290 c.2991 + 1655A>G p.(Cys998*)/p.=# c.2119_2123dupCAGCT p.(Gin709Serfs*ll) ND 
28 AIPLl c.834G>A p.(Trp278*) + + NA 
30 CEP290 c.2991+ 1655A>G p.(Cys998*)/p.=# c.5364+2T>G p.(?) AIPLl c.244C>T p.(His82Tyr) ND 
33 RP£65 c.l543C>T p.(Arg515Trp) c.130C>T p.(Arg44*) ND 
38 RP£65 c.329A>G p.(AspllOGiy) c.ll+5G>A p.(?) ND 
42 RP£65 c.329A>G p.(AspllOGiy) c.ll+5G>A p.(?) ND 
43 AIPLl c.834G>A p.(Trp278*) c.834G>A p.(Trp278*) ND 
46 RP£65 c.94G>T p.(Giy32Cys) c.130C>T p.(Arg44*) Yes 
49 GUCY2D c.2302C>T p.(Arg768Trp) c.l694T>C p.(Phe565Ser) ND 
51 RP£65 c.l328T>C p. (Vai443Aala) c.ll02T>C p.(Tyr368His) ND 
52 RP£65 c.ll+5G>A p.(?) c.ll02T>C p.(Tyr368His) ND 
55 RP£65 c.ll+5G>A p.(?) c.lOBBC>G p.(Pro363Arg) ND 
58 GUCY2D c.2135_2136delinsTC p.(Giu712Val) c.3043+5G>A p.(?) ND 
59 AIPLl c.815G>C p.(Arg272Pro) + + NA 
62 A!PU c.834G>A p.(Trp278*) c.834G>A p.(Trp278*) NO 
63 A!PLl c.834G>A p.(Trp278*) c.834G>A p.(Trp278*) NO 
64 CRBl c.4121_ 4130dell0 p.(Aial374Asnfs'20) c.4121_ 4130del l0 p. (Aial374Asnfs*20) ND 
65 CRBl c.613_619delATAGGAA p.(lle205Aspfs'l3) c.2401A>T p.(Lys801 *) ND 
66 CRBl c.584G>T p.(Cysl95Phe) c.613_619delATAGGAA p.(lle205Aspfs*l3) RPGR/Pl c.2869G>A p.(Giu957Lys) NO 
67 CEP290 c.l219_1220de1AT p. (Met407Giufs'l4) c.2991 + 165SA>G p.(Cys998')/p.=# NO 
68 GUCY2D c.1561C>T p.(Arg521*) c.1561C>T p.(ArrSll*) ND 
69 RDH12 c379G>T p.(Giyl 27') c.379G>T p.(Giy127') NO 8 
70 RDH12 c.2T>C p.(Metl Thr) c.582C>G p.(Tyrl94*) ND :;::: 
-o 
71 GUCY2D c.2302C>T p.(Arg768Trp) c.l877T>C p.(Ser626Phe) RPGR/Pl c.2555G>A p.(Arg852Gin) Yes ;:o rn I 
72 GUCY2D c.l957G>A p.(Giy653Arg) c.2234deiC p.(Pro 7 45Leufs'39) Yes :;:::rn cz 
GUCY2D c.2302C>T p.(Arg768Trp) c.2302C>T -1\£? 73 p.(Arg768Trp) Yes ~< 
rn rn 
74 GUCY2D c.2849C>T p.(Ala950Val) + + NA or?l Gl~ 
75 GUCY2D c.779T>C p.(Leu260Pro) c.779T>C p.(Leu260Pro) Yes rno ~::;! 
76 GUCY2D c.2849C>T p.(Ala950Val) (c.380C>T) p.(Prol27Leu) NA --o z-
77 RPE65 c.49S+ldup p.(?) c. l374G>A p.(Trp458*) 
,z 
Yes mG"l CIJ;:o 
78 RPE65 c.271C>T p.(Arg91 Trp) c.271C>T p.(Arg91Trp) Yes rn rn ::o< 
79 RPE65 c.329A>G p.(AspllOGiy) c.329A>G p.{AspllOGiy) Yes n~ O r 
ZU> 
80 RPE65 c.769T>G p.(Tyr239Asp) c.ll02T>C p.(Tyr368His) Yes Gl ~ rn-o 
81 RPGR/Pl c.930+3A>G p.(?) c .3618-Sdel p.(?) ND ~~ );!Ln 
c.1495_1496dup p.(AspSOOValfs*4) c.1495_1496dup p.(AspSOOValfs*4) 
r > 
82 TULPl NO )>(Jl 
:;:::-1 
83 CRBI c.613_619deiATAGGAA p.(lle205Aspfs'l3) c.2401A>T p.(Lys801') NO >I ern 
85 RPE65 c.ll02T>C p.(Tyr368His) c.l30C>T p.(Arg44*) 
;:o:;::: 
Yes oo 
Ullf) 
86 RPE65 c.329A>G p.(AspllOGiy) c.329A>G p.(AspllOGiy) NO i/) -1 
- " Z;:o 
om 
NA, not applicable; ND, not done; novel variants are marked in bold. 'The deep-intronic CEP290 mutation c.2991+1655A>G in -50% of the RNA results in the insertion of an 
mO 
zC 
:;:::rn 
N intronic sequence in the mRNA that carries a stop-mutation, and in - SO% of the RNA has no effect on splicing. >z 
,_. ;:o-1 
lO AC< 
.. 
N 
N 
0 
Table 2. In silico prediction of the functional effects of the identified variants 
A. Missense variants 
Gene eDNA Amino acid SIFT28 
AIPLl c.815G>C p.(Arg272Pro) Deleterious 
CRBl c.2549G>T p.(Gly850Va I) Deleterious 
CRBl c.4018G>A p.(Va\13401le) tolerated 
GUCY20 c.1877C>T p.(Ser626Phe) Deleterious 
GUCY2D c.2135_2136delinsTC p.(Glu712Val) Deleterious 
GUCY2D (c.380C>T) p.(Pro127Leu) Deleterious 
RPE65 c.94G>T p.(Gly32Cys) Deleterious 
RPE65 c.329A>G p.(AspllOGly) Deleterious 
RPE65 c.1088C>G p.(Pro363Arg) Deleterious 
B. Splice site variants 
Splice site prediction Splice Site MaxEntScan35 NNSPLICE36 tool Finder-like34 
Score range (0-100) (0-12) (0-1) 
Threshold ~70 ~0 >0.4 
GUCY20 c.3043+5G>A 7.55¢- 0.53¢-
RPGR/Pl c.3618-5del 81.46 ¢ 75.54 5.98¢6.71 0.97¢0.79 (-7.3%) (+12.2%) (-19.3%) 
RPGR/Pl c.930+3A>G 76.52¢- 8.40¢0.05 0.85¢-(-99.4%) 
PPH229 
Probably damaging 
Probably damaging 
Benign 
Probably damaging 
Probably damaging 
Probably damaging 
Probably damaging 
Probably damaging 
Probably damaging 
GeneSplicerl7 
(0-15) 
~0 
9.83¢2.60 
(-73.5%) 
PhyloP value30 Final classification 
1.09 Affect fu nction 
5.37 Affect function 
-0.04 No functional effect 
3.03 Affect function 
4.56/0.45 Affect function 
2.87 Affect function 
5.53 Affect function 
4.73 Affect function 
5.77 Affect function 
HSF38 
EVS alleles31 Final (0-100) classification 
~60 
80.99 ¢ 68.82 T=O/A=l3006 Affect function (-15.0%) 
82.94 ¢ 78.83 A1=0/R=l3006 Affect function (-5.0%) 
96.23 ¢ 80.67 G=33/A=12973 No functional (-16.2%) effect 
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(7 alleles), and surprisingly, a novel p.(AspllOGiy) variant in RPE65 (7 alleles). Segregation 
analysis in 12 families in which parents and/or siblings were available showed that the 
unaffected parents and/or siblings each carried one of the two variants (Figure 2). 
Three variants, each identified in a heterozygous state in one LCA proband, AIPLl 
c.286G>A; p.(Val96lle), AIPLl c.286G>A; p.(Tyrl34Phe), and GUCY2D c.2101C> T; p.(Pro701Ser) 
were identified in 2.8%, 1.0%, and 2.6% of2,000 ethnically matched Danish control individuals, 
respectively, ruling them out as highly penetrant LCA-causing alleles. In four probands with 
one or two causal variants in a given gene, we identified an additional variant in a different 
gene. 
The benign variant GUCY2D p.(Pro701Ser) variant was identified in two probands, 
together with a likely pathogenic variant, i.e. p.(Aia750Val). However, as p.(Pro701Ser) is 
deemed benign and sequencing was not completely performed for all exons of GUCY2D, 
these two cases remain unsolved but a 2"d mutation can be located in another exon. 
Pathogenicity prediction of novel variants 
Ofthe 46 identified variants in this study, 17 are novel, consisting of eight missense, five splice 
site, two frameshift and two nonsense variants. None of the missense variants was present in 
6,503 persons in the EVS database nor in 2,000 Danish control individuals. Based on in silica 
predictions, all missense variants except p.(Vai1340IIe) in CRBl (found in F2) are deemed 
pathogenic (Table 2A). The AIPLl missense variant p.(Arg272Pro) affects a highly conserved 
amino acid in the tetratricopeptide (TPR) domain and may disrupt the interaction with 
the Hsp70 and Hsp90 molecular chaperones, which is crucial for facilitating retinal protein 
maturation.37 The CRBl missense variant p.(Giy850Val) affects a conserved glycine in the 2"d 
Ia min in G domain, encoded by one of the most frequently mutated regions in CRBl. Three 
missense variants in RPE65 affect conserved amino acid residues located in the carotenoid 
oxygenase, which is essential for its isomerohydrolase activity. By using several in silica tools, 
four of five novel splice site variants in CEP290, GUCY2D, RPE65 and RPGR!Pl are predicted to 
affect normal splicing (Table 2B) . None of these splice site variants was found in 2,000 Danish 
control individuals. 
Clinical findings 
Clinical characteristics of the patients with novel variants are presented in Table 3 and 
Figure 3. Patients carrying CRBl variants display an early onset retinal degeneration with 
maculopathy and nummular pigmentations in the retina which are typical features for 
persons with variants in CRBlY As reported for other cases with RPGR!Pl variants, patient 81 
had poor vision in the first year of life with nystagmus and hypermetropic eyes (+5.5/+6.0).38 
Early onset visual impairment and nystagmus were also observed in patient 71 carrying 
GUCY2D variants, who showed no ERG responses at the age of one year.39•40 
Patients carrying two RPE65 variants presented with symptoms of nystagmus, lack of 
fixation, night blindness and/or orientation difficulties within the first year of age, except 
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Figure 2. Family pedigrees and segregation analysis. Pedigrees of patients for whom parent samples 
were available. All variants segregate as expected in the families. 
one patient that according to the anamnesis presented with visual impairment at two 
years of age. All patients showed extinct ERG responses and suffered from nystagmus and 
severe night blindness. The fundi were generally characterized by retinal degeneration and 
attenuated vessels with later signs of optic nerve atrophy and in some patients mottled or 
bone spicule pigmentations. Mean visual acuity at the age of7 years for all RP£65-associated 
cases was 0.18 (standard deviation 0.17) . Most patients had severely constricted visual fields 
at the age of 10 years; however a few patients had preserved visual fields at later stages. 
Similar phenotype data were described for persons with RPE65 variants in several previous 
stud ies.41•42 
RPE65 Leiden Open source Variation Database variant depositions 
Novel and previously described variants identified in this study have been listed in the 
respective Leiden Open Variant Databases (LOVD) forthe mutated genes.43-48 ln addition, we 
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Fam. Age at Refraction ERG Other 
ID Gene Origin Gender disease (age) Nystagmus (age) Fundus pathology presentation 
Nearly extinct Early bull' s eye maculopathy and 2 CRBl Denmark F 3 years +6.0/+5.5 (6) No (6) later nummulate pigmentations None and attenuated vessels 
21 RPE65 Denmark F congenital +7 (22) Yes Extinct (1) Attenuated vessels, no Epilepsia hyperpigmentation 
46 RPE65 Denmark M congenital -4.0/-4.0 Yes Extinct (1) Attenuated vessels, no None n (20) hyperpigmentation 0 :s:: 
Attenuated vessels and muddy \J 55 RPE65 Denmark F congenital -1/+2 (1) Yes Extinct (1) None :;o retinal pigmentation m I 
:S:: m 
71 GUCY2D Denmark F congenital +6/+6 (1) Yes Extinct (1) Attenuated vessels and muddy None c z retinal pigmentation ;;;~ 
'-1m 
Extinct cone mGl om 
79 RPE65 Denmark F congenital -2/-3.25 (1) Yes response and Attenuated vessels and pale optic None Glz reduced rod nerve mo ~ ~ response (1) 
- \J Z -
Attenuated vessels and no , z 81 RPGR/Pl Pakistan F 1 year +5.5/+6.0 (1) Yes Extinct (3) None mGl hyperpigmentation CD:;o 
m m 
Attenuated vessels, atrophic :;o< 
-1.5/-2.0 nm 86 RPE65 Jordan M 2 years Yes Extinct (17) optic nerve and bone spicule None of:: (15) pi mentations Z(/) Gl;:o 
m-o 
zrr, 
- Cf) );! <..n 
' GJ )>-l 
:;;: I 
E::m 
:;o:S:: 
o o 
Vl(/) 
V)-l 
- " Z :;o 
o m 
mO 
z C 
:s;:m 
t-J )> z 
t-J :;o--1 
w ;;<.;'=< 
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Figure 3. Fundus pictures of LCA 
cases with novel variants. A: The 
fundus of proband F2, with variants 
p.(Giy850Val) and p.(Val13401le) in 
CRBl, at the age of 28 years, shows 
central maculopathy, peripheral 
nummulate pigmentations and 
attenuated vessels. F2 had a 
refraction of +6.0/+5.5 at the age of 
6 years. B: Fundus of patient F21-
11:1, with variants c.495+1dup and 
p. (Arg44 *) in RPE65, at the age of 17 
years, showing attenuated vessels 
and no hyperpigmentation. At 22 
years, the refraction was + 7 /+ 7. 
C: Fundus of patient F46-11:1, with 
variants p.(Giy32Cys) and p.(Arg44*) 
in RPE65, at the age of 17 years, 
showing attenuated vessels and 
no hyperpigmentation. Refraction 
was -4.0/-4.0 at age of 20 years. 
D: Fundus picture of proband 
F55, with variants c.ll +5G>A and 
p.(Pro363Arg) in RP£65, at the age 
of 6 years, showing attenuated 
vessels and slight muddy retinal 
pigmentation in the periphery. 
Refraction was -1/+2 at age of one 
year. E: Fundus picture of proband 
F81, with variants c.930+3A>G 
and c.3618-5del in RPGR/Pl, at 9 
years of age, showing attenuated 
vessels and no hyperpigmentation. 
Refraction was +5.5/+6.0 at 
age of one year. F: Fundus of patient F79-11:2, with a homozygous RPE65 p.(AspllOGiy) variant, 
at the age of 9 years, showing attenuated vessels and a pale optic nerve. Refraction was -2/-3.25 
at the age of one year. G: Fundus of proband F86 with a homozygous p.(AspllOGiy) variant in RPE65, 
at the age of 40 years. The fundus shows attenuated vessels, atrophic optic nerve and pigment 
aggregations. Refraction was -1.5/-2.0 at age of one year. 
224 
COMPREHENSIVE GENOWPING REVEALS RPE65 AS THE MOST FREQUENTLY 
MUTATED GENE IN LEBER CONGENITPL AMAUROSIS IN DENMARK 
collected all RPE65variants that were published up to 2014.1n total, we identified 914 variant 
alleles in 539 affected persons that were described in 79 papers. In Supplementary Table 
S5, we list the 152 different variants according to their position in the RPE65 gene. Almost 
all variants were inherited in an autosomal recessive manner. Exceptions are p.(Asp477Giy), 
which was reported in a large autosomal dominant RP family,49 and one case showing 
uniparental isodisomy of chromosome 1 carrying c.ll +5G>A.50 For the missense and non-
canonical splice site variants, we show the in silica predictions of their pathogenic nature 
in Supplementary Tables S6 and S7, respectively. Based on the pathogenicity criteria 
described in Materials and Methods, 128 variants were designated 'affects function', 10 with 
no functional effect and 12 as variants of unknown significance. 
Missense variants that present in more than 20 of -60,000 persons in ExAc p.(Aia132Thr); 
p.(Lys294Thr); p.(Asn321Lys); p.(Aia434Val); each of which present in >300 alleles in ExAC) 
are considered as variants with no functional effect. Two hundred and thirty one and 144 
individuals carried homozygous and compound heterozygous variants, respectively. The 
number.of persons with heterozygous variants is more difficult to assess as the RPE65 gene 
was not fully sequenced in many studies. For six persons with one protein-truncating variant 
and 10 persons with one probably function-affecting missense variant, the entire gene was 
analysed by sequence analysis. 
The three most frequent variants are c.271C>T:p.(Arg91Trp); c.l102T>C:(p.Tyr368His), 
and c.ll +SG>A, identified in 100/864 (11.6%), 69/864 (8%), and 62/864 (7.2%) of the disease-
causing alleles, respectively. 
Discussion 
In this study, disease-causing variants were identified in 49% (42/86) of the Danish LCA 
probands using different genotypingtechniques. The recurrent mutation screening identified 
causal variants in 23% of the cases. The full potential of this approach was not used asAP EX 
analysis and selective Sanger sequencing had previously been performed for diagnostic 
purposes in some cases. Assuming that these cases also had undergone the recurrent 
mutation analysis, the potential yield would have been 36% (Table 1), which would render 
it an inexpensive prescreening method for Danish LCA cases, and potentially also for other 
populations. 
Sequence analysis of LRATyielded no results, but remarkably, RPE65 was found to be the 
most frequently mutated gene (16%) in the Danish LCA cohort, followed by GUCY2D (10%), 
CEP290 (7%), CRBl (7%), AIPLl (4%), RDH12 (3%), TULPl (1 %), and RPGR/Pl (1 %). We cannot 
rule out that as yet undiscovered LCA-associated genes are among frequently mutated genes 
in Danish LCA cases. Importantly, the most frequent RPE65 variant identified in this study 
was p.(AspllOGiy) (seven alleles), which hitherto was not described. It thereby is almost as 
frequent as the CEP290 variant c.2991 + 1655A>G, found in eight alleles, and equally frequent 
as the AIPLl variant p.(Trp278*) in seven alleles. The p.(Aspl10Giy) variant was found in 
225 
CHAPTER 4B 
persons from Denmark and Jordan, so it remains to be investigated whether this is a founder 
mutation. 
This study revealed the thus far highest prevalence for RP£65 variants in the Caucasian 
population. An equally high frequency of RPE65 variants (16.5%) was reported recently in 
the Indian population.51 Our findings facilitate the identification of Danish patients that 
are eligible for the AAV-RP£65 gene augmentation and/or 9-cis-retinoid supplementation 
therapies. By including the sequence analysis of RPE65 exons 1, 3, 4 and 10, carrying 19 
variants, to the recurrent mutation screening (8 exons) for Danish LCA cases, the potential 
yield would increase to 45%. The clinical phenotype of patients with two RPE65 variants was 
relatively mild compared with several other more severe genetic types of LCA and in general 
similar to what was previously reportedY 
In five persons with LCA (F1, F5, F14, F28, F59), one heterozygous variant was identified 
upon sequence analysis of the entire coding regions of the corresponding genes. The 
GUCY2D variant p.(Arg838Pro) has been reported in previous LCA studies as an autosomal 
dominant mutation. In our study, this variant occurs in a sporadic case. In the absence of 
parental DNAs, we cannot test the possibility that it is a de novo variant. In the remaining 
cases, the identification of heterozygous variants could be attributed to one of the following 
possibilities. A deletion or duplication in the other allele may not be detected as copy 
number variant analysis was not performed. Our screening also does not cover deep-intronic 
regions, thus variants in this part of the genome will not be identified.15•52 Moreover, variants 
in regulatory elements located far away from the respective genes cannot be ruled out. 
Finally, the aggregate carrier frequency of variants in the most intensively studied genes in 
this study (AIPLl, CEP290, CRBl, GUCY2D, LRAT, and RPE65) is estimated 1 in 25 individuals 
(Supplemental Table S3), which means that three or four probands could carry a variant 
in one of these genes in this cohort of 86 families, without pathologic consequences. The 
latter may also explain the identification of more than two variants in different genes in 
four probands in this study. The identification of the remaining causal variants requires a 
more comprehensive analysis of all genes associated with LCA and early-onset RP, e.g. using 
next-generation sequencing based gene-panel sequencing, whole exome, or whole genome 
sequencing. 
By collecting all RPE65 variants reported in literature we found RPE65 variants in 539 
persons, of which 375 carried two variants. Among all reported variants, several variants 
tend to occur exclusively or in high frequency in certain ethnicities suggesting possible 
founder effects, e.g. variant c.304G> T:p.(Glu102*) in the Greek population, c.ll02T>C:p. 
(Tyr368His) in the Dutch population and c.271C>T:p.(Arg91Trp) in Saudi arabia and Tunisia. 
Three variants (p.(Arg91 Trp), p.(Tyr368His), c.ll+5G>A) together comprise 26.7% of all RPE65 
variants identified to date. One splice site variant (c.94+ 10A>G) and 10 missense variants 
were designated benign. However, the latter missense variants are rare in LCA patients and in 
ExAC and therefore, in the absence of functional assay data, cannot completely be excluded 
to have functional effects. 
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Sixteen persons carried only one pathogenic RPE65 variant, despite the fact that all 
exons and exon-intron boundaries were analysed by Sanger sequencing. As described above 
and in Supplementary Table S3, we estimate the carrier frequency for RPE65 variants in the 
general population to be 1/158 individuals. Among the 516 persons with one or two recessive 
RPE65 variants, three or four would be expected to carry such a variant in a heterozygous 
state by chance. The fact that 16 persons were found to be heterozygous carriers of variants 
may point to the existence of 'missed mutations'. These could be heterozygous deletions, 
deep-intronic variants, or other variants affecting the expression of RPE65 mRNA. Persons 
carrying two causal RPE65 variants are eligible for the above-mentioned novel therapies. 
In summary, we identified the underlying mutations in a significant group of cases 
providing the most comprehensive genetic data of LCA in the Danish population. Most 
significantly we identified RPE65 as the most frequently mutated LCA gene in Denmark, which 
is of particular interest in view of the ongoing therapeutic trials using gene augmentation 
or 9-cis retinoid supplementation. Finally, we collected all published variants of the RPE65 
gene and performed in silica assessment of the missense and non-canonical splice variants 
to predict their functional effects. 
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Supplementary Table 51. Genotyping methods applied in each proband 
Sequence analysis of all exons CEP290 Case Sample ABCA4 Nijmegen 
No. ID LCAAPEX APEX USHAPEX lntronic screening AIPLJ CEP290 CRBl CRX GUCY2D LRAT RDHl2 RP£65 RPGRIPl TULPl mutation 
063070 R R R(·)/N R N 
2 063071 N/R N 
3 063072 R R R R N 
n 
4 063073 R N R R R R R R N 0 
:5: 
5 063074 R N R R R R R R N -u :;o 
m 
6 063075 R R R R R R R N :r: :5:m 
cz 
7 063076 R R R; 2006 N );!<£) 
'--'< 
mm 
8 063077 R R R R R R R N oGJ Cl~ 
9 063078 R R R R R N mo ~~ 
10 063079 N --u z-
,z 
11 063080 R R R R R R R N mCl OJ:;o 
m m 
12 063081 R R N :;o< nm 0~ 
12 063082 R; 2009 N z (/) Cl;:o 
R(-)/N m"I:J 13 063083 R R R R R R; 2006 N zr-r, ::::j~ 
14 063084 N R; 2011 N )>)> 
'Vl )> -l 
15 063086 R R R R R R R R; 2006 R N :;;: :r: 
2: m 
16 063087 N :;o:;;: oo 
(/)(/) 
17 063088 N R R R R; 2006 N V)-l 
- ,., 
Z:;o 
18 063089 R R R R R R; 2006 R N om 
,.,o 
zC 
19 063090 R R R R R R; 2006 N :,;:m 
N )>z 
w :;o-l ,_. ;>';~ 
.. 
N n w 20 063091 R N R R R R N :r: N )> 
21 063092 R R R R R(-)/N R; 2012 N ~ 
rn 
;:o 
22 063093 R R R R R R N .):>. 
CIJ 
23 063094 R N R R R R R R N 
24 063095 R R R R R R R N 
25 063096 R R R R R N 
26 063097 N R; 2006 N 
27 063098 N R; 2006 N 
28 063099 R/N R R R R R R R N 
29 063101 R R R R/N R; 2006 N 
30 063103 R N R R N 
31 063104 R R R R/N R N 
32 063105 R; 2009 N 
33 063106 N R; 2012 N 
34 063107 R; 2012 N 
35 063108 R; 2012 N 
36 063109 N 
37 063111 N 
38 063112 N N 
39 063113 N 
40 063114 N 
41 063115 N 
42 063116 N N 
43 063117 N N 
44 063118 N 
45 063119 N N 
46 063120 N R; 2012 N 
47 063121 N 
48 063122 N 
49 063123 N N 
50 063124 R; 2011 R N 
n 
51 063126 N R; 2008 N 0 ~ 
-u 
52 063127 N N ;;o rn 
I 
53 063128 N ~rn cz 
--~~ 
54 063129 R; 2010 N ~< mm 
55 063130 N R; 2011 N oCl GJS2 
56 063131 R; 2010 
mo 
N ~::<! 
- -u 
57 063132 R; 2010 N z-,z 
mCl 
58 063133 N R; 2011 N OJ;;o m m 
;;o< 
59 063134 N N nm 
of!': 
60 063135 N 
z (/) 
Cl;;o 
m-u 
61 063136 N Zi}l =i~ )>)> 
62 064259 R; 2007 'Vl )> -I 
63 R R R R R 
:;;: I 
064260 E: m 
;;o~ 
64 064261 R R R R R R R oo (/)(/) 
65 064262 R; 2010 
(/i -1 
- ""Tl Z;;o 
66 064263 R R R R R R R o m m.O 
zC 
67 064264 R; 2009 R :;;:m )> z 
"' 
;;o -1 w 
w ~C< 
N n w 68 064265 R R; 2009 I 
-1>- )> 
69 064266 R; 2009 ~ 
m 
AI 
70 064267 R R R R R R R R -1>-
CP 
71 064268 R R R R R R; 2006 
72 064287 R R 
73 064269 R R R R R 
74 064270 R R R 
75 064271 R R R 
75 064272 R R R 
76 064273 R R R R 
77 064275 R 
77 064276 R 
78 064277 R R R 
79 064278 R R R R R R R; 2006 
80 064279 R R R R R 
81 064281 R R R R R R R R; 2006 
82 064282 R; 2012 
83 064283 R; 2012 
84 064284 R R R R R R; 2012 
85 064285 R R R R R R; 2006 
86 064286 R R R; 2010 
R: Genotyping analysis performed in Regensburg, Germany (former affiliation of MNP and BL) 
N: Genotyping screening performed in Nijmegen, The Netherlands 
Supplementary Table 52. Primers used for mutation hotspot screening and second alle[e identification 
Gene Ex on Forward primer (5'-3') Reverse primer (5'-3') 
A!PLl Exon 1 TCTCAGCCGCCTAAGTGTCTTCC TCCCTTTCTTCTCACTCAACATTTAGG 
Exon 2 CGGGCCTTGAACAGTGTGTCTAG CGCACCAGAACTCGGCCAC 
Exon 3 GCCTGGCACACAGTTAACCACAG GTCCCTCTCCAGTGCTGGCAC 
Exon 4-5 AGGGAGATGTGCCACAGGGTC TGGCAGGTGTCTCCGTGGC 
Exon 6 TGCCTCTGAGGCTGGGAAGG CACGATCCTGGTCAATCGAACC 
CEP290 Exon 1 AGCGCCTTACCTCCTCTTCT GCCCTCAGGCTAAAGAACCT n 0 
Exon 2-3 AAAATGTAAGGTGCTAGAAAACCAA CCAGGTATTTTCACAAAGATTACCTTA :;;:: 
-o ;;o 
Exon4 TTGAGGACTTGAGGTAAAAAGGA CCATAATAAACTTTTTCCAAGGTG m I 
Exon 5 GGATCTGCCATATAATACTTTTTGTT CCCTTTCGTCACTATTCCTCA S:m cz 
Exon 6 TGCTTGTTGTTGACTCATTTGAA CCAATAATAATAAAAAGCCAGGTAA :;_;;!~ '--'~ 
mGl 
Exon 7 CATTTTCTACTTTGTTAGAGAGGATTT GAAGACTCCAGTCCTGGTTAAAA om Glz 
Exon 8-9 AATATGCATCATTTTCCCAAA AGGAACCATTGCTCTGAATTG mo Z--J 
m-< 
Exon 10 GGACACTTATGGCTGCGTTT AAGACAGACAAAAATTCACATCC - -o z-
,z 
Exon 11 TTCCAGGATGACTTCAATGAT CCCTAATAAACGTGTTATAAACCAG mGl CD;;o 
m m 
Exon 12 TGCCAGTAGTTGCTCATACTTTC TTCCAACTGTAATAAAACTGGTTGATA ;;o< 
nm 
Exon 13 AAAAGGCATACTTGTACCCACA GAAAATGCATCCATCATTTACAA 0~ ZVl 
- ~•"w•-• ·~---~- Gl;o Exon 14 TGGGATCACTGATTTGAAGGA CAGAATAGTCTGTGAATGGCAAG m-u 
zr:n 
Exon 15 GGATTTGGTTTATAAAAGCACAATAAA CACTTCAATCAGGTTAGCTCCA -0\ :;_:;1<-n 
Exon 16-17 TGACATTTTTGCAGCTTATTTGA TTCATATCCAGACAACTCACTTATCA r[;; ~--j 
Exon 18 TGGAGGGATTTTGGAAACAA TTTTCCTTTACTCTCTTTGCAATAC )>I em 
;;o:;;: 
Exon 19 TTTTTGTTTGCACTTTAACATCAG CCCTTTTAGGCCCATGATTT oo Vl {f) 
Exon 20 TGTGAAAAAGATCTGATCATCCA TGGCTAAATCTTTCTTGTAGCAAT U)--l 
- "Tl Z;;o 
Exon 21 TTATCATGCTTGGCAATGAA ACATTCTTATGTTTAGCATTTTCTTTT om mO 
Exon 22 TGGCAGGGCATTCACATATC TTGAGAAAAGTACTATCTGCATGCTT zC :;;:m 
N )>z Exon 23 TGTGTTGCTTACAGATTTGGTGA TTCACAATTAACAAGAATATACTGCAA ;;o--l w :AC< lT1 
"-' n w Exon 24 GCTATGATACCTCTTGTGTTGAGAAA TCAGAAAAAGCAAAATAAGAATCAGA I ~ )> 
Exons 25-26 TCTTTCTCAAAAGTGGCTAGTGC CCCCCAAACACAAAAATATTGA ~ 
m 
Exon 27 TGGATTGTGAGTTTTAAGGAGATG TTGGTGGGGTTAAGTACAGGA Al 
-"" 
Exon 28 TGGTACAGGCATCACACAGG TTTCAGAGATCCAGACAAACCA CP 
Exon 29 GGCCAAGTAAAGAGGATTGC GAATTGTATACCTGTAATTGGGTTTC 
Exon 30 TGAAAACGAATGGCTTTTTG AACATATCCCACTCCCAACA 
Exon 31 AACTTTCACTGGAAAAATTTGAAAC GCCTGGGAAACAGATCAAGA 
Exon 32 TCATCAATGGAGGAATGTTATTTG GTCATTTGTGCAATATTCTTGTTT 
Exon 33 TTTCTTCAATGTGTTGTGAGGA TCTGTGAGTTAACACTCTAGACTATGC 
Exon 34 AAGAGGGGTTTAATCTATGTTTTATCA CATTCTATGCATTGCCCTCA 
Exon 35 AAGCATGCAAATAACTGCTGTC TCCAATCACATGCAAGTAACAA 
Exon 36 GAGGGGACATGCATACCAGT TTTTGGCAACAAAAAGGGTAA 
Exon 37 TTTGATCATTTGAGGAACCAAA GCCTGGCATAGCAAACACTT 
Exon 38 TGAATTGCAGCAACCACTCT AAAAGCAATCTACCACATATTTTTCC 
Exon 39 TTTGTGAAATATGTTCCATTAAACTCA CACCAACAGTGCATTATAAATTCC 
Exon 40 TGGAAAAATATATGTAGTTTGTGGTT TTTGAAAGTCAGTTTTAACAAATACCA 
Exon 41 AAAATGCAGAAGCAGCTACCA AGCCAGGTCATCAAATTAAGG 
Exon 42 TCAACCTGTATAGCAAAATGAACA CGAGATCACAGGAAAATCCA 
Exon 43 TGGATTTTCCTGTGATCTCG CCCAAGCTTAAGACAACACACA 
Exon 44 CATTTAAAGGAGGCCTTCAGTG TGCTTTTGGCCAGATTAAGAA 
Exon 45 CCTTTTGACAGTATTTTCTTATCCA AAAAGTAAACATAACAACTAAGGAAGG 
Exon 46 TTTTCAATGGCTGTAGCTATGTT CAGGGCACTTGTAGAGGCATA 
Exon 47 AGAATTGTTTTAAGGATGAATTGAA AACCCTTAGCCTTGCCTCTC 
Exon 48 AACGTTGGGAACTTCGTTCT CTTCCAGTTTTTCCAAGAGGT 
Exon 49 GCATTTAGAGCCCCAGGTTA CAGGAAGAAACCAGGTTATCCA 
Exon 50 AGCTAAAACTTTGACTAGAAGAAACAG GGTGCCCTTCAGTTAGATGG 
Exon 51 ACGCTTTGTTAAAAATGTGTATCTT TCTCTAGTTGTAGCAATTCGGAGT 
Exon 52 CGATAAAGGCTAGCTTGTTCTGA GATCAGAAATCTGAGCCAAAAA 
Exon 53 CATCCAGTGTTTTCCAGGTTC TTTTTAGGATACGTAGTTAAAGATGGT 
Exon 54 TTGCTGTATTTGACCATTCAGG TCACCAGAGCTCACTGCCTA 
CRBl Exon 1 CGCTCCTCTCTGAGACAGAC TTTTATAGAACATGCAACATTATCC 
Exon 2.1 AATGAGTTTGGTTGAGGCAG ATATCCAGCAGGGCAGATG 
Exon 2.2 CAGTGGGACAATCTGTGAAAC AATGTCACCTCTGCTTCTGC 
Exon 3.1 GCTCTGGTAAACAAAGCATTG GAATCCAGGGGCACAGTCG 
Exon 3.2 GACGAATGTTGGTCCCAGC CAGAGTGGTAAAATAGTTCATG n 
0 
Exon4 GAAACAGTATAAAGATATCTGATC GCTATAAGCGATATGTGTATTC s:: 
-u 
Exon 5 AACCTCCTTTTAGGCAAATG GGTTAAAGCCATGGTCTGC ;;o m I 
Exon 6.1 GAGCTATTCATGCACTTCTGC GCCTCTGCAAATATTACCTCC s m c z 
Exon 6.2 GAAGCTGGAGCTGCTAAGTG TTTGCTGTTTCTGCTCTGC ;;;!<£? '--!r;i 
Exon 7.1 TCCATCCCTTCTGTCTTTTG TCCTAGGTTTTGTGAAGACTGA mCl om 
Clz 
Exon 7.2 GCAATGCTGACTCCAAACTC TGGTGGGTCAGTAACATCATC mo 
Exon 8 CAACATTTTTCTATTTAGTTGCC CTCAAATGTCGCAACTTAACTG ~~ - -u z-
Exon 9.1 AATGATCATTACTATTAATAACGG GTGTTTCGTTGTCCACTTCC , z mCl 
OJ;;o 
Exon 9.2 TTGCAGTCAGTGAATGATGG GGGACAGGAGCAATGATAAG m m :::o< 
Exon 10 CTTTTCTTGAATGAGATGAACAAG GAACTTTGAGTAATCCCATCATTC 
nm 0~ 
z (/) 
Exon 11 TTCACAACCAATGTATTCAACAG TCATACGCAAAATGAGGTAAG Cl;o ml:J 
zrr, 
Exons 12-13 TTCCTGAGTAGTTCCATTGTCC CCCAGTTGCAGATTAACATTG =i ~ )>)> 
Exon 14 GCTGTTCCAGAGAGATAAGGC CTCAACAACTGGCTCGTCAT 'V> )>___, 
GUCY2D Exon 1 TCAGCTTGGGGAGATTAAGG GAGGGGCCTCTGACATTTAC SI E:m 
Exon 2.1 TACTCGGGCTTGGAGAAAC CTTCTTCGGCGAGCAGC ;us; oo 
Ul(/) 
Exon 2.2 GACCCCATCTTCTCTCGG ATGATCACTGCTGCGGAC Vi---1 
- -n 
Exon 3 GGCTGTCCTCTCCCCTC Z;;o AGGTAGGCTCCCTTGCAG om 
mO 
Exon4 GAATCTGGTCTGTCTGTGGG CTCTCTTTCATCACTTTGTGG zC :;;:m 
N Exons 5-6 GAAGAGGCCTCCCCTGG GGAAGGAACCAAATTTACGG )>z w ;;o---1 
~ :A'=< 
N n w Exon 7 TCAACCCAGGACTCTGACAC AGGGCCTGAGCATTCTTC I 00 )> 
Exon 8 CCCATCGTGGGATTTTAAG TACCCAGCTGCAAAGAGAAG ~ 
m 
Exons 9-10 TCTTGATTAACAGCCCCTTC GAGAAGCCCTTGAAATAATGG :;o ..,. 
Exon 11 AACCTGGGCTTTCTGGTG CTTTTCTAACTGCAGGGTGC IJl 
Exon 12 AGAGGCAGCCTTTGTGTTC AGCTGTCTCAGGTTGCTGAC 
Exons 13-14 GGTTCAGAGTGAACAGCCC AGATTGATTGGGCAGGTAGG 
Exon 15 CGCTTCGTGTACTCGGG CCTCTACAGGAAATCTGGGG 
Exons 16-17 GGAGATAATGGGTGCGAAG AGGTCAGAAGGGTGAGCTG 
Exons 18-19 AGCTCACCCTTCTGACCTG GACACCTGGCTTGGGTG 
Exon 20 CTCTGTAGCTGGCAGAGCAG AAAGCAGCACACACCACAAC 
LRAT Exon 1.2 TTTGCCTTCCTCTCTCCTCAG CTGGCCACTTTGACAATAACG 
Exon 1.2 ATGCCCGACATCCTGTTG AAGAGAAAAGGTCAGGGATGG 
Exon 2 TCTTGGGTTTAGCCACCTTTC GTAAGCACTTTGCGTGATTCC 
RPE65 Exon 1 CAACTTCTGTTCCCCCTCCCTCAG CTCTTCAGGAGCCCTTGAAATAGC 
Exon 2 TCTATCTCTGCGGACTTTGAGCAT ATAGGAAGCCAGAGAAGAGAGACT 
Exon 3 CCCAAGGCAGGGATAAGAAGCAAT AAGCTAGGCCCTACTTTGAGGAGG 
Exon 4 ACATGGGCTGTACGGATTGCTCCT GAGAGAAAAAGGGCTAATATAAAA 
Exon 5 ATGGCTTGAAAATTACTGGACTGA TGGTGAATTAATTTTAAGTTCCAA 
Exon 6 AGGTATAATGTATCTTCCTTCTCT TTATCTTTCTCACAATACAGTAAC 
Exon 7 CTGTTCTAAATGCTTTGTATTAAA TAGGCCAAGCCAATCTTTAAACTT 
Exon 8 TGTGGCTTGAGAATCAGCCCTTTC GTGTACATTATTAAACACATCTTC 
Exon 9 GTACACTTTTTTCCTTTTTAAATG ACCCCGTAATTTCCAGGAACAATG 
Exon 10 AGAATCATCTCTCTAAAATTATTT CTGAGAGAGATGAAACATTCTGGT 
Exon 11 GAATTCTTTCCTGCTCACTGAGGT GAGCACATGCTTAGGAAAACTCTT 
Exon 12 ACTTCACACGGGAGTGAACAAATG GTCAATATGCTTTACTTGACTAGC 
Exon 13 GCTAGTCAAGTAAAGCATATTGAC CATACAGAGCTGCAGTAAGAAGAG 
Exon 14 TGACACTCAATCTATAGCTTCGGC GATTGCAGACCTGAAGCTGATTTT 
N 
w 
lO 
ARMS-primers used for screening CEP290 c.2991+1655A>G mutation 
ARMS Primer Sequence (5'-3') 
ARMS CEP290 c.2991 + 1655A>G wild type -forward ACCGCACCTGGCCCCAGTTGTAATTGTGGA 
ARMS CEP290 c.2991 + 1655A>G mutant- forward ACCGCACCTGGCCCCAGTTGTAATTGTGGG 
ARMS CEP290 c.2991 + 1655A>G reverse AGTAAGGAGGATGTAAGACTGGAGATAGAG 
Supplementary Table 53. Estimated carrier frequencies of causative variants in LCA genes 
LCA arRP 
GeneD'11ame % 
q2 2pq q2 2pq 
AIPLl 5.3 1/943396 1/486 
CEP290 15 1/333333 1/289 
CRBl 9.9 1/5050501 1/356 1/175000 1/210 
GUCY2D 11.7 1/427350 1/327 
LRA.T 0.5 1/10000000 1/1582 1/233333 1/242 
RPE65 6 1/833333 1/457 1/175000 1/242 
-1/103306 -1/70 -1/77 -1/37 
The Hardy-Weinberg equilibrium (p2+ 2pq+ q2=1) was used to estimate the carrier frequencies for autosomal recessive traits. p, frequency of the wild type allele; q, frequency 
of the recessive mutant allele; q2, prevalence of a homozygous recessive allele; 2pq, carrier frequency. Percentage of patients affected by mutations in the gene was 
calculated by assuming a prevalence LCA of 1:50,000. 
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N Supplementary Table S4. Allele frequencies of identified variants in this study n 
-1'> :r: 0 )> 
Gene Nucleotide change Amino acid change Number of alleles Reference ~ 
m 
AIPLl c.81SG>C p.(Arp272Pro) 1 novel ::0 
-1'> 
CP 
AIPLl c.834G>A p.(Trp278*) 7 l 
CEP290 c. 1219_1220deiAT p.(Met407Giufs*14) 1 2 
CEP290 c.2119_2123dupCAGCT p.( Gln709Serfs*ll) 2 novel 
CEP290 c.2991 + 1655A>G p.(Cys998*)/p.=# 8 3 
CEP290 c.S364+2T>G p.(?) 2 novel 
CRBl c.584G>T p.(Cysl 95Phe) 1 4 
CRBl c.613_619deiATAGGAA p.{lle205Aspfs*l3) 3 5 
CRBl c.2290C>T p.(Arg764Cys) 1 6 
CRBl c.2401A>T p.(Lys801*) 2 6 
CRBl c.2549G>T p.(GiySSOVal) 1 novel 
CRBl c.2843G>A p.(Cys948Tyr) 1 6 
CRBl c.4006G>A p.(Val1336lle) 1 novel 
CRBl c.4121_ 4130del l 0 p. (Ala 137 4Asnfs*20) 2 6 
GUCY2D c.779T>C p.(Leu260Pro) 2 7 
GUCY2D (c.380C>T) p.(Prol27Leu) 1 novel 
GUCY2D c.1561C>T p.(Arg521 *) 2 novel 
GUCY2D c.1694T>C p.(Phe565Ser) 1 8 
GUCY2D c.1877T>C p.(Ser626Phe) 2 novel 
GUCY2D c.1957G>A p.(Giy653Arg) 1 7 
GUCY2D c.2234deiC p.(Pro745Leufs*39) 1 7 
GUCY2D c.2135 _2136delinsTC p.(Giu712Val) 1 novel 
GUCY2D c.2302C>T p.(Arg768Trp) 5 9 
GUCY20 c.2513G>C p. (Arg838Pro) 1 10 
GUCY20 c.2849C>T p. (Aia950Va I) 2 7 
GUCY20 c.3043+SG>A p.(?) 1 novel 
RDH12 c.2T>C p.(Metl Thr) 1 11 
RDH12 c.379G>T p.(Giy127*) 2 12 
RDH12 c.582C>G p. (Tyr194 *) 1 11 
RPE65 c.ll+SG>A p.(?) 4 13 
RPE65 c.94G>T p.{Gly32Cys) 1 novel n 0 
RPE65 c.l30C>T p.{Arg44*) s 4 novel -u ;;o 
RPE65 c.272G>A p. (Arg91Gin) 1 14 m I sm 
RPE65 c.271C>T p.(Arg91 Trp) 2 15 cz ;;;!\,'? 
RPE65 c.329A>G p.{AspllOGly) 7 novel '--l;'ii mG) 
RPE65 495+1dup p.{?) novel o m 2 G) z 
m o 
RPE65 c.769T>G p.(Tyr239Asp) 1 16 ~ ~ 
- -u 
z-
RPE65 c.963T>G p.(Asp321Lys) 2 17 , z m G) 
RPE65 c.1088C>G p.{Pro363Arg) 1 novel OJ:;o m m 
::U< 
RPE65 c.ll02T>C p.(Tyr368His) 4 18 nr;; Or 
p.(Vai443Aia) z (f) RPE65 c.l328T>C 1 19 G);o 
m-o 
RPE65 c. l374G>A p. (Trp458*) 1 7 zrr, =i2-i 
RPE65 c.1543C>T p.(Arg515Trp) 1 20 )>)> 'V> )>'-I 
RPGR/Pl c.930+3A>G p.(?) 1 novel :SI E':m 
RPGR/Pl c.3618-Sdel p.(?) 1 novel :::03::: oo (/)(f) 
TULPl c.1495_1496du~ p.(Asp500Valfs*4) 1 novel U)'--1 
-, 
Z;;o 
om 
mO 
zC 
:;;::m 
N )>z 
~ I :::0 '-I ,_. :::><!:<: 
N n 
-1:> Supplementary Table 55. RP£65 variants registered in Leiden Open source Variation Database I N )> 
Exon/ ~ 
cDNAChange Protein Change Allele Count Coding Effect Classification Reference m lntron Al 
-1:> 
Variant of unknown OJ 
c.-4G>A p.(?) Unknown 
signifi cance 21 
c.2T>C p.{Metl?) 5 Start loss Affects function 15,22 
c.16G>T p.(Giu6') 2 Nonsense Affects function 23,24 
c.57_58del p.(Giu20Giyfs'31) 4 Frameshift Affects function 21,25 
c.65T>C p.(Leu22Pro) Missense Variant of unknown 26,27 
significance 
c.74C>T p.(Pro25Leu) Missense Affects function 28 
c.89dup p.(Thr31Asnfs'21) Frameshift Affects functi on 13 
c.89T>C p.(Vai30Aia) Missense Variant of unknown 29 
significance 
2 c.90_91insT p.(Thr31Tyrfs'21) Frameshift Affects function 22 
3 c.95G>T p.{Giy32Val) Missense Affects function 30 
3 c.97 _116del p.(lle34Ginfs' ll) 2 Frameshift Affects function 31 
c. l 06_114del p.(Leu36_Leu38del) 2 In-frame deletion Affects fu nction 30 
c.ll8G>A p.(Giy40Ser) 23 Missense Affects function 15,19,23,24,31-40 
3 c. l31G>A p.(Arg44Gin) 29 Missense Affects function 14,19,31,32,34,37,39-43 
3 c.l33T>C p.(Cys45Arg) Missense Varian t of unknown 38 
significance 
3 c.l38del p.(Pro47Ginfs'47) 4 Frameshift Affects function 9,19,33,36 
3 c.144_145insT p.(Leu49Serfs' 3) Frameshift Affects function 18 
3 c.177C>G p.(H is59Gin) Missense Affects function 44 
3 c.l79T>C p.(Leu60Pro) 10 Missense Affects function 24,45 
3 c.l83dup p.(Asp62') l Frameshift Affects function 44 
3 c.l90C>T p.(Gin64') 4 Nonsense Affects function 43,46 
3 c.200T>G p.(Leu67Arg} 7 Missense Affects function 25,47-49 
3 c.201_202deiGCinsn p.(His68Tyr) 1 Missense Affects function 27 
3 c.208T>G p.(Phe70Val) 2 Missense Affects function 26,50 
3 c.219dup p.(Giu74Argfs'l4) 6 Frameshift Affects function 51 
3 c.235T>C p.(Tyr79His) 1 Missense Affects function 22 n 
0 
3 c.289dup p.(Arg97Lysfs'34) 3 Frameshift Affects function 19,52 s:: 
-u ;:o 
c.249C>G p.(Phe83Leu) 2 Missense Affects function 25 rn I 
s::rn 
Variant of unknown cz 
c.253C>T p.(ArgBSCys) 1 Missense 
significance 19 ~c,Q 
--lr;;i 
4 c.254G>A p.(Arg85His) J Missense Affects function 22 mCl om 
Clz 
c.271C>T p.(Arg91 Trp) Missense Affects function 14,15,18,19,22,23,31,32,34- mo 4 100 36,39,40,42,50,53-58 ~=! 
--u 
Variant of unknown z-4 c.272G>A p.(Arg91Gin) 17 Missense 19,22,25,31,35,37,39,40 ,z 
signifi cance mCl CIJ;:o 
4 c.272G>C p.(Arg91Pro) Missense Affects function m m 1 26 ;;o< 
nm 
4 c.289_309del p.(Arg97 _Phel03del) 6 In-frame deletion Affects function 9,14,35 of': z (f) 
Cl;:o 
4 c.292_3lldel p.(lle98Hisfs'26} 20 Frameshift Affects function 22,32,37 19,39,40,59 m\) zrr, 
=i8; 
4 c.295G>A p.(Val99lle) 2 Missense Probably no functional effect 60 )>)> 
'IJl )>--1 
4 c.297 _308del p.(llelOO_Phel03del) 1 In-frame deletion Affects function 31 S::I 
E':m 
4 c.297del p.(lle100') 1 Nonsense Affects function 14 ;;os;: oo 
IJl(f) 
c.302C>T p.(Thr10111e) 3 Missense Affects function 19,34 V)--1 
- --n Z;;o 
4 c.304G>A p.(Giul02Lys) 3 Missense Affects function 15,26 om rnO 
zC 
4 c.304G>T p.(Giu102') 21 Nonsense Affects function 7,19,21,22,33,36,61 s;:rn )>z N ;;o--1 
-t> 
w :;.;;C:::: 
N n 
.)>. 4 c.310G>C p.(Gly104Arg) 2 Missense Affects function 62 I 
.)>. )> 
4 c.311G>A p.(Gly104Asp) Missense Affects function 31 ~ m 
;;lJ 
4 c.329A>T p.(AspllOVal) Missense Affects function 24 .)>. CJl 
c.344T>C p.(p.llell5Thr) Missense Affects function 63 
5 c.354G>T p.(Arg118Ser) 3 Missense Affects function 19,64 
5 c.361del p.(Ser121Leufs.6) 12 Frameshift Affects function 29,41,45,65 
5 c.361dup p.(Ser121Phefs•1o) 2 Frameshift Affects function 65 
5 c.370C>T p.(Arg124•) 11 Nonsense Affects function 15,19 ,22,23,26,33,36,41,66 
5 c.382G>C p.(Val128Leu) Missense Probably no functional effect 22 
5 c.394G>A p.(Alal32Thr) 13 Missense Probably no functional effect 15,19,22,55,65,67 
5 c.395C>A p.(Ala132Asp) 2 Missense Affects function 31 
5 c.406G>T p.(Vall36Phe) Missense Probably no functional effect 64 
5 c.427T>G p.(Tyr143Asp) 2 Missense Variant of unknown 68 
significance 
5 c.430T>C p.(Tyr144His) 1 Missense Affects function 47 
5 c.430T>G p.(Tyr144Asp) 13 Missense Affects function 14,19,26,31,37,39,69 
5 c.434C>A p.(Ala145Asp) 2 Missense Affects function 49 
5 c.440_ 441del p.(Thr147Argfs.9) 2 Frameshift Affects function 26 
5 c.444G>T p.(Glu148Asp) Missense Variant of unknown 43 
significance 
5 c.484A>C p.(Thrl62Pro) Missense Affects function 19 
6 c.499G>T p.(Aspl67Tyr) 6 Missense Affects function 19,22-24,26,51 
6 c.SOOdel p.(Asp167Valfs.41) 4 Frameshift Affects function 31 
6 c.540C>A p.(His180Gln) Missense Affects function 53 
6 c542C>T p.(Pro181Leu) 2 Missense Affects function 41 
6 c.S44C>A p.(His182Asn) 1 Missense Affects function 43 
6 c.544C>T p.(His182Tyr) 9 Missense Affects function 15,19,31-33,36,37 
6 c.545A>G p.(His182Arg) 8 Missense Affects function 14,31,39,55 
6 c.S65G>A p.(Val1891le) 1 Missense Variant of unknown 55 
sign ificance 
6 c.615_616del p.(lle206Cysfs'27) 2 Frameshift Affects function 22,43 
c.668_669del p.(Ser223') 1 Nonsense Affects function 22 n 0 
s:: 
7 c.700C>T p.(Arg234') 11 Nonsense Affects function 22,26,41,43,46,51, 70 -u ;:Q 
fTl 
I 
c.715T>G p.(Tyr239Asp) 12 Missense Affects function 19,31-34,36,50,71 I :;;:: rn c z 
;;;J ~ 
8 c.731G>T p.(Gly244Val) 2 Missense Affects function 55 '-I < rn rn 
oG'l 
8 c.746A>G p.(Tyr249Cys) 2 Missense Affects function 24 Gl ~ 
rn o 
8 c.751G>T p.(Val251Phe) 2 Missense Affects function 72 ii'i::<! 
- -u z -
8 c.778_785del p.(Asn260Glnfs'18) 4 Frameshift Affects function 13,22,51 , z m G'l 
ClJ ;:Q 
9 c.859G>T p.(Val287Phe) 14 Missense Affects functi on 9,19,31,32,39,40,55 m m ;:o < 
9 c.864G>T p.(Trp288Cys) 1 Missense Affects function 55 n~ o , Z<.n 
--~ Gl ;:o 
9 c.868C>T p.(His290Tyr) 3 Missense Affects function 65 fTl "'tJ z rr, 
9 c.871A>G p.(lle291Val) 1 Missense Probably no functional effect 55 =i 8i )> )> 
' tn 
9 c.88lA>C p.(Lys294Thr) 4 Missense Probably no functional effect 22,34,73 )> ___, :;;:I 
E: rn 
9 c.886dup p.(Arg296Lysfs'7) 1 Frameshift Affects function 41 ;:u s: 
oo 
Vl (/) 
9 c.893del p.(Lys298Serfs'27) 7 Frameshift Affects function 9,19,24,37,39,74 (Ji'-1 
- Tl Z ;:o 
9 c.907A>T p.(Lys303') 5 Nonsense Affects function 14,19,31,39,75 o rn 
rn O 
z C 
9 c.912C>A p.(Tyr304') 1 Nonsense Affects function 76 s;: rn )> z 
"" 
;:o '-1 
-1:-
tJl "' '=< 
N Variant of unknown () ~ 9 c.917C>T p.(Thr306lle) Missense 76 :r: m 
significance )> ~ 
9 c.938A>G p.(His313Arg) Missense Affects function 26 m ;;o 
~ 
9 c.939T>A p.(His313Gin) 2 Missense Affects function 65 {JJ 
9 c.952T>A p.(Tyr318Asn) 3 Missense Affects function 19,34 
9 c.962dup p.(Asn321Lysfs•15) Frameshift Affects function 15 
9 c.963_964insA p.(Giy322Argfs•14) Frameshift Affects function 36 
9 c.963T>G p.(Asn321Lys) 12 Missense Probably no functional effect 22,24,29,34,37,52,55,77,78 
9 c.989G>A p.(Cys330Tyr) 8 Missense Variant of unknown 43,46,79 
significance 
9 c.991_993dup p.(Trp331dup) 5 In-frame duplication Affects function 41,80 
9 c.993G>A p.(Trp331•) 2 Nonsense Affects function 25 
9 c.997G>C p.(Giy333Arg) Missense Affects function 60 
10 c.1022T>C p.(Leu341Ser) 29 Missense Affects function 14,15,19,25,31,32,39-41,64,81 
10 c.1028T>A p.(Leu343•) Nonsense Affects function 14 
10 c.1059dup p.(Lys354Giufs•ll) Frameshift Affects function 32,33,35,39,40,60 
10 c. l 067del p.(Asn356Metfs•l7) 13 Frameshift Affects function 18,19,22,43,46,51,70,82 
10 c.1067d up p.(Asn356Lysfs•9) Frameshift Affects function 19,31,32,36,53 
10 c.1069_1070insT p.(Aia35Nalfs•s) Frameshift Affects function 9 
10 c.1078G>C p.(Aia360Pro) 3 Missense Variant of unknown 29,34 
significance 
10 c.1087C>A p.(Pro363Thr) 16 Missense Affects function 13,22,24,43,46,69 
10 c.ll02T>C p.(Tyr368His) 69 Missense Affects function 14,18,19,22-24,31,32,39,42,50,68,83-85 
10 c.l103A>G p.(Tyr368Cys) 4 Missense Affects function 25,48 
11 c.1178C>A p.(Aia393Giu) Missense Affects function 9,19,33,36 
11 c.1205G>A p.(Trp402') 2 Nonsense Affects function 19,81 
11 c.1207 _1210dup p.(Giu404Aiafs'4) 4 Frameshift Affects function 15 
11 c.1220T>C p.(Val407 Ala) Missense Variant of unknown 15 
significance 
11 c.1223T>C p.(Leu408Pro) 10 Missense Affects function 19,31,34,39,40 
12 c.l244_1338del p.(Phe416Leufs'2) Frameshift Affects function 34 
12 c.1249G>C p.(Giu417Gin) 12 Missense Affects function 14,31,32,37,39,42 n 0 
:s:: 
12 c.1292A>G p.(Tyr431Cys) 5 Missense Affects function 14,19,31,75 -u ;;o 
rn 
12 c.1301C>T p.(Aia434Val) 11 Missense Probably no functional effect 9,24,34,43,46,55 I :s:: rn 
c z 
12 c.1304A>G p.(Tyr435Cys) Missense Affects function 30 ~ \!! 
'-i ;:ii 
12 c.1307G>T p.(Giy436Val) 2 Missense Affects function 22,24 rn G) o rn 
G1 z 
12 c.1328T>C p.(Vai443Aia) 3 Missense Affects function 19,64 rn o z --1 
rTl -< 
12 c.l336dup p.(Arg446Lysfs'4) Frameshift Affects function 29 - -u z -
, z 
13 c.1355T>G p.(Vai452Giy) Missense Affects function 15 rn G1 OJ ;;o 
rn rn 
13 c.1370C>A p.(Thr457 Asn) 2 Probably no functional effect AJ < Missense 18,22 nrn 0~ 
13 c.1379G>A p.(Trp460') Nonsense Affects function 31 z (f) G);;o 
rn -o 
13 c.1380G>A p.(Trp460') Nonsense Affects function 19 z rr, 
=i 8i )> )> 
13 c.l380G>C p.(Trp460Cys) Missense Affects function 64 ' r.n )> --1 
:S:: I 
13 c.1384G>T p.(Giu462') 4 Nonsense Affects function 9,19 E': rn 
;;o :S:: 
13 c.1409C>T p.(Pro470Leu) 2 Missense Affects function 17 oo r.nr.n (/) --1 
13 c.1418T>A p.(Vai473Asp) 5 Missense Affects function 15,36,43,46 - "T1 Z ;;o 
o rn 
13 c.1430A>G p.(Asp477Giy) 23 Missense Affects function 86 rn O z C 
:s;: rn 
N 14 c.1451G>A p.(Giy484Asp) Missense Affects function 64 )>z ;;o --1 
"""" 
;;;;;:'=< 
--J 
N n 
-1>- 14 c.1459_1460del p.(Leu487Giufs.25) 2 Frameshift Affects function 62 :r: CXl )> 
14 c.1501_1505del p.(Tyr501Profs•1o) 5 Frameshift Affects function 19,39 ~ m 
AJ 
14 c.1543C>T p.(Arg515Trp) 8 Missense Affects function 19,20,38,44 -1>-OJ 
14 c.1583G>T p. (Giy528Val) Missense Affects function 22 
14 c.1590C>A p.(Phe530Leu) Missense Affects function 87 
14 c.1590del p.(Phe530Leurs· 40) Frameshift Affects function 23,41,66 
14 c.1597T>A p.(Ser533Thr) 2 Missense Probably no functional effect 19,29 
1i c.ll+lG>T p.(?) Splice site variant Affects function 32 
9,13,14,18,19,22-24,31-
1i c.l1+5G>A p.(?) 62 Splice site variant Affects function 33,36,37,39,41,43,46,63,64,83-
85,88 
1i c.l2-2A>G p.(?) Splice site variant Affects function 23 
2i c.94+10A>G p.(?) Splice site variant Probably no functional effect 24 
2i c.95-1G>A p.(?) 8 Splice site variant Affects function 45 
2i c.95-2A>C p.(?) 4 Splice site variant Affects function 31,40 
2i c.95-2A>T p.(?) 6 Splice site variant Affects function 26,32,43 
2i c.95-3C>G p.(?) 6 Splice site variant Affects function 89 
6i c.643+1G>C p.(?) 10 Splice site variant Affects function 54 
6i c.643+4A>G p.(?) Splice site va riant Affects function 22 
6i c.644-2A>T p.(?) 3 Splice site variant Affects function 15,43 
7i c.725+4A>G p.(?) 5 Splice site variant Affects function 19,31,37,39 
7i c.726-3C>A p.(?) Splice site variant Affects function 90 
7i c.858+1G>A p.(?) Splice site variant Affects function 43,46 
Bi c.858+1G>T p.(?) 10 Splice site variant Affects function 13,56 
1'0 
.j>. 
1.0 
lli c.1243+2T>A 
Heterozygous Cases 
Dominant Cases 
Homozygous Cases 
Compound Heterozygous Cases 
Uniparentallsodisomy 
Total Cases 
p.(?) Splice site variant 
Total alleles 914 
Probably no functional effect 50 
140 
23 
231 
144 
539 
Affects function 87 
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N Supplementary Table 56. In silica analysis RPE65 missense variants n Ln I 0 )> 
Protein PolyPhen-2 PolyPhen-2 SIFT SIFT 
ExAC (AC, TA, HZ, AF) ~ Exon eDNA Change AC PhyloP Closslflcatlon References Chango score Prediction Score Prediction m 
Al 
Probab ly no Variant of ... 
c.65T>C p.(Leu22Pro) 4.48 0.089 0.23 Tolerated 6, 118912, 0, 5.046e-05 unknown 7,8 OJ 
functional effect 
significance 
c.74C>T p.(Pro25Leu) 5.33 0.988 Probably 
damaging 
0.05 Damaging 3, 118980, 0, 2.521e-05 Affects function 
Variant of 
c.89T>C p.(Vai30Aia) 1.06 0.655 Possibly damaging 0.42 Tolerated unknown 11 
significance 
c.95G>T p.(Giy32Val) 5.77 Probably 
damaging 
Damaging Affects !unction 12 
c.118G>A p.(Giy40Ser) 23 5.77 Probably Damaging Affects function 3-5,13-23 
damaging 
c.131G>A p.(Arg44Gin) 29 5.77 Probably 
damaging 
Damaging 7, 121406,0, 5.766e-05 Affects function 13,14,16,19,21-27 
Variant of 
c.133T>C p.(Cys45Arg) 1.06 0.536 Possibly damaging 0.2G Tolerated unknown 20 
significance 
c.l77C>G p.(His59Gin) 1.58 Probably 
damaging 
Damaging Affects function 30 
c.l79T>C p.(Leu60Pro) 10 4.73 Probably 0.26 Tolerate~ Affects function 5,31 damaging 
c.200T>G p.(Leu67Arg) 4.73 Damaging Affects function 6,33-35 
c.201_202deiGCinsTT p.(His68Tyr) -0.36/5.77 Probably 0.28 Tolerated Affects function 
damaging 
c.208T>G p.(Phe70Val) 4.73 Probably 0.22 Tolerated Affects function 7,36 damaging 
c.235T>C p.(Tyr79His) 4.73 0.97 Probab ly 
damaging 
0.07 Tolerated Affects function 
c.249C>G p.(Phe83leu) 0.77 0.776 Possibly damaging 0.04 Damaging Affects function 
Variant of 
c.253C>T p.(Arg8SCys) 2.63 Probably 0.06 Tolerated 14, 120410,0,0.0001163 unknown 21 
damaging 
significance 
c.254G>A p.(Arg85His) 3.19 0.887 Possibly damaging 0.04 Damaging 2, 120484, 0, L66e-05 Affects function 
c.271C>T p.(Arg91Trp) 100 1.09 0.999 Probably 
damaging 
0.01 Damaging 10, 120738, 0, 8.282e-05 Affects function 
2-4,13,14,16-18,21-
23,25,26,29,36,39-44 
Probably no Variant of 
c.272G>A p.(Arg91Gi n) 17 5.86 0.283 0.52 Tolerated 4, 120746,0, 3.313e-05 unknown 2,6,13,17,19,21-23 
functional effect 
significance 
4 c.272G>C p.(Arg91Pro) 1 5.86 0.926 Possibly damagin g 0.2 Tolerated Affects function 
c.295G>A p.(Val99lle) 2 5.77 0.077 Probably no 
functional effect 
0.12 Tolerated 36, 120964, 1, 0.0002976 Probably no 46 functional effect 
c302C>T p.(ThrlD111e) 3 5.77 0.982 Probably 0.25 Tolerated Affects function 16,21 damaging 
c.304G>A p.(Giu102Lys) 3 5.77 1 Probably 0.19 Tolerated Affects function 3.7 damaging 
c.310G>C p.(Giy104Arg) 2 0.86 1 Probably Q.01 Damaging Affects function 49 n damaging 0 
:5: 
c.311G>A p.(Giy104Asp) 1 5.77 1 Probably 0.01 Damaging Affects function -u 13 ;;o damaging rn 
Probably I 
c.329AoT p.(AspllOVal) 1 4.73 0.991 0 Damaging Affects function 5 :5:rn damaging cz 
Probably ~~ 
c.344T>C p.(p.lle115Thr) 1 4.73 0.989 0.07 Tolerated Affects function 50 '-I~ damaging rnCl 
orn 
c354G>T p.(Argl185er) Probably Affects function Cl z 5 3 1.17 0.969 0.04 Damaging 21,51 rno damaging z---l 
Probably no Probably no rTl-< p.(Vai128Leu) - -u c.382G>C 1 1.25 0 1 Tolerated 2 Z -functional effect functional effect ,z 
rn Cl 
c.394G>A p.(Aial32Thr) 13 3.6 0.012 Probably no 0.24 Tolerated 348, 121220, 4, 0.002871 Probably no 2,3,21,41,52,54 CJJ;;o rn rn functional effect functional effect ;;o < 
Probably no n rn 
c.395C>A p.(Aial32Asp) 2 3.84 0.159 0.03 Damaging Affects function 13 0~ functional effect z Vl 
Probably no Probably no 
Cl ::Q 
c.406G>T p.(Vall36Phe) 1 0.21 0 Tolerated 1, 121256,0, 8.247e-06 m i:J 0.19 51 zrr-, 
functional effect functional effect =i~ 
Variant of )>)> 
Probably 'V> 
c.427T>G p.(Tyr143Asp) 2 1.06 0.995 0.13 Tolerated unknown 55 )> ---l 
damaging 
significance :s: :r: E:rn 
c.430T>C p.(Tyr144His) 1 4.81 1 Probably 
damaging 
0.09 Tolerated Affects function 
;;o :5: 
33 oo 
Vl(J) 
Probably U)-J 
c.430T>G p.(Tyr144Asp) 13 1.06 1 0.01 Damaging Affects function 7,13,19,21,22,2G,56 _ ...,., damaging Z ;;o 
o rn 
c.434CoA p. (Aia145Asp) 2 0.91 0.944 Possibly damaging 0.05 Damaging Affects function 35 rnrO zC 
:;;:: rn 
i'J ~z 
l11 I ;;o ---l 
~ ;;o;; !:( 
N 
Variant of n lJ1 Probably no I N 
c.444G>T p.(Glu148Asp) 2.47 0.028 0.24 Tolerated unknown <7 )> functional effect -u 
significance ---1 
m 
Probably :::0 
c.484A>C p.(Thr162Pro) 4.81 0.994 0.25 Tolerated 2, 121378, 0, 1.648e-05 Affects function 21 -1'-damaging OJ 
c.499G> T p.(Asp167Tyr) 5.69 Probably 
damaging 
0.07 Tolerated 1, 119408, 0, 8.375e-06 Affects function 2,4,5,7,21,37 
c.540C>A p.(His180Gln) 0.61 Probably 
damaging 
Damaging Affects function 39 
c.542C>T p.(Pro181Leu) Probably 
damaging 0.03 Damaging Affects function 
24 
6 c.544C>A p.(His182Asn) 5.69 0.995 Probably 0.1 Tolerated Affects function 27 
damaging 
6 c.544C>T p.(His182Tyr) 5.69 0.995 Probably 
damaging 
0.34 Tolerated 1, 120778, 0, 8.28e-06 Affects function 3,13-15,18,19,21 
c.545A>G p.(His182Arg) 4.73 0.993 Probably 
damaging 
0.32 Tolerated Affects function 13,22,26,41 
Variant of 
c.565G>A p.(Val189lle) 5.69 0.46 Possibly damaging 0.49 Tolerated 11,120912, o, 9.098e-05 unknown 41 
significance 
c.715T>G p.(Tyr239Asp) 12 4.73 Probably Damaging Affects function 13-16,18,21,36,58 
damaging 
c.731G>T p.(Gly244Val) 6.26 Probably 
damaging 
0.38 Tolerated Affects function 41 
c.746A>G p.(Tyr249Cys) 3.51 Probably 
damaging 
Damaging 5,120826,1, 4.138e-05 Affects function 
c.751G>T p.(Val251Phe) 6.26 Probably Damaging Affects function 59 
damaging 
c.859G>T p.(Val287Phe) 14 3.51 0.989 Probably 
damaging 
0.02 Damaging Affects function 13,14,21-23,28,41 
c.864G>T p.(Trp288Cys) 5.45 0.994 Probably 
damaging 
0.16 Tolerated Affects function 41 
c.868C>T p.(His290Tyr) 5.45 Probably 
damaging 
0.93 Tolerated Affects function 52 
c.871A>G p.(lle291Val) 0.45 Probably no 
functional effect 
Tolerated 2, 121084, 0, 1.652e-05 
Probably no 
41 
functional effect 
c.881A>C p.(Lys294Thr) 4 4.56 Probably 0.01 Damaging 486,121148,8,0.004012 Probably no 2,16,60 
damaging functional effect 
Probably Variant of 
c.917C>T p.(Thr30611e) 0.89 0.999 0.29 Tolerated unknown 63 damaging 
significa nce 
c.938A>G p.(His313Arg) 4.4 Probably 
damaging 
0.01 Damaging Affects function 
9 c.939T>A p.(His313Gin) -0.12 Probably Damaging 1, 121400,0, 8.237e-06 Affects function 52 
damaging 
c.952T>A p.(Tyr318Asn) 4.4 Probably Damaging 1, 121392, 0, 8.238e-06 Affects function 16,21 
damaging 
c.963T>G p.(Asn321Lys) 12 0.12 0.013 Probably no 
functional effect 
0.27 Tolerated 651, 121402,18,0.005362 
Probably no 
2,5,11,16,19,38,41,64,65 n 
functional effect 0 
Variant of 
:;;:: 
Probably -u 
c.989G>A p.(Cys330Tyr) 2.47 0.998 0.72 Tolerated 1, 121412,0, 8.236e-06 unknown 27,32,66 ;;o damaging rn 
significance I :;;:: rn 
Probably cz 
c.997G>C p.(Gly333Arg) 5.29 
damaging 
0.01 Damaging Affects function 46 ;;;!~ 
'-1< 
Probably rnrn 
10 c.1022T>C p.(Leu341Ser) 29 4.436 0.02 Damaging Affects function 3,6,13,14,21-24,26,51,68 oCl damaging Cl!;2 
Variant of rno 
10 c.1078G>C p.(Ala360Pro) 5.77 0.047 Probably no 0.24 Tolerated unknown 11,16 ~:;;! functional effect --u z-significance ,z 
10 c.1087C>A p.(Pro363Thr) 16 5.77 0.64 Possibly damaging 0.41 Tolerated 2, 121120. o, 1.651e-05 Affects fun ction 2,5,10,27,32,56 rnCl OJ;;o 
Probably 2,4,5,13,14,21,22, rn rn 
10 c.l102T>C p.(Tyr368His) 69 4.73 Damaging 8, 121144,0, 6.604e-05 Affects function ;;o< damaging 25,26,29,36,55,70-72 n rn 0)> 
10 c.1103A>G p.(Tyr368Cys) 4.73 Probably 0.1 Tolerated Affects function zu; damaging 6,34 Cl;;o rn-u 
Probably z r-r, 
11 c.1178C'A p.(Ala393Glu) 5.45 0.03 Damaging Affects function 15,18,21,28 =i & damaging )> )> 
Variant of ' Vl )> -l 
11 c.1220T>C p.(Val407Ala) 4.48 0.426 Probably no 0.88 Tolerated 1, 120798, o, 8.278e-06 unknown :;;: I funct ional effect 
significance e=rn ;;o:;;: 
Probably oo 
11 c.1223T>C p.(Leu408Pro) 10 4.48 0.01 Damaging Affects function 13,16,21-23 Vl(f) damaging Ui-l 
-" Probably Z;;o 
12 c.1249G>C p.(Glu417Gln) 12 545 O.Ql Damaging Affects function 13,14,19,22,25,26 orn damaging rntO 
Probably zC 
12 c.1292A>G p.(Tyr431Cys) 4.48 0.05 Damaging 1, 120968, o, 8.267e-06 Affects function 13,21,26,62 :;;:rn )>z 
"" 
damaging ;;o-l Ul 
w :A'< 
N Probably no Probably no n (.J1 
12 c.1301C>T p.(Ala434Val) 11 5.45 0.026 Tolerated I .t. 846, 120978, 25, 0.006993 5,16,27,28,32,41 functional effect functional effect )> 
Probably ~ 
12 c.1304A>G p.(Tyr435Cys) 2.87 Damaging Affects function 12 m damaging ::0 
.t. 
12 c.1307G>T p.(Gly436Val) 5.45 Probably 
damaging 
0.07 Tolerated Affects function 
CP 
2,5 
12 c.1328T>C p.(Val443Ala) 4.48 0.871 Possibly damaging 0.38 Tolerated Affects funct ion 21,51 
13 c.1355T>G p.(Val452Gly) 4.89 0.996 Probably 0.1 Tolerated Affects function 
damaging 
13 c.1370C>A p.(Thr457Asn) 0.85 Proba bly no 
functional effect 
0.36 Tolerated 1, 120960, o, 8.267e-06 
Probably no 
2,29 functional effect 
13 c.1380G>C p.(Trp460Cys) 0.86 Probably 
damaging 
0.03 Damaging Affects function 51 
13 c.1409C>T p.(Pro470Leu) 5.94 Probably 
damaging 0.01 
Damaging Affects function 73 
13 c.1418T>A p.(Val473Asp) 4.97 Probably Damaging Affects fu nction 3,18,27,32 damaging 
13 c.1430A>G p.(Asp477Gly) 23 2.3 Probably no Tolerated 
functional effect 
Affects function' 74 
14 c.1451G>A p.(Gly484Asp) 5.94 Probably 
damaging 
Damaging 2, 120516, 0, 1.66e-05 Affects function 51 
14 c.l543C>T p.(ArgSlSTrp) 0.53 Probably 
damaging 
Damaging 2, 120986, o, 1.653e-05 Affects function 20,21,30, 75 
14 c.l583G>T p.(Gly528Val) 6.02 Probably Damaging Affects function 
damaging 
14 c.1590C>A p.(Phe530Leu) 4.24 0.929 Possibly damaging 0.01 Damaging Affects function 76 
14 c.l597T>A p. (Ser533Thr) 0.37 Probably no 
functio nal effect 
0.43 Tolerated 2, 120712,0, 1.657e-05 
Probably no 
11,21 
functional effect 
Total alleles 573 
AC, allele count; AF, allele frequency; ExAC, exome aggregation consortium; HZ, homozygous individuals; TA, total alleles 
*Variant c.l430A>G; p.(Asp477Giy) is considered as Affects function due to its different mutational mechanism in an autosomal dominant manner 
N 
U1 
U1 
Supplementary Table 57. Splice prediction non-canonical splice site variants in RPE65 
Ex on 
1i 
2i 
2i 
6i 
7i 
7i 
eDNA 
Clt.ange 
c.ll+SG>A 
c.94+10A>G 
c.95-3C>G 
c.643+4A>G 
c.725+4A>G 
c.726-3C>A 
Protein Allele 
Change Count 
p.(?) 62 
p.(?) 
p.(?) 6 
p.(?) 
p.(?) 5 
p.(?) 
Splice Site 
Finder-like 
(0-100) 
~70 
78.95¢-
=80.04 
84.15 ¢ 73.33 
(-12.9%) 
95.64 ¢ 85.56 
(-10.S%) 
83.18 ¢ 73.10 
(-12.1%) 
78.75¢-
MaxEntScan 
(0-12) 
~0 
9.09 Q 1.53 
(-83.2%) 
=8.08 
9.37¢0.62 
(-93.3%) 
10.67 Q 8.56 
(-19.8%) 
6.43 Q 3.16 
(-50.8%) 
9.36¢6.22 
(-33.6%) 
NNSPI.ICE 
(0-1) 
>0.4 
0.96 Q 0.61 
(-36.4%) 
=0.88 
0.97¢-
0.98¢0.83 
(-15.4o/o) 
0.60¢-
GeneSpllcer HSF 
(0-1S) (0-100) 
~ ~ 
84.67 ¢ 72.51 6.82¢ -
H.4.4%) 
4.89¢3.15 
=86.63 (-35.6%) 
8.64¢- 91.38 ¢ 81.08 (-11.3%) 
98.84 Q 90.50 
(-8.4%) 
0.70¢- 86.00 ¢ 77.66 (-3.7%) 
84.53 ¢ 75.14 
(-11.1%) 
ExAC (AC, TA, Classification HZ,AF) 
11, 120956, 0, 
9.094e-05 Affects function 
Probably no 
functional effect 
Affects function 
Affects function 
Affects function 
2, 120388, 0, 
Affects function 1.661e-05 
Reference No. 
2,4,5,10,13-
15,18,19,21,22,24,26-
29,32,50,51, 70-72,77 
5 
78 
2 
13,19,21,22 
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CHAPTER SA 
Abstract 
Purpose: AGBLS, encoding ATP/GTP binding protein-like 5, was previously proposed as an 
autosomal recessive retinitis pigmentosa (arRP) candidate gene based on the identification 
of missense variants in two families. In this study, we performed next-generation sequencing 
to reveal additional RP cases with AGBLS variants, including protein-truncating variants. 
Methods: Whole-genome sequencing (WGS) or whole-exome sequencing (WES) was 
performed in three pro bands. Subsequent Sanger sequencing and segregation analysis were 
performed in the selected candidate genes. The medical history of individuals carryingAGBL5 
variants was reviewed and additional ophthalmic examinations were performed, including 
fundus photography, fundus autofluorescence imaging and optical coherence tomography. 
Results: AGBLS variants were identified in three unrelated arRP families, comprising of 
homozygous variants in family 1 (c.l775G>A:p.(Trp592*)) and family 2 (complex allele: 
c.[323C>G; 2659T>C]; p.[(Prol08Arg; *887Argext*l)], and compound heterozygous variants 
(c.752T>G:p.(Val251Gly) and c.l504dupG:p.(Ala502Glyfs*l5)) in family 3. All affected 
individuals displayed typical RP phenotypes. 
Conclusions: Our study convincingly shows that variants in AGBLS are associated with arRP. 
The identification of AGBLS and TTLLS, a previously described RP-associated gene encoding 
the tubulin tyrosine ligase-like family, member 5 protein, highlights the importance of poly-
and de-glutamylation in retinal homeostasis. Further studies are required to investigate the 
underlying disease mechanism of AGBLS variants. 
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Introduction 
MUTATIONS IN AGBLS, ENCODING a-TUBULIN DEGLUTAMYLASE, 
ARE ASSOCIATED WITH AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA 
Retinitis pigmentosa (RP) (MIM268000) encompasses a clinically and genetically heterogenous 
group of inherited retinal dystrophies (IRDs) with a worldwide prevalence of approximately 1 
in 4,000 individuals. RP is characterized by initial rod photoreceptor degeneration resulting 
in night blindness, followed by mid-peripheral field loss and deterioration of central vision 
due to cone photoreceptor degeneration.1 The clinical presentation of RP is highly variable 
in terms of onset, disease progression, fundus appearance and associated ocular features. 
The ophthalmic features indicative for RP include bone-spicule pigmentations with atrophy 
of the retinal pigment epithelium (RPE), waxy disc pallor, and retinal arterioles attenuation.2.3 
To date, 79 genes have been implicated in RP (https:j/sph.uth.edu/retnet). These genes 
encode proteins involved in different retinal pathways, including the phototransduction 
cascade, the retinoid cycle, ciliary transport, retinal development and RNA splicing factors.4 
Recent whole-exome sequencing (WES) studies demonstrated that approximately 65% 
of RP cases can be explained by variants in these genes (L. Haer-Wigman et al., personal 
communication),5·3 suggesting that several genes are yet to be identified. This study aimed to 
identify novel genes associated with RP using next generation sequencing (NGS) technology. 
Here, we describe the identification of biallelic variants in AGBLS in four arRP patients 
from three unrelated families. 
Subjects and methods 
Subjects and Clinical Evaluation 
The study protocol adhered to the tenets of the Declaration of Helsinki and received approval 
from the respective local ethics committees. Written informed consent was obtained from 
all participants or parents of children prior to their inclusion in this study. Patients were 
ascertained from the inherited retinal disease clinics at the Rotterdam Eye Hospital (The 
Netherlands) and Moorfields Eye Hospital (London, UK). 
Each patient underwent a full clinical examination including visual acuity and dilated 
fundus examination. Retinal fundus imaging was obtained by 35 degree colour fundus 
photography (Topcon Great Britain Ltd, Berkshire, UK), 55 degree fundus autofluorescence 
(FAF) imaging (Spectralis; Heidelberg Engineering Ltd, Heidelberg, Germany) and Spectralis 
optical coherence tomography (OCT). 
Full-field and pattern electroretinography (ERG, PERG) were available from three 
patients, performed with gold foil electrodes, which incorporated the International Society 
for Clinical Electrophysiology of Vision (ISCEV) standards.9•10 We also studied all retrospective 
data including Stratus (Carl Zeiss Meditec, Dublin, CA, USA) OCTs. 
Genetic analysis 
Genomic DNA was isolated from peripheral blood lymphocytes according to standard salting 
out procedures.U In one unaffected individual from family 1, DNA was extracted from saliva 
material using the Oragene system (OG-500; Genotek, Ottawa, Canada). 
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WES of the proband from family 1 was performed usingAgilent's SureSelectAll Human Exome 
version 2 kit (SO Mb; Agilent Technologies, Santa Clara, CA, USA), followed by sequencing on 
a SOLiD4 sequencing platform (Life Technologies, Carlsbad, CA, USA). Reads were mapped 
against the UCSC browser's human genome Hg19 assembly (build 37) using Lifescope v2.1 
software (Life Technologies) and variants were called using the Genome analysis Toolkit 
(GATK) v2 according to the recommended guidelines (https://software.broadinstitute.org/ 
gatk/best-practices/). 
The proband from family 2 underwent WES analysis using Agilent's SureSelectXT Human 
All Exon version 5 exon capture (Agilent Technologies, Santa Clara, CA, USA), followed by 
sequencing on a HiSeq 2000 platform (lllumina Inc., San Diego, CA, USA) at AROS Applied 
Biotechnology (Aarhus, Denmark). Raw fastq files were aligned to the GRCh37 reference 
genome using novoalign version 2.08.03. Duplicate reads were marked using Picard tools 
MarkDuplicates. Calling was performed using the haplotype caller module of GATK (https:/ I 
www.broadinstitute.org/gatk, version 3.3-0), creating gVCF formatted files for each sample. 
The individual gVCF files for the exomes discussed in this study, in combination with 
-3,000 clinical exomes (UCL-exomes consortium), were combined into merged VCF files 
for each chromosome, on average containing 100 samples each. The final variant calling 
was performed using the GATK Genotype gVCFs module jointly for all samples (cases and 
controls). Variant quality scores were then re-calibrated according to GATK best practices 
separately for indels and SNPs. Resulting variants were annotated usingANNOVAR based on 
Ensembl gene and transcript definitions. Candidate variants were filtered based on function 
(non synonymous, presumed loss-of-function or splicing, defined as intronic sites within 5 bp 
of an exon-intron junction) and minor allele frequency(< 0.5% minor allele frequency in our 
internal control group, as well as the NHLBI exome sequencing dataset). 
The patient from family 3 underwent WGS as part of a large collaborative study: DNA 
from 599 unrelated patients with inherited retinal disease, ascertained from the Inherited Eye 
Disease clinics at Moorfields Eye Hospital (MEH), London, underwent WGS as part ofthe NIHR 
BioResource- Rare Diseases project, Specialist Pathology Evaluating Exomes in Diagnostics 
(SPEED). Briefly, peripheral blood mononuclear cell-derived genomic DNA was processed 
using the lllumina TruSeq DNA PCR-Free Sample Preparation kit (lllumina Inc., San Diego, CA, 
USA) and sequenced using an lllumina HiSeq 2500, generating a minimum coverage of 15X 
for -95% of the genome. Reads were aligned to the genome (GRCh37) using Isaac aligner 
(lllumina Inc, Great Chesterford, UK). SNVs and indels were identified using Isaac variant 
caller. Variant examination was performed only on the SNVs and indels that met the following 
criteria: passed standard quality filters, predicted to alter the sequence of a protein, and had 
an allele frequency <0.01 in the 1000 genomes database, the NHLBI GO Exome Sequencing 
Project (http://evs.gs.washington.edu/EVS/ release 20130513), the UK10K database 
(http://www.uk10k.org), the Exome Aggregation Consortium (ExAC) database (http:/ /exac. 
broadinstitute.org) and allele frequency <0.02 in -6,000 internal control genomes. 
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Primers for amplification of coding exons and flanking exon-intron boundaries of AGBLS 
(NM_021831.5) were designed with Primer3 plus (http://www.bioinformatics.nl/cgi-bin/ 
primer3plus/ primer3plus.cgi). Primer sequences and PCR conditions are available upon 
request. 
Pathogenicity interpretation of missense variant 
The Combined Annotation Dependent Depletion (CADD) (http://cadd.gs.washington.edu/) 
score was used to predict the pathogenicity of missense variants. This scoring system 
incorporates several widely used in silica tools, such as SIFT (http://sift.jcvi.org/), PolyPhen-2 
(http:/ /genetics.bwh.harvard.edu/pph2/), Mutation Taster (http:/ jwww.mutationtaster. 
org/), PhyloP and Grantham score. Minor allele frequencies were obtained from the Exome 
Aggregation Consortium (ExAC) databasecontaining~60,000 exomesof unrelated individuals, 
accessed March 2016. YASARA (Yet Another Scientific Artificial Reality Application; http:// 
www.yasara.org/) Structure molecular modeling package (Ver. 11.3.2) was used to build the 
three-dimensional structure of AGBLS (AAH07415.2). Thereafter, two missense variants were 
introduced into this 3D model to assess the predicted effect of these variants on the structure 
ofthe protein. 
Results 
Clinical findings 
The clinical characteristics of patients (for pedigrees, see Figure 1) are summarized in Table 
1 and retinal imaging pictures are shown in Figure 2. Patient F1-IV:3 was referred to the 
Rotterdam Eye Hospital at age 32 with end-stage RP complicated by cystoid maculopathy. 
Visual acuity at presentation was hand movements in the right and light perception in the left 
eye. He was pseudophakic (cataract extraction performed at age 29), and retrospective data 
on visual acuity and visual fields were not available. The cystoid maculopathy was responsive 
to subcutaneous octreotide, but visual acuity did not improve. Through the years the cysts 
disappeared and atrophy of the macular region developed (Figures 1A and B). He was also 
suffering from Behcet's disease, but did not have a history of recurring uveitis. His older sister 
(F1-IV:2) was examined only once at the age of 43. She also presented with end-stage RP. She 
was pseudophakic and visual acuity was hand movement and counting fingers. Her fundus 
examination revealed optic disk pallor, attenuated vessels, macular atrophy, mid-peripheral 
and peripheral RPE atrophy and heavy bone spicule pigmentation but no cystoid macular 
edema (not shown). The DNA sample of this patient was not available. 
Patients from families 2 and 3 initial ly developed nyctalopia, with a range of onset from 9 
to 30 years before subsequent development of peripheral visual field loss. At last review (age 
range 24-45 years), there was mild visual acuity loss with best corrected visual acuity mean 
0.34log MAR (range 0.30- 0.48). All patients developed posterior subcapsular cataract. F2-11:1 
had learning difficulties but no other symptoms suggestive of syndromic disease. There were 
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F1 
IV:1 IV:2 IV:3 IV:4 
M11+ M11M1 
M1 :c.1775G>A; p.(Trp592*) 
F2 
11:1 11:2 
[M2;M3JI[M2;M3] 
11:3 
[M2;M3JI[M2;M3] 
M2: c.323C>G; p.(Pro108Arg) 
M3: c.2&59T>C; p.raa7 Argext"1) 
F3 
11:1 11:2 
M41M5 M51+ 
M4: c.752T>G; p.(Vai251Giy) 
M5: c.1504dupG; p.(Aia502Giyfs*15) 
Figure 1. Pedigrees of families carrying AGBL5 variants. AGBLS variants were identified in three 
autosomal recessive retinitis pigmentosa (RP) families. Affected individuals are indicated with filled 
symbols and unaffected relatives are indicated with open symbols. Genotypes are shown below the 
pedigree symbols. M represents mutant allele and'+' represents wild-type alleles. Variant c.l775G>A:p. 
(Trp592*) occurred in a homozygous state in Fl, variants c.323C>G:p.(Prol08Arg) and c.2659T>C:p. 
(*887Argext*l) occurred in a homozygous manner in F2, and compound heterozygous variants 
c.752T>G:p.(Vai251Giy) and c.l504dupG:p.(Ala502Giyfs*l5) were found in F3. 
fundus abnormalities consistent with RP including attenuated vessels, macular and mid-
peripheral retinal pigment epithelium mottling/ atrophy and peripheral intra retinal pigment 
migration, most prominent in the proband of family 3 (Figure 21). 
FAF imaging demonstrated a ring of increased autofluorescence para-foveally in F2-
ll:l, focally increased autofluorescence corresponding to macular edema in F2-11:3 and a 
partial ring of reduced autofluorescence in F3-ll:l (Figures 20, 2G and 2J). All patients had 
mid-peripheral reduced autofluorescence in keeping with regions of RPE atrophy and 
increased pigmentation. On OCT, there was outer retinal atrophy with variable preservation 
of photoreceptors most apparent in F2-ll:l with a centrally preserved inner segment 
ellipsoid band (Figure 20). OCT imaging demonstrated intraretinal cysts of the inner nuclear 
layer which responded to topical carbonic anhydrase inhibitors (Figures 2E, 2H, and 2K). 
Electrophysiology demonstrated rod and cone system dysfunction (Table 1). 
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Fundus photograph Fundus 
autofluorescence 
Optical coherence 
tomography 
Figure 2. Retinal imaging of affected individuals. Color fundus imaging (2A, 2C, 2F, 21) in four patients 
demonstrated optic disc pallor, attenuated vessels, macular and mid-peripheral retinal pigment 
epithelium mottling/atrophy and peripheral intra-retinal pigment migration, heaviest in 2A and 21. 
FAF imaging in three patients demonstrated a ring of increased autofluorescence para-foveally in F2-
ll:l (20) with focal para-foveal increased autofluorescence in F2-11:3 (2G) likely representing cystoid 
macular edema. There was an incomplete ring of reduced autofluorescence para-foveally for F3-ll:l 
(2J). All patients had mid-peripheral reduced autofluorescence in keeping with regions of RPE atrophy 
and increased pigmentation. Stratus OCT ofthe right eye in Fl-IV:3 (28) at age 34 showed large cysts 
at the macula comprising several retinal layers with cysts in the inner nuclear layer of the paramacular 
region (upper panel). In the lower scan (at 39 years), complete atrophy of retinal layers at the fovea can 
be observed. OCT imaging also demonstrated loss of outer retina with partial preservation of the inner 
segment ellipsoid band in patient F2-ll:l (2E), very limited photoreceptor preservation for F2-11.3 (2H) 
and F3-ll.l (2K), and intraretinal cysts of the inner nuclear layer for all patients. 
271 
"-> Table 1. Clinical phenotype of patients carryingAGBLS variants n 
-.J :r: 
"-> )> 
Family Variants Age Visual Optical ~ ID/ diagnosis/ acuity Full field ERG Fundus Other m (allele 1/ History Refraction Ophthalmoscopy coherence A! Gender/ recent Snellen autofluorescence symptoms (.J1 
Origin allele2) examination (LogMAR) tomography )> 
Pseudophakia, 
Mild optic disk Cystoid cataract 
F1 Central pallor, attenuated maculopathy extraction 
IV:3 c.1775G>A vision vessels, macular and progressing (age 29), band 
(DNA12- p.(Trp592*) I loss and RE:LP+ NA (pseudo- (mid-) peripheral RPE into complete keratopathy, 
19185)1 c.l775G>A: 161 43 nyctalopia LE:LP- aphakia) atrophy with heavy NA loss of outer NP cystoid macular 
Ml p.(Trp592*) (2"' intra retinal bone retinal layers and oedema, 
Turkey decade) spicule pigmentations thinning inner (responsive to 
and deep nummular retinal layers at subcutaneous 
pigmentations. fovea. octreotide), 
Morbus Beh~et. 
Age8yrs, Parafoveal hyper- Posterior findings 
autofluorescent subcapsular 
c. [323C>G; Optic disc pallor, of marked Cysts in inner 
ring larger on cataract, 
c.2659T>C]: attenuated vessels, rod system nuclear layer cystoid macular F2 p.[(Pro108Arg); RE:6I18 RE:+O.SOI macular and dysfunction L>R, centrally L, R additional oedema 11 :1 (*887Argext*1)] Nyctalopia (0.48) -2.00x180 mid-peripheral with cone preserved inner ring of hypo- (responsive to (GC15894.1)1 I c.[323C>G; 9124 (age9) LE:6112 LE -0.501 RPE mottling system segment ellipsoid autofluorescence topical carbonic Fl 
c.2659T>C]: (0.3) -1.50 xl70 and occasional dysfunction band and outer surrounding anyhydrase UK p.[(Pro108Arg); hyperpigmented R>L. Marked nuclear layers this in macula, inhibitor, CAl), 
mid-peripheral (*887Argext*1)] spots. macular L>R. 
spots of hypo- right amblyopia, involvement 
autofluorescence. right secondary 
on R exotropia. 
c.[323C>G; Foveal hyper- Posterior 
c.2659T>C]: Nyctalopia Optic disc pallor, Cysts inner autofluorescence subcapsular F2 p.[(Pro108Arg); (2'' RE:6I18 RE:-1.501 attenuated vessels, Age20 nuclear layer, surrounded by cataract, 11:3 (*887Argext•1)] decade) {048) -2.50x48 macular and mid- yrs,severe small foveal parafoveal hypo- cystoid macular (GC15894.2)1 20127 Central generalized region of oedema 
Fl 
I c.[323C>G; 
vision loss LE: 6118 LE:-1.501 peripheral RPE loss of retinal preserved inner autofluorescent (responsive to 
c.2659T>C]: {048) -2.00xl mottling, minimal ring, mid-peripheral UK p.[(Pro108Arg); Visual field pigment spots. function segment ellipsoid spots of hypo- CAl) 
(*887Argext*1)] loss band. autofluorescence. Learning difficulties. 
F3 
11:1 
(GC3687)/ 
F/ 
UK 
c.752T>G: 
p.(Val251Gly) I 
c.1504dupG:p. 
(Ala502Glyfs'15) 
39/63 
Nyctalopia 
and 
peripheral 
field loss 
(start 4th 
decade) 
RE:G/12 
(0.3) 
LE:G/12 
(0.3) 
RE:O/ 
-1.00 x65• 
LE:+0.25DS 
Optic disc pallor, 
attenuated vessels, 
macularRPE 
mottling, heavy 
mid-peripheral bone 
spicule pigmentation. 
Age 39 yrs, 
findings 
consistent with 
RP, report not 
available 
Cysts in inner 
nuclear layer, 
centrally 
preserved outer 
nuclear layer and 
inner segment 
ellipsoid band 
(disrupted). 
epiretinal 
membrane. 
Para foveal 
spots of hypo-
autofluorescence, 
extensive speckled 
mid-peripheral loss 
of autofluorescence. 
Cataract, 
cystoid macular 
oedema 
(responsive to 
CAl). 
CAl, Carbonic Anhydrase Inhibitor; DS, Dioptres Sphere; FAF, fundus autofluorescence; L,left; LE,left eye; log MAR, Logarithm of the Minimum Angle of Resolution, to measure metric visual acuity; LP, 
light perception; NA, not applicable; NP, not performed; OCT, optical coherence tomography; R, right; RE, right eye; RPE, retinal pigmented epithelium. > ;;o 
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Genetic findings 
Biallelic variants in AGBL5 were identified in four patients from three families. These variants 
are summarized in Tables 1 and 2. None ofthem have been previously reported in RP patients. 
WES data analysis did not yield other biallelic variants in the genes known to be mutated in 
IRD (Retinal Information Network; https://sph.uth.edu/retnet/). The proband of family 1 was 
homozygous for the c.1775G>A:p.(Trp592*) nonsense variant in the AGBLS gene (Figure 3). 
The resulting transcript is expected to undergo nonsense mediated decay (NMD), suggesting 
that this variant is a true loss-of-function allele. This variant was reported in 1/ 121,398 alleles 
(0.0008%) in the ExAC dataset. 
Table 2. AGBLS variants identified in this study 
ExACallele Mutation CADD DNA variant Protein variant frequency SIFT PolyPhen-2 
Taster Ph red 
PhyloP 
(%) 
c.323C>G p.(Pro108Arg) 0 Deleterious Probably Disease 24.0 5.45 damaging causing 
c.752T>G p.(Vai251Giy) 0 Deleterious Probably Disease 27.1 4.73 damaging causing 
c.1775G>A p.(Trp592•) 0.0008 N.A. N.A. N.A. NA NA 
c.l504dupG p.(Ai a502Giyfs•l5) N.A. N.A. N.A. NA N.A. 
c.2659T>C p.(.887Argext' 1) 0 N.A. N.A. N.A. N.A. N.A. 
Two affected siblings from family 2 (GC15894) were homozygous for the missense variant 
c.323C>G:p.(Pro108Arg). All in silica tools predict this variant to be pathogenic (Table 2). The 
altered proline residue is fully conserved throughout AGBLS orthologues up to Tetraodon 
nigroviridis (Figure 3A) and is located in the core of AGBLS (Figure 3B) . A change to arginine 
introduces a larger amino acid which may destabilize the protein structure. Moreover, proline 
provides a rigid structure important for interaction with ligands or other proteins. A second 
homozygous variant, c.2659T>C:p.(*887Argext*1), was also identified in the two affected 
members of this family. This stop-loss variant is predicted to result in a single amino acid 
residue extension of the protein. Two rare stop-loss variants affecting other nucleotides of 
the AGBLS stop codon, c.2661A>G:p.(*887Trpext*1) and c.2661A> T:p.(*887Cysext*1), were 
found in one and seven alleles in the ExAC dataset, respectively. 
The compound heterozygous variants, c.1504dupG:p.(Aia502fs*15) and c.752T>G:p. 
(Vai251Giy) were identified in a simplex RP patient of family 3. The p.(Vai251Giy) variant alters 
the valine residue flanking the consensus zinc-binding residues of the M14-like peptidase 
domain . This valine is conserved throughout paralogues and orthologues of AGBLS (up to 
Tetraodon nigroviridis) . Furthermore, it affects a highly conserved nucleotide with a PhyloP 
score of4.73.Accordingto Visseretal., by using PhyloP score distribution ofdbSNP and HGMD 
variants, this variant can be considered as pathogenic as it is close to the mean PhyloP score 
(4.7) of the pathogenic de novo variants identified in persons with Intellectual DisabilityP All 
in silica prediction tools indicate that this variant is pathogenic (Table 2). Alteration of this 
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hydrophobic valine to glycine may destabilize the secondary structure of AGBLS in this domain 
(Figure 3B). All variants co-segregated with disease in the family members available for testing 
(Figure 1). 
A. PeptidaseM1.tdomain 
r---~ 
, -~ .Ji_2 t~~t ~ - llsrhb~J-:i__J=~:.-:.~JtirJ! . ~iJ~~-~ ~~tGff1~ f'"J 
Human 
Chimp 
Gorilla 
Orangutan 
Rat 
Mouse 
Dog 
Chicken 
Frog 
Tetraodon 
B. 
p.(Pro103Arg)* p.(Va12o1Giy) p.(Arg276Trp)t p.(Asp295Asn)t p.(Aia&02Gr.(fs"15) p.(Trp5921 p.("BB7ArgExl"1)' 
~ ~ ' . 
G M~PFV R SSRVHPG L N POGVV 
G MA P FV R SSAVHPG LN PDGVV 
G MA PF V R SSRV H PG LN PDGVV 
G MA P FV R SSRVHPG LNPOGVV 
G roiA PF V R SSRVHPG LN POGVV 
G MAPFV R SSRVH P G I. HPrlGVV 
MAPFV R SSRVHPG LHPDGVV 
P ISJ R SSRVHPG LNPOGVV 
~ MA P FV R SSHVHPG LNPOGVV ;c M A r> F V R SSRVHPG 0 0 P R A LN P OGVV 
Figure 3. Exon-intron structure of AGBL5, RP-associated variants and 3-dimensional modeling of 
missense variants. A: Schematic representation of AGBL5 variants identified in this and previous studies. 
Cross-species amino acid comparison showed that all missense variants affect highly conserved residues. 
Variants identified in this study are colored in red and variants in previous studies are in black. *These 
two variants occurred homozygously in F2; B: Three-dimensional protein modeling of AGBL5 missense 
variants. Three-dimensional structure of cytosolic carboxypeptidase-like protein 5; ATP/GTP-binding 
protein-like 5. Wild-type and mutant residues are shown and colored in cyan and green, respectively. The 
p.(Prol08Arg) variant, alter proline in position 108 to arginine is located in the core of the AGBL5 protein. 
This alteration created a larger amino acid which may destabilize the protein structure. The p.(Val251Gly) 
missense variant, changed the hydrophobic valine to glycine and may destabilize the structure of AGBL5. 
tThese two variants were identified from previous studies by Patel et al5 and Kastner et al.13, respectively. 
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Discussion 
AGBLS is a novel gene associated with RP 
Previous studies by Patel etal.5 and Kastneret al. 13 discoveredAGBL5 as a novel candidate gene 
associated with RP. These studies identified homozygous missense variants (p.(Arg276Trp) and 
p.(Asp295Asn)) in arRP cases from Saudi and Turkish origin. In our study, we identified five novel 
variants in AGBLS in three unrelated RP cases which further confirm the causality of this gene. 
The novel variants consist of two missense, two protein-truncating and one stop-loss variants. 
To date, all missense variants in AGBLS with an exception of p. (Prol08Arg) are located within 
the Ml4-like carboxypeptidase A domain (Figure 3A), which highlights the importance of this 
protein domain for AGBLS function. This protein domain encode cytosolic carboxypeptidases 
(CCPs) that has been implicated to play role in the post-translational modifications of 
tubulin. Furthermore, mutation of the active site of the carboxypeptidase domain causes 
abnormal cilia development in zebrafish .14 The protein-truncating variants, i.e. p.(Trp592*) 
and p.(Ala502Glyfs*l5), are expected to result in complete loss-of-function due to premature 
translation termination and nonsense mediated decay. 
The stop-loss p.(*887Argext*l) variant found in family 2 results in loss of the canonical 
termination codon which leads to the extension of the t ranscript by one codon and consequent 
extension ofthe protein by a single amino acid residue. This finding in addition to the presence 
of eight alleles in control data (ExAC) with similar stop loss variants may suggest that the stop 
loss variant is a bystander in the pathogenesis of AGBLS- retinopathy although a modifier or 
indeed pathogenic effect cannot be ruled out. 
The two arRP families reported by Patel et al.5 and Kastner et alY display a classical RP 
phenotype, as do our patients. There was some variability in visual function; our eldest patient 
(age 63) still had relatively well preserved visual acuity, whereas one subject was blind at age 
32. All patients showed retinal cysts in the macula region at some stage of the disease, but this 
occurs in 18-32% of RP patients.15 
Interestingly, Kastner et al.U reported intellectual disability in an affected male and 
proposed a possible correlation between gender and brain phenotype. In our study, learning 
difficulties occurred in a female patient, which does not support a correlation between gender 
and brain phenotypes. Additional RP patients with AGBLS variants need to be identified to gain 
more insight into a possible association with brain phenotypes. 
Pathak et al. demonstrated that knockdown of Agb/5 in zebrafish leads to ciliopathy 
phenotypes, i.e. axis curvature, hydrocephalus, pronephric cysts, and abnormal multicilia 
motility.15 However in human, variants in AGBLS are associated with non-syndromic RP. These 
phenotypic discrepancies might be caused by homologous genes in human that might 
compensate for the effect caused by these mutations. Alternatively, as the N MD event was not 
functionally assessed, there is a possibility that in the human patients, truncated proteins with 
residual activity are being produced. Finally, recent studies shown that the use of morpholinos 
for gene knockdown in zebrafish may lead to off-target effects thereby explaining additional 
phenotypes observed in the zebrafish studies.16 
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Imbalance of poly- and de-glutamylation in post-translational modifications is associated 
withRP 
Approximately one-third of IRD-associated genes play roles in maintaining the structure and 
function of photoreceptor sensory ciliumY Previous studies have implicated TTLL5, a gene 
encoding a polyglutamylase (tubulin tyrosine ligase-like family, member 5) in the pathogenesis 
of autosomal recessive cone-rod dystrophy.18 AGBL5, also known as CCP5, is known to function in 
polyglutamylation and deglutamylation oftubulin and perturbations in this pathway may lead 
to photoreceptor cell degeneration.19 Tubulin glutamylation is an essential posttranslational 
modification associated with stable microtubules, neuronal axons, mitotic spindles, centrioles 
and cilia.20 TTLL tubulin ligases and CCP deglutamylases are required to maintain the balance 
oftubulin glutamylation in ciliogenesis.21•22 Any imbalance in poly- and de-glutamylation might 
disrupt cilia function. Hyperglutamylation is known to diminish Tetrahymena cilia motility 
and to induce axonemal microtubules defects.23 Tt/15 mutant mice displayed a complete 
loss of RPGR glutamylation without marked changes in tubulin glutamylation levels. The 
Tt/15 mutant mouse developed slow photoreceptor degeneration with early mislocalization 
of cone opsins, features resembling those of Rpgr-null mice.18 Ccp5 knockdown in zebrafish 
led to hyperglutamylation and reduced the disorganized cilia beat pattern. Ttll5 on the other 
hand, plays a role in polyglutamylation which is crucial for microtubule sliding and cilia 
waveform regulation.15 lnterestingly, a recent study demonstrates the role of TTLL5 in RPGR0 RFls 
glutamylation.24 The opposite function of AGBLS (CCPS) in the deglutamylation process may 
also play an important role in the balance of glutamate chains in RPGR0 RF15. Post-translational 
modifications are regulated by several members of the TTLL and CCP gene families, and we 
hypothesize that beside AGBL5 and TTLL5, other TTLL (TTLLl through TTLLll) and CCP (CCPl 
through CCP6) genes are plausible candidate genes for I RD. 
In conclusion,this study strengthens the role of AGBL5variants in retinitis pigmentosa. The 
involvement of both AGBL5 and TTLL5 in inherited retinal dystrophies underlines the critical 
importance of glutamylation in retinal function. 
Acknowledgements 
We are grateful to the patients and family members for participation in the study. The research 
of GDNA was supported by the Directorate General for Higher Education (DIKTI) of the Ministry 
for National Education of Indonesia, and the Radboud University Medical Center, Nijmegen, 
The Netherlands. The research of GA, SH and AW was supported by the National Institute for 
Health Research England (NIHR) BioResource- Rare Diseases (RG65966), the NIHR Biomedical 
Research Centre at Moorfields Eye Hospital and the UCL lnstituteofOphthalmology (BRC2_003); 
The Foundation Fighting Blindness (USA, C-CL:0710-0505-MEH10-02); Fight For Sight (1318 and 
1801); Moorfields Eye Hospital Special Trustees (ST1109B); Rosetrees Trust (M184); RP Fighting 
Blindness (GR581). LP is supported by Foundation Combined Ophthalmic Research Rotterdam 
(CORR). 
277 
I 
CHAPTER5A 
References 
1. Hamel C. Retinitis pigmentosa. Orphanet J Rare Dis 2006;1:40. 
2. Weleber R, Gregory-Evans K. Retinitis pigmentosa and allied disorders. In Ryan. Retina 2001;362-
470. 
3. Friedenwald J. Discussion of Verhoeff's observations of pathology of retinitis pigmentosa. Arch 
Ophthalmol 1930;767-770. 
4. den Hollander AI, Black A, BennettJ, Cremers FP. Lighting a candle in the dark: advances in genetics 
and gene therapy of recessive retinal dystrophies. J Clin Invest 2010;120:3042-3053. 
5. Patel N, Aldahmesh MA, Alkuraya H, et al. Expanding the clinical, allelic, and locus heterogeneity of 
retinal dystrophies. Genet Med 2016;18:554-562. 
6. Abu-Safieh L, Alrashed M, Anazi S, et al. Autozygome-guided exome sequencing in retinal 
dystrophy patients reveals pathogenetic mutations and novel candidate disease genes. Genome 
Res 2013;23:236-247. 
7. Beryozkin A, Shevah E, Kimchi A, et al. Whole exome sequencing reveals mutations in known retinal 
disease genes in 33 out of 68 israeli families with inherited retinopathies. Sci Rep 2015;5:13187. 
8. Weisschuh N, Mayer AK, Strom TM, et al. Mutation detection in patients with retinal dystrophies 
using targeted next generation sequencing. PLoS One 2016;11:e0145951. 
9. Bach M, Brigell MG, Hawlina M, et al.ISCEV standard for clinical pattern electroretinography (PERG): 
2012 update. Doc Ophthalmol 2013;126: 1-7. 
10. McCulloch DL, Marmor MF, Brigell MG, et al.ISCEV Standard for full-field clinical electroretinography 
(2015 update). Doc Ophthalmol 2015;130:1-12. 
11. Miller SA, Dykes DO, Polesky HF. A simple salting out procedure for extracting DNA from human 
nucleated cells. Nucleic Acids Res 1988;16:1215. 
12. Vissers LE, de Ligt J, Gilissen C, et al. A de novo paradigm for mental retardation. Nat Genet 
2010;42:1109-1112. 
13. Kastner S, Thiemann IJ, Dekomien G, et al. Exome sequencing revealsAGBL5 as novel candidate 
gene and additional variants for retinitis pigmentosa in five turkish families. invest Ophthalmol Vis 
Sci 2015;56:8045-8053. 
14. Pathak N, Austin-Tse CA, Liu Y, Vasilyev A, Drummond lA. Cytoplasmic carboxypeptidase 5 regulates 
tubulin glutamylation and zebrafish cilia formation and function. Mol Bioi Cell 2014;25:1836-1844. 
15. Hajali M, Fishman GA. The prevalence of cystoid macular oedema on optical coherence 
tomography in retinitis pigmentosa patients without cystic changes on fundus examination. Eye 
{Land) 2009;23:915-919. 
16. Bedell VM, Westcot SE, Ekker SC. Lessons from morpholino-based screening in zebrafish. Brief 
FunctGenomics 2011;10:181-188. 
17. Estrada-Cuzcano A, Roepman R, Cremers FP, den Hollander AI, Mans DA. Non-syndromic retinal 
ciliopathies: translating gene discovery into therapy. Hum Mol Genet2012;2l:R111-124. 
18. Sergouniotis PI, Chakarova C, Murphy C, et al. Biallelic variants in TTLLS, encoding a tubulin 
glutamylase, cause retinal dystrophy. Am J Hum Genet2014;94:760-769. 
278 
MUTATIONS IN AGBLS, ENCODING a-TUBULIN DE GLUT AMYLASE, 
ARE ASSOCIATED WITH AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA 
19. Yu I, Garnham CP, Roli-MecakA. Writing and reading the tubulin code. J Bioi Chern 2015;290:17163-
17172. 
20. Ed deB, Rossier J, Le Caer JP, Desbruyeres E, Gras F, Denoulet P. Posttranslational glutamylation of 
alpha-tubulin. Science 1990;247:83-85. 
21. Rogowski K, van Dijk J, Magiera MM, et at. A family of protein-deglutamylating enzymes associated 
with neurodegeneration. Ce//2010;143:564-578. 
22. van Dijk J, Rogowski K, Miro J, Lacroix B, Edde B, Janke C. A targeted multienzyme mechanism for 
selective microtubule polyglutamylation. Mol Ce//2007;26:437 -448. 
23. Janke C, Rogowski K, Wloga D, et at. Tubulin polyglutamylase enzymes are members of the TIL 
domain protein family. Science 2005;308:1758-1762. 
24. Sun X, Park JH, Gumerson J, et at. Loss of RPGR glutamylation underlies the pathogenic mechanism 
of retinal dystrophy caused by TTLLS mutations. Proc Nat/ Acad Sci USA 2016;113:E2925-2934. 
279 
E 
Lt-mrence H.!\/1. Pierrache '', J.\dva Kimchl*, Rinki Ratnapriya" , 
Lisa Roberts*. G[il i._!h _[~-~.:. AsttR,ti Alexey Oboiensky, Avigail Beryozkin, 
r·fi.artha J.H. Tjon-Fo-8ang, Caroline C.VV. Klaver, 
Ernie i\ILH.F. Bongers, Lonneke Haer-V\/igman, Nicoline Schalij, 
Martijn H. Breuning, Gratia M. Fischer, Eyal Banin#, Raj S. Rarnesar#, 
Anand Swarbop#. L. lngeborgh van den Borrr1:~ . Dror Sharon#, and 
Frans P.M. Crerne1~s# 
'These authors have contributed equally. 
#These last authc.rs have contributed equally. 
Ophthalmology, submitted 
CHAPTERSB 
Abstract 
Purpose: To identify the genetic cause and describe the phenotype in 4 families with 
autosomal recessive retinitis pigmentosa (arRP)thatcan be associated with pseudocoloboma. 
Design: Case series. 
Subjects: Seven patients from 4 unrelated families with arRP of which 3 patients had bilateral 
early-onset macular pseudocoloboma. 
Methods: We performed homozygosity mapping and whole-exome sequencing (WES) 
in 4 probands and 2 unaffected family members. Subsequently, Sanger sequencing and 
segregation analysis were done in additional family members. We reviewed the medical 
history of individuals carrying IDH3A variants and performed additional ophthalmic 
examinations, including full field electroretinography (ffERG), fundus photography, fundus 
autofluorescence imaging and optical coherence tomography. 
Main Outcome Mezsures: /DH3Avariants, age at diagnosis, visual acuity, fundus appearance, 
visual field, ffERG, fundus autofluorescence and OCT findings. 
Results: We identified 7 new variants in IDH3A in 4 unrelated families, 5 missense, 1 nonsense 
and 1 frameshift variant. All subjects developed symptoms early in life ranging from night 
blindness to decreased visual acuity and were diagnosed between the ages of 1 and 11 years. 
Four subjects with biallelic IDH3A variants displayed a classic arRP phenotype and 3 subjects 
were diagnosed with arRP and pseudocoloboma of the macula. 
Conclusions: IDH3A variants were identified as a novel cause of classic arRP, in some 
individuals associated with macular pseudocoloboma. We observed both phenotypes in 2 
siblings carrying the same compound heterozygous variants, which could be explained by 
variable disease expression and warrants caution when making assertions about genotype-
phenotype correlations. 
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Introduction 
WHOLE-EXOME SEQUENCING IDENTIFIES BIALLELIC /OH3AVARIANTS AS A CAUSE 
OF RETINITIS PIGMENTOSAACCOMPANIED BY PSEUDO-COLOBOMA 
Inherited retinal dystrophies {IRDs) are a major cause of incurable blindness in children and 
young adults and are characterized by progressive degeneration of photoreceptor and/or 
retinal pigment epithelium (RPE) cells. Retinitis pigmentosa (RP) is the most common IRD, with 
a worldwide prevalence of approximately 1 per 4,000 individualsl-4. In classic RP, patients suffer 
from night blindness, visual field constriction, and eventually decreased visual acuity5. Typical 
fundus features of RP are bone spicule-like pigmentations, narrowed blood vessels, a waxy, 
pale appearance of the optic disk, and a relatively preserved macular region. 
Leber congenital amaurosis (LCA) is considered the most severe and earliest occurring 
form of IRD, characterized by severe visual loss, roving eye movements or nystagmus and non-
recordable or severely reduced cone and rod electroretinography (ERG) amplitudes within 
the first year of life6• In practice, the demarcation between LCA and early-onset RP (also called 
juvenile RP or early onset retinal dystrophy (EORD)) is not always clear and nowadays both 
disorders are considered as part of the same spectrum due to clinical and molecular overlap. 
RP can be inherited in all Mendelian inheritance patterns, and non-Mendelian inheritance 
patterns such as digenic, mitochondrial or the occurrence of de novo mutations. Eighty-two 
genes have been associated with this disorder(Retnet; https://sph.uth.edu/retnet/). LCA mainly 
transmits in an autosomal recessive manner and 22 genes have been identified up to now, of 
which 12 overlap with early forms of RP. Mutations in these IRD genes reveal various underlying 
biochemical pathways such as phototransduction, visual cycle regulation, ion homeostasis, 
cell structure maintenance, ciliary processes, pre-mRNA processing, gene transcription and 
lipid metabolism. In approximately 60% of LCA and RP cases7-11 disease-causingvariants can be 
identified by whole-exome sequencing (WES). The remaining cases are interesting candidates 
for the identification of novel disease-associated genes. WES studies increasingly identify genes 
that are very rarely mutated in IRD cases. By sharing WES data and homozygosity mapping data 
within the European Retinal Disease Consortium (ERDC; 15 research groups in 11 countries), 
we have been able to identify several rarely mutated genes underlying IRDs12-15• In this study we 
report IDH3A as a novel gene to be mutated in 7 cases with autosomal recessive RP, with early 
macular involvement and pseudocoloboma. Of notable interest is the identification of IDH3A 
variants underlying RP in an indigenous African family. 
Methods 
Subjects and Clinical Evaluation 
The study protocol adhered to the tenets of the Declaration of Helsinki and received approval 
from the respective local ethics committees. Written informed consent was obtained from all 
participants or parents of children prior to their inclusion in this study. Patients were ascertained 
in the Rotterdam Eye Hospital (Rotterdam, The Netherlands), Hadassah-Hebrew University 
Medical Center (Jerusalem, Israel), Leiden University Medical Center (The Netherlands) and the 
IRD registry in the Division of Human Genetics, University of Cape Town (South Africa). 
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A full medical and family history was taken and retrospective data were retrieved from referring 
ophthalmologists. Patients underwent a clinical examination includingvisual acuitytestingand 
retinal imaging. Retinal fundus imaging was obtained by color fundus photography (Topcon 
Great Britain Ltd, Berkshire, UK). Fundus autofluorescence (FAF) imaging (Spectral is; Heidelberg 
Engineering Ltd, Heidelberg, Germany) of the posterior pole and Spectral domain optical 
coherence tomography (SO-OCT). Wide angle color and autofluorescence fundus photos were 
obtai ned in 2 patients using an OPTOS system ( model200T x, 0 PTOS Pic, Du nferm line, Scotia nd, 
United Kingdom). Color vision was evaluated using the Ishihara 38-plate and the Farnsworth 
D-15 panel. Visual field (VF) testing was performed using a Goldmann kinetic perimeter. Full-field 
electroretinography (ffERG) was available from 4 patients, which incorporated the International 
Society for Clinical Electrophysiology of Vision (ISCEV) standards. 
Genetic analysis 
Whole exome sequencing 
Genomic DNA was isolated from peripheral blood lymphocytes according to standard salting 
out procedures16• Whole exomesequencingofthe pro bands of family A, Band C was performed 
usingAgilent's SureSelectAII Human Exome version 4 kit (Agilent Technologies, Santa Clara, CA, 
USA), followed by sequencing on a SOLiD4 sequencing platform (Life Technologies, Carlsbad, 
CA, USA) with an average depth of SOX. Exome capture for family D was performed using the 
Nextera Rapid Capture Expanded Exome kit (lllumina, San Diego, CA, USA), and sequenced 
on on a HiSeq2500 platform (Ilium ina). Reads were subsequently mapped against the UCSC 
genome browser's Human hgl9 assembly (build 37) using Lifescope v2.1 software (Life 
Technologies, Carlsbad, CA, USA) and variants were called using the Genome analysis Toolkit 
(GATK) v2 according to the recommended guidelines (https://software.broadinstitute.org/ 
gatk/best-practices/). 
Homozygosity mapping 
Runs of homozygosity were determined using the online tool Homozygosity Mapper, using 
variant call format (*.vcf) file as an input file. Homozygous regions larger than 4Mb were then 
selected and ranked. Assuming autosomal recessive inheritance, we used the identity by 
descent (IBD) regions to narrow down candidate disease-associated variants identified from 
the WES data. 
Sanger sequencing 
Primers for amplification of coding exons and flanking exon-intron boundaries of IDH3A 
(NM_005530.2) were designed with Primer3 plus (http://www.bioinformatics.nl/cgi-bin/ 
primer3plus/primer3plus.cgi). Primer sequences and PCR conditions are available upon 
request. 
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Pathogenicity interpretation of missense variant 
The Combined Annotation Dependent Depletion (CADD) (http://cadd.gs.washington.edu/) 
score was used to predict the pathogenicity of missense variants. This program incorporates 
several widely used in silico tools, such as SIFT (http://sift.jcvi.org/), PolyPhen-2 (http:// 
genetics.bwh.harvard.edu/pph2/), Mutation Taster (http://www.mutationtaster.org/), PhyloP 
and Grantham score. Minor allele frequencies were obtained from the Exome Aggregation 
Consortium (ExAC) database containing -60,000 exome data of unrelated individuals, 
accessed November 4th 2016. 
Results 
Clinical findings 
We ascertained 7 patients from 4 families, between the ages of 3 to 26 years. Their clinical 
characteristics are summarized in Table 1 and the family pedigrees are shown in Figure 1. All 
patients had early onset night blindness and were diagnosed between the ages of 1 and 11 
years (y). Visual acuity (VA) was available for all patients and ranged from 20/20 to counting 
fingers (CF) at 1m. 
The youngest patient (A-11:2) of a Dutch family was diagnosed with a macula lesion at the age 
of 1 y and was referred to the Rotterd am Eye Hospital with decreased VA and strabismus at3 y 
of age. Atthatstage VA was CF without nystagmus. On fundus examination a pseudomacular 
coloboma was noted with peripheral RPE alterations (Figure 2D). The OCT scan showed 
severe atrophy of the outer retinal layers and the RPE at the colobomatous lesion (Figure 
2E). With ERG testing no responses could be distinguished from noise level under light and 
dark adapted circumstances. His family history revealed that his sister (A-11:1), who was 3 
years older, suffered from nightblindness. Although her visual acuity was still normal, RPE 
alterations were noted at her macula, and OCT scans showed alterations of the ellipsoid zone, 
confirming early macular involvement (Figure 2A,B). Fundus examination also revealed early 
signs of peripheral degeneration, and ERG and Goldman visual field testing were compatible 
with the diagnosis of RP. 
The Israeli family included 2 affected siblings, an older brother and a younger sister 
(Figure 1, Table 2), who were evaluated at age 11 y, based on suspicion of nightblindness. 
Best corrected visual acuity (BCVA) in the eldest sibling (B-11:1) was well preserved up until 
his last exam at 18 y of age (20/20 in both eyes), despite severe bilateral cystoid macular 
edema (CME) (Figure 2G,H) that was noted already at age 12 y. CME was treated although 
visual acuity was optimal but remained refractory to multiple trials of treatment with 
systemic and topical carbonic anhydrase inhibitors as well as topical Voltaren<~> drops. He 
was known to have hyperopia from a young age that was corrected by glasses. On fundus 
examination midperipheral bone spicule-like pigmentations and atrophy were noted (Figure 
2F), ffERG testing and Goldman visual field testing were compatible with his symptoms and 
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Family A 
M11 M2 
M1: c.716T>C; p.(Met239Thr) 
M2: c.403del; p.(Thr135fs*) 
FamilyC 
1:1 1:2 
MS I+ MSI+ 
11:1 
MSI MS 
MS: c.524C>T; p.(Aia175Val) 
~~Affected with RP 
FamilyB 
M31 M4 M31 M4 
M3: c.911C>A; p.(Pro304His) 
M4: c.938T>C; p.(Met313Thr) 
FamilyD 
M6: c.463G>T; p.(Giy155*) 
M7: c.946C>T; p.(Arg316Cys) 
e II Affected with RP and macular pseudocoloboma 
Figure 1. Pedigrees of families included in this study and segregation of causal variants in IDH3A. 
an RP phenotype. Color vision testing using the Ishihara 38-plate and the Farnsworth D-15 
panel was within normal limits. OCT and fundus autofluorecence imaging reflect CME and 
peripheral atrophy oft he outer segment (Figure 2G,H). The patient was generally healthy with 
exception of idiopathic unilateral lower limb edema which he developed at age 19 y. BCVA in 
his younger sister (B-11:2) was also preserved up until her last exam at age 15 y (20/20 in both 
eyes), with myopic correction. Fundus findings (Figure 21) include normal-appearing optic 
discs and blood vessels, an abnormal macular reflex without CME, and grayish discoloration 
of the retina in the mid periphery associated with salt and pepper changes as well as mild 
bones spicule pigmentations nasal>temporal. ffERG testing revealed better responses than 
those observed in her brother at the same age (Table 1). Goldmann visual fields to a IV4e 
target were preserved and color vision was normal. OCT imaging showed that the outer 
nuclear layer was still present in the foveal area, but markedly thins out in para foveal regions 
(Figure 2J). An hyperautofluorescent ring was seen in the maculas and hypoautofluorescent 
patches are present beyond the vascular arcades (Figure 2F). 
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ID 
Refractive 
Snellen 
gender Age of eiTor, Initial visual Electroretinography Perimetry Fundus Origin Variants spherical Fundus OCT(ago) 
•c•last onset symptoms acuity <•c•l (age) autofluoresence (ace) 
vfslt 
equivalent (age) (age) 
OA: no isolated rod 
Bilateral pink optic discs 
responses, small 
Peripheral 
c.403del mixed responses -.•:ith Intact autofluorescence :2: 
A-11:1 p.(Thr135Profs'6) RE 10/20 and mild attenuated constriction Bilateral disruption I RE -0.500 normal latencies of the posterior pole 0 
female Dutch Nyctalopia LE 8/20 blood vessels. Broad and of the el lipsoid ,-LE -0.500 LA 30Hz no responses, with fundus-camera m 
7y c.716T>C (7) BE 10/20 foveal reflexes. RPE small single flash sensiti'.'ity zone in the foveola based autofluorescence r'n (7) alterations in the fovea losswithlf4 (6) X p.(Met239Th r) 
and periphery. 
response with delayed 
target (6) (6) 0 b-\o·.:ave os: 
(6)' 
..,m 
;;o Vl 
Bilateral pink optic discs, 
m m 
-10 
attenuated vessels, -c Z m 
c.403del distinct atrophy of the =iZ Strabismus, RE 2/20 -n p.(Thr135Profs'6) RPE and choriocapillaris (f) -A-11:2male RE +O.SOD nyctalopia, LE 3/20 Atrophy of the RPE, -uZ 
Dutch LE+1.00D 
impaired 
demarcated by a NR(3)' NP abnormal outer NP Ci~ 3y 
c.716T>C (2) BE 8/20 hyperpigmented retinal layers (3) s:o 
visual acuity (3) m m p.(Met239Th r) ring in the macular z z 
-1 -1 
region, peripheral RPE o=n (f) -
alterations. )>m 
Severe cystoid 
)>(f) 
n~ 
mawlar edema n> 
Goldmann or-BE +3.500 s: ::;:; 
c.911C>A (11) Hypenmetropic optic VFs mildly (RE>LE)with Enlarged central j2C::: 
p.(Pro304His\ discs, normal retinal OA: NR constricted thickening of the hypoautofluorescent z~ B-11:1 BE 20/20 blood vessels, CME, and LA markedly reduced retina and loss RE+2.250 superiorly area surrounded m (J 
male Israel 11 Nyctalopia (11-16) BSP associated \'lith and delayed 30Hz of normal foveal 0 :r: 
c.938T>C LE +2.000 and nasally by a faint OJ~ 18y p.(Met313Th r) (15) grayish RPE atrophy in cone fl icker responses LE>RE with structure, thinning hyperautofluorescent -<< 
the mid periphery of the (12) and loss of the "U )> 
IV4etarget ring(l8) Vl;;o 
retina LE>RE. photoreceptorONL m-(18) c> 
in the para-macular oz 
regions (18) <?uJ 
n > 
O V> 
')> O n OJ)> 
"" 
Oc 
CD SV> 
--.1 )>m 
.. 
Normal-appearing 
N optic discs and blood DA: no isolated rod Presence of the n ():) I ():) c.911C>A vessels, an abnormal responses, significant Goldmann photoreceptor )> 
p.(Pro304His) macular reflex without mixed rod-cone VFs nuclei layer in the Prominent ~ 
B-11:2 CME, and grayish responses to a preserved foveas without hyperautofluorescent m 
BE -3.75D BE 20/20 AI 
female Israel c.938T>C 11 Nyctalopia discoloration of the RPE standard white flash for iV4e edema, but marked ring surrounds the c..n (13) (11-16) CJJ 
15y p.(Met313Th r) in the midperiphery LA: moderately target in thinning and loss of center of the maculas in 
associated with salt and reduced and delayed both eyes the ONL is evident ODS(15) 
pepper changes as well 30Hz cone flicker (15) in para-macular 
as mild BSP changes responses (12) regions (15) 
nasal>tempora l. 
Pale (grayish) aspect 
Goldmann 
of the optic disc, 
DA: almost NR VFs severe 
attenuated blood peripheral 
Extensive 
c.524C>T 
vessels, broad foveal 
LA: 30 Hz cone 
peripheral C-11:1 p.(Alal75Val) BE 16/20 flicker responses constriction 
BE -2.00D reflex with orange degeneration, 
female Dutch 10 Nyctalopia LE 18/20 recognizable, single (<10 NP (20) coloured aureola distortion of 
20y c.524C>T (20) 
around the foveola, 
flash responses degrees) 
the macular p.(Ala175Val) significantly reduced with 
RPE alterations from architecture (20) 
midperiphery towards far 
and delayed (14) sensitivity 
periphery. 
loss (20) 
Optic atrophy, mild 
D-11:2 c.463G>T arteriolar narrov!ing, 
severe macular 
female p.(Gly155') Nyctalopia, South BECF1m pigmentation, 
26y NP impaired NP NP NP NP 
Africa (26) pseudocoloboma of the (deceased) c.946C>T visual acuity 
macula and severe mid 
p.(Arg316Cys) 
peripheral bone spicule 
pigmentary changes. 
Optic atrophy, mild Macular atrophy 
arteriolar narrowing, and macular Strongly reduced 
c.463G>T severe macular pseudocoloboma, autofluorescence within 
D-11:3 
female South 
p.(Gly155') Nyctalopia, 
BECF 1m 
pigmentation, showing lamellar the macula, diffuse ly 
NP impaired coloboma-like atrophy NP NP disorganization increasing in a broad 
26y Africa (23) 
c.946C>T visual acuity ofthe macula and severe (lamellar structures ring around the macula, 
p.(Arg316Cys) mid peripheral bone were visible but and fading towards the 
spicule pigmentary could not be periphery (26) 
changes. identified) (26) 
soTL electrodes, 'skin electrodes, &fundus-camera-based autofluorescence photography To peon TRC-SOEX/SOIX (Megaplus2), BE: both eyes, BSP: bone spicule-like pigmentation, 
CF: counting fingers, CME: ....... , D: diopters, DA: dark adapted, LA: light adapted, LE: left eye, NR: no response, NP: not performed, ODS, ....... , ONL: outer nuclear layer, RE: right 
eye, RPE: retinal pigment epithelium, VF: visual field. 
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An isolated case of Dutch descent was referred to the Leiden University Medical Center with 
complaints of night blindness at the age of 10 y. BCVA was suboptimal at last examination 
(OD 16/20, OS 18/20) with myopic correction. On fundus examination typical RP features 
were present (Figure 2L). ffERG showed severely reduced dark- and light adapted responses. 
Visual fields were severely constricted {10° radius). On OCT imaging extensive peripheral 
degeneration was seen with distortion of the macular alterations of the outer segments and 
RPEarchitecture (Figure 2M). 
Two South African sisters {D-11:2, D-11:3) {Figure 1) had an onset age of 8 y with complaints 
of n i ghtbli ndess and decreased visual acuity. In their early twenties both were diagnosed with 
a rapid progressive form RP and macular pseudocoloboma. Their vision at that stage was 
limited to counting fingers at 1 meter. Fundus examination revealed severe mid peripheral 
bone spicule pigmentary changes, mild arteriolar narrowing, coloboma-like atrophy of the 
macula and optic atrophy {Figure 2N). One sister was examined 4 years later {Figure 2N), 
as the older sister had died due to and unrelated infection. The fundus autofluorescence 
was strongly reduced within the macula {Figure 2P). The OCT showed macular atrophy and 
confirmed the coloboma-like atrophy, also showing lamellar disorganization (i-igure 20). 
None of the patients had nystagmus or any other ocular associated diseases e.g. strabismus, 
hypermetropia, keratoglobus or cataract. Both the deceased patient from South Africa and 
the male patient from Israel developed edema of the lower extremities. In the South African 
patient the bilateral edema was thought to be caused by low serum albumin, but in the 
Israeli patient no cause could be appointed for the unilateral edema after a thorough work-
up. The significance of this is unknown and no additional systemic disorders were detected, 
nor any systemic associations. 
Genetic findings 
WES revealed biallelic variants in IDH3A in 7 patients from 4 families, and are summarized in 
Tables 1 and 2. All variants were novel and no other pathogenic variants were found in other 
IRD-associated genes after WES. 
Using Homoygosity Mapper, we identified eight homozygous regions larger than 30Mb in 
patient C-11:2. WES data analysis did not yield any variants in IRD genes that are located within 
this region. Upon stringent filtering step, two homozygous missense changess in IDH3A (p. 
(Alal75Val) and TSPAN3 {p.{Arg80Cys)) remained as candidate variants (Table 2). The TSPAN3 
variant, p.(Arg80Cys), had a minor allele frequency of 0.0017 in the ExAC database and was 
predicted to be benign by SIFT and PolyPhen2 in silico prediction tools, but had a high PhyloP 
{3.4), Grantham {180) and CADD-Phred score (15.70). There were no patients identified with 
TSPAN3 variants in our in-house-database and ERDC database. 
In parallel, a genetic analysis of Family B {MOL0655), which included Sanger sequencing 
of founder mutations identified previously in RP patients of Jewish origin followed by trio 
WES analysis (two affected siblings and their mother), revealed compound heterozygous 
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Fundus autofluorescence 
All:2 
811:1 
811:2 
Cll:l 
011:3 
Figure 2. Retinal imaging data for patients with IDH3A variants. (Wide field) colourfundus photographs, 
optical coherence tomography OCT and (wide field) fundus autofluorescence (FAF) imaging with 
fundus-camera-based autofluorescence photography. Patient A-11:1 at age 7 y, A: pink optic discs, mild 
attenuated blood vessels, RPE alterations in the fovea and periphery, B: small central disruptions in 
the ellipsoid zone, C: intact autofluorescence of the posterior pole. Patient A-11:2 at age 3 y, D: distinct 
atrophy of the RPE and choriocapillaris demarcated by a hyperpigmented ring in the macular region, 
peripheral RPE alterations, E: atrophy of the RPE, abnormal outer retinal layers. Patient B-11:1 at age 18 
y, F: midperipheral atrophy with bone spicule-like pigmentation nasal>temporal, OS>OD, G: bilateral 
severe cystoid macular edema (RE>LE) with thickening of the retina and loss of normal foveal structure, 
thinning and loss of the photoreceptor nuclei layer (ONL) is evident in the para-macular regions of the 
scans, H: hyper fluorescent ring around the fovea. Patient B-11:2 at age 15 y, 1: mid peripheral atrophy 
with bone spicule-like pigmentation nasal>temporal, OS>OD, J: presence of the photoreceptor nuclei 
290 
WHOLE-EXOME SEQUENCING IDENTIFIES BIALLELIC /OH3AVARIANTSAS A CAUSE 
OF RETINITIS PIGMENTOSAACCOMPANIED BY PSEUDO-COLOBOMA 
layer in the fovea without edema, but marked thinning and loss of the ONL is evident in para-macular 
regions, K: prominent hyperautofluorescent ring surrounding the center oft he macula. Patient C-11:1 at 
age 20 y, L: pale aspect of the optic disc, attenuated blood vessels, RPE alterations from midperiphery 
towards far periphery, M: extensive peripheral atrophy of the outer segments and distortion of the foveal 
architecture. Patient D-11:2 at age 26 y, N: peripheral bone-spicule pigmentary changes, peripheral and 
mid-peripheral pigmentary retinopathy, macular pigmentation with severe coloboma-like atrophy, 
mild arteriolar narrowing and mild optic atrophy, 0: macular atrophy with lamellar disorganization, P: 
strongly reduced autofluorescence within the macula, diffusely increasing in a broad ring around the 
macula, and fading towards the periphery. 
variants in IDH3A (p.(Pro304His); p.(Met313Thr)) in subjects B-11:1 and B-11:2. Screening these 
variants in a set of 261lsraeli index cases with RP was negative. 
Subject D-11:1 was.referred for molecular testing for a diagnosis of macular dystrophy in 2010. 
No variants were found with aABCA4 Microarrayfrom Asper Biotech, which atthatstage tested 
for 558 variants inABCA4 via arrayed-primer extension technology17• Therefore we performed 
additional genetic testing in 2013 using the LCA Microarray from Asper Biotech, which at that 
stage tested for 780 variants in 15 LCA-associated genes, but again no causal variants were 
found. Finally, WES data analysis revealed biallelic variants in IDH3A which segregated with 
the disease phenotype (Figure 1). 
Sequencing of nicotinamide nucleotide adenylyltransferase 1 (NMNATl), a candidate 
gene for this phenotype, in subject A-11:2, did not reveal a suspected disease-causing variant 
and neither did clinical exome sequencing of a panel of 256 genes associated with genetic 
vision disorders, including known lRD-associated genes. Subsequently clinical complete 
exome analysis was performed and 2 variants in /OH3Awere found. Additional genetic testing 
of his sister and parents showed that the variants segregated with the disease phenotype 
(Figure 1). 
The resulting transcripts of the two nonsense variants (p.(Thr135fs*), p.(Gly155*)) are 
predicted to undergo nonsense mediated decay, suggesting that these variants are true 
loss-of-function alleles. All missense variants (p.(Ala175Val), p.(Met239Thr), p.(Pro304His), 
p.(Met313Thr), p.(Arg316Cys)) were indicated as pathogenic by in silico prediction tools 
(Table 2). The p.(Ala175Val) variant is located in a region that is in close contact with other 
IDH3 subunit(s). The impact of the variant on the structure is minor; however due to its 
critical location it may disrupt the binding between subunits to form the IDH3 complex as 
the Valine amino acid is slightly bulkier than Alanine (Figure 3). The second listed missense 
variant p.(Met239Thr) affects an amino acid residue buried in the core close to the interaction 
surface with the lDH3gamma subunit (Figure 3). The smaller size ofThreonine will disturb the 
stabilizing hydrophobic interactions and might affect subunit interaction. The third missense 
variant, p.(Pro304His), might affect the interaction with the NADH ligand (Figure 3). Proline 
is predicted to be located closely to the NADH ligand, which allows them to interact. The 
rigidity of Proline provides a stabile structure for the interaction with the ligand. Hence, this 
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ExAC allele Grantham m DNA variant Protein variant dbSNPid SIFT Polyphen-2 PhyloP CADD Phred :::0 frequency (%) Score <..n 
OJ 
c.403del p.(Thrl35fs*) N.A 0 N.A N.A N.A N.A N.A 
c.463G>T p. (Giy155*) N.A 0 N.A N.A N.A. N.A 38 
c.524C>T p.(Aia175Val) rs765473830 0.0008 Deleterious Probably damaging 5.9 64 34 
c.716T>C p.(Met239Thr) N.A 0 Deleterious Possibly damaging 4.97 81 14.32 
c.911C>A p.(Pro304His) rs756712426 0.0008 Deleterious Probably damaging 5.94 77 33 
c.938T>C p.(Met313Thr) rs149862950 0.0002 Deleterious Probably damaging 4.97 81 23.5 
c.946C>T p.(Arg316Cys) rs770798851 0.0008 Deleterious Probably damaging 4.32 180 28.9 
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alteration may destabilize and deform the rigid structure, and affect the interaction with the 
ligand. Moreover, Histidine is a large amino acid, which may also alter the van der Waals 
atomic contacts with other amino acids nearby. The fourth missense variant, p.(Met313Thr), 
has no predicted impact on the protein structure but changes the hydrophobic amino 
acid to polar. Thus any hydrophobic activity needed in this position will be reduced. The 
last missense variant, p.(Arg316Cys), is located in the same helix as mutant p.(Met313Thr). 
However, the Arginine sidechain is located on the surface where it can make stabilizing ionic 
interactions with Glutamic Acid 328. The insertion of Cystein at this position does not have a 
big effect on the size ofthe amino acid at this position, but the stabilizing interaction in this 
domain will be affected. Additionally, a reactive sulphur atom will appear on the surface of 
the protein. 
Discussion 
In this study, we identified novel variants in IDH3A in 4 cases with classic arRP and 3 cases 
with arRP and macular pseudocoloboma from 4 unrelated families. These families originated 
from the Netherlands, Israel and South-Africa. All patients had visual complaints early in life 
ranging from night blindness to severe visual impairment. In patients with RP and macular 
pseudocoloboma the visual impairment was more severe than in patients with isolated 
RP, probably explaining why they were diagnosed at a younger age. The fact that all three 
patients (even the one of age 3) with pseudocoloboma did not display nystagmus suggests 
that the coloboma-like lesion was not congenital but developmental. 
In 21sraeli siblings (B-11:1 and B-11:2) with arRP, the visual acuity and visual field remained 
optimal up until the last examination at age 16, despite bilateral severe CME in B 11:1 (Figure 
2G). We did not observe CME in any other patient during follow-up. Although patient A-11:1 
did not present with overt macular pseudocoloboma as her brother, there were some RPE 
alterations visible in the macular region with abnormalities in the ellipsoid zone on OCT 
examination, which could account for her reduced visual acuity at age 6 years (Table 1, 
Figure 28). Two of our patients would meet the criteria for early-onset RP because they were 
diagnosed before the age of 6 years. 
IDH3A encodes the mitochondrial NAD+-specific IDHa subunit (IDH3A), a 339 amino 
acid long protein that is a part of the heterotetramer IDH3, comprised of 2 a subunits, one 
~ subunit (the product of the IDH3B gene) and one y subunit (the product of the IDH3G 
gene. IDH3 catalyzes the oxidation of isocitrate to a-ketoglutarate in the citric acid cycle, 
also known as the Krebs cycle. Biallelic variants in IDH3B, coding for the beta-subunit, were 
previously described by Hartong et al. in 3 cases from 2 families with autosomal recessive 
RP18. A combination of expression analysis and direct sequencing revealed a homozygous 
frameshift variant that segregated with the disease. Screening of IDH38 in 546 unsolved 
cases with RP led to the discovery of a second homozygous missense variant. Subsequent 
functional studies showed a significant decrease in NAD-IDH activity in lymphoblast cell 
lysates from homozygous patients, compared with wildtype controls and heterozygous 
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carriers. All patients with /DH3Bvariants presented with RP without macular pseudocoloboma 
or systemic involvement. As IDH3A codes for the 2 alpha subunits in the NAD-IDH enzyme, it 
is plausible that variants affecting the IDH3A protein influence NAD-IDH function in a similar 
manner as do IDH3B variants. Additional functional studies need to be performed to support 
this prediction. There have been no reports on disease associations for the gene encoding 
the third component of the NAD-IDH enzyme, IDH3G,, but it can be an interesting candidate 
gene for IRDs. 
Figure 3. 30 structure of the IDH3 complex and the location ofthe missense variants. The IDH3 protein 
complex contains 2 alpha subunits (pink, yellow), 1 beta subunit (purple) and 1 gamma subunit (blue). 
Missense variants are indicated in red in only one of the two alpha subunits for clarity. In patients with 
compound heterozygous variants the NAD-IDH complex may consist of two identical alpha subunits 
altered by the same variant or two different alpha subunits. 
In our IDH3A cohort, patients carried 2 missense variants or a combination of a missense and 
a null variant. Some missense variants might be hypomorphic variants that allow for residual 
IDH3A activity. Remarkably, all patients with arRP and macular pseudocoloboma carried a 
null variant, which could explain the more severe phenotype. However, one sibling with only 
mild foveal abnormalities carried the same null and missense variant as her brother who had 
a macular pseudocoloboma. This difference in phenotype could be caused by differences in 
/DH3A expression between the siblings. A higher expression of the mutant IDH3A carrying the 
missense variant in the classic arRP sibling could potentially result in the milder phenotype. 
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However, the NAD-IDH protein complex is subject to strict stoichiometric rules, so it is also 
possible that different expression levels of IDH3B and IDH3G influence the phenotypic 
outcome. 
RPE abnormalities at the macula at an early stage are more frequently observed in I RDs 
caused by mutations in genes associated with Leber congenital amaurosis and early-onset RP 
(e.g. CRBl). Rarely noted is macular pseudocoloboma, a term to describe early degeneration 
of a normally appearing macula. 'Macular coloboma' is often misused for describing atrophic 
lesions in the central retina, where true coloboma are the resultoffailed or incomplete closure 
of the embryonic fissure during the sixth and seventh week of fetal development and are 
often associated with microphthalmos or other closure defects. Macular pseudocoloboma 
were first described by Clausen in 1921 in a family with a dominant inheritance pattern 
and no systemic involvement19• They were also mentioned in Foxman's classification of 
congenital and early-onset RP as a common finding in patients with uncomplicated (or 
non-syndromic) LCN. Since molecular diagnostics has become more widely available we 
acknowledge that mutations in different genes involved in various pathways underlying 
genetic vision disorders can be causal. Pseudocolobomas are characteristic for nicotinamide 
nucleotide adenylyltransferase 1 NMNATl-associated LCN°-23, DEAH box polypetide 38 
(OHX38)-associated RP24, and North Carolina type macular dystrophy (NCMD)25•26, all in which 
macular atrophy is caused by early-onset neurodegeneration20• Severe macular atrophy 
is often observed in patients with end-stage cone (rod) dystrophy or retinitis pigmentosa, 
however the rate of progression is significantly slower. 
NMNATl is an essential enzyme for regenerating the nuclear pool of NAD+ in all nucleated 
cells in the body, and plays a role in neuroprotection2a-23• Pseudocolobomas in patients 
with NMNATl-associated LCA are the result of retinal degeneration after normal anatomical 
development, in contrast to true coloboma where the retinal structure was abnormally 
developed in utero. Mice studies27 support these findings and show that photoreceptors are 
extremely susceptible to NMNATl dysfunction as their metabolic activity is very high. The 
need for NAD+ is critical after light exposure and cannot be met when enzymatic NMNATl 
activity is disrupted20• RPE cells and inner retinal cells undergo degeneration to a lesser 
extent27• 
A homozygous variant in DHX38 was found in a Pakistani patient with early-onset RP 
and macular pseudocoloboma24. DHX38 encodes the pre-mRNA splicing factor PRP16, that 
is involved in catalysing the second step in pre-mRNA splicing. Splicing factor genes are 
widely expressed, but mutations in some of these genes, such as PRPF3, PRPFB, PRPF31 and 
SNRNP2000, exclusively result in retinal degeneration without other systemic manifestations. 
Macular pseudocoloboma were also described in patients with autosomal dominant 
North Carolina type macular dystrophy (NCMD)25• 26, which is caused by variants in DNase1 
hypersensitivity chromosome 6 site 1 (DHS6Sl), a section of non-coding DNA that is thought 
to regulate PR domain 13 {PRDM13) expression28• 29 • One family with NCMD showed a 
duplication of PRDM13. PRDM13 encodes a retinal transcription factor that controls gene 
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expression during development. The severity of NCMD is expressed in grades 1 to 3, of which 
grade 3 is based on the presence of macular pseudocoloboma30• The pathogenesis remains 
unknown, but degeneration is thought to start in utero. NCMD patients do not suffer from 
night blindness and apart from midperipheral drusenoid deposits (grade 1-2) there are no 
signs of peripheral retinal degerenation30• The disease seems to be confined to the macula in 
contrast with our observations in IDH3A patients and data from NMNATl and DHX38 patients24• 
31 
All genes associated with macular pseudocoloboma are widely expressed and are 
involved in different pathways, such as energy metabolism (IDH3A, NMNATl), pre-mRNA 
splicing (DHX38) and transcription control (PRDM13) . However, the disease manifestation 
seems to be restricted to the retina. Possible explanations might be the exceptionally high 
metabolic turnover in photoreceptor cells, which requires significantly more energy and 
higher levels of pre-mRNA splicing molecules compared with other cell types. Alternatively, 
other factors or pathways may compensate for this high consumption in other cell types. 
There are no reports on IRD patients with two null variants in IDH3A, NMNATl and DHX38, 
which leads us to believe that complete inactivity of these proteins might be incompatible 
with life. 
In conclusion, we identified 7 (likely) pathogenic variants in IDH3A and thereby have 
implicated a second subunit of the IDH3 protein complex to play a crucial role in the human 
retina. 
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CHAPTER6 
The extreme clin ical and genetic variability of IRDs has been the major challenge of IRD studies 
throughout the years. The evolvement of genomic technologies has continuously enhanced 
our understanding of the molecular genetic basis of IRDs.ln this doctoral thesis, I have aimed 
to detect genetic variants associated with different forms of IRD using several genotyping 
approaches. Among these methods, the main focus was the application of whole-exome 
sequencing (WES) technologies for gene discovery in dogs with PRA and humans with IRDs. 
This chapter reviews our main discoveries and current challenges in performing genomics 
studies, for IRDs in man and its companion. 
Whole-exome sequencing in dogs with PRA: discoveries and challenges 
The dog as a suitable model for IRDs 
The man's best friend is a very valuable model to study IRD due to a number of important 
characteristics. Dogs with PRA display a similar degree of genetic heterogeneity as humans 
with IRDs, as was illustrated by the discovery of mutations in 22 genes that underlie PRA 
in more than 52 different dog breeds.1·3 In addition, 17 of these 22 genes have also been 
associated with IRDs in humans. The clinical featu res of PRA also resemble human RP, in 
terms of molecular mechanisms and disease progression. Moreover, the com parable 
anatomical structure and size of the human and canine eye render the dog as a very suitable 
mammalian model for assessing the delivery of therapeutic molecules. 
In Chapter 28, we applied WES technology to decipher gene defects underlying PRA in 
different dog breeds. In humans, this approach has revolutionized genetic studies. Its major 
advantage over single gene or gene panel analysis is that in comparison to the conventional 
approaches, this method allows simultaneous genotyping of all coding regions in the 
genome. In addition, large patient cohorts and familial cases are not required to detect 
genetic variants associated with a disease. We established a pipeline that maps sequence 
reads to the canine genome, annotates variants and predicts the effect of variants at the 
DNA, RNA and protein level, allowing automatic data filtering analysis to select potentially 
pathogenic variants. Quality assessment of WES data demonstrated that the huge majority 
of variants could be confirmed by Sanger sequencing, including those with a low number of 
sequence reads (i .e. 2-4 reads). 
To fully utilize the potential of WES in dogs however, a few chal lenges need to be 
addressed. First , the incomplete dog genome annotation hinders an accurate mapping ofWES 
data. In comparison to humans, the domestic dog has 20 times fewer expressed sequence 
tag libraries,4 complicating gene annotation and the detection of alternative splicing in dog 
genes. To improve th is, we combined the multi species whole-genome alignments approach 
using the liftOver tool from the UCSC genome browser and a hidden-Markov model-based 
sequence similarity using Gnomon gene prediction program. By this approach, more than 
19,000 genes were annotated and mapped to the dog genome. However, many genetic 
variants may have been missed in several protein-coding regions because they were not 
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covered by the exome enrichment kit used in this study. Second, although the number of 
identified variants in the human and dog exome are comparable, the lack of knowledge 
of normal canine genetic variation has limited variant filtering. By removing the common 
SNPs from a human exome variant dataset, 90% of all variants to underlie a rare disease 
can be excluded. In contrast, the current number of reported dog SNPs is only 4.9% of those 
in human. Consequently, large numbers of variants still remain after filtering out known 
polymorphisms. As an alternative, we incorporated whole-exome and whole-genome data 
from 250 unrelated dogs without ophthalmological problems to narrow down our list of 
candidate variants. By using this dataset, I was able to exclude around 60% of variants, but 
obviously still lacks the power compared to human WES data. Hence, variant interpretation, 
in particular missense variants, remains a challenging task. The continuous addition of 
genetic variation information in public databases will likely further facilitate the identification 
of genes underlying rare genetic disorders in dogs. Third, copy number variant (CNV) analysis 
using WES data will potentially increase the mutation detection yield. In addition, the 
performance of an exome enrichment kit is highly depending on the completeness of the dog 
genome annotation. Prior versions of the enrichment kit used in this study yielded around 
86% mapped reads, while the enrichment kit based on the latest canine reference genome 
(build 3.1.72) yielded 87%-90% mapped reads.5 
PKM is an excellent candidate gene for PRA in the Old German Shepherd dogs 
One of the main findings in this study is the identification of the homozygous PKM 
c.34_34+ 14del variant that affects the last nucleotide of exon 2 and either induces a frameshift 
(consequently removing505 amino acids which encode all pyruvate kinase domains) orwould 
alter PKM pre-mRNA splicing. In human, PKM encodes two isoforms, an Ml isoform which is 
mainly expressed in skeletal muscle and brain tissues and an M2 isoform mainly expressed 
in proliferative cells, but also in the retina. 6• 7 These two major isoforms differ by the presence 
of either exon lOa or lOb which encode the kinase domain. Among seven known alternative 
PKM transcripts in human, the 15-bp deletion in the canine PKM gene only affects two of the 
transcripts. The ubiquitous expression of PKM and the absence of extra-ocular phenotypes 
in the affected Old German Shepherd suggest that transcripts affected by this variant are 
probably predominantly or exclusively expressed in the retina. A recent study suggested that 
isoform M2 may be involved in the energy production for opsin synthesis in the mammalian 
retina.8 In addition, the identification of a canine EST DT538122 from canine retinal tissue 
further supports our hypothesis.9 Gene expression studies and further functional analysis 
will provide evidence on the causality of the PKM variant. In addition, genetic screening of 
PKM gene in a larger cohort of Old German Shepherd dogs may also confirm the association 
ofthis gene with PRA. 
Selective breeding to generate dog IRD models 
Around 20% of healthy individuals carries a heterozygous loss-of-function variant in genes 
associated with IRD without having any clinical consequences.7 Considering the inbreeding 
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in dogs, a somewhat lower frequency of heterozygous variants may also occur in dogs. 
The identification of these carriers may open an avenue in generating dog models carrying 
homozygous mutations in IRD-associated genes. In our study, we identified heterozygous 
nonsense variants in EYS in the PRA-affected Chihuahua and in CNGB3 in the PRA-affected 
Husky dogs. Both variants occur exclusively in the corresponding affected dogs. The EYS 
c.1666C> T:p.(Arg556*) variant is predicted to result in a protein that has lost most of the 
crucial domains (i.e. all the five LamininG, fourteen EGF and seven EGF-like and one calcium-
binding domains) or alternatively, the corresponding mRNA may be degraded by nonsense 
mediated decay (NMD). The c.2106_2107del :p.(Ser706*) mutation occurs in the last exon of 
CNGB3, likely escapes NMD, and would result in a truncated CNGB3 protein missing the 103 
carboxy-terminal amino acids. In the Chihuahua and Husky dog, CNV analysis did not yield a 
second mutation in the EYS and CNGB3 genes, respectively. 
The identification of these heterozygous variants however does allow the breeding 
of mutant animal models carrying homozygous protein-truncating variants. This would 
particularly be interesting for EYS, since a mammlalian animal model with mutations in this 
gene is not yet available, also because the gene is absent in the genomes of several rodent 
species including mouse and rat. 
Overall, we demonstrated the potential ofWES for disease gene identification in the PRA 
affected dogs. The current growing number of whole-exome and whole-genome studies will 
largely contribute to the improvement of gene annotation and genetic variation datasets in 
dogs. In addition, a combination ofWES data together with positional cloning data will further 
narrow down the region of interest and increase the mutation identification rate. Eventually, 
unraveling genetic causes for PRA in dogs will pave the way towards better understanding 
of IRD disease mechanisms and, importantly, to develop and test the preclinical efficacy of 
novel therapies. 
The evolving genomic technologies for inherited retinal diseases: 
The past, present, and future 
Disease gene identification through conventional approaches 
Inherited retinal diseases (IRDs) were first recognized after the invention of the Helmholtz 
ophthalmoscope. In 1857, Donders first defined the group of hereditary disorders affecting 
the retina. 10 The first non-syndromic IRD for which the biochemical defect was solved was 
gyrate atrophy, an autosomal recessive degeneration of the RPE and neural retina with a very 
typical fundus appearance consisting of scalloped atrophic areas. Gyrate atrophy patients 
show high plasma ornithine levels due to an ornithine amino transferase deficiency (1973)_11 
Genetic defects were discovered after the biochemical defect was establishedY The first IRD-
associated gene identified without prior knowledge of the protein defect was the CHM gene. 
Both genetic linkage studies in families with X-linked choroideremia as well as deletions 
varying in size from 45 kb to 15Mb pinpointed the causal gene to Xq21.2 and subsequently 
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led to its positional cloningP Using a linkage and candidate gene approach, RHO was 
identified as the first gene to be associated with autosomal dominant retinitis pigmentosa 
(RP).14 Thereafter, animal model orthologs with or without positional cloning analysis 
facilitated the identification of severaiiRD-associated genes, such as PDE68, MERTK, NR2E3, 
NRL and SEMA4A. 15.19 The identification of RP2 marked the first implementation of linkage 
analysis for disease gene identification in IRDs.20 Thereafter, several IRD-associated genes 
were discovered using homozygosity mapping, such as BESTl, C2orf71, CEP290, CERKL, EYS, 
RLBPl and SPATA7.21.27 Altogether, these approaches resulted in the discovery of mutations in 
more than 90 genes to underlie IRD (Figure 1). Nevertheless, these methods also have several 
limitations: they either require (1) prior knowledge on the function of the candidate gene; (2) 
available animal models with natural or induced mutations in I RD gene orthologs; or (3) large 
cohorts of families, consanguineous families, or very large families. 
IRD gene discoveries in the era of whole-exome sequencing: then and now 
Whole-exome sequencing (WES) has been instrumental for disease gene hunting in the 
IRD field since 2011.28.30 The implementation of this technology has contributed to the 
identification of -40 novel genes associated with IRDs in the last five years. Importantly, 
WES also identified novel genotype-phenotype correlations for several genes. A gene can 
be implicated in multiple clinical subtypes of non-syndromic IRDs, either due to different 
disease mechanisms (loss-of-function vs. gain-of-function) or due to differences in residual 
protein function (hypomorphic mutations vs. complete loss-of-function). Alternatively, 
different mutations in the same gene can underlie both syndromic or non-syndromic forms 
of IRDs, which is the case for USH2A variants that are involved in non-syndromic RP31• 32 and 
Usher syndrome type 2,33 or HGSNATvariants that can underlie Sanfilippo syndrome ( 34 or 
cone-dystrophy.35 
Interpretation of variants remains a key challenge of WES analysis. In general, WES 
detects around 45,000 variants in each genomic DNA sample; hence many variants with 
unknown significance may remain upon filtering and prioritization. Although several in silica 
prediction programs and variant databases are available, the consequences of variants in 
candidate genes remain uncertain without identification ofthe same or other variants in the 
same gene in additional families and supporting functional data. 
It stands to reason that the IRD-associated genes that were discovered initially are 
mutated in more cases than the more recently identified genes. A study of homozygosity 
mapping and WES in the Saudi-Arabian population showed thatonly-3-4% ofiRD cases carry 
variants in novellRD-associated genes36•37• In addition, a targeted next generation sequencing 
study in 5371RD cases revealed that 79% of solved cases carry mutations in genes discovered 
between 1995 to 2004.38 The plethora of genetic variants identified by WES poses another 
challenge on their interpretation and consequences for the disease phenotype. Altogether, 
the low mutational load and the uncertain variant interpretation led to the identification of 
many variants in candidate genes in singleton cases without any known consequences. 
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Figure l. The evolving genomic technologies for non-syndromic IRD gene discoveries. Several 
genotyping methods, ranging from the conventional candidate gene approach, sequence analysis of 
animal models with a retinal phenotype, linkage analysis or homozygosity mapping, up to the recent 
whole-exome sequencing and whole-genome sequencing technologies, have been applied to identify 
novel genes associated with I RD. 
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Mutation hunting beyond the WES era 
The search for genetic defects underlying IRDs is yet to be completed, as -40% of IRD cases 
remain unsolved upon WES analysis. Albeit it's excellent contribution in IRD gene discoveries, 
WES only covers -1% of the genome, i.e. the protein-coding segments. Thus, variants in the 
remaining -99% cannot be detected using this strategy. Consequently, exome sequencing 
misses many deep-intronic variants in IRD genes, for instance those found in ABCA4, CEP290, 
PROMl, OFDl and USH2A.23· 3941 An attractive alternative is whole genome sequencing (WGS) 
which outperforms WES in several ways: (1) coverage: in addition to covering non-coding 
regions, recent studies suggest that WES captures 95% of the coding regions with a minimal 
coverage of 20x, while WGS yields 98% at 87-fold coverage and higher sequencing depth 
(95x-160x};42 (2) the distribution of coverage depth, genotype quality, and minor read ratio 
are more uniform; (3} false-positives for single nucleotide variants (SNVs) are higher in WES 
(78%} compared to WGS (17%}; (4} WGS is more reliable for the detection of copy-number 
variations.42 Nevertheless, the functional consequences of variants identified by WGS often 
remain unclear. The ongoing growth of public databases containing genomic variants will 
likely facilitate a better assessment of candidate variants based on their allele frequency. 
In addition, the combination of transcriptome analysis with WGS may offer a great value to 
unravel non-coding variants associated with IRDs. The transcriptional landscape is complex 
with multiple isoforms of genes and non-coding RNAs that are often expressed in a cell- or 
tissue-specific manner. This approach can be used to detect novel splicing isoforms, gene-
fusion transcripts and genesjexons that are not yet annotated. Moreover, through the 
analysis of SNPs in the transcribed regions, it is possible to reveal allele-specific transcription. 
Transcriptome sequencing in normal human neural retinal tissue revealed 79,915 novel 
alternative splicing events and 116 genes that for the first time were found to be specifically 
expressed in the retina.43 In 15-36% of these splicing events, an open reading frame was 
maintained and can be transcribed in novel protein products. Nevertheless, one major 
limitation is that affected and healthy tissues must be compared for transcriptomic analysis. 
The analysis of RNA sequences in patient's blood cells can be a solution, as 149/221 (63%} 
of human IRD-associated genes are ubiquitously expressed.44 The generation of induced 
pluripotent stem cells (iPSC}-derived photoreceptor precursor cells and/or RPE may also 
provide valuable resources for transcriptome analysis.39•45•46 
The implementation of the emerging genomic technologies for IRD diagnostics 
Genotyping approaches of homogeneous monogenic IRDs 
Although IRDs are known to consist of many genetically heterogeneous disorders, a few retinal 
degenerations are exclusively associated with mutations in one single gene. In Chapter 4A, 
we performed CYP4V2 screening on a cohort of patients with Bietti corneoretinal dystrophy 
(BCD). Currently, CYP4V2 is the only gene associated with BCD, a form of IRD with a distinctive 
feature, namely the presence of crystalline deposits. Other examples are the involvement of 
ABCA4 in autosomal recessive Stargardt disease, CHM in choroideremia and OAT in gyrate 
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atrophy. For this type of diseases, Sanger sequencing is still cost- and time-effective when 
the gene spans a maximum of 50 amplicons. Upon the identification of clear-cut monoallelic 
variants in the genomic DNA, multiplex ligation probe assay may detect an exonic deletion 
or duplication as a second allele. In addition, RNA analysis can be performed using material 
derived from any given cell type or tissue that robustly expresses the gene of interest, 
such as peripheral blood lymphocytes or skin-derived fibroblasts. Reverse transcription 
followed by direct eDNA sequencing may detect splice variants, by identifying the insertion 
of pseudoexons or the deletion of coding exons. Furthermore, eDNA analysis can reveal the 
occurrence of NMD due to protein-truncating mutations, when it only reveals the presence of 
one of the two alleles. 
Genotyping approaches for heterogeneous monogenic IRDs 
Unraveling the molecular genetic causes for the genetically heterogeneous types of IRD, such 
as RP, LCA, CRD and CD is more challenging, for several reasons. First, mutations in one gene 
may cause different types of IRDs and vice versa, i.e. one subtype of IRD can be caused by 
mutations in multiple genes. For example, 82 genes are currently known to be involved in 
RP and each of these genes potentially can be mutated in a sporadic case. Second, as most 
IRDs occur as sporadic cases, gene analysis based on the mode of inheritance is only possible 
in familial cases with a clear inheritance pattern. Finally, clinical manifestations of different 
types of IRD are often indistinguishable, particularly in later stages of disease when both rod 
and cone cells are involved. 
In some IRD subtypes however, several variants or genes underlie a significant 
proportion of the cases, allowing a cost- and time-effective genetic pre-screening analysis. In 
achromatopsia, the majority of cases are explained by mutations in either CNGB3 (50-87%) 
or CNGA3 (5-20%).47• 48 Mutations in RHO and RPGR ORF15 account for approximately 30% of 
adRP49 and 70%ofXLRP cases,50.52 respectively. Previous studies demonstrated thatvariants in 
a few genes are associated with a significant percentage of LCA cases, i.e. the CEP290 intronic 
c.2991 + 1655A>G variant in -15% in the Caucasian population; theAIPLl p.(Trp278*) variant in 
7% of cases and the GUCY2D p.(Arg768Trp) variant in 7% ofthe cases.23•53•56 ln addition, exon 7 
and 9 of CRBl are mutational hotspot regions that may explain 13% of LCA cases. In Chapter 
48, we therefore performed the genetic pre-screening ofthese variants and exons in a cohort 
of LCA patients from the Danish population. As a therapy based on the oral administration 
of QLT091001 (synthetic 9-cis-retinyl acetate) has been developed for patients with RPE65 
or LRAT variants,57 we also performed Sanger sequencing of the coding regions of RPE65 
and LRAT. Altogether, sequencing of these amplicons and genes yielded causative variants 
in around 26% of cases in the Danish cohort. Interestingly, it revealed RPE65 as the most 
commonly mutated gene, rendering additional amplicons for pre-screening analysis in the 
Danish population. Such a pre-screening method is relatively inexpensive and straightforward 
and therefore affordable for centers with only basic genotyping facilities. These findings also 
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GENERAL DISCUSSION 
highlight the value of genetic repositories for IRDs based on ethnic background which can be 
used to determine an effective genetic pre-screening for diagnostic purposes. 
The recently developed molecular inversion probe (MIPs) strategy represents a technique 
that allows rapid and cost-effective sequencing. We applied the MIPs capture and amplified 
1,524 coding exons of 108 known genes associated with non syndromic IRD (https://sph. 
uth.edu/Retnet/). This analysis revealed causal variants in -60% of the cases (M.I. Khan et 
al. unpublished data). Moreover, MIPs outperforms traditional Sanger sequencing and WES 
for two main reasons, i.e. (1) Ml Psis inexpensive in comparison to both approaches; (2) The 
tailored design of MIPs allows higher coverage ofGC-rich regions and allows the extra analysis 
of deep intronic variants that are not detected by WES. In addition, MIPs may facilitate the 
screening of large cohorts with the same phenotype to detect additional unrelated individuals 
carrying mutations in a candidate gene identified by WES or WGS. 
If no causal variants are identified using MIPs, WES is the preferred genotyping method as 
it covers the entire coding region ofthe human genome and because the costs are decreasing 
consistently. The robust identification of structural variations, such as heterozygous deletions 
or duplications, still needs to be improved, both in MIPs and WES analyses. 
Using this knowledge, we proposed a stepwise workflow that can be implemented to identify 
genetic causes in the IRD-associated genes. Thereafter, subsequent experimental and 
collaborative approaches can be implemented in search of novel genes and understanding 
the disease mechanism underlying IRD (Figure 2). 
Tubulin postatranslational modifications (PTMs) defects in inherited 
retinal diseases (IRDs) 
The connecting cilium, a structure that is homologous to the transition zone in the 
conventional primary cilium, is situated between the photoreceptor inner and outer 
segments (Figure 3). The photoreceptor sensory cilium is formed by nine microtubule triplets 
at the basal body, which further extends into doublet microtubule pairs in the connecting 
cilium and eventuallyconsistofninesingletA-tubulesatthe distal end of outer segments. The 
microtubule is a cytoskeletal structure that is dynamically assembled from a- and ~-tubulin 
heterodimers. Tubulin molecules are evolutionary conserved proteins and subjected to a vast 
range of post translational modifications (PTMs) allowing complex microtubule properties 
and functions in many specialized organelles and cells. PTMs might occur ubiquitously, 
such as acetylation, phosphorylation or palmitoylation,58•59 or tubulin-specific, such as de-/ 
tyrosination, de-/poly -glutamylation or polyglycylation.60 
In this study, we identified AGBLS variants in four RP cases (Chapter SA) strengthening 
the initial candidate gene discoveries by Kastner et al.61 and Patel et al.36 AGBLS, also known 
as CCPS, is a gene encoding a deglutamylase enzyme. Interestingly, causal variants in TTLLS, 
a gene encoding a glutamylase, were identified in patients with cone dystrophy.62 The 
involvement of AGBLS and TTLLS suggests the critical roles of poly- and de- glutamylation 
309 
CHAPTER6 
n 
Outer i 
' segment ~~~ 
: ' ~ 
lransition ~ ,; -
zon t! ; ·'• , 
; ~ -~ 
lnn(!r 1 i • 
segMent .r i : 
~ ·, . . •' 
' / \ Cellbody , . 
L \ / 
; - ~ J 
~ynaptic - / \ 
area ' 
:.. '--~ --" 
CCfTZ 
PCC/CP 
BB 
ss------<1.---'-! I 
Rootlet~ 
! ) \._ ~/ 
-------
Figure 3. Schematic representation of the photoreceptor transition zone depicting the intraflagellar 
transport complexes and retinal disease-associated protein RPGR and NPHP complex proteins. 
BB: basal body; CC: connecting cilium; DC: daughter centriole; M: mitochondria; OS: outer segment; 
PCC: periciliary complex CP: ciliary pocket; TZ: transition zone. {Figure derived from Rachel, 2012 and 
published with permission) 
post-translational modification in modulating binding affinity of the protein-interacting 
partners in photoreceptor cells.63 
Tubulin glutamylation and glycylation 
Tubulin polyglutamylation was first observed in the mammalian brain using mass 
spectrometry in 1990,64 and encompasses the addition of secondary glutamate chains 
onto carboxyl groups of glutamate residues near the (-terminus of polymerized tubulin. 
Glutamylation can occur on either a- or ~-tubulin , forming both short and long chains. This 
event is regulated by polyglutamylase modifying enzymes encoded by several genes from 
the TTLL (tubulin tyrosinase ligase-like) family. This gene family encodes 11 different proteins 
which catalyze either glutamylation (TTLLl, TTLL2, TTLL4, TTLLS, TTLL6, TTLL7, TTLLll, and 
TTLL13) 6S-67 or glycylation (TTLL3, TTLLB and TTLLlO) (Figure 4).68-70 Glycylation is an enzymatic 
mechanism of adding glycine residues to the tubulin (-terminal tails of proteins, but also 
at the glutamate residues close to the (-terminus. Glutamylation and glycylation have an 
overlapping modification site and have been shown to be interdependent in cells.71 Several 
studies showed that polyglutamylation is required for ciliary assembly and function. Mice 
lacking TtlllO showed that polyglutamylation might regulate motor activity, demonstrated 
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by a mislocalization of the Kinesin-3 motor KIFlA in the hippocampal neurons.72 Furthermore, 
low polyglutamylation also led to decreased ciliary beating in Chlamydomonas reinhardtii 
and Tetrahymena thermophila. In addition, it regulates the assembly of mitotic spindles by 
inducing enzymatic severing of microtubules.73. 74 
Interestingly, a reverse enzymatic mechanism called deglutamylation was observed 
in mice with Purkinje cell degeneration (Pcd). Analysis of brain tissue demonstrated an 
accumulation of hyperglutamylated microtubules in regions that had degenerated. A partial 
rescue in pcd mice by down regulation of TTLLl suggested an involvement of degluta mylati on 
in causing neurodegeneration. 68 The members of the cytosolic carboxypeptidases (CCPs) 
family catalyze the removal of post-translationally added glutamate chains, and are also 
involved in the generation of £1.2-tubulin, a modified form of a-tubulin which lacks its 
C-terminal tyrosine and glutamate. The hydrolysis of the linear glutamate chains is not limited 
to tubulin, but also detected in other proteins, for instance the myosin light chain kinase. 
Six CCPs have been identified, of which four have been shown to reverse polyglutamylation 
(CCPl, CCP4, CCP5 and CCP6}. Up till now, there is no evidence of a deglycylation mechanism 
and the enzyme(s) involved. 
Generation of !J2-tubulin 
Despite their roles in the tubulin deglutamylation, the CCP enzymes are also responsible 
in forming £1.2-tubulin from detyrosinated a-tubulin. Both detyrosination and £1.2-tubulin 
formation occur specifically in a-tubulin. Since the majority of a-tubulin genes encode 
Tyr in their carboxy-terminal end, the tyrosination-detyrosination cycle is initiated by the 
removal of the Tyr residue (Figure 4).75• 76 Nevertheless, this event is reversible by the addition 
of Tyr residue, which is catalyzed by tubulin tyrosine ligase (TTL) enzyme.77 Subsequently, 
the detyrosinated tubulin may transform to £1.2-tubulin by the removal of its (-terminal Glu 
residue which is catalyzed by deglutamylases enzymes.76• 78 
IRD-associated genes implicated in tubulin poly- and de- glutamylation 
TTLL5 (Tubulin Tyrosine Ligase-Like Protein 5} 
Genetic defects in TTLL5 have been associated with retinal dystrophy, with a predominant 
involvement of cone photoreceptor cells. A recent study identified a significant decrease 
in sperm motility and fertility in male patients carrying protein-truncating TTLL5 variants, 
confirming a similar reduction of sperm motility observed in Tt/15 knockout mice.79 
The phenotypic features are mainly depending on the type of mutations, as missense 
mutations only affect the retina while protein-truncating variants also affect fertility. 
Immunohistochemical analysis in the human retina detected TTLLS predominantly in 
cone cells, in particular at the base of the connecting cilium between the mother centriole 
and adjacent daughter centriole. TTLLS might catalyze polyglutamylation of tubulin in 
the microtubule triplets of centrioles, allowing the formation of a stable structure capable 
of handling mechanical forces. The absence of TTLLS may lead to destabilization of the 
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microtubule cytoskeleton of photoreceptor cells, and affect cones more than rods since 
cones are characterized by open membrane discs lacking the complete sheath of the plasma 
membrane present in rods. 
ATP/GTP-binding protein-like 5 (AGBL5) 
ATP/GTP-binding protein-like 5 (AGBL5), also known as cytosolic carboxypeptidase 5 (CCP5), 
catalyzes the removal of glutamate chains from tubulin.80 Using quantitative RT-PCR, Kastner 
et al. (2015)61 found higher expression of AGBL5 in human retina compared to skeletal 
muscle. In postnatal day 10 mouse tissues, expression of Agbl5 was high in testis, moderate 
in eye, retina and brain, and very low in skeletal muscle. In adult mice, its expression 
pattern remained similar, except in the eye without retina where a decrease was observed.61 
Immunohistochemical analysis detected mouse and human AGBL5 in all layers of the retina. 
Database analysis suggested expression of differentAGBL5 splice variants in human retina, 
lymphocytes and muscle, and in mouse retina. Using porcine brain a-tubulin and P-tubulin 
as substrates, Berezniuk et al.80 found that purified mouse Ccp5 was able to remove multiple 
glutamate residues and branch-point glutamate from tubulin side chains. Ccp5 also removed 
(-terminal glutamates from detyrosinated a-tubulin, multiple glutamate residues from side 
chains and (-termini of stabilized microtubules, and side-chain glutamates from synthetic 
peptides corresponding to the (-terminal region of ~-3 tubulin. 
Retinitis pigmentoso GTPose regulator (RPGR-ORF15) 
RPGR is a ciliary expressed gene which can be found in two different mRNA isoforms, i.e. 
RPGJ?iefautt which comprises of 19 exons, and RPGf?ORFls which shares the first 14 exons with 
RPGJ?iefautt.52•81•82 The first ten exons encode the regulator of chromatin condensation 1 (RCC1)-
like domain, which likely regulates small GTPase activity. RPGf?ORFls ends with an alternative 
ORF15 exon that is comprised of multiple Glu-Gly motif repeats followed by a stretch of basic 
amino83 acid with an unknown function.82 Approximately 50-60% of XLRP cases are caused 
by mutations in the ORF15 hotspot region of RPGR0Rm. 51• 52• 84 This region exhibits similar 
characters as the Glu rich regions of alpha tubulin, which is subjected to polyglutamylation. 
In a recent study Sun et al.85 demonstrated that TTLL5 was a unique enzyme for RPGRoRrls 
and catalyzes glutamylation of the Glu-Gly rich tandem repeats region of RPGf?ORm. The 
noncatalytic cofactor interaction domain of TTLL5 binds specifically to the (-terminal basic 
domain of RPGR0 RF15. Tti/Y mice manifest a slowly progressive photoreceptor degeneration 
with early mislocalization of cone opsins resembling features of Rpgr knockout mice. 
Moreover TTLLS disease mutants that cause human retinal dystrophy show an impaired 
glutamylation of RPGR0 RF15. Thus, RPGRoRFls is a novel glutamylation substrate, and this 
posttranslationalmodification is critical for its function in photoreceptors. This study 
uncovered the pathogenic mechanism whereby absence of RPGR0 RFls glutamylation leads 
to retinal pathology in patients with TTLL5 gene mutations and connects these two genes 
into a common disease pathway. This study also suggested that RPGR0 RFls is glutamylated 
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at multiple residues and partial elimination of the consensus sites may lead to a decrease in 
glutamylation levels.85 Further studies using glutamylated RPGR0 RFls as affinity ligand might 
yield novel binding partners of RPGR and uncover its functions. 
Future outlook 
The identification of TTLLS and AGBLS/ CCPS variants in individuals with IRD has emphasized 
the crucial role of tubulin poly- and de-glutamylation in the retina. In addition, CCPS might 
also regulate the generation of 112-tubulin via tubulin detyrosination. This also suggests that 
other TTLL and CCP family genes are potential candidate genes for IRD. Although several 
TTLL genes play a role in glycylation, one could hypothesize that there is interdependency 
between glutamylation and glycylation due to the overlapping modification site. Further 
functional studies are needed to unravel the exact disease mechanism related to these genes. 
Further proteomics approaches may detect new substrates for polyglutamylation in the 
retina besides RPGf?ORF15. Tubulin glutamylation is important for microtubule structure and 
dysregulation might affect ciliogenesis, but the in vivo function is still poorly understood. The 
TTLL enzymes catalyze several overlapping enzymatic activities, which consequently might 
compensate each other. Therefore, gaining a better understanding of how glutamylation is 
modulated, and how it affects cellular function, could reveal the mechanism that connect 
these PTMs and I RD. 
The involvement of isocitrate dehydrogenases in retinitis pigmentosa 
(RP) 
Visual phototransduction and its recovery processes in the photoreceptor outer segment 
(OS) require a high rate of energy for the turnover of nucleotides including ATP, GTP, 
NAD• and NADP•. The citric acid cycle, also referred as Krebs cycle, is an aerobic biochemical 
reaction to generate ATP through the oxidation of acetyl-CoA which is known to occur in 
the OS.86 IDH3 catalyzes the decarboxylation of isocitrate to a-ketoglutarate and converts 
the nicotine adenine dinucleotide (NAD+) to NADH in the Krebs cycle.87 The IDH3 complex 
is a heterotetramer that is formed by 2 a subunits, 1 ~ subunit, and 1 y subunit encoded 
by IDH3A, IDH38 and IDH3G, respectively. Through collaboration with multiple centers, we 
identified IDH3A variants in four families segregating autosomal recessive RP. Two families 
carry homozygous missense variants and two other families carry compound heterozygous 
variants with a combination of a missense and a null variant. Interestingly, a more severe 
form with macular pseudocoloboma occurs in all affected individuals carrying protein-
truncating variants. Nevertheless, one sibling with mild foveal abnormalities carries the same 
null and missense variant as her brother who had a macular pseudocoloboma. Assuming 
that the missense variants are hypomorphic, the phenotypic differences may be due to the 
expression levels of the IDH3A gene. A milder phenotype may occur when the IDH3A alleles 
are highly expressed. Variants in IDH38, encoding the ~-subunit, were previously described 
in 3 cases from 2 families with non-syndromic autosomal recessive RP18.88 A combination of 
314 
GENERAL DISCUSSION 
expression analysis and direct sequencing revealed a homozygous frameshift variant that 
segregated with the disease. Subsequent functional studies showed a significant decrease in 
NAD-IDH activity in lymphoblast celllysates from homozygous patients, compared with wild 
type controls and heterozygous carriers.88 A similar disease mechanism may also explain the 
effect of IDH3A variants. 
Concluding remarks 
In the last decade, we have witnessed a fast evolvement of genetics knowledge and genomic 
technologies in the field of IRD. For instance, the WES era for human IRDs is approaching 
towards its end with the identification of the majority of genetic defects in the protein-coding 
region of IRD-associated genes. The search of causal variants for IRD will gradually shift to 
the RNA or protein level. On the other hand, the continuous completion of the dog genome 
annotation will improve WES designs and pipelines, which consequently increase possibilities 
to unravel novel PRA genes. The identification of PKM as a novel candidate gene for PRA 
and two novel arRP genes, AGBLS and IDH3A, has suggested the involvement of pyruvate 
metabolism and post-translational glutamylation in causing retinal diseases. Eventually, 
the increased understanding on the genetic and disease mechanisms underlying IRD will 
allow a proper genetic diagnosis for patients and, importantly, to facilitate the development 
of therapeutic strategies. 
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SUMMARY 
Summary 
Inherited retinal diseases (IRDs) not only display a high degree of clinical and genetic 
heterogeneity, but they also show overlapping genotypes and phenotypes. Endeavors 
in both clinical and genetic studies have advanced our understanding about the disease 
mechanisms underlying IRDs. Multiple genotyping approaches, ranging from positional 
cloning, candidate gene approaches to whole exome sequencing (WES), have successfully 
elucidated a large fraction of the molecular genetic basis of this group of disorders. In 
parallel, the emergence of gene-specific therapeutics has shown the potential to stop 
disease progression or even reverse visual impairment in some IRD patients. Therefore, a 
comprehensive genetic understanding as well as the identification of suitable animal models 
are prerequisites to develop treatments for IRDs. In this thesis, we implemented different 
genotyping approaches to provide molecular diagnoses and IRD gene discoveries in humans. 
In addition, we performed WES in dogs with progressive retinal atrophy (PRA) from twelve 
different breeds, aiming to identify large animal models to study IRDs. 
Chapter 1 outlines a structural and functional overview of the human and dog retinae. 
In addition, this chapter describes the genomic technologies that have facilitated the 
dissection ofthe molecular genetic basis of hereditary retinal diseases in humans and dogs. 
Chapter 2A describes several aspects that need to be considered when selecting 
the most suitable vertebrate animal model to study IRD and to develop therapies. This 
chapter comprehensively compares the differences on the genetic architecture and the 
morphological and functional characteristics of the retina in a subset of vertebrate animals, 
and describes the pros and cons for each species. Moreover, it explains the lack of phenotype 
in the existing IRD animal models due to either genetic or morphological differences. Finally, 
it underlines the importance of knowledge on the absence or duplication of certain IRD-
associated genes when generating animal models for a given genetic defect. In Chapter 28, 
we report on the implementation of WES to study PRA in 26 dogs from 12 different breeds. 
This chapter explains the setup, analysis, discoveries and challenges of performing WES in 
dogs. The main discoveries of this study are: 1) the incidental finding of heterozygous EYS 
and CNGB3loss-of-function variants in Chihuahua and Husky dogs, respectively, that would 
enable the generation of homozygous mutant animal models for IRDs. This is particularly 
attractive for EYS, as the Eys gene is absent in mice, and currently, no mammalian animal 
model with mutations in this gene exists; 2) the identification of PKM as a novel candidate 
gene underlying PRA in Old German Shepherd dogs, and thereby potentially also for IRDs in 
humans. One major challenge that has become obvious in this study is that the dog reference 
genome is not completed to the same standard as is the human genome. Consequently, this 
influences the design of capture probes, could result in misinterpretation of the functional 
consequences of certain variants, and thereby hampers the identification of the genetic 
causes of PRA. In addition, the limited availability of databases harboring information on 
natural genetic variation in dogs also impedes the selection of candidate variants, as too 
many variants remained for further analysis after filtering the WES data. 
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Chapter 3 provides the most comprehensive molecular genetic analysis of IRDs in the 
Indonesian population conducted so far. Chapter 3A describes the application of targeted 
sequencing of 108 IRD-associated genes using the MIPs approach in IRD cases from 
Indonesia. In combination with screening of previously identified IRD variants from the same 
population and homozygosity mapping, this study yielded a clear molecular diagnosis in 
27 of 50 cases (54%), with CRBl being the most frequently mutated gene (14%), followed by 
RHO (10%), RPE65 (10%), CEP290 (7%) and PDE6A {7%). In addition, some variants, i.e. CRBl 
c.3914C> T:p.(Prol305Leu), RHO c.482G>A:p.(Trp161 *)and RHO c.403C> T:p.(Argl35Trp), were 
detected in more than one IRD case, indicating possible recurrence of these variants in this 
specific population. As expected, we found novel variants in 88% of the cases, highlighting 
the importance of population-specific IRD genetic repositories. Chapter 38 outlines the 
identification of a homozygous p.(Arg338*) variant in exon 4 of RPl in an autosomal recessive 
RP case. This represents another example of a biallelic RPl variant, a gene in which the 
majority of causative variants are associated with autosomal dominant RP. The majority 
of RPl mutations are protein-truncating variants in the last exon, and the resulting mutant 
transcripts are predicted to escape nonsense-mediated decay (NMD). Variants associated 
with adRP are clustered between amino acids 500 to 1053. The resulting truncated proteins 
will retain their binding property with microtubule-associated proteins and thereby result 
in a dominant-negative effect. On the other hand, protein-truncating variants outside this 
"hot-spot" region may lack important domains required for interactions with other proteins 
or may be subjected to NMD. 
Chapter 4 describes the genetic analysis of retinal diseases that are associated with 
variants in only one or a few genes. In Chapter4A, we performed Sanger sequencing followed 
by copy-number variation (CNV) analysis of CYP4V2 in patients with Bietti corneoretinal 
dystrophy (BCD) that led to the identification of four novel variants and the first large deletion 
of CYP4V2. No genotype-phenotype correlation could be established as affected individuals 
displayed heterogeneous clinical features. The identification of BCD patients without CYP4V2 
variants suggests genetic heterogeneity or the occurrence of variants outside the protein-
coding region. Chapter 48 describes a genetic screening offrequently mutated genes in LCA 
in the Danish population. Biallelic variants were detected in 42 of 86 cases (49%) through the 
combination of this screening and prior APEX analysis. Our analysis revealed RPE65 to be the 
most frequently mutated gene in this population (16%), with a novel p.(AspllOGly) variant 
found as the most prevalent one (7 /27 alleles). In addition, we compiled all published 914 
RPE65 variants of 539 patients with LCA or early-onset RP, and deposited them in the RPE65 
Leiden Open Variation Database (LOVD). 
Chapter 5 focuses on the effort to discover novel IRD-associated genes using whole 
exome sequencing (WES) and through a multi-center collaboration. Chapter 5A describes 
convincing evidence for an association of AGBLS variants with autosomal recessive RP. In 
addition, we described the clinical features of affected individuals carrying pathogenic 
variants in this gene. These results highlightthe importance of glutamylation events regulated 
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by AGBLS and TTLLS in IRDs. In Chapter SB, we identified IDH3A as a novel genetic cause 
of classic arRP and arRP with macular pseudocoloboma. Furthermore, clinical variability 
was observed in the two affected siblings with compound heterozygous IDH3A variants. 
This finding underlines the involvement of the IDH3 complex in retinal homeostasis and 
furthermore, given a previous association between IDH3B mutations and arRP, also suggests 
IDH3G to be a good ca ndidate gene for I RD. 
The main findings and the importance of this study in the IRD field are discussed in 
Chapter 6. We describe the current challenges and considerations in implementing WES 
to study hereditary retinal disorders in humans and dogs. Accordingly, we explore possible 
explanations for the missing mutations in the - 40% unexplained IRD cases upon WES analysis. 
Eventually, the novel association of AGBL5 and IDH3A with arRP highlights the involvement 
of posttranslational glutamylation and citric acid cycle for retinal homeostasis. Overall, this 
work has led to an increased understanding of the genetic basis underlying IRD, and may be 
of benefit for the many patients worldwide, either by improving molecular diagnostics, or by 
aiding the development of novel therapies that could halt these blinding diseases. 
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Samenvatting 
Erfelijke retinale ziekten ('inherited retinal diseases', IRD) Iaten niet aileen een hoge mate 
van klinische en genetische heterogeniteit zien, maar ze vertonen ook overlappende 
genotypes en fenotypes. Klinische en genetische studies hebben onze kennis vergroot over 
de ziektemechanismen die ten grondslag liggen aan IRDs. Opeenvolgende genotypering 
methoden, van positionele klonering tot kandidaatgen analyses en exoom sequencing, 
hebben een groat deel van de moleculaire genetische basis van deze groep van 
aandoeningen opgehelderd. Tegelijkertijd heeft de opkomst van gen-specifieke therapie 
de mogelijkheden aangetoond om de progressie van de ziekte te stoppen. Daarom zijn 
een uitgebreide genetische kennis, alsmede de identificatie van geschikte diermodellen, 
voorwaarden om behandelingen voor IRDs te kunnen ontwikkelen. In dit proefschrift 
gebruikten wij verschillende methoden om te komen tot genetische diagnoses en nieuwe 
IRDs-geassocieerde genen bij de mens te vinden. Daarnaast voerden we exoom sequencing 
uit bij honden van twaalfverschillende rassen met progressieve retinale atrofie (PRA), om op 
deze wijze grate diermodellen voor IRD studies te identificeren. 
Hoofdstuk 1 schetst de structuur en functie van het netv!ies in de mens en de hond. 
Daarnaast beschrijft dit hoofdstuk de genomische technologieen die het mogelijk hebben 
gemaakt om de moleculair genetische basis van erfelijke retinale ziekten bij mensen en 
honden op te helderen. 
Hoofdstuk 2A beschrijft de verschillende aspecten die moeten worden overwogen 
bij het kiezen van het meest geschikte gewervelde diermodel om IRD te bestuderen 
en therapieen te ontwikkelen. Dit hoofdstuk vergelijkt de verschillen in de genetische 
architectuur en de morfologische en functionele kenmerken van het netvlies in een aantal 
gewervelde dieren, en beschrijft de voor- en nadelen van elke soort. Tevens wordt hierin 
aangegeven waarom sommige dieren geen fenotypen vertonen als gevolg van genetische 
en morfologische verschillen. Tot slot wordt het belang van kennis over de afwezigheid 
of duplicatie van bepaalde IRD geassocieerde genen bij het genereren van diermodellen 
voor een bepaald genetisch defect onderstreept. In Hoofdstuk 28 rapporteren we over 
het gebruik van exoom sequencing om PRAte studeren in 26 honden van 12 verschillende 
rassen. In dit hoofdstuk worden de aanpak, analyse, ontdekkingen en uitdagingen van het 
uitvoeren van WES in honden uitgelegd. De belangrijkste ontdekkingen van dit onderzoek 
zijn: 1) de toevalsbevindingen van heterozygote EYS en CNGB3 verlies-van-functie varianten 
in Chihuahua en Husky honden, welke gebruikt zouden kunnen worden voor het genereren 
van homozygote mutante diermodellen. Dit is bijzonder aantrekkelijk voor EYS, vanwege 
de afwezigheid van het Eys gen in muizen, en omdat momenteel er geen zoogdier-model 
met mutaties in dit gen bestaat; 2) de identificatie van PKM als een nieuw kandidaat-gen 
verantwoordelijk voor PRA in de Old German Shepherd, en daarmee mogelijk ook voor IRDs 
bij de mens. In deze studie is duidelijk geworden dat het referentie genoom van de hand niet 
zo compleet is als het menselijk genoom. Doordat niet alle exonen worden verrijkt voor de 
exoom sequencing, worden bepaalde varianten gemist en daarmee de identificatie van de 
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genetische oorzaken van PRA. Bovendien, de beperkte beschikbaarheid van databases met 
informatie over natuurlijke genetische variatie bij honden belemmert ook de selectie van 
kandidaat varianten, waardoor teveel varianten resteren voor verdere analyse. 
Hoofdstuk 3 biedt de meest uitgebreide moleculair genetische analyse van IRDs in de 
lndonesische bevolki ng die tot nu toewerd uitgevoerd. Hoofdstuk3A beschrijft detoepassing 
van gerichte sequentie analyse van 108 IRD-geassocieerde genen met behulp van MIPs in 
IRD gevallen uit lndonesie. In combinatie met het screenen van eerder ge"identificeerde IRD 
varianten van dezelfde cohort en homozygosity mapping, leverde deze studie een duidelijke 
moleculaire diagnose in 27 van de 50 patienten (54%), met CRBl als het meest frequent 
gemuteerde gen (14%), gevolgd door RHO (10% ); RPE65 (10%); CEP290 (7%) en PDE6A 
(7%). Bovendien werden sommige varianten, namelijk CRBl c.3914C> T:p.(Prol305Leu), 
RHO c.482G>A:p.(Trp161 *) en RHO c.403C> T:p.(Argl35Trp), gedetecteerd in meerdere IRD 
patienten, hetgeen er op wijst dat sommige varianten vaker voorkomen in deze specifieke 
populatie. Zoals verwacht vonden we bij de meeste gevallen 88% nieuwe IRD-geassocieerde 
varianten. Om met name missense varianten goed te kunnen interpreteren is het daarom 
van belang dat er databanken komen met sequentievarianten afkomstig van verschillende 
populaties. Hoofdstuk 38 schetst de identificatie van een homozygote p.(Arg338 *) variant 
in exon 4 van RPl in een persoon met autosomaal recessieve RP. Dit is een voorbeeld van 
een bi-allelische variant in RPl, een gen waarbij de meerderheid van oorzakelijke varianten 
geassocieerd is met autosomaal dominante RP. De meeste mutaties betreffen stopmutaties 
in het laatste exon van RP1, waardoor de resulterende mutante transcripten ontsnappen a an 
'nonsense mediated decay' (NMD). Varianten geassocieerd met autosomaal dominante RP 
zijn geclusterd tussen de aminozuren 500 tot 1053. De resulterende verkorte eiwitten zullen 
hun binding met microtubule-geassocieerde eiwitten behouden en daardoor leiden tot 
een dominant-negatief effect. lndien stopmutaties zich aan het begin van exon 4 bevinden 
verdwijnen waarschijnlijk eiwit domeinen, waardoor oak interacties verloren gaan met 
andere eiwitten waardoor het dominant-negatieve karakter verloren gaat. Stopmutaties die 
optreden in de overige exonen zullen waarschijnlijk resulteren in NMD waardoor er helemaal 
geen RP1 eiwit meer aanwezig is. lndien stopmutaties optreden aan de uiterste 3' zijde van 
exon 4 dan heeft dit geen oogfenotype tot gevolg. 
Hoofdstuk 4 beschrijft de genetische analyse van retinale ziekten die zijn geassocieerd 
met varianten in slechts een of enkele genen. In Hoofdstuk 4A voerden we Sanger sequentie 
analyse uit gevolgd door 'copy number variation' (CNV) analyse van CYP4V2 bij patienten met 
Bietti corneoretinal dystrofie (BCD). Dit leidde tot de identificatie van vier nieuwe varianten 
en de eerste grate deletie van CYP4V2. Gegeven de heterogene klinische kenmerken bij 
aangedane individuen kon geen genotype-fenotype correlatie worden vastgesteld. De 
identificatievan BCD patienten zonderCYP4V2varianten suggereert genetische heterogeniteit 
of het optreden van varianten buiten het eiwit coderende gebied. Hoofdstuk 48 beschrijft 
een genetische screening van vaak gemuteerde genen in LCA in de Deense bevolking. Bi-
allelische varianten werden gedetecteerd in 42 van 86 gevallen (49%) door deze screening 
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in combinatie met de daaraan voorafgaande APEX analyse. Onze analyse toonde RPE65 
als het meest frequent gemuteerde gen in deze populatie (16%), met een nieuwe variant 
p.(AspllOGiy) als een van de meest voorkomende (7 /27) allelen. Daarnaast verzamelden wij 
aile 914 gepubliceerde RPE65 varianten van 539 patienten met LCA of vroeg optredende RP 
en deponeerden deze in de RPE65 Lei den Open source Variation Database (LOVD). 
In Hoofdstuk 5 wordt beschreven hoe nieuwe IRD-geassocieerde genen werden 
ontdekt m.b.v. exoom sequencing en een multi-center samenwerking. In Hoofdstuk SA 
wordt overtuigend bewezen dat AGBLS varianten geassocieerd zijn met met autosomaal 
recessieve RP. Verder beschrijven we de klinische kenmerken van aangedane personen 
die pathogene varianten in dit gen dragen. Deze resultaten benadrukken het belang van 
glutamylatie gereguleerd door AGBLS en TTLLS in IRDs. In Hoofdstuk 58 identificeerden we 
/DH3A-varianten als een nieuwe genetische oorzaak voor klassieke arRP en arRP met macula 
pseudocoloboma. Verder werd klinische variabiliteit waargenomen bij een aangedane broer 
en zus met samengestelde heterozygote IDH3A varianten. Deze bevinding onderstreept de 
betrokkenheid van het IDH3 complex bij retina homeostase. Gegeven het feit dat ook IDH38 
varianten eerder werden geassocieerd met arRP, maakt het aannemelijk dat ook IDH3G een 
goed kandidaatgen is voor I RD. 
De belangrijkste bevindingen en het belang van deze studie in het IRD veld worden 
besproken in Hoofdstuk 6. We beschrijven de huidige uitdagingen en overwegingen bij 
de uitvoering van exoom sequencing om erfelijke retinale aandoeningen te bestuderen bij 
mensen en honden. We geven mogelijke verklaringen voor de ontbrekende mutaties in de 
-40%van IRD gevallen die na exoom analyse genetisch nog niet konden worden opgehelderd. 
Tenslotte, de nieuwe associaties van AGBLS en IDH3A met arRP wijzen op het belang van 
posttranslationele glutamylatie en de citroenzuur cyclus voor de netvlies homeostase. Dit 
werk heeft geleid tot een beter begrip van de genetische basis van IRDs. Dit is van belang voor 
veet patienten wereldwijd, hetzij door verbetering van de moleculaire diagnostiek als ook 
voor de ontwikkeUng van nieuwe therapieen die deze progressieve ziekten kunnen stoppen. 
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Disamping keragaman klinis dan genetik yang tinggi, penyakit retina diturunkan atau 
inherited retinal diseases (IRD), memiliki kesamaan genotip dan fenotip yang tumpang 
tindih satu sama lain. Berbagai upaya baik melalui studi klinis dan genetik telah berhasil 
meningkatkan pemahaman tentang mekanisme yang mendasari IRD. Berbagai metode 
genotyping, mulai dari positional kloning, skrining kandidat gen serta exome sequencing 
(WES) berhasil menemukan penyebab genetik dari berbagai kelainan genetik. Secara 
bersamaan, berkembangnya penelitian mengenai terapi untuk mutasi di beberapa 
gen tertentu menunjukkan adanya potensi dalam menghentikan perjalanan penyakit 
atau mengembalikan ketajaman penglihatan pada pasien dengan IRD. Oleh karena 
itu, pemahaman komprehensif dalam aspek genetik serta ketersediaan animal model 
diperlukan untuk mengembangkan penelitian di bidang terapi untuk I RD. Dalam tesis ini, 
kami mengimplementasikan berbagai metode berbeda untuk menegakkan diagnosis 
molekuler dan untuk menemukan gen baru penyebab IRD pada man usia. Di samping itu, 
kami melakukan anal isis WES pad a dua bel as ras anjing anjing dengan atrofi retina progresif 
atau progressive retinol atrophy (PRA) dengan tujuan untuk mengidentifikasi animal model 
untuk penelitian mengenai I RD. 
Bab 1 menjelaskan gambaran struktural dan fungsional retina dari manusia dan anjing. 
Di samping itu, bab ini menjelaskan berbagai teknologi genomik yang digunakan untuk 
mengidentifikasi penyebab genetik molekuler penyakit retina herediter pada manusia dan 
anjing. 
Bab 2A menjelaskan beberapa aspek yang perlu dipertimbangkan dalam pemilihan 
animal model vertebrata untuk mempelajari mekanisme penyakit IRD dan pengembangan 
terapi. Bab ini secara membandingkan secara komprehensif perbedaan arsitektur genetik, 
morfologi dan fungsi retina berbagai dari hewan vertebrata, dan menjelaskan pro dan kontra 
pada masing-masing spesies. Bab ini terutama menjelaskan mengenai ketidaksesuaian 
fenotipe pada animal model IRD baik karena perbedaan genetik maupun morfologi. Dalam 
bab ini ditekankan pentingnya mengetahui ada atau tidaknya dan duplikasi gen IRD dalam 
menemukan animal model dengan kelainan genetik tertentu. Bab 28 mengulas penggunaan 
WES pada 26 anjing dari 12 ras dengan PRA. Bab ini menguraikan persiapan, analisis, hasil 
serta hambatan dalam penggunaan WES pad a anjing. Hasil utama pada penelitian ini adalah 
sebagai berikut: 1) penemuan insidental varian heterozigot pada EYS dan CNGB3 pada ras 
Chihuahua dan Husky yang membuka kemungkinan pengembangbiakan animal model 
dengan mutasi homozigot pada gen IRD. Hal ini terutama menarik untuk Eys, mengingat 
tidak adanya gen ini pada genome tikus. Hingga saat ini belum ada animal model mamalia 
dengan mutasi pada gen ini; 2) identifikasi PKM sebagai kandidat gen penyebab PRA 
pada ras Old German Shepherd, serta sebagai kandidat gen penyebab IRD pada manusia. 
Salah satu tantangan pada penelitian ini adalah tidak lengkapnya referensi genomik pada 
anjing dibandingkan dengan manusia. Hal ini berpengaruh pada desain capture probe 
serta interpretasi efek varian genetik, sehingga mempersulit identifikasi penyebab genetik 
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pada PRA. Di samping itu, terbatasnya informasi mengenai variasi genetik pada anjing 
menghambat seleksi varian untuk tahap anal isis berikutnya. 
8ab 3 Menerangkan mengenai analisis genetika molekuler pada IRDs pada populasi 
Indonesia yang paling komprehensif hingga saat ini. 8ab 3A Menjelaskan penerapan 
sequencing pada 108 gen IRD dengan menggunakan MIPS pada pasien dari Indonesia. 
Kombinasi an tara skrining varian IRD diidentifikasi sebelumnya dan homozygosity mapping, 
penelitian ini berhasil menemukan diagnosis molekuler pada 30 dari total 50 kasus (60%), 
dimana mutasi terbanyak ditemukan pada CRBl (14%), diikuti dengan RHO (10%), RPE65 
(10%), CEP290 (7%) dan PDE6A (7%). Beberapa varian, yaitu CRBl c.3914C> T:p.(Prol305Leu); 
RHO c.482G>A:p.(Trp16l*) dan RHO c.403C> T:p.(Argl35Trp), terdeteksi pad a lebih dari 
satu pasien IRD, menunjukkan bahwa varian ini lebih prevalen pada populasi Indonesia. 
Ditemukannya varian baru pada 88% kasus IRD menunjukkan pentingnya repositori genetik 
IRD pada populasi Indonesia. 8ab 38 menguraikan identifikasi varian p.(Arg338*) secara 
homozigot pada exon 4 dari gen RPl pada kasus RP yang diturunkan secara autosomal 
resesif. Varian ini termasuk salah satu dari sedikit varian biallelik pad a gen RP 1 yang sebagian 
besarvarian diturunkan secara autosomal dominan. Sebagian besarvarian pada RPl ada!ah 
protein truncating yang terletak pada exon terakhir, sehingga menghasilkan transkrip yang 
tidak akan mengalami nonsense mediated decay (NMD). Mutasi-mutasi terkait adRP ini 
terletak antara asam amino 500 untuk 1053. Mutasi ini dapat berakibat pada produk protein 
yang lebih pendek, namun dengan struktur yang masih memungkinkan interaksi dnegan 
protein terkait mikrutubul, sehingga dapat menyebabkan efek dominan-negatif. Di sisi lain, 
varian yang terletak di luar posisi "hot spot" diperkirakan akan kehilangan domain yang 
penting untuk interaksi dengan protein lain dan mungkin akan mengalami NMD. 
8ab 4 Menjelaskan mengenai analisis genetik dari penyakit herediter retina yang 
hanya disebabkan oleh beberapa varian atau beberapa gen tertentu. Dalam Bab 4A, saya 
melakukan sanger sequencing dan analisis copy number variant (CNV) dari gen CYP4V2 pad a 
pasien dengan Bi,etti corneoretinal distrofi (BCD) yang menemukan em pat varian baru pad a 
CYP4V2dan delesi dari seluruh gen CYP4V2 beserta beberapa gen di sekitarnya. Kelainan klinis 
yang beragam menunjukkan tidak adanya korelasi genotip-fenotip. Tidak ditemukannya 
varian CYP4V2 pada beberapa pasien BCD menunjukkan keragaman penyebab genetik 
dan kemungkinan adanya varian yang terletak pada daerah non coding dari gen. 8ab 48 
menjelaskan mengenai skrining genetik pad a beberapa gen dengan prevalensi tinggi pad a 
LCA di populasi Denmark. Varian biallelik ditemukan pada 42 dari 86 kasus (49%) melalui 
skrining genetik ini serta analisis APEX. Dari analisis kami menemukan mutasi terbanyak 
pad a gen RPE65 (16%), dimana varian baru p. (AspllOGly) ditemukan paling banyak (7 /27 
aiel) . Di samping itu, kami mengumpulkan seluruh 914 varian RPE65 yang telah terpublikasi 
pad a 539 pasien dengan LCA atau early-onset RP, yang kemudian diregister di RPE65 Leiden 
Open Variant Database (lovd). 
8ab5terfokus pad a upaya untuk menemukan gen baruterkait IRD dengan menggunakan 
whole exome sequencing (WES) serta kolaborasi dengan beberapa pusat penelitian. 8ab SA 
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menunjukkan asosiasi antara varian pada gen AGBLS dengan RP yang diturunkan secara 
autosomal resesif. Gambaran klinis dari pasien dengan varian patogenik pada AGBLS juga 
diuraikan pad a bab ini. Hal ini menunjukkan pentingnya proses glutamilasi yang diatur oleh 
AGBLS dan TTLLS dalam menyebabkan I RD. Dalam Bab 58, kami menemukan IDH3Asebagai 
gen baru yang dapat menyebabkan arRP klasik dan arRP dengan pseudocoloboma pada 
makuta. Terlebih, bab ini menunjukkan adanya variabilitas klinis pad a dua saudara kandung 
dengan varian compound heterozygous di IDH3A. Hasil ini menunjukkan keterlibatan 
kompleks IDH3 untuk homeostasis retina, terlebih dengan keterlibatan IDH3B pada RP dari 
penelitian terdahulu, menunjukkan kemungkinan IDH3G sebagai kandidat gen untuk I RD. 
Bab 6 mengulas hasil utama dan kontribusi penelitian ini dalam bidang IRD. Disamping 
itu, kami menguraikan tantangan dan pertimbangan yang diperlukan dalam penerapan 
WES untuk studi mengenai gangguan retina herediter pada man usia dan anjing. Beberapa 
penjelasan juga dikemukakan mengenai tidak ditemukannya penyebab genetik pada 
-40% kasus setelah analisis WES. Akhirnya, asosiasi antara AGBLS dan IDH3A dengan arRP 
menunjukkan pentingnya glutamylasi post-translasi dan siklusasam sitratuntuk homeostasis 
retina. Hasil pad a penelitian ini akan meningkatkan pemahaman dasar mengenai penyebab 
IRD dan dapat bermanfaat bagi pasien, baik dalam peningkatan diagnosis molekuler atau 
dalam memfasilitasi pengembangan terapi yang dapat menghambat penyakit kebutaan ini. 
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